Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R)-2-([(3R,4R)-4-amino-1-[1-(4-ethynylphenyl)ethyl]pyrrolidin-3-yl]carbonyl)cyclopentanecarbonitrile
-
(1R)-2-([(3R,4R)-4-amino-1-[2-methyl-4-(1H-1,2,4-triazol-1-yl)benzyl]pyrrolidin-3-yl]carbonyl)cyclopentanecarbonitrile
-
(1R)-2-([(3R,4R)-4-amino-1-[3-methyl-4-(1H-1,2,4-triazol-1-yl)benzyl]pyrrolidin-3-yl]carbonyl)cyclopentanecarbonitrile
-
(1R)-2-[[(3R,4R)-4-amino-1-(3,4-dihydro-2H-chromen-4-yl)pyrrolidin-3-yl]carbonyl]cyclopentanecarbonitrile
-
(1R)-2-[[(3R,4R)-4-amino-1-[1-[4-(1H-1,2,4-triazol-1-yl)phenyl]ethyl]pyrrolidin-3-yl]carbonyl]cyclopentanecarbonitrile
-
(1R,3S)-2-([(3R,4R)-4-amino-1-[4-(5-methyl-1,3,4-oxadiazol-2-yl)benzyl]pyrrolidin-3-yl]carbonyl)-3-fluorocyclopentanecarbonitrile
-
(1S)-1-(4-[[(2,4-difluorophenyl)sulfonyl]amino]cyclohexyl)-2-[(3S)-3-fluoropyrrolidin-1-yl]-2-oxoethanaminium
-
(1S,2S)-1-(4'-fluorobiphenyl-4-yl)-3-[(3S)-3-fluoropyrrolidin-1-yl]-3-oxo-1-(1H-tetrazol-1-yl)propan-2-amine
-
(1S,3S,5S)-2-[(2S)-2-amino-2-[(1R,3S,5S)-3-hydroxytricyclo[3.3.1.13,7]dec-1-yl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
-
(2-(4-((2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl)-2-oxoethyl)amino)-4-methyl-1-piperidinyl)-4-pyridine carboxylic acid
i. e. ABT-279, a very potent, selective, effective, and well-tolerated inhibitor useful for the treatment of diabetes
(2R)-1-(2,4-difluorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(2,5-difluorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(2-fluorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(2-methylphenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(3,4-dichlorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(3,4-difluorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(3-fluorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(4-chlorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(4-fluorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(4-iodophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-(4-nitrophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-1-cyclohexyl-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-4-(1,4-diazepan-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-(4-acetyl-1,4-diazepan-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-(4-benzyl-1,4-diazepan-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-(4-ethyl-1,4-diazepan-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-oxo-1-phenyl-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-4-oxo-1-pyridin-2-yl-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-4-oxo-1-pyridin-3-yl-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-4-oxo-1-pyridin-4-yl-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2R)-4-oxo-4-(1,3-thiazolidin-3-yl)-1-(3,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-oxo-4-(1,3-thiazolidin-3-yl)-1-[2-(trifluoromethyl)phenyl]butan-2-amine
-
(2R)-4-oxo-4-(1,3-thiazolidin-3-yl)-1-[3-(trifluoromethyl)phenyl]butan-2-amine
-
(2R)-4-oxo-4-(1,3-thiazolidin-3-yl)-1-[4-(trifluoromethyl)phenyl]butan-2-amine
-
(2R)-4-oxo-4-(4-pyrazin-2-yl-1,4-diazepan-1-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-oxo-4-(4-pyrimidin-2-yl-1,4-diazepan-1-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-oxo-4-[4-(phenylcarbonyl)-1,4-diazepan-1-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-oxo-4-[4-(pyridin-3-ylcarbonyl)-1,4-diazepan-1-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-[4-(1,3-benzodioxol-5-ylcarbonyl)-1,4-diazepan-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine hydrochloride
-
(2R)-4-[4-(methylsulfonyl)-1,4-diazepan-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-[4-[(4-methylphenyl)sulfonyl]-1,4-diazepan-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-[4-[(4-methylpiperazin-1-yl)carbonyl]-1,4-diazepan-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R)-4-[4-[(4-nitrophenyl)sulfonyl]-1,4-diazepan-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
(2R,3S)-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N1,N1-dimethyl-4-oxobutane-1,3-diamine
-
(2R,5S)-1-[N-[1-(5-cyanopyridin-2-yl)-4-methylpiperidin-4-yl]glycyl]pyrrolidine-2,5-dicarbonitrile
-
(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)-N-phenylpyrrolidine-2-carboxamide
-
(2R,5S)-N-(4-bromophenyl)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidine-2-carboxamide
-
(2S)-1-(((2S,5R)-5-[(1,3-benzodioxol-4-yloxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(1-naphthyloxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(2,4-dichlorophenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(2,6-dichlorophenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(2-chloro-4-cyanophenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(2-chlorophenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(2-methylphenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(4-bromophenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(4-cyanophenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(4-methoxyphenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(4-methylphenoxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(((2S,5R)-5-[(benzyloxy)methyl]pyrrolidin-2-yl)carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-(3-furyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2S)-1-([(2S,5R)-5-(([2-chloro-5-(dihydroxymethyl)pyridin-3-yl]oxy)methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-(([dihydroxy(phenyl)-'4-sulfanyl]amino)methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-(anilinomethyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-(morpholin-4-ylmethyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-(phenoxymethyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-([(2-chloropyridin-3-yl)oxy]methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-([(4-bromophenyl)amino]methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-([(6-bromo-1,3-benzodioxol-5-yl)oxy]methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-([2,4-dichloro-5-(dihydroxyamino)phenoxy]methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-([2-bromo-4-(methylsulfonodithioyl)phenoxy]methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(2S,5R)-5-([2-chloro-4-(methylsulfonodithioyl)phenoxy]methyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(3R,4R)-4-amino-1-[4-(1,2,3-thiadiazol-4-yl)benzyl]pyrrolidin-3-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(3R,4R)-4-amino-1-[4-(1-methyl-1H-pyrazol-4-yl)benzyl]pyrrolidin-3-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(3R,4R)-4-amino-1-[4-(1H-1,2,4-triazol-1-yl)benzyl]pyrrolidin-3-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(3R,4R)-4-amino-1-[4-(1H-pyrazol-5-yl)benzyl]pyrrolidin-3-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(3R,4R)-4-amino-1-[4-(2H-1,2,3-triazol-2-yl)benzyl]pyrrolidin-3-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(3R,4R)-4-amino-1-[4-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl]pyrrolidin-3-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([(3R,4R)-4-amino-1-[4-(5-methyl-1,3,4-oxadiazol-2-yl)benzyl]pyrrolidin-3-yl]carbonyl)pyrrolidine-2-carbonitrile
-
(2S)-1-([[(1R,3S,5S)-3-hydroxytricyclo[3.3.1.13,7]dec-1-yl]amino]acetyl)pyrrolidine-2-carbonitrile
-
(2S)-1-cyclopentyl-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
(2S)-1-[(1-adamantylamino)acetyl]pyrrolidine-2-carbonitrile
-
(2S)-1-[(2R)-2-amino-2-cyclopentylacetyl]pyrrolidine-2-carbonitrile
-
(2S)-1-[(2S)-pyrrolidin-2-ylcarbonyl]pyrrolidine-2-carbonitrile
-
(2S)-1-[(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile
-
(2S)-1-[(tert-butylamino)acetyl]pyrrolidine-2-carbonitrile
-
(2S)-1-[[(3R,4R)-4-amino-1-(3-cyano-4-fluorobenzyl)pyrrolidin-3-yl]carbonyl]pyrrolidine-2-carbonitrile
-
(2S)-1-[[(3R,4R)-4-amino-1-(4-cyanobenzyl)pyrrolidin-3-yl]carbonyl]pyrrolidine-2-carbonitrile
-
(2S)-1-[[(3R,4R)-4-amino-1-(quinolin-3-ylmethyl)pyrrolidin-3-yl]carbonyl]pyrrolidine-2-carbonitrile
-
(2S)-2-(4-[[(1-[(3S)-3-amino-4-[2,5-difluoro-4-(trifluoromethyl)phenyl]butanoyl]-L-prolyl)amino]methyl]phenoxy)-3-methylbutanoic acid
-
(2S)-2-(4-[[(1-[(3S)-3-amino-4-[2-fluoro-4-(trifluoromethyl)phenyl]butanoyl]-L-prolyl)amino]methyl]phenoxy)-3-methylbutanoic acid
-
(2S)-2-(4-[[(1-[(3S)-3-amino-4-[2-fluoro-5-(trifluoromethoxy)phenyl]butanoyl]-L-prolyl)amino]methyl]phenoxy)-3-methylbutanoic acid
-
(2S)-2-(4-[[(1-[(3S)-3-amino-4-[2-fluoro-5-(trifluoromethyl)phenyl]butanoyl]-L-prolyl)amino]methyl]phenoxy)-3-methylbutanoic acid
-
(2S)-2-(4-[[([(4R)-3-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-1,3-thiazolidin-4-yl]carbonyl)amino]methyl]phenyl)-3-methylbutanoic acid
-
(2S)-2-[2-[([1-[(2S)-2-amino-2-cyclohexylacetyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(2,5-difluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(2-chloro-4-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]propanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(3,4-difluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(5-chloro-2-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(5-fluoro-2-methylphenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-(pentafluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-2-[4-[([1-[(3S)-3-amino-4-phenylbutanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
(2S)-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxopropan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-phenylbutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-[2'-(trifluoromethyl)biphenyl-4-yl]butan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-[3'-(1H-1,2,4-triazol-3-yl)biphenyl-4-yl]butan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-[3'-(1H-tetrazol-1-yl)biphenyl-4-yl]butan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-[3'-(1H-tetrazol-5-yl)biphenyl-4-yl]butan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-[4'-(trifluoromethyl)biphenyl-4-yl]butan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-[4-(trifluoromethyl)phenyl]butan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-[4-([[4-(trifluoromethoxy)phenyl]sulfonyl]amino)cyclohexyl]butan-2-aminium
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(2'-methoxybiphenyl-4-yl)-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(2'-methylbiphenyl-4-yl)-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(4'-methoxybiphenyl-4-yl)-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(4'-methylbiphenyl-4-yl)-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(4-methoxyphenyl)-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(4-[[(4-methoxyphenyl)carbonyl](methyl)amino]cyclohexyl)-1-oxobutan-2-aminium
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(4-[[(4-methoxyphenyl)carbonyl]amino]cyclohexyl)-1-oxobutan-2-aminium
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-[3'-(1,3,4-oxadiazol-2-yl)biphenyl-4-yl]-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-[3'-(methylsulfonyl)biphenyl-4-yl]-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-[4'-(methylsulfonyl)biphenyl-4-yl]-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-[4-(methylthio)phenyl]-1-oxobutan-2-amine
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-[4-fluoro-2-(trifluoromethyl)phenyl]-1-oxobutan-2-amine
-
(2S,3S)-3-(2',4'-difluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(2',5'-difluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(2'-chlorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(2'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(2,4-difluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(2-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(2-fluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(3',4'-difluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(3',5'-difluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(3,4-difluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(3,5-difluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(3-chloro-4-fluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(3-chlorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(3-fluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxo-4-pyrrolidin-1-ylbutan-2-amine
-
(2S,3S)-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-5-pyrrolidin-1-ylpentan-2-amine
-
(2S,3S)-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium
-
(2S,3S)-3-(4-bromophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(4-chloro-2-fluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(4-fluorophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-(4-[[(2,4-difluorophenyl)sulfonyl]amino]cyclohexyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium
-
(2S,3S)-3-(4-[[(2,4-difluorophenyl)sulfonyl]amino]cyclohexyl)-4-(dimethylamino)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxobutan-2-aminium
-
(2S,3S)-3-(4-[[(4-fluorophenyl)carbonyl](methyl)amino]phenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium
-
(2S,3S)-3-amino-2-(2',4'-difluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(2',5'-difluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(3',4'-difluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(3'-ethynylbiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3R)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutan-1-ol
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanoic acid
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N',N'-dimethyl-4-oxobutanehydrazide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N-(1-methylethyl)-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N-(2-hydroxyethyl)-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N-methoxy-N-methyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N-methyl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-morpholin-4-yl-4-oxobutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxo-4-(1,3-thiazolidin-3-yl)butanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxo-4-piperidin-1-ylbutanamide
-
(2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxo-4-pyrrolidin-1-ylbutanamide
-
(2S,3S)-3-amino-4-(1,1-dioxido-1,3-thiazolidin-3-yl)-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-4-(3,3-difluoroazetidin-1-yl)-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-4-(3-fluoroazetidin-1-yl)-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-4-aziridin-1-yl-2-(4'-fluorobiphenyl-4-yl)-N,N-dimethyl-4-oxobutanamide
-
(2S,3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-2-[3'-(methylsulfonyl)biphenyl-4-yl]-4-oxobutanamide
-
(2S,3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxo-2-(4-pyridin-3-ylphenyl)butanamide
-
(2S,3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxo-2-(4-pyridin-4-ylphenyl)butanamide
-
(2S,3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxo-2-[3'-(2H-tetrazol-2-yl)biphenyl-4-yl]butanamide
-
(2S,3S)-3-amino-N,N-diethyl-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanamide
-
(2S,3S)-3-amino-N-(3,4-dihydro-2H-tetrazol-2-yl)-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanamide
-
(2S,3S)-3-amino-N-cyclopropyl-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanamide
-
(2S,3S)-3-amino-N-ethyl-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanamide
-
(2S,3S)-3-amino-N-ethyl-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N-methyl-4-oxobutanamide
-
(2S,3S)-3-biphenyl-4-yl-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-methyl-1-oxo-1-(1,3-thiazolidin-3-yl)pentan-2-amine
-
(2S,3S)-3-[3'-(5-cyclopropyl-2,3-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
(2S,3S)-3-[4-(acetylamino)phenyl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium
-
(2S,3S)-3-[4-[(cyclopropylcarbonyl)(methyl)amino]cyclohexyl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium
-
(2S,3S)-3-[4-[acetyl(methyl)amino]cyclohexyl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium
-
(2S,3S)-3-[4-[acetyl(methyl)amino]cyclohexyl]-4-(dimethylamino)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxobutan-2-aminium
-
(2S,3S)-3-[4-[acetyl(methyl)amino]phenyl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium
-
(2S,3S)-3-[4-[acetyl(methyl)amino]phenyl]-4-(dimethylamino)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxobutan-2-aminium
-
(2S,3S)-4-(dimethylamino)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxo-3-[4-([[4-(trifluoromethoxy)phenyl]sulfonyl]amino)cyclohexyl]butan-2-aminium
-
(2S,3S)-4-(dimethylamino)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxo-3-[4-[(phenylsulfonyl)amino]phenyl]butan-2-aminium
-
(2S,3S)-4-(dimethylamino)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(4-[methyl[(4-methylphenyl)carbonyl]amino]phenyl)-1,4-dioxobutan-2-aminium
-
(2S,3S)-4-(dimethylamino)-1-[(3S)-3-fluoropyrrolidin-1-yl]-3-(4-[methyl[(4-methylphenyl)sulfonyl]amino]phenyl)-1,4-dioxobutan-2-aminium
-
(2S,3S)-4-(dimethylamino)-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxobutan-2-aminium
-
(2S,3S)-4-(dimethylamino)-3-(4-[[(3-fluorophenyl)carbonyl]amino]cyclohexyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxobutan-2-aminium
-
(2S,3S)-4-(dimethylamino)-3-(4-[[(4-fluorophenyl)carbonyl](methyl)amino]phenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxobutan-2-aminium
-
(2S,3S)-4-azetidin-1-yl-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxobutan-2-amine
-
(2S,5R)-1-[(2R)-2-amino-2-cyclohexylacetyl]-5-ethynylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(2R)-2-amino-2-cyclopentylacetyl]-5-ethynylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(2R)-2-amino-2-cyclopentylacetyl]-5-methylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(2R)-2-amino-2-cyclopentylacetyl]-5-prop-1-yn-1-ylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(2R)-2-amino-2-cyclopentylacetyl]-5-vinylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(2R)-2-amino-4-methylpentanoyl]-5-ethynylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(2R)-2-amino-4-methylpentanoyl]-5-methylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(cyclohexylamino)acetyl]-5-ethynylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(cyclopentylamino)acetyl]-5-ethynylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(cyclopentylamino)acetyl]-5-prop-1-yn-1-ylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[(tert-butylamino)acetyl]-5-ethynylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[N-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)glycyl]-5-prop-1-yn-1-ylpyrrolidine-2-carbonitrile
-
(2S,5R)-1-[[(cis-1-ethyl-4-hydroxycyclohexyl)amino]acetyl]-5-ethynylpyrrolidine-2-carbonitrile
-
(2S,5S)-1-[(cyclopentylamino)acetyl]-5-methylpyrrolidine-2-carbonitrile
-
(3,3-difluoro-pyrrolidin-1-yl)-[(2S,4R)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin)-2-yl]-methanone
-
(3,3-difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl)-piperazin-1-yl)-pyrrolidin-2-yl]-methanone
PF-00734200, potent, selective, orally active dipeptidyl peptidase IV inhibitor
(3R)-1-[6-[(3R,4R)-3-amino-4-(2,4,5-trifluorophenyl)piperidin-1-yl]pyrimidin-4-yl]pyrrolidin-3-ol
-
(3R)-3-amino-1-(2-cyclopropyl-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-(2-phenyl-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-(3-cyclopropyl-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-(3-ethyl-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-(5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-(5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4R)-1,4-dimethyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4R)-1-methyl-4-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4R)-4-(4-fluorobenzyl)-1-methyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4R)-4-ethyl-1-methyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4S)-1-methyl-4-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4S)-1-methyl-4-propyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4S)-4-(4-fluorobenzyl)-1-methyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(4S)-4-ethyl-1-methyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(5R)-5-methyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(5S)-5-methyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(6R)-6-methyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(6S)-6-methyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-2-(trifluoromethyl)-8-[4-(trifluoromethyl)benzyl]-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-3-(trifluoromethyl)-8-[2-(trifluoromethyl)benzyl]-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(1H-1,2,4-triazol-1-ylmethyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(2-fluorobenzyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(4-fluorobenzyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(4-fluorobenzyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(4-methoxybenzyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(cyclopropylmethyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-(prop-2-en-1-yl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-benzyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-methyl-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8R)-8-methyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-3-(trifluoromethyl)-8-[2-(trifluoromethyl)benzyl]-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-(2-fluorobenzyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-(4-fluorobenzyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-(4-methoxybenzyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-(prop-2-en-1-yl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-benzyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-ethyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-methyl-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[(8S)-8-methyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[2,3-bis(trifluoromethyl)-4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl]-4-(2,5-difluorophenyl)butan-1-one
-
(3R)-3-amino-1-[2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[2-cyclopropyl-3-(trifluoromethyl)-4,7-dihydrofuro[2,3-c]pyridin-6(5H)-yl]-4-(2,5-difluorophenyl)butan-1-one
-
(3R)-3-amino-1-[3-(difluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-(2-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[(4R)-1,4-dimethyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[(4S)-1,4-dimethyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[(8R)-8-ethyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[1-(4-fluorobenzyl)-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[1-(4-fluorophenyl)-3-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[1-ethyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[1-methyl-3-(2,2,2-trifluoroethyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[1-methyl-3-(trifluoromethyl)-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[1-methyl-3-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-(4-fluorophenyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-(4-fluorophenyl)-3-(trifluoromethyl)-4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-(4-fluorophenyl)-6,7-dihydro[1,3]thiazolo[4,5-c]pyridin-5(4H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-(trifluoromethyl)-6,7-dihydro[1,3]thiazolo[4,5-c]pyridin-5(4H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-methyl-3-(2,2,2-trifluoroethyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-methyl-3-(trifluoromethyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-methyl-3-(trifluoromethyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-methyl-3-(trifluoromethyl)-4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-[4-(methylsulfanyl)phenyl]-3-(trifluoromethyl)-4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-[4-(methylsulfonyl)phenyl]-6,7-dihydro[1,3]thiazolo[4,5-c]pyridin-5(4H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[2-[4-(trifluoromethyl)phenyl]-6,7-dihydro[1,3]thiazolo[4,5-c]pyridin-5(4H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(2,2,2-trifluoroethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(2,5-difluorophenyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(4-fluorobenzyl)-2-(trifluoromethyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(4-fluorophenyl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(4-fluorophenyl)-2-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(4-fluorophenyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(hydroxymethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(pyridin-4-yl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]-4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(trifluoromethyl)-4,5-dihydro[1,2]oxazolo[3,4-c]pyridin-6(7H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-(trifluoromethyl)-6,7-dihydro[1,2]oxazolo[4,3-c]pyridin-5(4H)-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-ethyl-2-(trifluoromethyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-methyl-2-(4-fluorophenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]butan-1-one
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-[3-methyl-2-(trifluoromethyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]butan-1-one
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one
i.e. evogliptin
(3R,4R)-1-(1,3-benzothiazol-2-ylcarbonyl)-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-1-(1,3-benzothiazol-6-ylcarbonyl)-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-1-(2-naphthoyl)-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-1-(3,4-difluorobenzyl)-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-1-(6-phenylpyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
(3R,4R)-1-(6-piperidin-1-ylpyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
(3R,4R)-1-(6-pyrrolidin-1-ylpyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
(3R,4R)-1-(isoquinolin-3-ylcarbonyl)-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-1-[(5-chloro-1-benzofuran-2-yl)carbonyl]-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-1-[1-methyl-1-(4-nitrophenyl)ethyl]-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-1-[4-[3-(methylsulfonyl)phenyl]-1,3,5-triazin-2-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
(3R,4R)-1-[6-(3,3-difluoropyrrolidin-1-yl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
(3R,4R)-1-[6-[2-(trifluoromethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
(3R,4R)-1-[6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
(3R,4R)-3-amino-N-phenyl-4-(2,4,5-trifluorophenyl)piperidine-1-carboxamide
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinolin-3-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinolin-3-ylmethyl)pyrrolidin-3-amine
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinolin-6-ylcarbonyl)pyrrolidin-3-amine
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-[4-(1,2,3-thiadiazol-4-yl)benzyl]pyrrolidin-3-amine
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-[4-(1H-1,2,4-triazol-1-yl)benzoyl]pyrrolidin-3-amine
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-[4-(1H-1,2,4-triazol-1-yl)benzyl]pyrrolidin-3-amine
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-[4-(1H-tetrazol-1-yl)benzoyl]pyrrolidin-3-amine
-
(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-[4-(1H-tetrazol-1-yl)benzyl]pyrrolidin-3-amine
-
(3R,4S)-1-(6-phenylpyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
(3R,4S)-1-acetyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine
-
(3R,4S)-1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine
-
(3R,4S)-1-[4-[3-(methylsulfonyl)phenyl]-1,3,5-triazin-2-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
efficacious in vivo, lowering blood glucose in ZDF rats that were allowed to feed freely on a mixed meal
(3R,4S)-1-[6-(3-thienyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
(3R,4S)-1-[6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
(3R,4S)-1-[6-[3-(morpholin-4-ylsulfonyl)phenyl]pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
(3R,4S)-1-[6-[3-fluoro-5-(methylsulfonyl)phenyl]pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
(3R,4S)-3-amino-4-(2,4-dichlorophenyl)-N-(3-fluorobenzyl)pyrrolidine-1-carboxamide
-
(3R,4S)-3-amino-4-(2,4-dichlorophenyl)-N-(3-methoxybenzyl)-N-methylpyrrolidine-1-carboxamide
-
(3R,4S)-3-amino-4-(2,4-dichlorophenyl)-N-ethyl-N-methylpyrrolidine-1-carboxamide
-
(3R,4S)-3-amino-4-(2,4-dichlorophenyl)-N-ethylpyrrolidine-1-carboxamide
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-(6-phenylpyridin-2-yl)pyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-pyridin-2-ylpyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-pyrimidin-2-ylpyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-[(4-methylphenyl)sulfonyl]pyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-[2-(3-thienyl)pyrimidin-4-yl]pyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-[4-(3-thienyl)pyrimidin-2-yl]pyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-[5-(4-methoxyphenyl)pyrimidin-2-yl]pyrrolidin-3-amine
-
(3R,4S)-4-(2,4-dichlorophenyl)-1-[6-(3-thienyl)pyrimidin-4-yl]pyrrolidin-3-amine
-
(3R,4S)-4-(2-chloro-4,5-difluorophenyl)-1-[6-(3-thienyl)pyrimidin-4-yl]pyrrolidin-3-amine
-
(3R,4S)-4-(2-chloro-4-fluorophenyl)-1-[6-(3-thienyl)pyrimidin-4-yl]pyrrolidin-3-amine
-
(3S)-1-oxo-5-phenyl-1-(1,3-thiazolidin-3-yl)pentan-3-amine
-
(3S,4S)-5-(dimethylamino)-2-[(3S)-3-fluoropyrrolidin-1-yl]-5-oxo-4-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)pent-1-en-3-aminium
-
(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl 4-cyanobenzoate
-
(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl benzoate
-
(3S,5S)-N-(4-chlorophenyl)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-amine
-
(3S,5S)-N-(4-methoxyphenyl)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-amine
-
(3S,5S)-N-(4-nitrophenyl)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-amine
-
(3S,5S)-N-benzyl-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-amine
-
(3S,5S)-N-phenyl-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-amine
-
(4-[[([(4R)-3-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]-1,3-thiazolidin-4-yl]carbonyl)amino]methyl]phenyl)acetic acid
-
(4-[[([(4R)-3-[(3R)-3-amino-4-phenylbutanoyl]-1,3-thiazolidin-4-yl]carbonyl)amino]methyl]phenyl)acetic acid
-
(4R,5R)-5-amino-1-(2-phenylethyl)-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-(2-pyridin-4-ylethyl)-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-(3-phenylpropyl)-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-(morpholin-4-ylmethyl)-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-benzyl-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-benzyl-4-(2-chlorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-[(2S)-2-phenylpropyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-[2-[3-(methylsulfonyl)phenyl]ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-1-[2-[4-(methylsulfonyl)phenyl]ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
(4R,5R)-5-amino-4-(2-chlorophenyl)-1-(cyclohexylmethyl)piperidin-2-one
-
(4R,5R)-5-amino-4-(2-chlorophenyl)-1-phenylpiperidin-2-one
-
(6-methylpyridin-2-yl)methyl (3R,4S)-3-amino-4-(2,4-dichlorophenyl)pyrrolidine-1-carboxylate
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid (1H-benzoimidazol-2-ylmethyl)amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4-morpholin-4-ylphenyl)amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4-sulfamoyl phenyl)amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid 4-amino benzyl amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid 4-ethoxycarbonyl phenyl ester
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid 4-methoxycarbonyl benzyl ester
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid 4-methoxycarbonyl methyl phenyl ester
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid benzyl amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid benzyl ester
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid phenyl amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid phenyl ester
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carboxylic acid(pyridin-2-ylmethyl)amide
-
(R)-2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-4-sulfamoyl benzyl amide
-
(R)-4-([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino) benzoic acid ethyl ester
-
(R)-4-([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)benzenesulfonic acid
-
(R)-4-([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)benzoic acid
-
(R)-4-[([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)methyl]benzoic acid
-
(R)-4-[([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)methyl]benzoic acid methyl ester
-
(R)-[2-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]acetic acid
-
(R)-[2-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]acetic acid ethyl ester
-
(R)-[3-[([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)methyl]phenoxy]acetic acid
-
(R)-[3-[([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)methyl]phenoxy]acetic acid ethyl ester
-
(R)-[3-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]acetic acid
-
(R)-[3-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]acetic acid ethyl ester
-
(R)-[4-[([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)methyl]phenoxy]acetic acid
-
(R)-[4-[([2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino)methyl]phenoxy]acetic acid ethyl ester
-
(R)-[4-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]-(R)-isopropyl acetic acid
-
(R)-[4-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]-(R)-isopropyl acetic acid ethyl ester
-
(R)-[4-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]-(S)-isopropyl acetic acid
-
(R)-[4-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]-(S)-isopropyl acetic acid ethyl ester
-
(R)-[4-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]acetic acid
-
(R)-[4-[[2-[3-amino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl]amino]phenoxy]acetic acid ethyl ester
-
1-(1-methyl-6-phenyl-1H-benzimidazol-7-yl)methanamine
-
1-(4-cyanophenyl)-3-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]urea
-
1-([(5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methyl)-3-phenylurea
-
1-cyclohexyl-2-oxo-2-(1,3-thiazolidin-3-yl)ethanaminium 2,2,2-trifluoro-1-oxoethanide
-
1-phenyl-3-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]urea
-
1-[(3R,4R)-3-amino-4-[[(2R)-2-cyanocyclopentyl]carbonyl]pyrrolidin-1-yl]indane-5-carbonitrile
-
1-[(3R,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine
-
1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-N-benzyl-L-prolinamide
-
1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-N-[4-(1H-1,2,3-triazol-4-yl)butyl]-L-prolinamide
-
1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-N-[4-(2,3-dihydro-1H-tetrazol-5-yl)butyl]-L-prolinamide
-
1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-N-[4-(trifluoromethyl)benzyl]-L-prolinamide
-
1-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]-1,2,3,4-tetrahydroquinoline
-
1-[1-benzyl-6-(2-chlorophenyl)-1H-benzimidazol-7-yl]methanamine
-
1-[1-methyl-6-(2-methylphenyl)-1H-benzimidazol-7-yl]methanamine
-
1-[5-bromo-6-(2-chlorophenyl)-1-methyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2,4-dichlorophenyl)-1-ethyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2,4-dichlorophenyl)-1-methyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2,4-dichlorophenyl)-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2,4-difluorophenyl)-1-methyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2-chloro-5-fluorophenyl)-1-methyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2-chlorophenyl)-1,2-dimethyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2-chlorophenyl)-1-methyl-1H-1,2,3-benzotriazol-7-yl]methanamine
-
1-[6-(2-chlorophenyl)-1-methyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2-chlorophenyl)-1-methyl-2-pyridin-3-yl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2-chlorophenyl)-2-ethyl-1-methyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2-chlorophenyl)-2-methoxy-1-methyl-1H-benzimidazol-7-yl]methanamine
-
1-[6-(2-methoxyphenyl)-1-methyl-1H-benzimidazol-7-yl]methanamine
-
2-(4-[(3R,5S)-5-[(3,3,4,4-tetrafluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)pyrimidine
-
2-(4-[(3R,5S)-5-[(3,3-difluoroazetidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)pyrimidine
-
2-(4-[(3R,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)-1,3-benzoxazole
-
2-(4-[(3R,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)pyrazine
-
2-(4-[(3R,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)pyridine-3-carbonitrile
-
2-(4-[(3R,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)pyrimidine
-
2-(4-[(3R,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)[1,3]oxazolo[5,4-b]pyridine
-
2-(4-[(3R,5S)-5-[(3-fluoroazetidin-1-yl)carbonyl]pyrrolidin-3-yl]piperazin-1-yl)pyrimidine
-
2-([6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]methyl)benzonitrile
-
2-([8-[(3R)-3-aminopiperidin-1-yl]-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl]methyl)benzonitrile
most potent inhibitor tested, exhibits moderate antihyperglycemic activity as compared to the standard antidiabetic drug Linagliptin in ther oral glucose tolerance test. The compound effectively improves the pathological state of diet-induced obesity mice. IC50 value with isoforms DPP-8 and DPP-9 is above 0.1 mM
2-ethoxy-4-[2-(methylsulfanyl)ethyl]-1,3,2-oxazaphospholidine 2-sulfide
-
2-[(2R)-2-amino-4-oxo-4-(1,3-thiazolidin-3-yl)butyl]benzonitrile
-
2-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]isoindoline
-
2-[(4-cyanobenzyl)[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]acetamide
-
2-[(8R)-7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-8-yl]-N,N-dimethylacetamide
-
2-[(8S)-7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-8-yl]-N,N-dimethylacetamide
-
2-[4-[(3R,5S)-5-(azetidin-1-ylcarbonyl)pyrrolidin-3-yl]piperazin-1-yl]pyrimidine
-
2-[4-[(3R,5S)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]piperazin-1-yl]pyrimidine
-
2-[4-[(3R,5S)-5-[[(3R)-3-fluoropyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]piperazin-1-yl]pyrimidine
-
2-[4-[(3R,5S)-5-[[(3R,4R)-3,4-difluoropyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]piperazin-1-yl]pyrimidine
-
2-[4-[(3R,5S)-5-[[(3R,4S)-3,4-difluoropyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]piperazin-1-yl]pyrimidine
-
2-[4-[(3R,5S)-5-[[(3S)-3-fluoropyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]piperazin-1-yl]pyrimidine
-
2-[7-(aminomethyl)-1-methyl-1H-benzimidazol-6-yl]benzamide
-
2-[7-(aminomethyl)-1-methyl-1H-benzimidazol-6-yl]phenol
-
2-[7-(aminomethyl)-6-(2-chlorophenyl)-1H-benzimidazol-1-yl]ethanol
-
3-(4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-yl)-1,2,4-oxadiazolidin-5-one
-
3-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]carbonyl)benzoic acid
-
3-bromo-4-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methoxy)benzoic acid
-
3-chloro-4-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methoxy)benzoic acid
-
3-[(2R)-2-amino-4-oxo-4-(1,3-thiazolidin-3-yl)butyl]benzonitrile
-
3-[(2S)-pyrrolidin-2-ylcarbonyl]-1,3-thiazolidine
-
3-[2-[(4R,5R)-5-amino-2-oxo-4-(2,4,5-trifluorophenyl)piperidin-1-yl]ethyl]benzoic acid
-
3-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]-N,N-dimethylbenzamide
-
3-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]benzoic acid
-
4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-carboxamide
-
4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-carboxylic acid
-
4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-sulfonamide
-
4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-4-carboxylic acid
-
4,4'-([[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]imino]dimethanediyl)dibenzonitrile
-
4-(4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-yl)-1,3-dihydro-2H-imidazol-2-one
-
4-([(1-methylethyl)[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]methyl)benzonitrile
-
4-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methoxy)-3-methoxybenzoic acid
-
4-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]carbonyl)benzamide
-
4-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]carbonyl)benzenesulfonamide
-
4-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]carbonyl)benzoic acid
-
4-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]sulfonyl)benzoic acid
-
4-([butyl[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]methyl)benzonitrile
-
4-([methyl[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]methyl)benzonitrile
-
4-([[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]methyl)benzonitrile
-
4-bromo-3-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methoxy)benzoic acid
-
4-chloro-3-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methoxy)benzoic acid
-
4-cyano-N-(4-cyanobenzyl)-N-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]benzamide
-
4-cyano-N-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]benzamide
-
4-cyano-N-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]benzenesulfonamide
-
4-[(1-[[2-oxo-2-(3-thienyl)ethyl]amino]cyclopentyl)methoxy]benzamide
-
4-[(2R)-2-amino-4-oxo-4-(1,3-thiazolidin-3-yl)butyl]benzonitrile
-
4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-N-(4-methylphenyl)-1,4-diazepane-1-carboxamide
-
4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-N-phenyl-1,4-diazepane-1-carboxamide
-
4-[(3R)-3-[(2-oxo-2-phenylethyl)amino]butyl]benzamide
-
4-[(3R)-3-[[2-(2-fluorophenyl)-2-oxoethyl]amino]butyl]benzamide
-
4-[(3R)-3-[[2-(3,4-difluorophenyl)-2-oxoethyl]amino]butyl]benzamide
-
4-[(3R)-3-[[2-(4-chlorophenyl)-2-oxoethyl]amino]butyl]benzamide
-
4-[(3R)-3-[[2-(4-fluorophenyl)-2-oxoethyl]amino]butyl]benzamide
-
4-[(3R)-3-[[2-oxo-2-(3-thienyl)ethyl]amino]butyl]benzamide
-
4-[([1-[(2S)-2-amino-2-cyclohexylacetyl]-L-prolyl]amino)methyl]benzoic acid
-
4-[2-(methylsulfanyl)ethyl]-2-phenoxy-1,3,2-oxazaphospholidine 2-sulfide
-
4-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]benzoic acid
-
4-[[(2R)-2-[[2-oxo-2-(3-thienyl)ethyl]amino]propyl]oxy]benzamide
-
4-[[(3R,4R)-3-amino-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]methyl]benzonitrile
-
4-[[(3R,4R)-3-amino-4-[[(2R)-2-cyanocyclopentyl]carbonyl]pyrrolidin-1-yl]methyl]-2,6-diethylbenzonitrile
-
4-[[(3R,4R)-3-amino-4-[[(2R)-2-cyanocyclopentyl]carbonyl]pyrrolidin-1-yl]methyl]-2,6-dimethylbenzonitrile
-
4-[[(3R,4R)-3-amino-4-[[(2R)-2-cyanocyclopentyl]carbonyl]pyrrolidin-1-yl]methyl]-2-methylbenzonitrile
-
4-[[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]benzonitrile
-
5-(4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-4-yl)-1,2,4-triazolidin-3-one
-
5-(aminomethyl)-6-(2,4-dichlrophenyl)-2-(3,5-dimethoxyphenyl)pyrimidin-4-amine
base compound for inhibitor design, form hydrogen bonds with residues Arg125, Glu205, Glu206, Tyr547, Ser630, Tyr662 and His740
5-(aminomethyl)-6-[2-chloro-4-(trifluoromethyl)phenyl]-2-(3,5-dimethoxyphenyl)pyrimidin-4-amine
proposed inhibitor, displays three hydrogen bonds with Ser209, two with Glu205 and His740 each, and one with each of the amino acids Arg358 and Tyr662. Compounds is predicted to have good oral absorption and bioavailability
5-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]carbonyl)pyridine-2-carboxylic acid
-
5-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]carbonyl)pyridine-3-carboxylic acid
-
5-([4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepan-1-yl]carbonyl)tetrahydrofuran-2-carboxylic acid
-
5-bromo-2-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]isoindoline
-
5-chloro-2-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methoxy)benzoic acid
-
5-chloro-2-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]isoindoline
-
5-chloro-6-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methoxy)nicotinic acid
-
5-fluoro-2-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]isoindoline
-
5-methoxy-2-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]isoindoline
-
5-nitro-2-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]isoindoline
-
5-[[(3R,4R)-3-amino-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]methyl]-2-fluorobenzonitrile
-
6-(aminomethyl)-1,3-dimethyl-7-(1-methylpiperazinium)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
compound exhibits low exposure, high clearance, high selectivity for dipeptidyl peptidase IV over dipeptidyleptidase DPP8
6-(aminomethyl)-1,3-dimethyl-7-(morpholin-4-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
compound exhibits excellent exposure, low clearance, high selectivity for dipeptidyl peptidase IV over dipeptidyleptidase DPP8
6-[(3R,4R)-3-amino-4-(2,4,5-trifluorophenyl)piperidin-1-yl]-N,N-diethylpyrimidin-4-amine
-
6-[4-([2-[(2R,5S)-2,5-dicyanopyrrolidin-1-yl]-2-oxoethyl]amino)-4-methylpiperidin-1-yl]pyridine-3-carboxylic acid
-
6-[[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]nicotinonitrile
-
6-[[4-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)cyclohexyl]oxy]nicotinonitrile
-
6-[[4-([2-[(2S,5R)-2-cyano-5-ethynylpyrrolidin-1-yl]-2-oxoethyl]amino)cyclohexyl]oxy]pyridine-3-carbonitrile
-
7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one
-
7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile
-
7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carboxamide
-
7-amino-6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
compound exhibits good exposure, moderate clearance, high selctivity for dipeptidyl peptidase IV over dipeptidyleptidase DPP8
7-amino-6-(aminomethyl)-5-(2-fluoro-6-methoxyphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
compound exhibits good exposure, moderate clearance, high selectivity for dipeptidyl peptidase IV over dipeptidyleptidase DPP8
7-[(2-butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)amino]-N-[(3R)-1-[3-[(2-cyanophenyl)methyl]-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl]piperidin-3-yl]heptanamide
fluorescent probe based on inhibitor alogliptin
7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-N-tert-butyl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine-3-carboxamide
-
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione
a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. Potential for once-daily treatment of type 2 diabetics
8-[(3R)-3-aminopiperidin-1-yl]-1-[(1,3-benzothiazol-2-yl)methyl]-3-methyl-7-(3-methylbut-2-en-1-yl)-3,7-dihydro-1H-purine-2,6-dione
IC50 value with isoforms DPP-8 and DPP-9 is above 0.1 mM
benzyl 4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,4-diazepane-1-carboxylate
-
cis-(2S)-1-([(2S)-5-(2-hydroxyethyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
cis-(2S)-1-([(2S)-5-ethylpyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
cis-(2S)-1-([(2S)-5-methylpyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
cis-(2S)-1-([(2S)-5-phenylpyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
cis-(2S)-1-([(2S)-5-prop-2-yn-1-ylpyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
cis-(2S)-1-([(2S)-5-propylpyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
di{4-[(erythrocarbonyl)methylaminoacrbonyl]-phenyl} 1-((S)-prolyl)pyrrolidine-2(R,S)-phosphonate
irreversible
ethyl (3R,4S)-3-amino-4-(2,4-dichlorophenyl)pyrrolidine-1-carboxylate
-
ethyl 4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-carboxylate
-
ethyl 4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-4-carboxylate
-
ethyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine-3-carboxylate
-
ethyl 7-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine-3-carboxylate
-
ethyl N-(4-cyanobenzyl)-N-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]glycinate
-
ethyl-2-(4-(((S)-1-((S)-2-amino-(4-fluorophenyl)propanoyl)pyrrolidine-2-carboxamido)-methyl)phenoxy)acetate
compound exhibits high selectivities against dipeptidyl peptidases FAP, DPP 7, DPP 8, and DPP 9, with inhibition rates <50% at 20 microg/ml
ethyl-2-(4-(((S)-1-((S)-2-amino-3-(2-fluorophenyl)propanoyl)pyrrolidine-2-carboxamido)-methyl)phenoxy)acetate
compound exhibits high selectivities against dipeptidyl peptidases FAP, DPP 7, DPP 8, and DPP 9, with inhibition rates <50% at 20 microg/ml
Ile-Pro-Ile
i.e. diprotin A, inhibition mechanism, binds covalently to Ser630
methyl (2S,3S)-3-amino-2-(4'-fluorobiphenyl-4-yl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanoate
-
methyl (4-[[([(4R)-3-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]-1,3-thiazolidin-4-yl]carbonyl)amino]methyl]phenyl)acetate
-
methyl 4-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]benzenesulfinate
-
methyl 4-[([1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]benzoate
-
N-(4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-yl)-1,1,1-trifluoromethanesulfonamide
-
N-(4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-yl)methanesulfonamide
-
N-(4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-4-yl)methanesulfonamide
-
N-(4-cyanobenzyl)-N-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]-b-alanine
-
N-([(2R,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-2-yl]methyl)benzamide
-
N-isoleucyl-3-fluoro-pyrrolidine
reversible
N-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]benzamide
-
N-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]benzenesulfonamide
-
trans-(2S)-1-([(2S)-5-(2-hydroxyethyl)pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
trans-(2S)-1-([(2S)-5-ethylpyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
trans-(2S)-1-([(2S)-5-prop-2-yn-1-ylpyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
[(4-cyanobenzyl)[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]amino]acetic acid
-
[2-[([1-[(2S)-2-amino-2-cyclohexylacetyl]-L-prolyl]amino)methyl]phenyl]acetic acid
-
[2-[([1-[(3S)-3-amino-4-phenylbutanoyl]-L-prolyl]amino)methyl]phenyl]acetic acid
-
[2-[7-(aminomethyl)-1-methyl-1H-benzimidazol-6-yl]phenyl]methanol
-
[3-[([1-[(2S)-2-amino-2-cyclohexylacetyl]-L-prolyl]amino)methyl]phenyl]acetic acid
-
[3-[([1-[(3S)-3-amino-4-phenylbutanoyl]-L-prolyl]amino)methyl]phenyl]acetic acid
-
[4-[([1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]acetic acid
-
[4-[([1-[(3S)-3-amino-4-(2-fluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenyl]acetic acid
-
[4-[([1-[(3S)-3-amino-4-(3,4-difluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenyl]acetic acid
-
[4-[([1-[(3S)-3-amino-4-phenylbutanoyl]-L-prolyl]amino)methyl]phenyl]acetic acid
-
(11bS)-9,10-dimethoxy-3-(3-methylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(11bS)-9,10-dimethoxy-3-phenyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(1R)-1-(4-bromophenyl)-2-(2,5-difluorophenyl)ethanamine
-
-
(1R)-1-[4-(3-chloropyridin-4-yl)phenyl]-2-(2,5-difluorophenyl)ethanamine
-
-
(1R)-2-(2,5-difluorophenyl)-1-(4-pyridin-4-ylphenyl)ethanamine
-
-
(1R,3S)-2-[(2S)-2-amino-2-cyclopentylacetyl]-3-ethynylcyclopentanecarbonitrile
-
-
(1S)-1-cyclohexyl-2-(3,3-difluoropyrrolidin-1-yl)-2-oxoethanamine
-
-
(1S)-1-cyclohexyl-2-(3-fluoropyrrolidin-1-yl)-2-oxoethanamine
-
-
(1S)-1-cyclohexyl-2-oxo-2-(3,3,4,4-tetrafluoropyrrolidin-1-yl)ethanamine
-
-
(1S,2R,5S)-5-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-(2,4,5-trifluorophenyl)cyclohexanamine
-
-
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
-
-
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
-
-
(2R)-1-(2,5-difluorophenyl)-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
-
(2R)-1-(2,5-difluorophenyl)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-2-amine
-
-
(2R)-1-(2-fluorophenyl)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-2-amine
-
-
(2R)-1-(3,4-difluorophenyl)-4-(3-ethyl-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-oxobutan-2-amine
-
-
(2R)-1-(3,4-difluorophenyl)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butan-2-amine
-
-
(2R)-1-[(2R)-2-(dihydroxyboranyl)pyrrolidin-1-yl]-1-oxopropan-2-aminium
-
-
(2R)-1-[8-(trifluoromethyl)bis[1,2,4]triazolo[4,3-a:3',4'-c]pyrazin-3-yl]-3-(2,4,5-trifluorophenyl)propan-2-amine
-
-
(2R)-1-[9-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4',3':1,2]pyrido[3,4-d]pyrimidin-3-yl]-3-(2,4,5-trifluorophenyl)propan-2-amine
-
-
(2R)-1-[N-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)glycyl]pyrrolidine-2-carbonitrile
-
-
(2R)-4-(2-benzoylpyrazolidin-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-(2-cyclopropyl-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-(3-methyl-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-(5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-oxo-4-(2-phenyl-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-oxo-4-pyrazolidin-1-yl-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-oxo-4-[(8R)-2-(trifluoromethyl)-8-[4-(trifluoromethyl)benzyl]-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-oxo-4-[(8R)-8-(1H-1,2,4-triazol-1-ylmethyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-oxo-4-[2-(phenylcarbonyl)-1,2-diazepan-1-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
competitive
(2R)-4-oxo-4-[2-(phenylcarbonyl)tetrahydropyridazin-1(2H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
the inhibitor displays a greater than 1400fold selectivity over all the enzymes tested including DPP-8 and DPP-9
(2R)-4-oxo-4-[2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
(2R)-4-oxo-4-[8-(1H-pyrazol-1-ylmethyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[(2R)-2-benzylpiperazin-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[(8R)-8-(4-fluorobenzyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[(8R)-8-(cyclopropylmethyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[(8R)-8-methyl-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[(8R)-8-[(1-fluorocyclopropyl)methyl]-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[(8S)-8-methyl-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[1,4-dimethyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[2-[(4-methylphenyl)sulfonyl]pyrazolidin-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[4-(4-fluorobenzyl)-1-methyl-2-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[8-(1H-imidazol-1-ylmethyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[8-(4-fluorobenzyl)-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[8-(4-fluorobenzyl)-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[8-methyl-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-[8-methyl-3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R,3R)-1-(2,5-difluorophenyl)-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butan-2-amine
-
-
(2R,3R)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine
-
potent, selectiveDPP-4 inhibitor
(2R,3R)-3-[3-(2,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R,3R)-3-[3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R,3R,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N,N,2-trimethylpyrrolidine-3-carboxamide
-
-
(2R,3S,11bS)-3-(3,4-dimethylphenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2R,3S,11bS)-3-(3-chlorophenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2R,3S,11bS)-9,10-dimethoxy-3-(3-methoxyphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2R,3S,11bS)-9,10-dimethoxy-3-(3-methylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2R,3S,11bS)-9,10-dimethoxy-3-(4-methylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2R,3S,11bS)-9,10-dimethoxy-3-phenyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2R,3S,11bS)-9,10-dimethoxy-3-pyridin-2-yl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2R,3S,5R)-5-[2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-2-(2,4,5-trifluorophenyl)tetrahydro-2H-pyran-3-amine
-
-
(2R,3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N,N,2-trimethylpyrrolidine-3-carboxamide
-
-
(2R,4R)-2-(dihydroxyboranyl)-4-hydroxypyrrolidin-1-yl (4S)-4-hydroxy-L-prolinate
-
best selectivity for dipeptidyl peptidase IV over dipeptidyl peptidases DPP8 and DPP9
(2R,4R)-4-fluoro-1-(3-methyl-D-valyl)pyrrolidine-2-carbonitrile
-
-
(2R,4R)-4-fluoro-1-(3-methyl-L-valyl)pyrrolidine-2-carbonitrile
-
-
(2R,4S)-4-fluoro-1-(3-methyl-D-valyl)pyrrolidine-2-carbonitrile
-
-
(2R,4S)-4-fluoro-1-(3-methyl-L-valyl)pyrrolidine-2-carbonitrile
-
-
(2S)-1-([(2S,4S)-4-[(2E)-but-2-en-1-yl]pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
-
(2S)-1-([(2S,4S)-4-[(3-chloro-4-cyanophenyl)amino]pyrrolidin-2-yl]carbonyl)pyrrolidine-2-carbonitrile
-
-
(2S)-1-([[2-methyl-4-oxo-4-(pyrrolidin-1-yl)butan-2-yl]amino]acetyl)pyrrolidine-2-carbonitrile
-
-
(2S)-1-L-prolylpyrrolidine-2-carbonitrile
-
IC50: 2.9 nmol/L
(2S)-1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-1-oxo-3-phenylpropan-2-amine
-
-
(2S)-1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-1-oxohexan-2-amine
-
-
(2S)-1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-3,3-dimethyl-1-oxobutan-2-amine
-
-
(2S)-1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-3-(4-chlorophenyl)-1-oxopropan-2-amine
-
-
(2S)-1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-3-methyl-1-oxobutan-2-amine
-
-
(2S)-1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-4-methyl-3-(1-methylethyl)-1-oxopentan-2-amine
-
-
(2S)-1-[(2R)-2-(dihydroxyboranyl)pyrrolidin-1-yl]-1-oxopropan-2-aminium
-
-
(2S)-1-[(2S)-2-amino-2-cyclopentylacetyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[(2S)-pyrrolidin-2-ylcarbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1,4-dioxo-4-(1,3-thiazolidin-3-yl)butan-2-amine
-
-
(2S)-1-[(4R)-4-tricyclo[3.3.1.13,7]dec-2-yl-L-prolyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[(4S)-4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)-5,5-dimethyl-L-prolyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[(4S)-4-(azocan-1-ylcarbonyl)-L-prolyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[([2-[(5-nitropyridin-2-yl)amino]ethyl]amino)acetyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[([4-[(3R)-3-hydroxypyrrolidin-1-yl]-2-methyl-4-oxobutan-2-yl]amino)acetyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[3-([2-[(5-nitropyridin-2-yl)amino]ethyl]amino)propanoyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[N-[3-(1,3-dihydro-2H-isoindol-2-yl)-1,1-dimethyl-3-oxopropyl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[N-[4-(1,3-dihydro-2H-isoindol-2-yl)-2-methyl-4-oxobutan-2-yl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(1R,3S,5R,7R)-tricyclo[3.3.1.13,7]dec-2-ylamino]acetyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(1R,5R)-tricyclo[3.3.1.13,7]dec-2-ylamino]acetyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(2,6-dimethylphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(2-ethyl-4-hydroxy-6-methylphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(2-hydroxyethyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(2-hydroxyphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(3-hydroxy-2,4,6-trimethylphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(3-hydroxy-2,6-dimethylphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(3-hydroxy-2-methoxy-6-methylphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(3-hydroxyphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(4-hydroxy-2,6-dimethoxyphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(4-hydroxy-2,6-dimethylphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(4-hydroxy-2-methoxy-6-methylphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-(4-hydroxyphenyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-cyclohexylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4R)-4-phenylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(azepan-1-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(azetidin-1-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(hydroxymethyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(morpholin-4-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(piperidin-1-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-(thiomorpholin-4-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-allylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-isobutylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-phenylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S)-4-propylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S,5S)-4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)-5-methylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S,5S)-4-(azetidin-1-ylcarbonyl)-5-methylpyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S,5S)-5-methyl-4-(morpholin-4-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S,5S)-5-methyl-4-(piperidin-1-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S,5S)-5-methyl-4-(pyrrolidin-1-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(2S,4S,5S)-5-methyl-4-(thiomorpholin-4-ylcarbonyl)pyrrolidin-2-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile
-
-
(2S)-1-[[(3R,4R)-4-amino-1-(4-cyano-3-methylbenzyl)pyrrolidin-3-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S)-2-(1-adamantyl)-2-amino-N-(1-cyanoethyl)acetamide
-
-
(2S)-2-(1-adamantyl)-2-amino-N-(cyanomethyl)-N-cyclopropylacetamide
-
-
(2S)-2-(1-adamantyl)-2-amino-N-(cyanomethyl)-N-ethylacetamide
-
-
(2S)-2-(1-adamantyl)-2-amino-N-(cyanomethyl)-N-methylacetamide
-
-
(2S)-2-(1-adamantyl)-2-amino-N-(cyanomethyl)-N-propylacetamide
-
-
(2S)-2-(1-adamantyl)-N-allyl-2-amino-N-(cyanomethyl)acetamide
-
-
(2S)-2-amino-N-(1-cyanoethyl)-3,3-dimethylbutanamide
-
-
(2S)-2-amino-N-(1-cyanoethyl)-N,3,3-trimethylbutanamide
-
-
(2S)-2-amino-N-(cyanomethyl)-2-(3,5-dihydroxy-1-adamantyl)-N-methylacetamide
-
-
(2S)-2-amino-N-(cyanomethyl)-2-(3-hydroxy-1-adamantyl)-N-methylacetamide
-
-
(2S)-2-amino-N-(cyanomethyl)-N,3,3-trimethylbutanamide
-
-
(2S)-2-amino-N-(cyanomethyl)-N,3-dimethylbutanamide
-
-
(2S)-2-amino-N-(cyanomethyl)-N-cyclobutyl-3,3-dimethylbutanamide
-
-
(2S)-2-amino-N-(cyanomethyl)-N-cyclopropyl-3,3-dimethylbutanamide
-
-
(2S)-2-amino-N-(cyanomethyl)-N-ethyl-2-(3-hydroxy-1-adamantyl)acetamide
-
-
(2S)-2-amino-N-(cyanomethyl)-N-ethyl-3,3-dimethylbutanamide
-
-
(2S)-2-[4-[([1-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-L-prolyl]amino)methyl]phenoxy]-3-methylbutanoic acid
-
-
(2S)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-amine
-
-
(2S)-N-allyl-2-amino-N-(cyanomethyl)-3,3-dimethylbutanamide
-
-
(2S)-{((3-Hydroxyadamantan-1-yl)amino) acetyl}pyrrolidin-2-carbonitrile
-
vldagliptin is rapidly and well absorbed with an estimated absolute bioavailability of 85%. Two possible sites of absorption are identified, and the absorption rates are slower than the elimination rate, indicating a flip-flop phenomenon after oral dosing
(2S,3R)-1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-3-methyl-1-oxopentan-2-amine
-
-
(2S,3R,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N,N,2-trimethylpyrrolidine-3-carboxamide
-
-
(2S,3S)-1-oxo-1-pyrrolidin-1-yl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butan-2-amine
-
-
(2S,3S)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxo-3-(4-pyridin-4-ylphenyl)butan-2-amine
-
-
(2S,3S)-2-amino-1-((1S,5S)-2-azabicyclo[3.1.0]hexan-2-yl)-3-methylpentan-1-one
-
-
(2S,3S)-2-amino-3-methyl-1-(thiazolidin-3-yl)pentan-1-one
-
-
(2S,3S)-3-(4'-fluorobiphenyl-4-yl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
-
(2S,3S)-3-(4-bromophenyl)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
-
(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide
-
-
(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(trans-4-[1,2,4]triazolo[1,5-a]pyridin-6-ylcyclohexyl)butanamide
-
-
(2S,3S)-3-methyl-1-oxo-1-pyrrolidin-1-ylpentan-2-amine
-
-
(2S,3S)-3-[3-(2,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
-
(2S,3S)-3-[3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
-
(2S,3S)-3-[4-(3-chloropyridin-4-yl)phenyl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
-
-
(2S,3S)-9,10-dimethoxy-3-(3-methylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-(2,5-dimethylphenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-(3,4-dimethylphenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-(3-chlorophenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-(3-cyclopropylphenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-(3-ethylphenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-butyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-pyrido[2,1-a]isoquinoline-2,11b-diamine
-
-
(2S,3S,11bS)-3-butyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-[3-(fluoromethyl)phenyl]-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-3-[4-(fluoromethyl)pyridin-2-yl]-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-9,10-dimethoxy-3-(3-methoxyphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-9,10-dimethoxy-3-(3-methylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-9,10-dimethoxy-3-(4-methylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-9,10-dimethoxy-3-(4-methylpyridin-2-yl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-9,10-dimethoxy-3-phenyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-9,10-dimethoxy-3-pyridin-2-yl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,11bS)-9,10-dimethoxy-3-[3-(propan-2-yl)phenyl]-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
(2S,3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-2-ethyl-N,N-dimethylpyrrolidine-3-carboxamide
-
-
(2S,3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N,N,2-trimethylpyrrolidine-3-carboxamide
-
-
(2S,3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N-ethyl-N,2-dimethylpyrrolidine-3-carboxamide
-
-
(2S,4R)-4-fluoro-1-(3-methyl-D-valyl)pyrrolidine-2-carbonitrile
-
-
(2S,4R)-4-fluoro-1-(3-methyl-L-valyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-((2S)-2-amino-3-methylpentanoyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(N-1-adamantylglycyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(N-2-adamantylglycyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(N-cyclobutylglycyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(N-cyclooctylglycyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(N-cyclopentylglycyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(N-cyclopropylglycyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(N-[2-[(5-chloropyridin-2-yl)amino]ethyl]-glycyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-(O-benzyl-L-threonyl)-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-L-alloisoleucyl-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[(2S)-2-amino-2-cyclohexylacetyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile
-
potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV
(2S,4S)-1-[N-(tert-butyl)glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[N-[(2E)-1,1-dimethyl-3-phenylprop-2-en-1-yl]glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[N-[1-(1-benzofuran-2-yl)-1-methylethyl]glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[N-[2-(3,4-dimethoxyphenyl)ethyl]glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[N-[2-(diethylamino)-1,1-dimethylethyl]glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[N-[4-(3,6-dihydropyridin-1(2H)-yl)-2-methyl-4-oxobutan-2-yl]glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[N-[4-(7-azabicyclo[2.2.1]hept-7-yl)-2-methyl-4-oxobutan-2-yl]glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[N-[4-(azepan-1-yl)-2-methyl-4-oxobutan-2-yl]glycyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[O-(tert-butyl)-L-threonyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-1-[[(3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-3-yl]carbonyl]-4-fluoropyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(3-methyl-D-valyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(3-methyl-L-valyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(N-isopropylglycyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(N-methyl-L-isoleucyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(N-[2-methyl-4-[(2R)-2-methylpyrrolidin-1-yl]-4-oxobutan-2-yl]glycyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(N-[2-methyl-4-[4-(methylsulfonyl)piperazin-1-yl]-4-oxobutan-2-yl]glycyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(N-[2-[(4-cyanobenzyl)amino]-1,1-dimethylethyl]glycyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(N-[2-[(5-cyanopyridin-2-yl)-amino]ethyl]glycyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(N-[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-methyl-4-oxobutan-2-yl]glycyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-(O-methyl-L-threonyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-([[2-methyl-4-oxo-4-(1,3-thiazolidin-3-yl)butan-2-yl]amino]acetyl)pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-L-valyl-pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[(2S)-pyrrolidin-2-ylcarbonyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[([4-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-4-oxobutan-2-yl]amino)acetyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[([4-[(3R)-3-hydroxypyrrolidin-1-yl]-2-methyl-4-oxobutan-2-yl]amino)acetyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[([4-[(3S)-3-hydroxypyrrolidin-1-yl]-2-methyl-4-oxobutan-2-yl]amino)acetyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-(1-methyl-1-pyridin-2-ylethyl)glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-(2-hydroxy-1,1-dimethylethyl)glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-(2-methoxy-1,1-dimethylethyl)glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-(3-hydroxy-1-adamantyl)-glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-(3-isopropoxypropyl)glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-(3-methoxy-1-adamantyl)-glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-(5-hydroxy-2-adamantyl)-glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[1-(2-furyl)-1-methylethyl]-glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[1-(hydroxymethyl)cyclopentyl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[1-methyl-1-(2-thienyl)-ethyl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[2-(pyridin-2-ylamino)ethyl]-glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[2-methyl-4-(4-methylpiperazin-1-yl)-4-oxobutan-2-yl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[2-methyl-4-(morpholin-4-yl)-4-oxobutan-2-yl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[2-methyl-4-oxo-4-(4-oxopiperidin-1-yl)butan-2-yl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[N-[2-methyl-4-oxo-4-(piperidin-1-yl)butan-2-yl]glycyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[[(3S)-7-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S)-4-fluoro-1-[[(3S)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-3-yl]carbonyl]pyrrolidine-2-carbonitrile
-
-
(2S,4S,5S)-N-(cyanomethyl)-4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)-N-ethyl-5-methylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-4-isobutyryl-5-methyl-N-prop-2-yn-1-ylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-4-isobutyryl-5-methyl-N-propylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-4-isobutyryl-5-methylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-4-isobutyryl-N,5-dimethylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-N-cyclopropyl-4-isobutyryl-5-methylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-N-ethyl-4-isobutyryl-5-methylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-N-ethyl-5-methyl-4-(morpholin-4-ylcarbonyl)pyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-N-ethyl-5-methyl-4-(piperidin-1-ylcarbonyl)pyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-(cyanomethyl)-N-ethyl-5-methyl-4-(pyrrolidin-1-ylcarbonyl)pyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N-allyl-N-(cyanomethyl)-4-isobutyryl-5-methylpyrrolidine-2-carboxamide
-
-
(2S,4S,5S)-N4-benzyl-N2-(cyanomethyl)-N2-ethyl-5-methylpyrrolidine-2,4-dicarboxamide
-
-
(2S,5R)-1-[(2S)-2-amino-2-cyclopentylacetyl]-5-prop-1-yn-1-ylpyrrolidine-2-carbonitrile
-
-
(3'S,5'S)-5'-(1,3-thiazolidin-3-ylcarbonyl)-1,3'-bipyrrolidine
-
-
(3-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]phenyl)methanol
-
-
(3R)-1-[(1R)-1-(dihydroxyboranyl)ethyl]-2-oxopyrrolidin-3-aminium
-
-
(3R)-3-amino-1-[(2S)-2-([[2-(trifluoromethyl)pyrimidin-4-yl]oxy]methyl)pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-1-[(2S)-2-([[4-(trifluoromethyl)pyrimidin-2-yl]amino]methyl)pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-1-[(2S)-2-([[6-(trifluoromethyl)pyridin-3-yl]amino]methyl)pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-1-[(2S)-2-[(cyclopropylmethoxy)methyl]pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-1-[(2S)-2-[(pyrimidin-2-ylamino)methyl]pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-1-[(2S)-2-[[(5-fluoropyridin-2-yl)amino]methyl]pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-1-[(2S)-2-[[(5-fluoropyrimidin-2-yl)amino]methyl]pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
-
-
(3R)-3-amino-4-(2,5-difluorophenyl)-1-(3-methyl-1,2,4-oxadiazol-5-yl)butan-1-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,3-dimethyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1-(2-hydroxyethyl)-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1-cyclopropyl-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1-tert-butyl-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-1-[2-(benzyloxy)ethyl]-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-1-cyclopropyl-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-1-ethyl-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-3-methyl-1-(2-oxopropyl)-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
-
-
(3R)-4-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one
-
-
(3R)-4-[(3S)-3-amino-4-(2-oxopiperidin-1-yl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
-
-
(3R)-4-[(3S)-3-amino-4-(2-oxopiperidin-1-yl)butanoyl]-3-methyl-1,4-diazepan-2-one
-
-
(3R,4R)-1-(2-methyl-3-oxo-2,3-dihydro[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-(2-methyl-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-(2-methyl-4-oxo-4H-pyrimido[1,2-b]pyridazin-7-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
pharmacokinetic properties
(3R,4R)-1-(2-oxo-2H-pyrimido[1,2-b]pyridazin-7-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
(3R,4R)-1-(3-ethyl[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-(3-methyl[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-amine
-
-
(3R,4R)-1-(3-methyl[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
pharmacokinetic properties
(3R,4R)-1-(4-cyanopyridin-2-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-isoquinolin-1-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-phenyl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-pteridin-7-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-pyrazino[2,3-b]pyrazin-2-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-pyridin-2-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-pyridin-3-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-pyridin-4-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-pyrido[2,3-b]pyrazin-3-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-pyrido[2,3-b]pyrazin-6-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-quinolin-2-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-quinoxalin-2-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[1,2,4]triazolo[4,3-a]pyrimidin-7-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
pharmacokinetic properties
(3R,4R)-1-[1,2,4]triazolo[4,3-b]pyridazin-6-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[2-(trifluoromethyl)imidazo[1,2-b]pyridazin-6-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[2-(trifluoromethyl)[1,2,4]triazolo[1,5-b]pyridazin-6-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[3-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[3-(trifluoromethyl)pyridin-2-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[4-(trifluoromethyl)pyridin-2-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[5-(trifluoromethyl)pyridin-2-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-[6-(trifluoromethyl)pyridin-2-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-3-butyl-1-(3,4,5-trimethoxyphenyl)piperidin-4-amine
-
-
(3R,4R)-3-butyl-1-(3,4-dimethoxyphenyl)piperidin-4-amine
-
-
(3R,4R)-3-butyl-1-(4-methylphenyl)piperidin-4-amine
-
-
(3R,4R)-3-butyl-1-(4-phenoxyphenyl)piperidin-4-amine
-
-
(3R,4R)-3-butyl-1-(6-methoxybiphenyl-3-yl)piperidin-4-amine
-
-
(3R,4R)-3-butyl-1-naphthalen-2-ylpiperidin-4-amine
-
-
(3R,4R)-3-butyl-1-phenylpiperidin-4-amine
-
-
(3R,4S)-1-(6-phenylpyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-(6-pyridin-3-ylpyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[4-[3-(methylsulfonyl)phenyl]-1,3,5-triazin-2-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(2-chlorophenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(2-fluorophenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(2-methoxyphenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(3-chlorophenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(3-chlorophenyl)pyrimidin-4-yl]-4-phenylpyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(3-fluorophenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(3-methoxyphenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(3-nitrophenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(4-chlorophenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(4-fluorophenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(4-methoxyphenyl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(4-methoxyphenyl)pyrimidin-4-yl]-4-phenylpyrrolidin-3-amine
-
-
(3R,4S)-1-[6-(6-methoxypyridin-3-yl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-[3-(trifluoromethoxy)phenyl]pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-1-[6-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine
-
-
(3R,4S)-4-phenyl-1-(6-phenylpyrimidin-4-yl)pyrrolidin-3-amine
-
-
(3R,6S)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3,6-dimethyl-1,4-diazepan-2-one
-
-
(3R,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-7-(trifluoromethyl)-1,4-diazepan-2-one
-
-
(3R,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-7-(2-fluorobenzyl)-3-methyl-1,4-diazepan-2-one
-
-
(3R,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-7-ethyl-3-methyl-1,4-diazepan-2-one
-
-
(3R,S)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one
-
-
(3S)-1-[(1R)-1-(dihydroxyboranyl)ethyl]-2-oxopyrrolidin-3-aminium
-
-
(3S)-1-[6-[(3R,4R)-3-amino-4-(2,4,5-trifluorophenyl)piperidin-1-yl]pyrimidin-4-yl]pyrrolidin-3-ol
-
-
(3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-1-(3-methyl-1,2,4-oxadiazol-5-yl)-4-oxobutan-1-one
-
-
(3S)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3,6,6-trimethyl-1,4-diazepan-2-one
-
-
(3S,4R)-3-butyl-1-(3,4,5-trimethoxyphenyl)piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-(3,4-dichlorophenyl)piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-(3,4-dimethoxyphenyl)piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-(4-methylphenyl)piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-(4-phenoxyphenyl)piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-(6-methoxybiphenyl-3-yl)piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-(diphenylmethyl)piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-cyclohexylpiperidin-4-amine
-
-
(3S,4R)-3-butyl-1-naphthalen-2-ylpiperidin-4-amine
-
-
(3S,4R)-3-butyl-1-[3-methoxy-5-(trifluoromethyl)phenyl]piperidin-4-amine
-
-
(3S,4R)-3-butyl-1-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-amine
-
-
(3S,4S)-1-pyrazin-2-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3S,4S)-1-pyridazin-3-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3S,4S)-1-pyrimidin-2-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3S,4S)-1-pyrimidin-4-yl-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N,N-diethylpyrrolidine-3-carboxamide
-
-
(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N,N-dimethylpyrrolidine-3-carboxamide
-
-
(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N-ethyl-N-methylpyrrolidine-3-carboxamide
-
-
(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N-ethylpyrrolidine-3-carboxamide
-
-
(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N-methylpyrrolidine-3-carboxamide
-
-
(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-N-propylpyrrolidine-3-carboxamide
-
-
(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]pyrrolidine-3-carboxamide
-
-
(3S,5S)-N-(2-phenylethyl)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidine-3-carboxamide
-
-
(3S,5S)-N-benzyl-5-(pyrrolidin-1-ylcarbonyl)pyrrolidine-3-carboxamide
-
-
(3S,5S)-N-phenyl-5-(pyrrolidin-1-ylcarbonyl)pyrrolidine-3-carboxamide
-
-
(3S,6R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3,6-dimethyl-1,4-diazepan-2-one
-
-
(3S,6R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-ethyl-6-methyl-1,4-diazepan-2-one
-
-
(3S,6R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-6-methyl-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
-
-
(3S,6S)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3,6-dimethyl-1,4-diazepan-2-one
-
-
(3S,6S)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-ethyl-6-methyl-1,4-diazepan-2-one
-
-
(3S,6S)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-6-methyl-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
-
-
(3S,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3,7-dimethyl-1,4-diazepan-2-one
-
-
(3S,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2-fluorobenzyl)-7-methyl-1,4-diazepan-2-one
-
-
(3S,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-7-methyl-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
-
-
(3S,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-7-methyl-3-(2-methylbenzyl)-1,4-diazepan-2-one
-
-
(3S,7R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-7-methyl-3-(pyridin-2-ylmethyl)-1,4-diazepan-2-one
-
-
(3S,7S)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3,7-dimethyl-1,4-diazepan-2-one
-
-
(4-[4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazin-1-yl]phenyl)ethynamine
-
-
(4R,5R)-5-amino-1-[2-[3-(methylsulfonyl)phenyl]ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one
-
-
(7R,8R)-2-methyl-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydropyrido[3',2':4,5]imidazo[1,2-a]pyridin-8-amine
-
-
(S)-1-(2-(2-(2-oxo-3-(3,4,5-trimethoxyphenyl)imidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(2-oxo-3-p-tolylimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(2-oxo-3-phenylimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(2-fluorophenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(3,4-dimethoxyphenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(3,5-dimethoxyphenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(3-fluorophenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(3-methoxyphenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-(4-methoxyphenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-butyl-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-cyclohexyl-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-isopropyl-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
(S)-1-(2-(2-(3-tert-butyl-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile
-
-
1-(2-chlorophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(2-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]phenyl)ethanone
-
-
1-(3,4-dichlorophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(3,4-dimethoxyphenyl)-3-(3,4-dimethylphenyl)piperidin-4-amine
-
-
1-(3,4-dimethoxyphenyl)-3-(3-methoxyphenyl)piperidin-4-amine
-
-
1-(3,4-dimethoxyphenyl)-3-(3-methylphenyl)piperidin-4-amine
-
-
1-(3,4-dimethoxyphenyl)-3-(4-methylphenyl)piperidin-4-amine
-
-
1-(3,4-dimethoxyphenyl)-3-pyridin-2-ylpiperidin-4-amine
-
-
1-(3-benzyl-4-oxido-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-aminium
-
-
1-(3-chlorophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(3-methyl-1,2,4-thiadiazol-5-yl)-4-[[(2S,3S,5S)-2-methyl-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]carbonyl]piperazine
-
-
1-(3-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]phenyl)ethanone
-
-
1-(4-bromophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(4-chlorophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(4-ethynylpyridin-2-yl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(4-fluorophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(4-methoxyphenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(4-nitrophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]-1,4-diazepane
-
-
1-(4-nitrophenyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(4-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]phenyl)ethanone
-
-
1-(5-chloropyridin-2-yl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(5-nitropyridin-2-yl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(6-chloro-2-isobutyl-4-phenyl-3,4-dihydroquinolin-3-yl)methanamine
-
-
1-(diphenylmethyl)-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-(L-alanyl)pyrrolidine
-
reversible
1-(L-cyclohexylalanyl)piperidine
-
reversible
1-(L-cyclohexylalanyl)pyrrolidine
-
reversible
1-(L-isoleucyl)-1,2,5,6-tetrahydropyridine
-
reversible
1-(L-isoleucyl)-3(R,S)-azidopyrrolidine
-
reversible
1-(L-isoleucyl)-3(R,S)-chloropyrrolidine
-
reversible
1-(L-isoleucyl)-3(R,S)-hydroxypyrrolidine
-
reversible
1-(L-isoleucyl)-3-pyrroline
-
reversible
1-(L-isoleucyl)hexamethyleneimine
-
reversible
1-(L-isoleucyl)piperidine
-
reversible
1-(L-isoleucyl)pyrrolidine
-
reversible
1-(L-lysyl)piperidine
-
reversible
1-(L-lysyl)pyrrolidine
-
reversible
1-(L-phenylalanyl)pyrrolidine
-
reversible
1-(L-prolyl)pyrrolidine
-
reversible
1-(L-tyrosyl)pyrrolidine
-
reversible
1-(L-valyl)pyrrolidine
-
reversible
1-benzyl-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-methyl-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-phenyl-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-pyridin-2-yl-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-pyridin-4-yl-4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazine
-
-
1-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-4,4-dimethyl-1-oxopentan-2-amine
-
-
1-[(2R)-2-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]cyclopentyl]-2-(tricyclo[3.3.1.13,7]dec-1-ylamino)ethanone
-
-
1-[(2R)-4,4-difluoro-2-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]cyclopentyl]-2-(tricyclo[3.3.1.13,7]dec-1-ylamino)ethanone
-
-
1-[(2R,4R)-4-fluoro-2-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]cyclopentyl]-2-(tricyclo[3.3.1.13,7]dec-1-ylamino)ethanone
-
-
1-[(2S)-2-amino-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]butyl]piperidin-2-one
-
-
1-[(3R)-3-amino-4-phenylbutanoyl]-N-[5-chloro-2-[2-(cyclopropylamino)-2-oxoethoxy]benzyl]-L-prolinamide
-
-
1-[(3S,4S)-4-amino-1-[4-(3,3-difluoropyrrolidin-1-yl)-1,3,5-triazin-2-yl]pyrrolidin-3-yl]-4,4-difluoropiperidin-2-one
-
-
1-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]-4-[4-(trifluoromethyl)phenyl]piperazine
-
-
1-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]-4-[4-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperidine
-
-
1-[(4R)-4-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]tetrahydrothiophen-3-yl]-2-(tricyclo[3.3.1.13,7]dec-1-ylamino)ethanone
-
-
1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano(S)-pyrrolidine
-
competitive
1-[1-(2-chlorobenzyl)-5-methyl-4,6-dioxo-1,4,5,6-tetrahydropyrrolo[3,4-d]imidazol-2-yl]piperidin-3-aminium
-
-
1-[1-(2-cyanobenzyl)-4,5-bis(methylcarbamoyl)-1H-imidazol-2-yl]piperidin-3-aminium
-
-
1-[1-(2-cyanobenzyl)-5-methyl-4,6-dioxo-1,4,5,6-tetrahydropyrrolo[3,4-d]imidazol-2-yl]piperidin-3-aminium
-
potent and selective DPPIV inhibitor, but it showed a significant loss of activity in the presence of plasma
1-[1-(2-cyanobenzyl)-5-methyl-4-oxo-4,5-dihydro-1H-imidazo[4,5-d]pyridazin-2-yl]piperidin-3-aminium
-
-
1-[1-(2-cyanobenzyl)-6-methyl-7-oxo-3a,6,7,7a-tetrahydro-1H-imidazo[4,5-d]pyridazin-2-yl]piperidin-3-aminium
-
-
1-[1-(3-cyanobenzyl)-6-methyl-7-oxo-6,7-dihydro-1H-imidazo[4,5-d]pyridazin-2-yl]piperidin-3-aminium
-
-
1-[1-[3-(cyanomethyl)benzyl]-6-methyl-7-oxo-6,7-dihydro-1H-imidazo[4,5-d]pyridazin-2-yl]piperidin-3-aminium
-
-
1-[3-[2-[2-cyano-(S)-pyrrolidin-1-yl]-2-oxoethylamino]-1-oxopropyl]-4-[benzothiazol-2-yl]piperazine
-
-
1-[4,9-dioxo-1-[2-(trifluoromethyl)benzyl]-4,9-dihydro-1H-naphtho[2,3-d]imidazol-2-yl]piperidin-3-aminium
-
-
1-[5-benzyl-1-(3-cyanobenzyl)-4,6-dioxo-1,4,5,6-tetrahydropyrrolo[3,4-d]imidazol-2-yl]piperidin-3-aminium
-
-
1-[5-methyl-4,6-dioxo-1-[2-(trifluoromethoxy)benzyl]-1,4,5,6-tetrahydropyrrolo[3,4-d]imidazol-2-yl]piperidin-3-aminium
-
-
1-[5-methyl-4,6-dioxo-1-[2-(trifluoromethyl)benzyl]-1,4,5,6-tetrahydropyrrolo[3,4-d]imidazol-2-yl]piperidin-3-aminium
-
-
1-[7-(2-cyanobenzyl)-1,3-dimethyl-2,6-dioxo-2,3,4,5,6,7-hexahydro-1H-purin-8-yl]piperidin-3-aminium
-
-
1-[7-fluoro-6-methoxy-1-[2-(trifluoromethyl)benzyl]-1H-benzimidazol-2-yl]piperidin-3-aminium
-
-
1-[amino(cyclohexyl)acetyl]pyrrolidine-2-carbonitrile
-
-
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine
-
vildagliptin, reversible inhibitor
1-[[(8R)-7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-2-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyrazin-8-yl]methyl]cyclopropanol
-
-
2,2-bis(4-chlorophenyl)-N-[2-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-2-methylpropyl]acetamide
-
-
2-(2-[4-(4-chloro-phenyl)-piperazin-1-yl]-2-oxoethylsulfanyl)-4-hydroxy-6-phenyl-pyrimidine-5-carbonitrile
-
single dose of 10 mg/kg of the compound significantly reduces glucose excursion during oral glucose tolerance test in streptozotocin-induced diabetic rat model
2-(3-aminopiperidin-1-yl)-1-but-2-yn-1-yl-4-cyano-N-(naphthalen-1-ylmethyl)-1H-imidazole-5-carboxamide
-
-
2-(3-aminopiperidin-1-yl)-1-but-2-yn-1-yl-N-(naphthalen-1-ylmethyl)-1H-imidazole-5-carboxamide
-
-
2-(3-aminopiperidin-1-yl)-1-but-2-yn-1-yl-N-methyl-N-(naphthalen-1-ylmethyl)-1H-imidazole-5-carboxamide
-
-
2-(3-aminopiperidin-1-yl)-1-but-2-yn-1-yl-N-methyl-N-[(3-methylisoquinolin-1-yl)methyl]-1H-imidazole-5-carboxamide
-
-
2-(3-aminopiperidin-1-yl)-1-but-2-yn-1-yl-N-[(3-methylisoquinolin-1-yl)methyl]-1H-imidazole-5-carboxamide
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-(10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-ylmethyl)-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-(2-oxo-2-phenylethyl)-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-(naphthalen-1-ylmethyl)-3,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-(naphthalen-1-ylmethyl)-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-[(11R)-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-ylmethyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-[(11S)-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-ylmethyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-[(3-methylisoquinolin-1-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-[(3-methylisoquinolin-1-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-[(4-methylquinazolin-2-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-5-[(6-methyl-1,3-benzoxazol-2-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-7-methoxy-5-(naphthalen-1-ylmethyl)-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-7-methoxy-5-[(3-methylisoquinolin-1-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-7-methyl-5-(naphthalen-1-ylmethyl)-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-7-methyl-5-[(3-methylisoquinolin-1-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-7-methyl-5-[(4-methylquinazolin-2-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-(3-aminopiperidin-1-yl)-4-bromo-1-but-2-yn-1-yl-N-(naphthalen-1-ylmethyl)-1H-imidazole-5-carboxamide
-
-
2-(3-aminopiperidin-1-yl)-4-bromo-1-but-2-yn-1-yl-N-[(3-methylisoquinolin-1-yl)methyl]-1H-imidazole-5-carboxamide
-
-
2-(3-but-2-yn-1-yl-4-oxo-2-piperazin-1-yl-3,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl)benzonitrile
-
-
2-(N-tert-butylglycyl-L-prolyl)-5-(1-methylcyclohexyl)-1,3,4-oxadiazole
-
-
2-(N-tert-butylglycyl-L-prolyl)-5-(2,4,6-trimethylphenyl)-1,3,4-oxadiazole
-
-
2-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methoxy)pyridine-4-carbonitrile
-
-
2-([(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]carbonyl)isoindoline
-
-
2-([2-(4-aminopiperidin-1-yl)-2-oxoethyl]sulfanyl)-4-hydroxy-6-phenylpyrimidine-5-carbonitrile
-
single dose of 10 mg/kg of the compound significantly reduces glucose excursion during oral glucose tolerance test in streptozotocin-induced diabetic rat model
2-([2-[(1R,3S)-3-aminocyclohexyl]-5-benzyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]pyridin-3-yl]methyl)benzonitrile
-
-
2-([2-[(3R)-3-aminopiperidin-1-yl]-6-bromo-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
-
-
2-([2-[(3R)-3-aminopiperidin-1-yl]-6-fluoro-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
2-([6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]methyl)benzonitrile
-
SYR322, alogliptin
2-([8-(3-aminopiperidin-1-yl)-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl]methyl)benzonitrile
-
-
2-cyanopyrrolidines
-
-
-
2-methyl-2-[(2-[(2S)-2-[(5-methyl-1,2,4-oxadiazol-3-yl)carbonyl]pyrrolidin-1-yl]-2-oxoethyl)amino]propanoic acid
-
-
2-tert-butyl-5-(N-tert-butylglycyl-L-prolyl)-1,3,4-oxadiazole
-
-
2-tert-butyl-5-[N-(2-hydroxy-1,1-dimethylethyl)glycyl-(4S)-4-fluoro-L-prolyl]-1,3,4-oxadiazole
-
the inhibitor shows good potency against DPPIV, and good selectivity against DPPII, DPPVIII, and elastase
2-tert-butyl-5-[N-(2-hydroxy-1,1-dimethylethyl)glycyl-L-prolyl]-1,3,4-oxadiazole
-
-
2-tert-butyl-5-[N-[2-(4-fluorophenyl)-1,1-dimethylethyl]glycyl-(4S)-4-fluoro-L-prolyl]-1,3,4-oxadiazole
-
-
2-[(2-aminoethyl)(methyl)amino]-3-but-2-yn-1-yl-5-[(4-methylquinazolin-2-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-[(2S,3R,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]-2-methylpyrrolidin-3-yl]-N,N-dimethylacetamide
-
-
2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]-1-[(2R)-2-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]cyclopentyl]ethanone
-
-
2-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-N-phenylpyrazolidine-1-carboxamide
-
-
2-[(3R)-3-aminopiperidin-1-yl]-3-but-2-yn-1-yl-5-[(4-methylquinazolin-2-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-[(3R)-4-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]-3-benzylpiperazin-1-yl]-N-[3-[(methylsulfonyl)amino]phenyl]acetamide
-
-
2-[(3R,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]-N,N-dimethylacetamide
-
-
2-[(7-but-2-yn-1-yl-2-methoxy-6-oxo-8-piperazin-1-yl-6,7-dihydro-1H-purin-1-yl)methyl]benzonitrile
-
-
2-[([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)amino]pyridine-3-carbonitrile
-
-
2-[4-[(2S)-2-amino-3-phenylpropyl]-3-benzylpiperazin-1-yl]-N-[3-[(methylsulfonyl)amino]phenyl]acetamide
-
-
2-[4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazin-1-yl]nicotinonitrile
-
-
2-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]benzonitrile
-
-
2-[N-tert-butylglycyl-(4S)-4-fluoro-L-prolyl]-5-(1,1-dimethylpropyl)-1,3,4-oxadiazole
-
-
2-[N-tert-butylglycyl-(4S)-4-fluoro-L-prolyl]-5-cyclohexyl-1,3,4-oxadiazole
-
-
2-[[(2S)-2-aminopropyl](methyl)amino]-3-but-2-yn-1-yl-5-[(4-methylquinazolin-2-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
2-[[(3S)-3-[[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]carbonyl]-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy]acetamide
-
-
2-[[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]carbonyl]isoindoline
-
-
2-[[(3S,5S)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]carbonyl]-5-(trifluoromethyl)isoindoline
-
-
2-[[(3S,5S)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]carbonyl]isoindoline
-
-
2-[[(3S,5S)-5-[[(3R)-3-fluoropyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]carbonyl]isoindoline
-
-
2-[[(3S,5S)-5-[[(3S)-3-fluoropyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]carbonyl]isoindoline
-
-
2-[[2-(3-aminopiperidin-1-yl)-4-oxoquinazolin-3(4H)-yl]methyl]benzonitrile
-
-
2-[[2-(3-aminopiperidin-1-yl)-5,6-dimethyl-4,7-dioxo-4,5,6,7-tetrahydro-1H-imidazo[4,5-d]pyridazin-1-yl]methyl]benzonitrile
-
-
2-[[2-(3-aminopiperidin-1-yl)-5-methyl-4,6-dioxo-5,6-dihydropyrrolo[3,4-d]imidazol-1(4H)-yl]methyl]benzonitrile
-
-
3,4-dichloroisocoumarin
-
-
3-((2S,4S)-4-anilino-2-pyrrolidinylcarbonyl)-1,3-thiazolidine
-
IC50: 147 nmol/L
3-(1-amino-2-oxo-2-pyrrolidin-1-ylethyl)tricyclo[3.3.1.13,7]decan-1-ol
-
-
3-(aminomethyl)-2-isobutyl-4-phenylisoquinolin-1(2H)-one
-
-
3-(aminomethyl)-4-(2,4-dichlorophenyl)-7,8-dimethoxy-5H-indeno[1,2-b]pyridin-2-amine
-
-
3-(aminomethyl)-4-(2,4-dichlorophenyl)quinolin-2-amine
-
-
3-(N-tert-butylglycyl-L-prolyl)-5-(2-methylcyclohexyl)-1,2,4-oxadiazole
-
-
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-N-(3,4-dimethoxyphenyl)-3-methylbutanamide
-
-
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-(pyridin-2-yl)butanamide
-
-
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-N-(3,4-dimethoxyphenyl)-3-methylbutanamide
-
-
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-N-cyclopentyl-3-methylbutanamide
-
-
3-but-2-yn-1-yl-2-(1,4-diazepan-1-yl)-5-[(4-methylquinazolin-2-yl)methyl]-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
3-but-2-yn-1-yl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one
-
-
3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate
-
selective and competitive dipeptidyl peptidase-IV inhibitor
3-butyl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)piperidin-4-amine
-
-
3-butyl-1-(diphenylmethyl)piperidin-4-amine
-
-
3-butyl-1-naphthalen-1-ylpiperidin-4-amine
-
-
3-butyl-1-[3-methoxy-5-(trifluoromethyl)phenyl]piperidin-4-amine
-
-
3-butyl-1-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-amine
-
-
3-butyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-amine
-
-
3-L-prolyl-1,3-thiazolidine
-
IC50: 538 nmol/L
3-[(2S)-pyrrolidin-2-ylcarbonyl]-1,3-thiazolidine
-
-
3-[(2S,4S)-4-(2-chloro-4-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 18.2 nmol/L
3-[(2S,4S)-4-(2-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 24.1 nmol/L
3-[(2S,4S)-4-(3,4-dicyanophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 8.4 nmol/L
3-[(2S,4S)-4-(3,4-methylenedioxyphenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 29.0 nmol/L
3-[(2S,4S)-4-(3-chloro-4-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 11.1nmol/L
3-[(2S,4S)-4-(3-chloro-4-methoxyphenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 19.9 nmol/L
3-[(2S,4S)-4-(4-aminophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 105 nmol/L
3-[(2S,4S)-4-(4-chlorophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 45.4 nmol/L
3-[(2S,4S)-4-(4-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 25.2 nmol/L
3-[(2S,4S)-4-(4-methanesulfonylphenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 52.3 nmol/L
3-[(2S,4S)-4-(4-nitrophenyl)amino-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 19.2 nmol/L
3-[(2S,4S)-4-(5-cyano-2-pyridyl)amino-2-pyrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 25.4 nmol/L
3-[(2S,4S)-4-(p-anisidino)-2-pyrrolidinylcarbonyl]-1,3-thiazolidine
-
IC50: 51.5 nmol/L
3-[(3S,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]-N,N-dimethylpropanamide
-
-
3-[1-amino-2-(2H-isoindol-2-yl)-2-oxoethyl]tricyclo[3.3.1.13,7]decan-1-ol
-
-
3-[1-amino-2-(4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethyl]tricyclo[3.3.1.13,7]decan-1-ol
-
-
3-[1-amino-2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]tricyclo[3.3.1.13,7]decan-1-ol
-
-
3-[1-amino-2-[(1R,5S)-2-azabicyclo[3.1.0]hex-2-yl]-2-oxoethyl]tricyclo[3.3.1.13,7]decan-1-ol
-
-
3-[1-amino-2-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-2-oxoethyl]-5,7-dimethyltricyclo[3.3.1.13,7]decan-1-ol
-
-
3-[1-amino-2-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-2-oxoethyl]tricyclo[3.3.1.13,7]decan-1-ol
-
-
3-[6-[(3R,4R)-3-amino-4-(2,4,5-trifluorophenyl)piperidin-1-yl]pyrimidin-4-yl]phenyl methanesulfonate
-
-
3-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]benzoic acid
-
-
3-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]benzonitrile
-
-
3-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]phenol
-
-
3-[6-[(3R,4S)-3-amino-4-phenylpyrrolidin-1-yl]pyrimidin-4-yl]benzonitrile
-
-
4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide
-
-
4'-[(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl]biphenyl-3-carboxamide
-
-
4-(4-nitrophenyl)-1-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperidine
-
-
4-([1-[(2-oxo-2-thiophen-3-ylethyl)amino]cyclopentyl]methoxy)benzamide
-
-
4-nitrobenzyl[(5S)-5-amino-6-oxo-6-(1-pyrrolidinyl)hexyl]carbamate
-
-
4-phenyl-1-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperidine
-
-
4-[(2S)-2-amino-3-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-3-oxopropyl]phenol
-
-
4-[(3R)-3-[[2-(4-fluorophenyl)-2-oxoethyl]amino]butyl]benzamide
-
-
4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]morpholine
-
-
4-[4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazin-1-yl]benzene-1,2-dicarbonitrile
-
-
4-[6-[(3R,4S)-3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]pyrimidin-4-yl]benzonitrile
-
-
4-[[(2R,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]pyrrolidin-2-yl]methoxy]-3-(1-methylethyl)benzoic acid
-
-
4-[[2-(3-aminopiperidin-1-yl)-3-but-2-yn-1-yl-4-oxo-3,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl]methyl]naphthalene-1-carbonitrile
-
-
5,6-dichloro-2-[[(3S,5S)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]carbonyl]isoindoline
-
-
5-(3-aminopiperidin-1-yl)-4-but-2-yn-1-yl-N-(naphthalen-1-ylmethyl)-4H-1,2,4-triazole-3-carboxamide
-
-
5-(3-aminopiperidin-1-yl)-4-but-2-yn-1-yl-N-[(3-methylisoquinolin-1-yl)methyl]-4H-1,2,4-triazole-3-carboxamide
-
-
5-(aminomethyl)-6-(1,3-benzodioxol-5-yl)-2-phenylpyrimidin-4-amine
-
-
5-(aminomethyl)-6-(2,4-dichlorophenyl)-2-(3,5-dimethoxyphenyl)pyrimidin-4-amine
-
-
5-(aminomethyl)-6-(2,4-dichlorophenyl)-2-phenylpyrimidin-4-amine
-
-
5-(aminomethyl)-6-(2,4-dichlorophenyl)-N2-(2-methoxyethyl)-N2-methylpyrimidine-2,4-diamine
-
-
5-(aminomethyl)-6-(4-chlorophenyl)-2-phenylpyrimidin-4-amine
-
-
5-([2-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-2-oxoethyl]amino)tricyclo[3.3.1.13,7]decane-1,3-diol
-
-
5-chloro-2-[[(3S,5S)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]carbonyl]isoindoline
-
-
5-fluoro-2-[[(3S,5S)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]carbonyl]isoindoline
-
-
5-methyl-2-[[(3S,5S)-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]carbonyl]isoindoline
-
-
5-tert-butyl-3-[N-(2-hydroxy-1,1-dimethylethyl)glycyl-(4S)-4-fluoro-L-prolyl]-1,2,4-oxadiazole
-
-
5-tert-butyl-3-[N-(2-hydroxy-1,1-dimethylethyl)glycyl-L-prolyl]-1,2,4-oxadiazole
-
-
5-tert-butyl-3-[N-tert-butylglycyl-(4S)-4-fluoro-L-prolyl]-1,2,4-oxadiazole
-
-
5-[1-amino-2-(3-azabicyclo[3.1.0]hex-3-yl)-2-oxoethyl]tricyclo[3.3.1.13,7]decane-1,3-diol
-
-
5-[1-amino-2-[(1S,5R)-2-azabicyclo[3.1.0]hex-2-yl]-2-oxoethyl]tricyclo[3.3.1.13,7]decane-1,3-diol
-
-
6-(aminomethyl)-5-(2,4-dichlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
-
-
6-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methoxy)pyridine-3-carbonitrile
-
-
6-([(3S,5S)-5-([(2S)-2-cyanopyrrolidin-1-yl]carbonyl)pyrrolidin-3-yl]amino)pyridine-3-carbonitrile
-
IC50: 0.25 nmol/L
6-([2-((2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl)amino)ethyl]amino)pyridine-3-carbonitrile
-
IC50: 1.4 nmol/L
6-[(2-([2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]amino)ethyl)amino]pyridine-3-carbonitrile
-
IC50: 270 nmol/L
6-[([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)(methyl)amino]pyridine-3-carbonitrile
-
-
6-[([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)amino]pyridine-3-carbonitrile
-
-
6-[4-[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]piperazin-1-yl]nicotinonitrile
-
-
6-[[2-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)ethyl]amino]nicotinonitrile
-
-
6-[[2-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)ethyl]amino]nicotinamide
-
-
6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile
-
i.e. KR-62436, IC50: 0.00014 mM, selective competitive inhibitor, good lead compound for further development as a new anti-diabetic agent, almost completely inhibits DPP-IV mediated degradation of glucagon-like peptide-1
6-{[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)ethyl]amino}pyridine-3-carbonitrile
-
-
7-benzyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-1H-purine-2,6-dione
-
-
7-but-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one
-
a competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity
7-but-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one trifluoroacetate
-
-
7-[(2E)-but-2-en-1-yl]-8-(3,3-dimethylpiperazin-1-yl)-3-methyl-1-(2-oxo-2-phenylethyl)-3,7-dihydro-1H-purine-2,6-dione
-
-
7-[(3R,4R)-3-amino-4-(2,4,5-trifluorophenyl)piperidin-1-yl]-2H-pyrimido[1,2-b]pyridazin-2-one
-
-
7-[(3R,4R)-3-amino-4-(2-methoxyphenyl)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
-
-
7-[(3R,4S)-3-amino-4-(2-methoxyphenyl)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
-
-
7-[(3R,4S)-3-amino-4-(3,4-dichlorophenyl)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
-
-
7-[(3R,4S)-3-amino-4-(4-fluorophenyl)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
-
-
7-[(3R,4S)-3-amino-4-phenylpyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
-
-
8-(3-aminopiperidin-1-yl)-7-but-2-yn-1-yl-3-methyl-1-(naphthalen-1-ylmethyl)-3,7-dihydro-1H-purine-2,6-dione
-
-
8-(3-aminopiperidin-1-yl)-7-but-2-yn-1-yl-3-methyl-1-[(3-methylisoquinolin-1-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3R)-3-aminopiperidin-1-yl]-3-methyl-7-(3-methylbut-2-en-1-yl)-1-(2-oxo-2-phenylethyl)-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
-
linagliptin
Ala-Ala-Leu-Glu-Gln-Thr-Glu-Arg
-
inhibitory peptide from hydrolysate of Hypophthalmichthys molitrix muscle
alpha-amino boronic acid analogues of pyrrolidides
-
-
-
alpha-amino boronic acid analogues of thiazolidides
-
-
-
ASP-8497
-
(2S,4S)-4-fluoro-1-([[4-methyl-1-(methylsulfonyl)piperidin-4-yl]amino]acetyl)pyrrolidine-2-carbonitrile monofumarate, selective and competitive inhibitor of DPP-IV, ASP8497 is a DPP-IV inhibitor with long-acting antidiabetic effect that might be a potential agent for type 2 diabetes
benzyl 6-([5-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-(4S)-4-amino-5-oxopentanoyl]amino)hexanoate
-
-
benzyl [(5S)-5-amino-6-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-6-oxohexyl]carbamate
-
-
benzyloxycarbonyl-Pro-prolinal
-
-
bis(4-acetamidophenyl) 1-((S)-prolyl)pyrrolidine-2(R,S)-phosphonate
-
i.e. AB192
bis(4-acetamidophenyl) 1-(S)-prolylpyrrolidine-2(R,S)-phosphonate
-
AB-192, irreversible inhibitor
bis(4-[(ethoxycarbonyl)-methylaminocarbonyl]-phenyl) 1-((S)-prolyl)pyrrolidine-2-(R,S)-phosphonate
-
i.e. AB207
bis-(4-nitrophenylphosphate)
-
-
Bl-1356
-
ondero or linagliptin, competitive, reversible, and long-lasting inhibition
BMS-477118
-
saxagliptin, the proprietary name is Onglyza, covalently bound and reversible inhibitor
cyclohexylglycine thiazolidide
-
-
des-fluoro-sitagliptin
-
sitagliptin analogue, reversible inhibition
diaryl phosphonates
-
-
-
diisopropyl fluorophosphate
-
-
dipeptide-derived diphenyl phosphonate esters
-
mechanism-based inhibitors. Formation of a fairly weak initial complex, followed by a slow irreversible inactivation. Due to their stability and the irreversible nature of the inhibition, the diphenyl phosphonate ester promise to be useful tools in the continuing investigation of the physiological function of the dipeptidyl peptidase IV
-
DP-893
-
reversible inhibition
epsilon-(4-nitrobenzyloxycarbonyl)-L-Lys thiazolidide
-
-
ethyl 4-[3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methylbutanoyl]piperazine-1-carboxylate
-
-
glypican-3
-
Simpson-Golabi-Behmel syndrome is an X-linked condition shown to be the result of deletions of the glypican-3 gene. Glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Inhibition of CD26 reduces the rate of cell proliferation. A number of physical findings observed in SGBS patients may be a consequence of a direct interaction of GPC3 with CD26
-
GSK-823093C
-
denagliptin
H-(S)-alaninyl-(R)-boro-proline
-
-
H-(S)-Glu-(R)-boro-alanine
-
-
H-(S)-glutaminyl-(R)-boro-alanine
-
-
H-(S)-glutamyl-(R)-boro-proline
-
-
H-(S)-valinyl-(R)-boro-alanine
-
-
H-(S)-valinyl-(R)-boro-proline
-
-
H-glycyl-(R)-boro-proline
-
-
human HIV-1 Gly3-Tat(1-9) peptide
-
amino acid sequence MDGVDPNIE, parabolic mixed type inhibition
-
human HIV-1 Ile3-Tat(1-9) peptide
-
amino acid sequence MDIVDPNIE, parabolic mixed type inhibition
-
human HIV-1 Lys2-Tat(1-9) peptide
-
amino acid sequence MKPVDPNIE, linear mixed type inhibition
-
human HIV-1 Tat protein
-
viral protein, inhibits the enzyme activity and cell proliferation
-
human HIV-1 Tat(1-9) peptide
-
amino acid sequence MDPVDPNIE, N-terminal peptide of the viral Tat protein, inhibits the enzyme activity and cell proliferation, parabolic mixed type inhibition
-
human HIV-1 Trp1-Tat(1-9) peptide
-
amino acid sequence WDPVDPNIE, parabolic mixed type inhibition
-
human HIV-1 Trp2-Tat(1-9) peptide
-
amino acid sequence MWPVDPNIE, linear mixed type inhibition
-
Ile cyanothiazolidide
-
-
Ile-pyrrolidide
-
competitive
interleukin-2 peptide Met-IL-2(1-12)
-
amino acid sequence MAPTSSSTKKTQL, linear mixed type inhibition
-
interleukin-2 peptide Met-TRp1-IL-2(1-8)
-
amino acid sequence MWPTSSSTK, competitive inhibition
-
isoleucine thiazolidide
-
-
isoleucyl-(2)-cyanopyrrolidine
-
-
isoleucyl-thiazolidine
-
-
K-579
-
reversibile and long-lasting inhibition
L-isoleucinepyrrolidine
-
IC50: 0.022 mM
LAF-237
-
vildagliptin, potent, selective DPP IV inhibitor, the proprietary name is Galvus, covalently bound and reversible inhibitor
LC-150444
-
reversible inhibition
LC15-0444
-
selective and competitive inhibitor of dipeptidyl peptidase IV, more than 80% inhibition of DPP IV activity from baseline is sustained for more than 24 h in all dose groups (200, 400 or 600 mg of LC15-0444 once daily for 10 days)
LY-2463665
-
reversible inhibition
Lys-Ala-Val-Gly-Glu-Pro-Pro-Leu-Phe
-
inhibitory peptide from hydrolysate of Hypophthalmichthys molitrix muscle, exhibits the dual inhibition against both DPP-IV and angiotensin-converting enzyme
Lys[benzyloxycarbonyl(NO2)]-thiazolidide
-
-
Lys[Z(NO2)]-thiazolidide
-
the dipeptidyl peptidase IV inhibitor suppresses proliferation, enhances terminal differentiation and slightly decreases total neutral lipid production in sebocytes
Met-Trp-Pro
-
competitive inhibition
Met-Trp-Val
-
linear-mixed type inhibition
Met-Trp1-G-CSF(1-8) peptide
-
amino acid sequence MWPLGPASS, G-CSF is the granulocyte colony stimulating factor, linear mixed type inhibition
MK-0431
-
sitagliptin, potent, selective DPP IV inhibitor, the proprietary name is Januvia, reversible and long-lasting inhibition
N,N-diallyl-3-(bicyclo[3.2.0]hept-6-ylsulfonyl)-1H-1,2,4-triazole-1-carboxamide
-
-
N-(4-nitrobenzyloxycarbonyl)-L-Ile thiazolidide
-
-
N-(H-Phe-Pro-)-O-(4-nitrobenzoyl)hydroxylamine hydrochloride
-
irreversible
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-1,1,1-trifluoro-N-methylmethanesulfonamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-1,1,1-trifluoromethanesulfonamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-1-(trifluoromethyl)cyclopropanecarboxamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-2,2,2-trifluoroethanesulfonamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-2,2-difluoro-N-methylpropanamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-2,2-difluorocyclopropanecarboxamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-2,2-difluoropropanamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-2,2-dimethylpropanamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-2-fluoro-2-methylpropanamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-3,3,3-trifluoropropanamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-N,2,2-trimethylpropanamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-N-cyclopropyl-1,1,1-trifluoromethanesulfonamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)-N-methylcyclopropanecarboxamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)cyclobutanecarboxamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)cyclohexanecarboxamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)cyclohexanesulfonamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)cyclopentanecarboxamide
-
-
N-([(2S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]pyrrolidin-2-yl]methyl)methanesulfonamide
-
-
N-([(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl]methyl)-3-[(4-methyl-1,3-thiazol-2-yl)sulfamoyl]benzamide
-
-
N-acetyl-(S)-valinyl-(R)-boro-proline
-
-
N-Ala-Pro-O-(4-nitrobenzoyl)hydroxylamine
-
-
N-terminal nonapeptide of HIV-1 Tat protein
-
wild-type is a strong inhibitor, mutant exchange variants Ile5 and Leu6 show highly reduced inhibitory activity, replacement of Asp2 with Gly or Lys lead to enhanced inhibitory potency compared to the wild-type peptide, study of structure-function relationship
-
N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]-3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methylbutanamide
-
-
N-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butyl]-6-(trifluoromethyl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide
-
good enzyme inhibitory activity and excellent selectivity for isoform DPP4 over dipeptidyl peptidase family homologues DPP8 and DPP9. Compound shows efficacy similar to that of sitagliptin in the oral glucose tolerance test
N-[2-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-2-methylpropyl]-1-methylcyclohexanecarboxamide
-
-
N-[2-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-2-methylpropyl]-2,2-dimethylpropanamide
-
-
N-[2-[(2R)-2-(dihydroxyboranyl)pyrrolidin-1-yl]-2-oxoethyl]-N-methyl-5-oxoprolinamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-1H-1,2,3-benzotriazole-5-carboxamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-1H-benzimidazole-5-carboxamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2,3-dihydro-1-benzofuran-5-carboxamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-N-(4-cyanobenzyl)benzamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-N-isobutylbenzamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-N-methylbenzenesulfonamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]benzamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]benzenesulfonamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[2-[[2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]thiophene-2-carboxamide
-
-
N-[3-[(2-[4-[(2S)-2-amino-3-phenylpropyl]-3-benzylpiperazin-1-yl]ethyl)amino]phenyl]methanesulfonamide
-
-
N-[[(3S,5S)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-yl]methyl]-1,3-thiazole-4-carboxamide
-
-
nateglinide
-
prevents the degradation of glucagon-like peptide-1 in a time and concentration-dependent manner
Nepsilon-nitrobenzyloxycarbonyl-Lys-Pro
-
competitive
Nepsilon-nitrobenzyloxycarbonyl-Lys-pyrrolidide
-
competitive
Nepsilon-nitrobenzyloxycarbonyl-Lys-thiazolidide
-
competitive
Ngamma-(2,2,5,7,8-pentamethylchroman-6-sulfonyl)-L-Arg-cyanopyrrolidine
-
-
P-[(3S)-3-amino-2-oxopyrrolidin-1-yl]phosphonic diamide
-
-
P32/P98
-
isoleucine thiazolidide DPPIV, reversible inhibition
peptides
-
diacylhydroxylamine derivatives of Xaa-Pro or Xaa-Ala peptides. Different oligopeptides with N-terminal Xaa-Pro-sequences
PF-00734200
-
potent, competitive DPP-IV inhibitor, complete inhibition of DPP-IV for over 24 h after treatment with one single dose of 300 mg PF-00734200
Phe-Pro-PSI[P(OEt)2]
-
diastereomeric mixture, competitive
phenylmethylsulfonyl fluoride
-
-
PHX-1149
-
dutogliptin tartrate, reversible inhibition
Pro-Pro-[OPh-4 Cl]2
-
irreversible
pyrrolidine-carbonitrile derivatives
-
-
-
R-1438
-
aminomethylpyridine derivate
R-1579
-
carmegliptin, reversible inhibition
SYR-322
-
2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile monobenzoate, also called alogliptin or TAK-322, reversible inhibition
threo-Ile thiazolidide
-
-
thromboxane A2 receptor peptide TXA2-R(1-9)
-
N-terminal MWP sequence motif MWPNGSSLG, potent competitive inhibitor, possibly functionally involved in antigen presentation by inhibiting T-cell expressed enzyme
-
Trp-Pro
-
linear mixed-type
Trp-pyrrolidide
-
competitive
Trp-thiazolidide
-
competitive
Trp2,Ile3-Tat(1-9) peptide
-
amino acid sequence MWIVDPNIE, competitive inhibition
-
[(2R)-1-(4-oxo-4-phenylbutanoyl)pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-(N-acetyl-N-methylglycyl)pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-(N-acetylglycyl)pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[(1-oxo-1,3-dihydro-2H-isoindol-2-yl)acetyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[(2-oxopyridin-1(2H)-yl)acetyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-(2,2-dimethylpropanoyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-(2-methylpropanoyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-(cyclohexylcarbonyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-(cyclopentylcarbonyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-(methylsulfonyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-(phenylcarbonyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-methyl-N-(2-methylpropanoyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-methyl-N-(phenylcarbonyl)glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R)-1-[N-[(2,5-dichlorophenyl)carbonyl]glycyl]pyrrolidin-2-yl]boronic acid
-
-
[(2R,4R)-1-(L-arginyl)-4-hydroxypyrrolidin-2-yl]boronic acid
-
most potent inhibitor tested
[(2S)-1-([[2-(4-fluorophenyl)-1,1-dimethylethyl]amino]acetyl)pyrrolidin-2-yl](1,2,4-oxadiazol-3-yl)methanone
-
-
[(2S)-1-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]pyrrolidin-2-yl]methanol
-
-
[(2S)-1-[(3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-4-oxobutanoyl]pyrrolidin-2-yl]methanol
-
-
[(2S)-1-[(tert-butylamino)acetyl]pyrrolidin-2-yl][5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]methanone
-
-
[(2S)-1-[[(2-hydroxy-1,1-dimethylethyl)amino]acetyl]pyrrolidin-2-yl](5-methyl-1,2,4-oxadiazol-3-yl)methanone
-
-
[(2S)-1-[[(2-hydroxy-1,1-dimethylethyl)amino]acetyl]pyrrolidin-2-yl](5-methyl-1,3,4-oxadiazol-2-yl)methanone
-
-
[(3R)-4-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-3-methyl-2-oxo-1,4-diazepan-1-yl]acetic acid
-
-
[(3R,5S)-5-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]pyrrolidin-3-yl]acetic acid
-
-
[(R)-amino[(3S)-3-amino-2-oxoazepan-1-yl]phosphoryl]sulfamic acid
-
-
[(R)-amino[(3S)-3-amino-2-oxopiperidin-1-yl]phosphoryl]sulfamic acid
-
-
sitagliptin
-
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
-
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
-
sitagliptin
(3R,4R)-1-(2-oxo-2H-pyrimido[1,2-b]pyridazin-7-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
-
(3R,4R)-1-(2-oxo-2H-pyrimido[1,2-b]pyridazin-7-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-aminium
-
pharmacokinetic properties
2-([2-[(3R)-3-aminopiperidin-1-yl]-6-fluoro-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
-
-
2-([2-[(3R)-3-aminopiperidin-1-yl]-6-fluoro-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
-
Syrrx106124
alogliptin
-
-
alogliptin
-
competitive and reversible inhibitor
alogliptin
-
highly selective dipeptidyl peptidase-4 inhibitor, at single doses up to 800 mg alogliptin the mean peak DPP-4 inhibition ranges from 93% to 99% and mean inhibition at 24 hours after dosing ranges from 74% to 97%
alogliptin
-
nanomolar inhibitor of DPP-4, i.e. 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile monobenzoate, exhibits 10000fold selectivity for DPP-4 over the closely related serine proteases DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidase, and tryptase
alogliptin
-
synonyms are alogliptin benzoate, SYR-085, SYR-322, SYR-619, SYR-11792, SYR-110085A, SYR-111791, or TAK-322, highly potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes, non-covalent inhibitor of DPP-IV with selectivity of more than 10000fold over other proteases including tryptase, DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase and prolyl endopeptidase
ASP8497
-
-
ASP8497
-
potent, selective, and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity, i.e. (2S,4S)-4-fluoro-1-([[4-methyl-1-(methylsulfonyl)piperidin-4-yl]amino]acetyl)pyrrolidine-2-carbonitrile monofumarate
BI 1356
-
-
BI 1356
-
competitive inhibitor, i.e. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, proposed trade name Ondero, BI 1356 is more than 10000fold selective for DPP-4 than DPP-8, DPP-9, aminopeptidases N and P, prolyloligopeptidase, trypsin, plasmin, and thrombin and is 90-fold more selective than for fibroblast activation protein in vitro
BI 1356
-
proposed trade name ONDERO, exhibits a prominent concentration-dependent plasma protein binding due to a saturable high affinity binding to the DPP-4 target in plasma
BI 1356
-
proposed trade name ONDERO, highly potent and selective DPP-4 inhibitor
Cd2+
-
-
Diprotin A
-
-
Diprotin A
-
specific inhibitor of DPPIV enzyme activity, almost complete inhibition at 0.1 mM
Hg2+
-
-
Ile-thiazolidide
-
-
Ile-thiazolidide
-
competitive
linagliptin
-
-
linagliptin
-
Bl-1356, the proprietary name is Ondero
Lys[Z(NO2)]-pyrrolidide
-
-
Lys[Z(NO2)]-pyrrolidide
-
simultaneous application of DP IV and aminopeptidase N inhibitors significantly suppresses DNA synthesis in mitogen- or anti-CD3-stimulated human T cells in vitro when compared to the use of a single DP IV or aminopeptidase N inhibitor. The combined action of DP IV and aminopeptidase N inhibitors markedly increases TGF-beta1 production associated with the observed immunosuppressive effects. In vivo, targeting both DP IV and aminopeptidase N leads to a potent treatment of experimental autoimmune encephalomyelitis an animal model of multiple sclerosis
Lys[Z(NO2)]-pyrrolidide
-
the dipeptidyl peptidase IV inhibitor suppresses proliferation, enhances terminal differentiation and slightly decreases total neutral lipid production in sebocytes
NVP DPP728
-
-
NVP DPP728
-
slow-binding inhibitor
NVP-DPP728
-
-
NVP-DPP728
-
potent and selective DPP-4 inhibitor
PHX1149
-
pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor, double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects
PHX1149
-
selective DPP4 inhibitor, DPP4 inhibition on day 28 is 53%, 73% and 78% at 24 h after treatment with 100, 200 and 400 mg PHX1149, respectively
PSN-9301
-
-
PSN-9301
-
P93/01, reversible inhibition, short acting
saxagliptin
-
-
678693, 678967, 679397, 679409, 679411, 679973, 680224, 680339, 696134, 697519, 699748, 701371, 702583, 702611
saxagliptin
-
the oral dipeptidyl peptidase 4 inhibitor is efficious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose, the inhibitor has low risk of hypoglycemia and does not affect body weight
saxagliptin
-
BMS-477118, competitive and reversible inhibitor
saxagliptin
-
highly potent and selective inhibitor of DPP-IV
saxagliptin
-
highly selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes, synonyms are BMS-477118, Onglyza, and saxagliptin hydrate, saxagliptin is 400fold and 75fold more potent against DPP-IV than DPP-8 or DPP-9 respectively, DPP-IV is inhibited dose-dependently, with maximal inhibition at 150 mg/day
saxagliptin
-
the proprietary name is Onglyza
sitagliptin
-
-
677582, 677897, 678967, 679364, 679368, 679395, 679397, 679409, 679444, 679447, 679479, 679480, 679973, 680224, 680339, 680385, 681066, 681082, 682262, 682263, 696134, 697519, 698213, 699748, 702583, 702611
sitagliptin
-
addition of sitagliptin 50 mg b.i.d. to ongoing metformin therapy improves 24-h glycaemic control and beta-cell function, and is generally well tolerated in patients with type 2 diabetes
sitagliptin
-
dipeptidyl peptidase-4 inhibitor approved in the United States for the treatment of type 2 diabetes. The absolute bioavailability of sitagliptin final market image tablets is approximately 87%. Sitagliptin is Food does not affect the pharmacokinetics of sitagliptin and therefore can be administered without regard to food generally well tolerated when administered orally or intravenously
sitagliptin
-
does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects
sitagliptin
-
highly effective antihyperglycaemic agent that augments insulin secretion and reduces glucagon secretion via glucose-dependent mechanism
sitagliptin
-
highly selective DPP-4 inhibitor for the treatment of type 2 diabetes
sitagliptin
-
highly selective orally active dipeptidyl peptidase-4 inhibitor recently approved in the United States for the treatment of type 2 diabetes. Plasma AUC0_1 (area under the plasma concentration-time curve) increases in a dose-proportional manner over the 25-400 mg dose range
sitagliptin
-
in a 24-week study, once-daily sitagliptin monotherapy improves glycemic control in the fasting and postprandial states, improves measures of beta-cell function, and is well tolerated in patients with type 2 diabetes
sitagliptin
-
in a 24-week study, sitagliptin 100 mg once daily added to ongoing pioglitazone therapy is effective and well tolerated in these patients with type 2 diabetes who had not achieved adequate glycemic control with pioglitazone alone
sitagliptin
-
inhibitor for the treatment of type 2 diabetes, is excreted into the urine via active tubular secretion and glomerular filtration in humans. Sitagliptin is transported by human organic anion transporter hOAT3, organic anion transporting polypeptide OATP4C1, and multidrug resistance (MDR) P-glycoprotein, but not by human organic cation transporter 2 hOCT2, hOAT1, oligopeptide transporter hPEPT1, OATP2B1, and the multidrug resistance proteins MRP2 and MRP4
sitagliptin
-
potent and highly specific inhibitor of DPP-4
sitagliptin
-
potent, competitive, reversible inhibitor
sitagliptin
-
primary route of excretion of is via the kidneys, with a mean value of 87% of the administered dose recovered in urin. Because sitagliptin is eliminated primarily unchanged into urine, it is not expected to be a victim of metabolismbased drug interactions
sitagliptin
-
sitagliptin is a selective DPP-4 inhibitor that enhances intact incretin levels and improves 24-h glycemic control in patients with type 2 diabetes
sitagliptin
-
sitagliptin is one-daily, orally active, potent and selective DPP-4 inhibitor, which reduces both fasting and postprandial glucose levels and improves summary measures of beta-cell function to produce clinically meaningful reductions in HbA1c concentrations. Efficiacy as both a monotherapy and in combination with merformin or pioglitazone, without causing weight gain
sitagliptin
-
sitagliptin significantly improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus who have inadequate glycaemic control on exercise and diet
sitagliptin
-
the addition of sitagliptin compared with glipizide provides similar HbA1c-lowering efficacy over 52 weeks in patients with type 2 diabetes on ongoing metformin therapy. Sitagliptin is generally well tolerated, with a lower risk of hypoglycaemia relative to glipizide and with weight loss compared with weight gain with glipizide
sitagliptin
-
the oral dipeptidyl peptidase 4 inhibitor is efficious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose, the inhibitor has low risk of hypoglycemia and does not affect body weight
sitagliptin
-
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
sitagliptin
-
MK-0431 or Januvia, competitive and reversible inhibitor
sitagliptin
-
MK-0431, trade name Januvia, 100 mg sitagliptin inhibits plasma DPP-4 activity for more than 16 hours after a single administration
sitagliptin
-
selective inhibitor of DPP-IV, over 80% inhibition of DPP-IV with a single oral dose of 50 mg
sitagliptin
-
the proprietary name is Januvia
sitagliptin
-
trade name Januvia
SSR-162369
-
-
SSR-162369
-
reversibile and long-lasting inhibition
vildagliptin
-
-
664625, 677582, 677897, 679364, 679369, 679395, 679397, 679409, 679411, 679437, 679447, 679973, 680224, 680339, 681080, 681083, 681084, 681573, 682262, 682263, 696134, 698213, 699748, 702583, 702611
vildagliptin
-
competitive and reversible inhibitor of DPP-4. It is highly specific for DPP-4 relative to other peptidases. Vildagliptin is rapidly and almost completely absorbed following oral administration and inhibits plasma DPP-4 activity by 90% within 30-60 min. DPP-4 activity remains significantly inhibited for more than 12 h following a single dose
vildagliptin
-
highly effective antihyperglycaemic agent that augments insulin secretion and reduces glucagon secretion via glucose-dependent mechanism
vildagliptin
-
in pre-diabetic subjects, a 12-week treatment with vildagliptin markedly increases postmeal levels of active glucagon-like peptide 1 and gastric inhibitory polypeptide, improves both alpha- and beta-cell function, decreases postprandial hyperhlycemia and decreases A1C levels. Vildagliptin is well tolerated and weight neutral and does not cause hypoglycemia
vildagliptin
-
pharmacokinetic studies in patients with type 2 diabetes
vildagliptin
-
suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
vildagliptin
-
the oral dipeptidyl peptidase 4 inhibitor is efficious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose, the inhibitor has low risk of hypoglycemia and does not affect body weight
vildagliptin
-
there is no significant difference in exposure to vildagliptin in patients with mild, moderate or severe hepatic impairment
vildagliptin
-
twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
vildagliptin
-
highly potent and stable selective inhibitor of DPP-IV, over 90% inhibition of DPP-IV with a single oral dose of 100 mg
vildagliptin
-
i.e. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine
vildagliptin
-
LAF237 or Galvus, competitive and reversible inhibitor
vildagliptin
-
LAF237, 1-[[3-hydroxy-1-adamantyl]amino]acetyl-2-cyano-(S)-pyrrolidine
vildagliptin
-
LAF237, trade name Galvus, 100 mg vildagliptin inhibits plasma DPP-4 activity for more than 16 hours after a single administration
vildagliptin
-
more than 90% inhibition within 30 min of administration of vildagliptin and glyburide, while glyburide alone has no effect on DPP-4 activity
vildagliptin
-
NVP-LAF237
vildagliptin
-
potent, selective DPP-4 inhibitor
vildagliptin
-
the proprietary name is Galvus
vildagliptin
-
trade name Galvus
vildagliptin
-
specific inhibitor of DPPIV
Zn2+
-
-
additional information
alpha/beta-hydrolase domain and beta-propeller domain both participate in inhibitor binding
-
additional information
-
alpha/beta-hydrolase domain and beta-propeller domain both participate in inhibitor binding
-
additional information
3D-QSAR analysis of several DPP-IV inhibitors, which are aligned by the receptor-based technique
-
additional information
3D-QSAR studies on fluoropyrrolidine amide dipeptidyl peptidase IV inhibitors by comparative molecular field analysis and comparative molecular similarity analysis
-
additional information
in order to obtain information regarding the design of selective DPP4 inhibitors, a 3D-QSAR study is conducted using DPP4, which were evaluated in vitro for their inhibition of DPP4. A highly predictive CoMFA model based on the fast-docking for DPP4 inhibitors is obtained
-
additional information
interactions important for binding are the pi-pi stacking interaction of the pyridopyrimidine-dione ring with Tyr547, its H-bond interaction to the backbone NH of Tyr631 and the OH of Ser630, and polar interactions between the basic amine and Glu205, Glu206 and Tyr662, high selectivity for dipeptidyl peptidase IV over dipeptidyleptidase DPP8
-
additional information
development of a multiple linear regressions model for predicting the IC50 of a theoretical molecule. Best model is the penta-parametric with the descriptors molecular weight, molecular volume, molecular density, superficial area and polarizability
-
additional information
-
development of a multiple linear regressions model for predicting the IC50 of a theoretical molecule. Best model is the penta-parametric with the descriptors molecular weight, molecular volume, molecular density, superficial area and polarizability
-
additional information
-
therapeutical perspectives for dipeptidyl peptidase IV inhibitors
-
additional information
-
conformational flexibility of tyr548 is unique among protein family members and may be utilized in drug design to achieve peptidase selectivity
-
additional information
-
4beta-[4-(hydroxyphenyl)prolyl]prolinenitriles show a potent inhibitory activity with a long duration of action. Metabolic formation of the corresponding phenol glucuronates is found to contribute to their long duration of action
-
additional information
-
a three-dimensional pharmacophore model is a useful tool for designing novel DPP-IV inhibitors
-
additional information
-
beta-amino amides containing triazolopiperazine heterocycles are potent, selective, orally active dipeptidyl peptidase IV inhibitors. These compounds display excellent oral bioavailability and good overall pharmacokinetic profiles in preclinical species
-
additional information
-
DPP-IV inhibitors suppress the degradation of a variety of bioactive peptides, including GLP-1
-
additional information
-
substituted 3-aminopiperidines are evaluated as DPP-4 inhibitors. The inhibitors show good DPP-4 potency with superb selectivity over other peptidases (QPP, DPP8, and DPP9)
-
additional information
-
when assayed against L-Ala-L-Pro-p-nitroanilide or Gly-L-Pro-p-nitroanilide, the activity of DPP9 is not affected by the presence of reducing agents, such as 1 mM dithiothreitol or 18 mM beta-mercaptoethanol
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Spontaneous
Human miscarriage is associated with increased number of CD26 decidual lymphocytes.
Abscess
Histopathological studies on virulence of dipeptidyl aminopeptidase IV (DPPIV) of Porphyromonas gingivalis in a mouse abscess model: use of a DPPIV-deficient mutant.
Abscess
Importance of biofilm formation and dipeptidyl peptidase IV for the pathogenicity of clinical Porphyromonas gingivalis isolates.
Acne Vulgaris
Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation.
Acne Vulgaris
Possible role of DP IV inhibitors in acne therapy.
Acne Vulgaris
The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases.
Acquired Immunodeficiency Syndrome
Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.
Acquired Immunodeficiency Syndrome
Dipeptidyl peptidases of human lymphocytes.
Acquired Immunodeficiency Syndrome
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Acquired Immunodeficiency Syndrome
Stability enhancement of drug layered pellets in a fixed dose combination tablet.
Acquired Immunodeficiency Syndrome
The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding.
Acromegaly
Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
Acromegaly
Cardivascular Risk Profile in Patients with Diabetes and Acromegaly or Cushing's Disease - Analysis from the DPV Database.
Acute Coronary Syndrome
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes.
Acute Coronary Syndrome
Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.
Acute Coronary Syndrome
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
Acute Coronary Syndrome
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Acute Coronary Syndrome
CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
Acute Coronary Syndrome
Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.
Acute Coronary Syndrome
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
Acute Coronary Syndrome
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Acute Coronary Syndrome
Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Acute Coronary Syndrome
The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study.
Acute Kidney Injury
Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study.
Acute Kidney Injury
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
Acute Kidney Injury
Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.
Acute Kidney Injury
Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration.
Acute Kidney Injury
Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
Acute Kidney Injury
Odds of Acute Kidney Injury in Patients Receiving Dipeptidyl Peptidase 4 Inhibitors: A National Cohort Study Within the Department of Veterans Affairs.
Acute Lung Injury
Dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin alleviates lipopolysaccharide-induced acute lung injury via regulating the Nrf-2/HO-1 and NF-
?
B pathways.
Acute Lung Injury
Vildagliptin-induced acute lung injury: a case report.
Adenocarcinoma
Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas.
Adenocarcinoma
Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma.
Adenocarcinoma
Comparison of the effect of different short chain fatty acids on the growth and differentiation of human colonic carcinoma cell lines in vitro.
Adenocarcinoma
Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV.
Adenocarcinoma
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines.
Adenocarcinoma
Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade.
Adenocarcinoma
Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.
Adenocarcinoma
Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade.
Adenocarcinoma
Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
Adenocarcinoma
Immunohistochemical localization of adenosine deaminase complexing protein in intestinal mucosa and in colorectal adenocarcinoma as a marker for tumour cell heterogeneity.
Adenocarcinoma
Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma.
Adenocarcinoma
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Adenocarcinoma
Stromal cell-derived factor-1alpha-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma.
Adenocarcinoma, Follicular
Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines.
Adenocarcinoma, Follicular
Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma.
Adenocarcinoma, Papillary
Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
Adenoma
Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma.
Adenoma
Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours.
Adenoma
Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.
Adenoma
Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.
Adenoma
Neoplasia and hyperplasia of large bowel: focal lesions in an abnormal epithelium.
Adenoma
Staining for dipeptidyl aminopeptidase IV activity in nodular thyroid diseases.
Adenoma
Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.
Adenoma
[Tumor markers in the cytodiagnosis of thyroid nodules. Detection of dipeptidyl aminopeptidase IV (DAP IV) activity]
Adenoma, Oxyphilic
Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer.
Albuminuria
A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice.
Albuminuria
A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.
Albuminuria
Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4.
Albuminuria
Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study.
Albuminuria
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Albuminuria
Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study.
Albuminuria
Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes.
Albuminuria
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D trial.
Albuminuria
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1? in type 2 diabetic patients with incipient nephropathy.
Albuminuria
DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Albuminuria
Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Albuminuria
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Albuminuria
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product - receptor for advanced glycation end product axis, and albuminuria in Japanese type 2 diabetes.
Albuminuria
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.
Albuminuria
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Albuminuria
Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
Albuminuria
Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Albuminuria
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
Albuminuria
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Albuminuria
Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.
Albuminuria
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Albuminuria
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
Albuminuria
Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
Albuminuria
Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.
Albuminuria
Saxagliptin Attenuates Albuminuria by Inhibiting Podocyte Epithelial- to-Mesenchymal Transition via SDF-1? in Diabetic Nephropathy.
Albuminuria
Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications.
Albuminuria
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Albuminuria
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Albuminuria
The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Alopecia
Linagliptin-Associated Alopecia and Bullous Pemphigoid.
Alopecia Areata
Linagliptin-Associated Alopecia and Bullous Pemphigoid.
Alopecia Areata
[Alopecia areata universalis under treatment with sitagliptin : Possible immunological effect of dipeptidyl peptidase-4 inhibitors?]
alpha-Mannosidosis
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Alzheimer Disease
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Alzheimer Disease
Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-4 inhibitor.
Alzheimer Disease
Dipeptidyl peptidase 4 contributes to Alzheimer's disease-like defects in a mouse model and is increased in sporadic Alzheimer's disease brains.
Alzheimer Disease
Dipeptidyl peptidase IV, which probably plays important roles in Alzheimer disease (AD) pathology, is upregulated in AD brain neurons and associates with amyloid plaques.
Alzheimer Disease
Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease.
Alzheimer Disease
DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease.
Alzheimer Disease
Emerging links between type 2 diabetes and Alzheimer's disease.
Alzheimer Disease
GLP-1's role in neuroprotection: a systematic review.
Alzheimer Disease
Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Linagliptin, a DPP-4 inhibitor, ameliorates A? (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease.
Alzheimer Disease
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.
Alzheimer Disease
Repurposing GLP1 agonists for neurodegenerative diseases.
Alzheimer Disease
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus.
Alzheimer Disease
Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease.
Alzheimer Disease
Saxagliptin: a novel antiparkinsonian approach.
Alzheimer Disease
The Association Between Circulating Klotho and Dipeptidyl Peptidase-4 Activity and Inflammatory Cytokines in Elderly Patients With Alzheimer Disease.
Alzheimer Disease
The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease.
Alzheimer Disease
The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability.
Amnesia
The prolyl oligopeptidase family.
Anemia
Metformin and the risk of anemia of advanced chronic kidney disease in patients with Type 2 Diabetes mellitus.
Aneurysm
Diabetes Mellitus: Is It Protective against Aneurysm? A Narrative Review.
Aneurysm
Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
Aneurysm
Dipeptidyl peptidase-4 is increased in the abdominal aortic aneurysm vessel wall and is associated with aneurysm disease processes.
Aneurysm
Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats.
Angioedema
Angioedema induced by cardiovascular drugs: new players join old friends.
Angioedema
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.
Angioedema
Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database.
Angioedema
Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use.
Angioedema
Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema.
Angioedema
Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients.
Angioedema
Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema.
Angioedema
Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema.
Angioedema
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.
Angioedema
Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
Angioedema
Dipeptidyl peptidase-4 inhibitor induced angioedema - an overlooked and potentially lethal adverse drug reaction?
Angioedema
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Angioedema
Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.
Angioedema
DPP-4 inhibitors and angioedema: a cause for concern?
Angioedema
DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
Angioedema
Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report.
Angioedema
Nonallergic Hypersensitivity to Nonsteroidal Antiinflammatory Drugs, Angiotensin-Converting Enzyme Inhibitors, Radiocontrast Media, Local Anesthetics, Volume Substitutes and Medications used in General Anesthesia.
Angioedema
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV.
Angioedema
The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin.
Angioedema
[Angioedema during ACE and DPP-4 inhibition]
Angioedema
[Medicaments and oral healthcare. Medicaments potentially inducing angioedema and/or urticaria].
Angioedemas, Hereditary
Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients.
Aortic Aneurysm, Abdominal
A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice.
Aortic Aneurysm, Abdominal
A potential contribution of dipeptidyl peptidase-4 by the mediation of monocyte differentiation in the development and progression of abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
Aortic Aneurysm, Abdominal
Dipeptidyl peptidase-4 is increased in the abdominal aortic aneurysm vessel wall and is associated with aneurysm disease processes.
Aortic Aneurysm, Abdominal
Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?
Aortic Aneurysm, Abdominal
Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats.
Aortic Aneurysm, Abdominal
Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Aortic Aneurysm, Abdominal
The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review.
Aortic Valve Stenosis
Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis.
Arrhythmias, Cardiac
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies.
Arthralgia
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.
Arthralgia
Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
Arthralgia
Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus.
Arthralgia
Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.
Arthralgia
DPP-4 INHIBITORS INCREASE THE INCIDENCE OF ARTHRITIS/ARTHRALGIA BUT DO NOT AFFECT AUTOIMMUNITY.
Arthralgia
DPP-IV Inhibitor Associated Arthralgias.
Arthralgia
DPP-IV inhibitor-associated arthralgias.
Arthralgia
The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
Arthralgia
Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.
Arthritis
GLP-1 receptor agonist-induced polyarthritis: a case report.
Arthritis
Neutral aminopeptidase and dipeptidyl peptidase IV in the development of collagen II-induced arthritis.
Arthritis
Role of the neutrophil chemorepellent soluble dipeptidyl peptidase IV in decreasing inflammation in a murine model of arthritis.
Arthritis
Sitagliptin (DPP-4 Inhibitor)-induced Rheumatoid Arthritis in Type 2 Diabetes Mellitus: A Case Report.
Arthritis
Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV.
Arthritis
[Clinical significance of serum dipeptidyl aminopeptidase IV in rats with adjuvant arthritis]
Arthritis, Experimental
[Clinical significance of serum dipeptidyl aminopeptidase IV in rats with adjuvant arthritis]
Arthritis, Rheumatoid
Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis.
Arthritis, Rheumatoid
Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis.
Arthritis, Rheumatoid
Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest.
Arthritis, Rheumatoid
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Association of CD26/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis.
Arthritis, Rheumatoid
CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases.
Arthritis, Rheumatoid
Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
Arthritis, Rheumatoid
Collagenase-like peptidase activity in serum from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Decreased serum levels of various hydrolytic enzymes in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Arthritis, Rheumatoid
Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?
Arthritis, Rheumatoid
Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis.
Arthritis, Rheumatoid
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Arthritis, Rheumatoid
Dipeptidyl peptidase-IV in synovial fluid and in synovial fluid mononuclear cells of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis.
Arthritis, Rheumatoid
DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study.
Arthritis, Rheumatoid
In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes.
Arthritis, Rheumatoid
Inhibition of fibroblast activation protein and dipeptidyl peptidase IV increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity.
Arthritis, Rheumatoid
Republished: DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis.
Arthritis, Rheumatoid
Sitagliptin (DPP-4 Inhibitor)-induced Rheumatoid Arthritis in Type 2 Diabetes Mellitus: A Case Report.
Arthritis, Rheumatoid
Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.
Arthritis, Rheumatoid
Suppression of fibroblast activity by an inhibitor of dipeptidyl peptidase IV: a possible therapeutic strategy for rheumatoid arthritis.
Arthritis, Rheumatoid
Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110.
Arthritis, Rheumatoid
Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk.
Arthritis, Rheumatoid
The Epstein-Barr virus glycoprotein gp110, a molecular link between HLA DR4, HLA DR1, and rheumatoid arthritis.
Arthritis, Rheumatoid
Up-regulated dipeptidyl-peptidase IV (CD26) on monocytes was unaffected by effective DMARD treatment in early steroid and DMARD-naive rheumatoid arthritis.
Arthritis, Rheumatoid
Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
Arthritis, Rheumatoid
Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
Arthritis, Rheumatoid
[Dipeptidyl peptidase IV activity in the serum and synovia of patients with rheumatoid arthritis]
Asthma
Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
Asthma
CD26 and Asthma: a Comprehensive Review.
Asthma
Development and analytical performance of a new ARCHITECT automated dipeptidyl peptidase-4 immunoassay.
Asthma
Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells.
Asthma
Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and time.
Asthma
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Asthma
Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma.
Asthma
More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods.
Asthma
NLRP1 variant M1184V decreases inflammasome activation in the context of DPP9 inhibition and asthma severity.
Asthma
Periostin and Dipeptidyl Peptidase-4: Potential Biomarkers of Interleukin 13 Pathway Activation in Asthma and Allergy.
Asthma
Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats.
Asthma
The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship.
Astrocytoma
Activated lymphoid cells in human gliomas: morphofunctional and cytochemical evidence.
Astrocytoma
Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-? in transformed astrocytic cells.
Astrocytoma
Dipeptidyl peptidase IV in two human glioma cell lines.
Astrocytoma
Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Atherosclerosis
A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice.
Atherosclerosis
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Atherosclerosis
A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients.
Atherosclerosis
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
Atherosclerosis
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Atherosclerosis
Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Atherosclerosis
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice.
Atherosclerosis
Atherosclerosis and angiogenesis: what do nerves have to do with it?
Atherosclerosis
Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
Atherosclerosis
Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice.
Atherosclerosis
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Atherosclerosis
Dipeptidyl peptidase IV and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study.
Atherosclerosis
Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease.
Atherosclerosis
Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
Atherosclerosis
Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Atherosclerosis
Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis--A review.
Atherosclerosis
Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis.
Atherosclerosis
Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis.
Atherosclerosis
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice.
Atherosclerosis
DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages.
Atherosclerosis
DPP-4 inhibitors and atherosclerosis: The promise.
Atherosclerosis
DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway.
Atherosclerosis
DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway.
Atherosclerosis
DPP-4 inhibitors: A potential promising therapeutic target in prevention of atherosclerosis.
Atherosclerosis
Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.
Atherosclerosis
Effect of dipeptidyl peptidase-4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A meta-analysis of randomised controlled trials.
Atherosclerosis
Effect of linagliptin on pulse wave velocity in early type 2 diabetes (RELEASE): a randomized, double-blind, controlled 26-week trial.
Atherosclerosis
Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis.
Atherosclerosis
Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A 18F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.
Atherosclerosis
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, ?-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study.
Atherosclerosis
Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139-148.
Atherosclerosis
GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.
Atherosclerosis
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.
Atherosclerosis
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes.
Atherosclerosis
Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress.
Atherosclerosis
Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study.
Atherosclerosis
Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease.
Atherosclerosis
Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway.
Atherosclerosis
Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
Atherosclerosis
Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition.
Atherosclerosis
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Atherosclerosis
Novel 8-heterocyclyl xanthine derivatives in drug development - an update.
Atherosclerosis
Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study.
Atherosclerosis
Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis.
Atherosclerosis
Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice.
Atherosclerosis
Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
Atherosclerosis
Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Atherosclerosis
Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
Atherosclerosis
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
Atherosclerosis
Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Atherosclerosis
Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
Atherosclerosis
The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms.
Atherosclerosis
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Atherosclerosis
The Effect of Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: a Systematic Review of Randomized Placebo-controlled Trials.
Atherosclerosis
The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells.
Atherosclerosis
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Atherosclerosis
The relationship between carotid intima-media thickness and serum secreted frizzled-related protein-4 and dipeptidyl peptidase-4 in diabetic patients with cardiovascular diseases.
Atherosclerosis
The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort.
Atherosclerosis
Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.
Atrial Fibrillation
Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits.
Atrial Fibrillation
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Atrial Fibrillation
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Atrial Fibrillation
Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation.
Atrial Fibrillation
Liraglutide suppresses atrial electrophysiological changes.
Atrial Fibrillation
Potential role of dipeptidyl peptidase-4 inhibitors in atrial fibrillation.
Atrial Fibrillation
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Autoimmune Diseases
CD26 expression is down-regulated on CD8
Autoimmune Diseases
Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases.
Autoimmune Diseases
Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease.
Autoimmune Diseases
Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset.
Autoimmune Diseases
Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.
Autoimmune Diseases
Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Autoimmune Diseases
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Autoimmune Diseases
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Autoimmune Diseases
Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones.
Autoimmune Diseases
Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity.
Autoimmune Diseases
Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.
Autoimmune Diseases
Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.
Autoimmune Diseases
Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.
Autoimmune Diseases
The evolution of proteinase substrates with special reference to dipeptidylpeptidase IV.
Autoimmune Diseases
The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.
Autoimmune Diseases
[Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison]
Bacterial Infections
Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV).
Biliary Atresia
Increased urinary dipeptidyl peptidase IV activity in extrahepatic biliary atresia.
Blister
Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
Bone Diseases, Metabolic
High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women.
Bone Resorption
DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
Bone Resorption
Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms.
Bone Resorption
Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus.
Bowen's Disease
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Brain Diseases
Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke.
Brain Injuries
DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
Brain Injuries
Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage.
Brain Ischemia
Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia.
Brain Ischemia
Inhibition of DPP-4 Activity and Neuronal Atrophy with Genistein Attenuates Neurological Deficits Induced by Transient Global Cerebral Ischemia and Reperfusion in Streptozotocin-Induced Diabetic Mice.
Brain Ischemia
Neuroprotective effect of vildagliptin against cerebral ischemia in rats.
Brain Neoplasms
Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors--good or evil?
Breast Neoplasms
A simple method for the isolation and detailed characterization of primary human proximal tubule cells for renal replacement therapy.
Breast Neoplasms
CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology.
Breast Neoplasms
Cross talk between COVID-19 and breast cancer.
Breast Neoplasms
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12/CXCR4/mTOR/TGF? Signaling Pathway in Breast Cancer Cells.
Breast Neoplasms
Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-?B Activation.
Breast Neoplasms
Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.
Breast Neoplasms
Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Breast Neoplasms
Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer?
Breast Neoplasms
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Breast Neoplasms
Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin.
Breast Neoplasms
Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling.
Breast Neoplasms
Risk of dipeptidyl-peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis.
Breast Neoplasms
Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors.
Breast Neoplasms
Truncated dipeptidyl peptidase IV is a potent anti-adhesion and anti-metastasis peptide for rat breast cancer cells.
Breast Neoplasms
Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk.
Bronchiectasis
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Bronchiolitis
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Bronchitis, Chronic
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Capillary Leak Syndrome
Multiple limb compartment syndrome as a manifestation of capillary leak syndrome secondary to metformin and dipeptidyl peptidase IV inhibitor overdose: A case report.
Carcinogenesis
Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway.
Carcinogenesis
CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions.
Carcinogenesis
Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.
Carcinogenesis
Dipeptidyl peptidase IV is required for endometrial carcinoma cell proliferation and tumorigenesis via the IL-6/STAT3 pathway.
Carcinogenesis
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV).
Carcinogenesis
DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis.
Carcinogenesis
Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
Carcinogenesis
Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Carcinogenesis
Risk of dipeptidyl-peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis.
Carcinogenesis
Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10-dimethyl-1,2-benzanthracene.
Carcinogenesis
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in Apc(Min/+) mice fed a high-fat diet.
Carcinogenesis
The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice.
Carcinogenesis
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, reduces betel-nut induced carcinogenesis in female mice.
Carcinogenesis
[Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma]
Carcinoid Tumor
Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor.
Carcinoid Tumor
Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
Carcinoma
A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.
Carcinoma
Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.
Carcinoma
Alteration in dipeptidyl peptidase activities in cultured human carcinoma cells.
Carcinoma
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Carcinoma
Changes in serum dipeptidyl-aminopeptidase IV (glycylprolyl dipeptidyl-aminopeptidase) activity of patients with gastric carcinoma after surgical excision and the enzyme activity in the carcinoma tissue.
Carcinoma
Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma.
Carcinoma
Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours.
Carcinoma
Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.
Carcinoma
Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.
Carcinoma
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines.
Carcinoma
Dipeptidyl peptidase IV in tumor progression.
Carcinoma
Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells.
Carcinoma
Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database.
Carcinoma
Dipeptidyl peptidases of human lymphocytes.
Carcinoma
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV).
Carcinoma
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.
Carcinoma
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Carcinoma
Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
Carcinoma
Expression of dipeptidyl aminopeptidase IV activity in thyroid tumours: a possible marker of thyroid malignancy.
Carcinoma
Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines.
Carcinoma
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Carcinoma
Gene expression in poorly differentiated papillary thyroid carcinomas.
Carcinoma
Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma.
Carcinoma
Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells.
Carcinoma
Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV.
Carcinoma
Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients.
Carcinoma
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Carcinoma
Intracellular localization and endocytosis of brush border enzymes in the enterocyte-like cell line Caco-2.
Carcinoma
Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells.
Carcinoma
Neoplasia and hyperplasia of large bowel: focal lesions in an abnormal epithelium.
Carcinoma
Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma.
Carcinoma
Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV.
Carcinoma
Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase-IV.
Carcinoma
Renal therapeutics: patent highlights January to June 2003.
Carcinoma
Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.
Carcinoma
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Carcinoma
Staining for dipeptidyl aminopeptidase IV activity in nodular thyroid diseases.
Carcinoma
Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13.
Carcinoma
Survival time and invasive activity due to dipeptidyl peptidase IV overexpression in ovarian carcinoma.
Carcinoma
The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.
Carcinoma
The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.
Carcinoma
The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity.
Carcinoma
[Changes in dipeptidyl peptidase IV activity in oral squamous cell carcinoma]
Carcinoma
[Changes in dipeptidyl peptidase IV activity in the serum of patients with uterine cervix carcinoma before and after therapy]
Carcinoma
[Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma]
Carcinoma
[Dipeptidyl peptidase IV (DPP IV, CD 26): a tumor marker in cytologic and histopathologic diagnosis of lesions of the thyroid gland]
Carcinoma
[Dipeptidyl peptidase IV gene expression in ovarian carcinoma cell lines with various maligant behaviour]
Carcinoma, Basal Cell
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Carcinoma, Ehrlich Tumor
Serum activities of dipeptidyl-aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patients.
Carcinoma, Endometrioid
Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade.
Carcinoma, Hepatocellular
A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4.
Carcinoma, Hepatocellular
Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Biochemical properties of dipeptidyl peptidase IV in liver and hepatoma plasma membranes.
Carcinoma, Hepatocellular
Biosynthesis and metabolism of dipeptidylpeptidase IV in primary cultured rat hepatocytes and Morris hepatoma 7777 cells.
Carcinoma, Hepatocellular
Biosynthesis of the adenosine deaminase-binding protein in human fibroblasts and hepatoma cells.
Carcinoma, Hepatocellular
Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Characterization of different forms of dipeptidyl peptidase IV from rat liver and hepatoma by monoclonal antibodies.
Carcinoma, Hepatocellular
Development of monoclonal antibodies against different protein and carbohydrate epitopes of dipeptidyl peptidase IV from rat liver plasma membranes.
Carcinoma, Hepatocellular
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Carcinoma, Hepatocellular
Dipeptidyl peptidase IV is down-regulated in rat hepatoma cells at the mRNA level.
Carcinoma, Hepatocellular
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
Carcinoma, Hepatocellular
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Carcinoma, Hepatocellular
Dipeptidyl peptidase-4: a key player in chronic liver disease.
Carcinoma, Hepatocellular
Distribution of glycosyltransferases among Golgi apparatus subfractions from liver and hepatomas of the rat.
Carcinoma, Hepatocellular
gamma-Glutamyltranspeptidase and dipeptidyl peptidase IV activity in the serum of normal and hepatoma-bearing chickens and in the plasma membranes from liver and hepatoma Mc-29.
Carcinoma, Hepatocellular
Increased activity of dipeptidyl peptidase IV in serum of hepatoma-bearing rats coincides with the loss of the enzyme from the hepatoma plasma membrane.
Carcinoma, Hepatocellular
Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2.
Carcinoma, Hepatocellular
SerpinB3 induces dipeptidyl-peptidase IV/CD26 expression and its metabolic effects in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Carcinoma, Large Cell
Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
Carcinoma, Medullary
Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.
Carcinoma, Non-Small-Cell Lung
Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Carcinoma, Non-Small-Cell Lung
Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.
Carcinoma, Ovarian Epithelial
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.
Carcinoma, Ovarian Epithelial
[Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma]
Carcinoma, Papillary
Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours.
Carcinoma, Papillary
Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.
Carcinoma, Papillary
Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study.
Carcinoma, Papillary
Immunohistochemical localization of dipeptidyl aminopeptidase IV in thyroid papillary carcinoma.
Carcinoma, Papillary
Increase of endo-peptidases and exo-peptidases in thyroid-tumors.
Carcinoma, Papillary
Staining for dipeptidyl aminopeptidase IV activity in nodular thyroid diseases.
Carcinoma, Papillary
[Dipeptidyl peptidase IV (DPP IV, CD 26): a tumor marker in cytologic and histopathologic diagnosis of lesions of the thyroid gland]
Carcinoma, Renal Cell
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.
Carcinoma, Renal Cell
Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells.
Carcinoma, Renal Cell
Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators.
Carcinoma, Renal Cell
Renal therapeutics: patent highlights January to June 2003.
Carcinoma, Renal Cell
Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13.
Carcinoma, Small Cell
Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
Carcinoma, Squamous Cell
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Carcinoma, Squamous Cell
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV).
Carcinoma, Squamous Cell
Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma.
Carcinoma, Squamous Cell
Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase-IV.
Carcinoma, Squamous Cell
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Cardio-Renal Syndrome
Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
Cardiomegaly
Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
Cardiomegaly
DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.
Cardiomegaly
DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.
Cardiomegaly
Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats.
Cardiomyopathies
Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.
Cardiomyopathies
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.
Cardiomyopathies
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Cardiomyopathies
Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4+ stem cells into the ischaemic heart.
Cardiomyopathy, Hypertrophic
Exendin-4 therapy still offered an additional benefit on reducing transverse aortic constriction-induced cardiac hypertrophy-caused myocardial damage in DPP-4 deficient rats.
Cardiovascular Diseases
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Cardiovascular Diseases
A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis.
Cardiovascular Diseases
A DPP-4 Inhibitor Suppresses Fibrosis and Inflammation on Experimental Autoimmune Myocarditis in Mice.
Cardiovascular Diseases
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Cardiovascular Diseases
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Cardiovascular Diseases
Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.
Cardiovascular Diseases
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Cardiovascular Diseases
Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
Cardiovascular Diseases
Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
Cardiovascular Diseases
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Cardiovascular Diseases
Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm".
Cardiovascular Diseases
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Cardiovascular Diseases
Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.
Cardiovascular Diseases
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.
Cardiovascular Diseases
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
Cardiovascular Diseases
Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.
Cardiovascular Diseases
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Cardiovascular Diseases
Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
Cardiovascular Diseases
Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Cardiovascular Diseases
Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Cardiovascular Diseases
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.
Cardiovascular Diseases
Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension.
Cardiovascular Diseases
Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury.
Cardiovascular Diseases
Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease.
Cardiovascular Diseases
Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: Modulation of oxidative stress and inflammation.
Cardiovascular Diseases
Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
Cardiovascular Diseases
Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats.
Cardiovascular Diseases
Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
Cardiovascular Diseases
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Cardiovascular Diseases
Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
Cardiovascular Diseases
Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease.
Cardiovascular Diseases
Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease?- Recent Insights Focusing on Angiogenesis and Neovascularization.
Cardiovascular Diseases
Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial.
Cardiovascular Diseases
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice.
Cardiovascular Diseases
DPP-4 inhibition protects human umbilical vein endothelial cells from hypoxia-induced vascular barrier impairment.
Cardiovascular Diseases
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Cardiovascular Diseases
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Cardiovascular Diseases
Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.
Cardiovascular Diseases
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Cardiovascular Diseases
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cardiovascular Diseases
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease.
Cardiovascular Diseases
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Cardiovascular Diseases
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke.
Cardiovascular Diseases
Effects of vildagliptin vs. sitagliptin, on cardiac function, heart rate variability, and mitochondrial function in obese insulin resistant rats.
Cardiovascular Diseases
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Cardiovascular Diseases
Evaluating Peptides of Picrorhiza kurroa and Their Inhibitory Potential against ACE, DPP-IV, and Oxidative Stress.
Cardiovascular Diseases
Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs.
Cardiovascular Diseases
Fighting type-2 diabetes: present and future perspectives.
Cardiovascular Diseases
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Cardiovascular Diseases
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Cardiovascular Diseases
Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes.
Cardiovascular Diseases
Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?
Cardiovascular Diseases
Heterogeneous treatment effects on cardiovascular diseases with dipeptidyl peptidase-4 inhibitors versus sulfonylureas in type 2 diabetes patients.
Cardiovascular Diseases
Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4.
Cardiovascular Diseases
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Cardiovascular Diseases
Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.
Cardiovascular Diseases
Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Cardiovascular Diseases
Late gestational testosterone exposure causes glucose deregulation and elevated cardiac VCAM-1 and DPP-4 activity in rats.
Cardiovascular Diseases
Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.
Cardiovascular Diseases
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Cardiovascular Diseases
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Cardiovascular Diseases
Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Cardiovascular Diseases
Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Cardiovascular Diseases
Pancreatic Safety of Sitagliptin in the TECOS Study.
Cardiovascular Diseases
Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
Cardiovascular Diseases
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Cardiovascular Diseases
Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress.
Cardiovascular Diseases
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Cardiovascular Diseases
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Cardiovascular Diseases
Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities.
Cardiovascular Diseases
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Cardiovascular Diseases
Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial.
Cardiovascular Diseases
Sitagliptin-mediated preservation of endothelial progenitor cell function via augmenting autophagy enhances ischaemic angiogenesis in diabetes.
Cardiovascular Diseases
The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.
Cardiovascular Diseases
The effects of simvastatin on the pharmacokinectics of sitagliptin.
Cardiovascular Diseases
The relationship between carotid intima-media thickness and serum secreted frizzled-related protein-4 and dipeptidyl peptidase-4 in diabetic patients with cardiovascular diseases.
Cardiovascular Diseases
The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
Cardiovascular Diseases
The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease.
Cardiovascular Diseases
The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
Cardiovascular Diseases
Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Cardiovascular Diseases
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Cardiovascular Diseases
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
Cardiovascular Diseases
Vildagliptin reduced plasma stromal cell-derived factor (SDF)-1? in patients with type 2 diabetes compared to glimepiride.
Cardiovascular Diseases
Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism.
Cardiovascular Diseases
[Diabetes Mellitus Type 2: Recent Publications and New Drugs].
Cardiovascular Diseases
[TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH HISTORY OF CARDIOVASCULAR DISEASE].
Carotid Artery Diseases
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Carotid Artery Diseases
Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.
Carotid Artery Diseases
Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139-148.
Carotid Artery Diseases
Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
Carotid Artery Thrombosis
Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis.
Celiac Disease
Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting.
Celiac Disease
On the role of dipeptidyl peptidase IV in the digestion of an immunodominant epitope in celiac disease.
Celiac Disease
Serum and intestinal dipeptidyl peptidase IV (DPP IV/CD26) activity in children with celiac disease.
Celiac Disease
Study of two ectopeptidases in the susceptibility to celiac disease: two newly identified polymorphisms of dipeptidylpeptidase IV.
Central Nervous System Diseases
Dipeptidyl peptidase IV in inflammatory CNS disease.
Central Nervous System Diseases
TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26.
Cerebral Infarction
Efficacy of alogliptin combined with motor imagery under hyperbaric oxygen in diabetic nephropathy with silent cerebral infarction.
Cerebral Infarction
Inhibition of DPP-4 Activity and Neuronal Atrophy with Genistein Attenuates Neurological Deficits Induced by Transient Global Cerebral Ischemia and Reperfusion in Streptozotocin-Induced Diabetic Mice.
Cerebrovascular Disorders
Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study.
Cerebrovascular Disorders
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Cholangiocarcinoma
Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Cholangiocarcinoma
Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection.
Cholangiocarcinoma
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Cholecystitis
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Cholecystitis
DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy.
Cholestasis
Retrieval of the mrp2 gene encoded conjugate export pump from the canalicular membrane contributes to cholestasis induced by tert-butyl hydroperoxide and chloro-dinitrobenzene.
Cholesteatoma
Altered regulation of cell surface peptidases in human cholesteatoma.
Chondroblastoma
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Choroidal Neovascularization
An angiotensin-converting enzyme inhibitor modulates stromal-derived factor-1 through CD26/dipeptidyl peptidase IV to inhibit laser-induced choroidal neovascularization.
Chronic Limb-Threatening Ischemia
Paradoxical impairment of angiogenesis, endothelial function and circulating number of endothelial progenitor cells in DPP4-deficient rat after critical limb ischemia.
Chronic Periodontitis
Alanine aminopeptidase and dipeptidyl peptidase IV in saliva of chronic periodontitis patients.
Chronic Periodontitis
Enzymatic properties of dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis and its participation in virulence.
Colitis
Colitis development and resolution in mice with target deletion of dipeptidyl peptidase IV/CD26.
Colitis
Colonic inflammation induces changes in glucose levels through modulation of incretin system.
Colitis
Contribution of dipeptidyl peptidase IV to the severity of dextran sulfate sodium-induced colitis in the early phase.
Colitis
Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV.
Colitis
Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2.
Colitis
Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis.
Colitis
Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
Colitis
Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a new target complex for treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis.
Colitis
Influence of CD26/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution.
Colitis
Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling.
Colitis
Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice.
Colitis
New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration.
Colitis
Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis.
Colitis
The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal effect in the amelioration of colitis.
Colitis
The effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on dextran sulfate sodium-induced colitis in mice.
Colitis, Ulcerative
Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease.
Colitis, Ulcerative
Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
Colonic Neoplasms
Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway.
Colonic Neoplasms
Adenosine metabolism and cancer. Focus on "Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway".
Colonic Neoplasms
Angiogenesis is promoted by exosomal DPP4 derived from 5-fluorouracil-resistant colon cancer cells.
Colonic Neoplasms
Common targets for a deadly duo of diabetes mellitus and colon cancer: Catching two fish with one worm.
Colonic Neoplasms
Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation.
Colonic Neoplasms
Dissection of the asynchronous transport of intestinal microvillar hydrolases to the cell surface.
Colonic Neoplasms
DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells.
Colonic Neoplasms
Endocytosis, recycling, and lysosomal delivery of brush border hydrolases in cultured human intestinal epithelial cells (Caco-2).
Colonic Neoplasms
Expression of dipeptidyl aminopeptidase IV during enterocytic differentiation of human colon cancer (Caco-2) cells.
Colonic Neoplasms
Forskolin blocks the apical expression of dipeptidyl peptidase IV in Caco-2 cells and induces its retention in lamp-1-containing vesicles.
Colonic Neoplasms
Immunohistological evidence, obtained with monoclonal antibodies, of small intestinal brush border hydrolases in human colon cancers and foetal colons.
Colonic Neoplasms
Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.
Colonic Neoplasms
Release of multifunctional peptides from kiwicha (Amaranthus caudatus) protein under in vitro gastrointestinal digestion.
Colonic Neoplasms
Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells.
Colorectal Neoplasms
Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.
Colorectal Neoplasms
Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway.
Colorectal Neoplasms
CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context.
Colorectal Neoplasms
Dipeptidyl peptidase 10, a novel prognostic marker in colorectal cancer.
Colorectal Neoplasms
Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.
Colorectal Neoplasms
Dipeptidyl Peptidase 9 Increases Chemoresistance and is an Indicator of Poor Prognosis in Colorectal Cancer.
Colorectal Neoplasms
Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.
Colorectal Neoplasms
Dual Glycation-Inflammation Modulation, DPP-IV and Pancraetic Lipase Inhibitory Potentials and Antiproliferative Activity of Novel Fluoroquinolones.
Colorectal Neoplasms
Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.
Colorectal Neoplasms
Effect of growth and sodium butyrate on brush border membrane-associated hydrolases in human colorectal cancer cell lines.
Colorectal Neoplasms
Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
Colorectal Neoplasms
Intestinal brush-border-associated enzymes: co-ordinated expression in colorectal cancer.
Colorectal Neoplasms
Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study.
Colorectal Neoplasms
Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma.
Colorectal Neoplasms
The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice.
Compartment Syndromes
Multiple limb compartment syndrome as a manifestation of capillary leak syndrome secondary to metformin and dipeptidyl peptidase IV inhibitor overdose: A case report.
Congenital Hyperinsulinism
Dipeptidyl peptidase-4 expression in pancreatic tissue from patients with congenital hyperinsulinism.
Corneal Injuries
Dipeptidyl peptidase IV (DPPIV) activity in the tear fluid as an indicator of the severity of corneal injury: a histochemical and biochemical study.
Coronary Artery Disease
Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.
Coronary Artery Disease
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Coronary Artery Disease
Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes.
Coronary Artery Disease
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Coronary Artery Disease
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.
Coronary Artery Disease
Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
Coronary Artery Disease
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease.
Coronary Artery Disease
Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study.
Coronary Artery Disease
Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.
Coronary Artery Disease
Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study.
Coronary Artery Disease
Gender differences in variables associated with dipeptidyl peptidase 4 genetic polymorphisms in coronary artery disease.
Coronary Artery Disease
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Coronary Artery Disease
Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease.
Coronary Artery Disease
Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease.
Coronary Artery Disease
Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis.
Coronary Artery Disease
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Coronary Artery Disease
Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
Coronary Artery Disease
Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus.
Coronary Artery Disease
The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE-A multicenter randomized controlled trial.
Coronary Artery Disease
The relationship between carotid intima-media thickness and serum secreted frizzled-related protein-4 and dipeptidyl peptidase-4 in diabetic patients with cardiovascular diseases.
Coronary Disease
CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
Coronary Disease
Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Coronary Disease
Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
Coronary Disease
Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database.
Coronary Occlusion
Adaptive changes in the capillary network in the left ventricle of rat heart.
Coronary Stenosis
Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.
Coronary Stenosis
Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.
Coronavirus Infections
Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus.
Coronavirus Infections
Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus.
Coronavirus Infections
Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Is an Important Surface Attachment Factor Facilitating the Entry of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Coronavirus Infections
Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas.
Coronavirus Infections
Conjugation of Human ?-Defensin 2 to Spike Protein Receptor-Binding Domain Induces Antigen-Specific Protective Immunity against Middle East Respiratory Syndrome Coronavirus Infection in Human Dipeptidyl Peptidase 4 Transgenic Mice.
Coronavirus Infections
Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome.
Coronavirus Infections
Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection.
Coronavirus Infections
Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease.
Coronavirus Infections
Glycosylation of Mouse DPP4 Plays a Role in Inhibiting Middle East Respiratory Syndrome Coronavirus Infection.
Coronavirus Infections
Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4.
Coronavirus Infections
Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry.
Coronavirus Infections
Inability of rat DPP4 to allow MERS-CoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein.
Coronavirus Infections
Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells.
Coronavirus Infections
Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4.
Coronavirus Infections
Mouse dipeptidyl peptidase 4 is not a functional receptor for middle East respiratory syndrome coronavirus infection.
Coronavirus Infections
Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants.
Coronavirus Infections
Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.
Coronavirus Infections
Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus.
Coronavirus Infections
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Coronavirus Infections
Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus.
Coronavirus Infections
Replication of MERS and SARS coronaviruses in bat cells offers insights to their ancestral origins.
Coronavirus Infections
SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications.
Coronavirus Infections
Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors.
Coronavirus Infections
Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein.
Coronavirus Infections
Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein.
Coronavirus Infections
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4.
Coronavirus Infections
The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.
Coronavirus Infections
The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.
Coronavirus Infections
Tissue Distribution of the MERS-Coronavirus Receptor in Bats.
Cough
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Cough
[A new cause of drug-induced cough: The dipeptidyl peptidase-IV inhibitors].
COVID-19
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19.
COVID-19
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
COVID-19
Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19.
COVID-19
Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity.
COVID-19
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.
COVID-19
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease.
COVID-19
COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
COVID-19
COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus.
COVID-19
COVID-19, ferrosenescence and neurodegeneration, a mini-review.
COVID-19
Cross talk between COVID-19 and breast cancer.
COVID-19
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
COVID-19
Diabetes and COVID-19.
COVID-19
Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.
COVID-19
Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.
COVID-19
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
COVID-19
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.
COVID-19
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies.
COVID-19
Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection.
COVID-19
Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis.
COVID-19
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
COVID-19
DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?
COVID-19
DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis.
COVID-19
DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
COVID-19
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment.
COVID-19
Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.
COVID-19
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).
COVID-19
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.
COVID-19
Efficacy and safety of DPP-4 inhibitor in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
COVID-19
Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.
COVID-19
Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy.
COVID-19
Impact of Sitagliptin in Non-Diabetic Covid-19 Patients.
COVID-19
Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.
COVID-19
Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review.
COVID-19
Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.
COVID-19
No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.
COVID-19
Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus.
COVID-19
Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.
COVID-19
Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports.
COVID-19
Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance.
COVID-19
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
COVID-19
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.
COVID-19
The Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis.
COVID-19
The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.
COVID-19
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands.
COVID-19
Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.
COVID-19
Use of DPP-4 inhibitors in patients with COVID-19.
Crohn Disease
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Crohn Disease
Dipeptidyl peptidase-4 expression is reduced in Crohn's disease.
Crohn Disease
Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
Crohn Disease
DPP IV and mental depression in Crohn's disease.
Crohn Disease
The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease.
Cystadenocarcinoma, Serous
Dipeptidyl peptidase IV in tumor progression.
Cystadenocarcinoma, Serous
Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma.
Cystic Fibrosis
Transimmortalized mouse intestinal cells (m-ICc12) that maintain a crypt phenotype.
Cysts
Acute Pancreatitis in a Patient Receiving Vildagliptin.
Death, Sudden, Cardiac
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies.
Deglutition Disorders
Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
Dementia
A questionnaire survey on current status of anti-diabetic therapy for diabetic patients with dementia.
Dementia
Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan.
Dementia
Correction: Kim, Young-Gun; Jeon, Ja Young; Kim, Hae Jin; Kim, Dae Jung; Lee, Kwan-Woo; Moon, So Young; Han, Seung Jin. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors versus Sulfonylureas: A Real-World Population-Based Cohort Study. Journal of Clinical Medicine 2019, 8, 28.
Dementia
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Dementia
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Dementia
Neuroprotective effects of vildagliptin on drug induced Alzheimer's disease in rats with metabolic syndrome: Role of hippocampal klotho and AKT signaling pathways.
Dementia
Oral diabetes medication and risk of dementia in elderly patients with type 2 diabetes.
Dementia
Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.
Dementia
The impact of dementia on antidiabetic drug use in Medicare beneficiaries with diabetes: findings post-Medicare part D.
Dementia, Vascular
Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia.
Dental Plaque
[The study of the activities of salivary proteolytic enzymes in children]
Dermatitis, Allergic Contact
Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis.
Dermatitis, Atopic
?-casomorphin-7 alters ?-opioid receptor and dipeptidyl peptidase IV genes expression in children with atopic dermatitis.
Dermatitis, Atopic
Expression of dipeptidyl-peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis.
Dermatitis, Atopic
Periostin and Dipeptidyl Peptidase-4: Potential Biomarkers of Interleukin 13 Pathway Activation in Asthma and Allergy.
Diabetes Complications
A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats.
Diabetes Complications
Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians' Perspective in a Real-World Setting, Insight from a Web Survey.
Diabetes Complications
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Diabetes Complications
Erratum to: DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Diabetes Complications
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Diabetes Complications
How to interpret the role of SDF-1? on diabetic complications during therapy with DPP-4 inhibitors.
Diabetes Complications
Inventing and understanding catalytic, enantioselective reactions.
Diabetes Complications
Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
Diabetes Complications
Remediation of undesirable secondary interactions encountered in hydrophilic interaction chromatography during development of a quantitative LC-MS/MS assay for a dipeptidyl peptidase IV (DPP-IV) inhibitor in monkey serum.
Diabetes Complications
Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.
Diabetes Complications
The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.
Diabetes Complications
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
Diabetes Complications
[Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].
Diabetes Mellitus
A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Diabetes Mellitus
A Decision-Focused Mixed Treatment Comparison (MTC) of Alternative Dpp-4 Inhibitors (Dpp-4i's) Used in Combination With Metformin or a Sulfonylurea for the Treatment of Type 2 Diabetes Mellitus (T2DM).
Diabetes Mellitus
A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats.
Diabetes Mellitus
A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.
Diabetes Mellitus
A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma.
Diabetes Mellitus
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Diabetes Mellitus
A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans.
Diabetes Mellitus
A novel artificial intelligence protocol to investigate potential leads for diabetes mellitus.
Diabetes Mellitus
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
Diabetes Mellitus
A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Diabetes Mellitus
A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.
Diabetes Mellitus
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Diabetes Mellitus
A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.
Diabetes Mellitus
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Diabetes Mellitus
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Diabetes Mellitus
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
Diabetes Mellitus
A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
Diabetes Mellitus
A review upon medicinal perspective and designing rationale of DPP-4 inhibitors.
Diabetes Mellitus
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Diabetes Mellitus
Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan.
Diabetes Mellitus
Activity and selectivity cliffs for DPP-IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening.
Diabetes Mellitus
Acute Kidney Injury Associated with Linagliptin.
Diabetes Mellitus
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
Diabetes Mellitus
Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis.
Diabetes Mellitus
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Diabetes Mellitus
Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Diabetes Mellitus
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Diabetes Mellitus
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Diabetes Mellitus
Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Diabetes Mellitus
Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
Diabetes Mellitus
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies.
Diabetes Mellitus
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Diabetes Mellitus
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Diabetes Mellitus
Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Diabetes Mellitus
Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Diabetes Mellitus
Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.
Diabetes Mellitus
An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin.
Diabetes Mellitus
An overview of recent dipeptidyl peptidase-IV inhibitors: linking their structure and physico-chemical properties with sar, pharmacokinetics and toxicity.
Diabetes Mellitus
An Overview, Advantages and Therapeutic Potential of Nonpeptide Positive Allosteric Modulators of Glucagon-Like Peptide-1 Receptor.
Diabetes Mellitus
An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
An updated review on cancer risk associated with incretin mimetics and enhancers.
Diabetes Mellitus
An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.
Diabetes Mellitus
Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study).
Diabetes Mellitus
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
Diabetes Mellitus
Anti-diabetic effect of the lupinalbin A compound isolated from Apios americana: In vitro analysis and molecular docking study.
Diabetes Mellitus
Anti-glycemic potential of benzophenone thio/semicarbazone derivatives: synthesis, enzyme inhibition and ligand docking studies.
Diabetes Mellitus
Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke.
Diabetes Mellitus
Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.
Diabetes Mellitus
Antidiabetic Agent DPP-4i Facilitates Murine Breast Cancer Metastasis by Oncogenic ROS-NRF2-HO-1 Axis via a Positive NRF2-HO-1 Feedback Loop.
Diabetes Mellitus
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Diabetes Mellitus
Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction.
Diabetes Mellitus
Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.
Diabetes Mellitus
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
Diabetes Mellitus
Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
Diabetes Mellitus
Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus.
Diabetes Mellitus
Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus.
Diabetes Mellitus
Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus.
Diabetes Mellitus
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
Diabetes Mellitus
Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study.
Diabetes Mellitus
Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects.
Diabetes Mellitus
Association of Plasma DPP4 Activity and Brain-Derived Neurotrophic Factor With Moderate to Severe Depressive Symptoms in Patients With Type 2 Diabetes: Results From a Cross-Sectional Study.
Diabetes Mellitus
Association of Plasma DPP4 Activity to BDNF Ratio with Moderate to Severe Depressive Symptoms in Patients With Type 2 Diabetes: Results from a Cross-Sectional Study.
Diabetes Mellitus
Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.
Diabetes Mellitus
Autophagy deficiency in ? cells blunts incretin-induced suppression of glucagon release from ? cells.
Diabetes Mellitus
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus
Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability.
Diabetes Mellitus
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Diabetes Mellitus
Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.
Diabetes Mellitus
Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Diabetes Mellitus
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
Diabetes Mellitus
Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
Diabetes Mellitus
Canagliflozin (CANA) Added on to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) or Glucagon-like Peptide-1 (GLP-1) Agonists with or Without Other Antihyperglycemic Agents (AHAs) in Type 2 Diabetes Mellitus (T2DM).
Diabetes Mellitus
Cancer Biology and Prevention in Diabetes.
Diabetes Mellitus
Cardiometabolic Effects of a New Class of Antidiabetic Agents.
Diabetes Mellitus
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Diabetes Mellitus
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus
Cardiovascular actions of incretin-based therapies.
Diabetes Mellitus
Cardiovascular Biology of the Incretin System.
Diabetes Mellitus
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
Diabetes Mellitus
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Diabetes Mellitus
Cardiovascular effects of gliptins.
Diabetes Mellitus
Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
Diabetes Mellitus
Cardiovascular Effects of Incretin-Based Therapies.
Diabetes Mellitus
Cardiovascular Manifestations of Insulin Resistance.
Diabetes Mellitus
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Diabetes Mellitus
Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis.
Diabetes Mellitus
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
Diabetes Mellitus
Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.
Diabetes Mellitus
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors.
Diabetes Mellitus
Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Diabetes Mellitus
Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
Diabetes Mellitus
Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan.
Diabetes Mellitus
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Diabetes Mellitus
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Cardiovascular safety of therapies for type 2 diabetes.
Diabetes Mellitus
CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions.
Diabetes Mellitus
Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.
Diabetes Mellitus
Changing prevalence of diabetes mellitus in bullous pemphigoid: It is the dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
Diabetes Mellitus
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Diabetes Mellitus
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Diabetes Mellitus
Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Diabetes Mellitus
Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edema syndrome.
Diabetes Mellitus
Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.
Diabetes Mellitus
Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
Diabetes Mellitus
CLINICAL CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS CONTINUED ON ORAL ANTIDIABETES MEDICATIONS IN THE HOSPITAL.
Diabetes Mellitus
Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Diabetes Mellitus
Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Clinical overview of saxagliptin for Type 2 diabetes management.
Diabetes Mellitus
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
Diabetes Mellitus
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.
Diabetes Mellitus
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Clinical Review: Safety and Efficacy comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
Diabetes Mellitus
Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin.
Diabetes Mellitus
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.
Diabetes Mellitus
Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Diabetes Mellitus
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.
Diabetes Mellitus
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Diabetes Mellitus
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Diabetes Mellitus
Combination pharmacotherapy with incretins: what works best and when?
Diabetes Mellitus
Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea.
Diabetes Mellitus
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
Diabetes Mellitus
Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Diabetes Mellitus
Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice.
Diabetes Mellitus
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Diabetes Mellitus
Commentary on "Changing prevalence of diabetes mellitus in bullous pemphigoid: It is the dipeptidyl peptidase-4 inhibitors".
Diabetes Mellitus
Comparative Cardiovascular Safety of Glucagon-Like Peptide-1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study.
Diabetes Mellitus
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
Diabetes Mellitus
Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Diabetes Mellitus
Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Diabetes Mellitus
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Diabetes Mellitus
Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study.
Diabetes Mellitus
Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.
Diabetes Mellitus
Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study.
Diabetes Mellitus
Comparison between SGLT2 Inhibitors and DPP4 Inhibitors Added to Insulin Therapy in Type 2 Diabetes: A Systematic Review with Indirect Comparison Meta-analysis.
Diabetes Mellitus
Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Diabetes Mellitus
Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example.
Diabetes Mellitus
Comparison of Efficacy between Dipeptidyl Peptidase-4 Inhibitor and Sodium-Glucose Cotransporter 2 Inhibitor on Metabolic Risk Factors in Japanese Patients with Type 2 Diabetes Mellitus: Results from the CANTABILE Study.
Diabetes Mellitus
Comparison of Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter 2 Inhibitors Between Japanese and Non-Japanese Patients: A Meta-Analysis.
Diabetes Mellitus
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Diabetes Mellitus
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Diabetes Mellitus
Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.
Diabetes Mellitus
Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
Diabetes Mellitus
Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Diabetes Mellitus
Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
Diabetes Mellitus
Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
Diabetes Mellitus
Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Diabetes Mellitus
Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Diabetes Mellitus
Cord serum dipeptidyl-peptidase 4 activity in gestational diabetes.
Diabetes Mellitus
Corrigendum to 'Demographic and Clinical Characteristics of Type 2 Diabetes Mellitus Patients Initiating Dipeptidyl Peptidase-4 Inhibitors - A Retrospective Study of UK General Practice' Clin Ther 2016;8:1825-1832.e15.
Diabetes Mellitus
Corrigendum to 'Demographic and clinical characteristics of type 2 diabetes mellitus patients initiating dipeptidyl peptidase-4 inhibitors - a retrospective study of UK general practice'.
Diabetes Mellitus
Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes.
Diabetes Mellitus
Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Diabetes Mellitus
Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Diabetes Mellitus
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Diabetes Mellitus
Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Diabetes Mellitus
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Diabetes Mellitus
Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications.
Diabetes Mellitus
Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden.
Diabetes Mellitus
Critical role of Dipeptidyl Peptidase IV: A therapeutic target for cancer & diabetes.
Diabetes Mellitus
Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Diabetes Mellitus
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
Diabetes Mellitus
Dapagliflozin Versus a Dipeptidyl Peptidase 4 Inhibitor (DPP4) Both Added to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM): Impact on Health, Quality of Life and Costs in the Turkish Clinical Setting.
Diabetes Mellitus
Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions.
Diabetes Mellitus
Decreased mortality after long term treatment with DPP-4 inhibitors: A retrospective study of US veterans with type 2 diabetes.
Diabetes Mellitus
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Diabetes Mellitus
Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Diabetes Mellitus
Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2-Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors.
Diabetes Mellitus
Development and validation of a UPLC-MS/MS method for simultaneous determination of fotagliptin and its two major metabolites in human plasma and urine.
Diabetes Mellitus
Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma.
Diabetes Mellitus
Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV).
Diabetes Mellitus
Development of a validated HPLC method for the quantitative determination of trelagliptin succinate and its related substances in pharmaceutical dosage forms.
Diabetes Mellitus
Diabetic nephropathy: newer therapeutic perspectives.
Diabetes Mellitus
Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings?.
Diabetes Mellitus
Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Diabetes Mellitus
Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and ?-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis.
Diabetes Mellitus
Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.
Diabetes Mellitus
Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
Diabetes Mellitus
Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
Diabetes Mellitus
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like Peptide 1-dependent mechanism.
Diabetes Mellitus
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
Diabetes Mellitus
Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia-reperfusion injury in rats with diabetes mellitus type 2.
Diabetes Mellitus
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
Diabetes Mellitus
Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Diabetes Mellitus
Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats.
Diabetes Mellitus
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
Diabetes Mellitus
Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment.
Diabetes Mellitus
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study).
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Diabetes Mellitus
Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients.
Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
Diabetes Mellitus
Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease?- Recent Insights Focusing on Angiogenesis and Neovascularization.
Diabetes Mellitus
Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
Diabetes Mellitus
Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials.
Diabetes Mellitus
Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes.
Diabetes Mellitus
Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and de novo Evolution.
Diabetes Mellitus
Divergent effects of various diabetes drugs on cardiovascular prognosis.
Diabetes Mellitus
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials.
Diabetes Mellitus
Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Diabetes Mellitus
Dose-Ranging Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
Diabetes Mellitus
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis.
Diabetes Mellitus
DPP-4 inhibitor treatment: ?-cell response but not HbA1c reduction is dependent on the duration of diabetes.
Diabetes Mellitus
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Diabetes Mellitus
DPP-4 Inhibitors and GLP-1 Receptor Agonists for Prevention or Delay of Type 2 Diabetes Mellitus and Associated Complications.
Diabetes Mellitus
DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Diabetes Mellitus
DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin.
Diabetes Mellitus
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Diabetes Mellitus
DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews.
Diabetes Mellitus
DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus.
Diabetes Mellitus
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
DPP-4 inhibitors: a patent review (2012 - 2014).
Diabetes Mellitus
DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.
Diabetes Mellitus
DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses.
Diabetes Mellitus
DPP4 Activities Are Associated with Osteopenia/Osteoporosis and Fracture Risk in Newly Diagnosed Type 2 Diabetes.
Diabetes Mellitus
DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice.
Diabetes Mellitus
DPP4 inhibitor-induced polyarthritis: a report of three cases.
Diabetes Mellitus
DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
Diabetes Mellitus
Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
Diabetes Mellitus
Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin.
Diabetes Mellitus
Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.
Diabetes Mellitus
Echocardiographic feature of diabetic cardiomyopathy: where are we now?
Diabetes Mellitus
Effect of a DPP-4 Inhibitor on Orthodontic Tooth Movement and Associated Root Resorption.
Diabetes Mellitus
Effect of a Moderate Carbohydrate-Restricted Diet on DPP-4 Inhibitor Action among Individuals with Type 2 Diabetes Mellitus: A 6-Month Intervention Study.
Diabetes Mellitus
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
Diabetes Mellitus
Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus.
Diabetes Mellitus
Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Diabetes Mellitus
Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
Diabetes Mellitus
Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.
Diabetes Mellitus
Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.
Diabetes Mellitus
Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure?- Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
Diabetes Mellitus
Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-? concentrations: A systematic review and meta-analysis of controlled trials.
Diabetes Mellitus
Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study.
Diabetes Mellitus
Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Diabetes Mellitus
Effect of dipeptidyl peptidase-4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A meta-analysis of randomised controlled trials.
Diabetes Mellitus
Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Diabetes Mellitus
Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
Diabetes Mellitus
Effect of divalent cations on the porcine kidney cortex membrane-bound form of dipeptidyl peptidase IV.
Diabetes Mellitus
Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI.
Diabetes Mellitus
Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
Diabetes Mellitus
Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice.
Diabetes Mellitus
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
Diabetes Mellitus
Effect of Saxagliptin on the Pharmacokinetics of the Active Components of Ortho-Cyclen®, a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate, in Healthy Women.
Diabetes Mellitus
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Diabetes Mellitus
Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
Diabetes Mellitus
Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
Diabetes Mellitus
Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).
Diabetes Mellitus
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease.
Diabetes Mellitus
Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Diabetes Mellitus
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea.
Diabetes Mellitus
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Diabetes Mellitus
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Diabetes Mellitus
Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.
Diabetes Mellitus
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus
Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Diabetes Mellitus
Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
Diabetes Mellitus
Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).
Diabetes Mellitus
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.
Diabetes Mellitus
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
Diabetes Mellitus
Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor.
Diabetes Mellitus
Effects of alogliptin on the ratio of glycated albumin to HbA1c in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Effects of anagliptin on the stress induced accelerated senescence of human umbilical vein endothelial cells.
Diabetes Mellitus
Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Diabetes Mellitus
Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Diabetes Mellitus
Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
Diabetes Mellitus
Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
Diabetes Mellitus
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Diabetes Mellitus
Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Diabetes Mellitus
Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.
Diabetes Mellitus
Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Diabetes Mellitus
Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Diabetes Mellitus
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic ?-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Diabetes Mellitus
Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes.
Diabetes Mellitus
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.
Diabetes Mellitus
Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying - preclinical evidence.
Diabetes Mellitus
Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
Diabetes Mellitus
Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan.
Diabetes Mellitus
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Diabetes Mellitus
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Diabetes Mellitus
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes.
Diabetes Mellitus
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.
Diabetes Mellitus
Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Diabetes Mellitus
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Diabetes Mellitus
Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial.
Diabetes Mellitus
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Diabetes Mellitus
Efficacy and safety of combination therapy with an ?-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
Diabetes Mellitus
Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Diabetes Mellitus
Efficacy and safety of Dipeptidyl Peptidase-4 Inhibitors in kidney transplant recipients with Post-transplant diabetes mellitus (PTDM)-a systematic review and Meta-Analysis.
Diabetes Mellitus
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
Diabetes Mellitus
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
Diabetes Mellitus
Efficacy and safety of DPP-4 inhibitor in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Diabetes Mellitus
Efficacy and safety of DPP-IV inhibitors combined with basal insulin in the treatment of type 2 diabetes.
Diabetes Mellitus
Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study.
Diabetes Mellitus
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Diabetes Mellitus
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.
Diabetes Mellitus
Efficacy and safety of linagliptin in persons with Type?2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study(1).
Diabetes Mellitus
Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials.
Diabetes Mellitus
Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.
Diabetes Mellitus
Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: an open-label, phase 3 exploratory study.
Diabetes Mellitus
Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Diabetes Mellitus
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Diabetes Mellitus
Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury.
Diabetes Mellitus
Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.
Diabetes Mellitus
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Mellitus
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study.
Diabetes Mellitus
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
Diabetes Mellitus
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
Diabetes Mellitus
Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Diabetes Mellitus
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: A 24-week multicenter, randomized, double-blind, placebo-controlled phase III trial.
Diabetes Mellitus
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, ?-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study.
Diabetes Mellitus
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Diabetes Mellitus
Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Diabetes Mellitus
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Diabetes Mellitus
Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.
Diabetes Mellitus
Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia.
Diabetes Mellitus
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on ?-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.
Diabetes Mellitus
Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.
Diabetes Mellitus
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
Diabetes Mellitus
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Diabetes Mellitus
Emerging Roles of Dipeptidyl Peptidase 4 Inhibitors: Anti-Inflammatory and Immunomodulatory Effect and Its Application in Diabetes Mellitus.
Diabetes Mellitus
Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus.
Diabetes Mellitus
Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats.
Diabetes Mellitus
Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
Diabetes Mellitus
Enhancing effects of anagliptin on myoblast differentiation and the expression of mitochondrial biogenetic factors in C2C12 mouse skeletal muscle cells.
Diabetes Mellitus
Enzymatic preparation of 5-hydroxy-L-proline, N-Cbz-5-hydroxy-L-proline, and N-Boc-5-hydroxy-L-proline from (?-N-protected)-L-ornithine using a transaminase or an amine oxidase.
Diabetes Mellitus
Ephedrine as a lead compound for the development of new DPP-IV inhibitors.
Diabetes Mellitus
Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
Diabetes Mellitus
Ethnic difference in the pharmacodynamics-efficacy relationship of dipeptidyl peptidase-4 inhibitors between Japanese and non-Japanese patients: A Systematic Review.
Diabetes Mellitus
Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Diabetes Mellitus
Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus.
Diabetes Mellitus
Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs.
Diabetes Mellitus
Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study.
Diabetes Mellitus
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Diabetes Mellitus
Evogliptin: First Global Approval.
Diabetes Mellitus
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
Diabetes Mellitus
Fabrication of a water-soluble near-infrared fluorescent probe for selective detection and imaging of dipeptidyl peptidase IV in biological systems.
Diabetes Mellitus
Factors associated with utilization of dipeptidyl-4 inhibitors in patients with type 2 diabetes mellitus: a cross-sectional retrospective study.
Diabetes Mellitus
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study.
Diabetes Mellitus
First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults.
Diabetes Mellitus
Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Diabetes Mellitus
From sequence analysis of DPP-4 to molecular docking based searching of its inhibitors.
Diabetes Mellitus
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
Diabetes Mellitus
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus.
Diabetes Mellitus
Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.
Diabetes Mellitus
Generation of dipeptidyl peptidase-IV-inhibiting peptides from ?-lactoglobulin secreted by Lactococcus lactis.
Diabetes Mellitus
Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
Diabetes Mellitus
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Diabetes Mellitus
GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Diabetes Mellitus
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
Diabetes Mellitus
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Glucagon-like Peptide-1 and its cardiovascular effects.
Diabetes Mellitus
Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes.
Diabetes Mellitus
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Diabetes Mellitus
Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population.
Diabetes Mellitus
Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Diabetes Mellitus
GPR119 agonists for the treatment of type 2 diabetes.
Diabetes Mellitus
GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Diabetes Mellitus
Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Diabetes Mellitus
Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and ?-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Diabetes Mellitus
High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study.
Diabetes Mellitus
Highly efficient asymmetric synthesis of sitagliptin.
Diabetes Mellitus
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.
Diabetes Mellitus
Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations.
Diabetes Mellitus
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Diabetes Mellitus
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Diabetes Mellitus
Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4.
Diabetes Mellitus
Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening.
Diabetes Mellitus
Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts.
Diabetes Mellitus
Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Diabetes Mellitus
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Diabetes Mellitus
Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.
Diabetes Mellitus
Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.
Diabetes Mellitus
Impact of type 1 diabetes mellitus and sitagliptin treatment on the neuropeptide Y system of rat retina.
Diabetes Mellitus
Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.
Diabetes Mellitus
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.
Diabetes Mellitus
Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
Diabetes Mellitus
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Diabetes Mellitus
Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Diabetes Mellitus
In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Diabetes Mellitus
In silico studies on the interaction between bioactive ligands and DPP-IV: insights on potential candidates for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
In vitro anti-diabetic effect of flavonoids and pheophytins from Allophylus cominia Sw. on the glucose uptake assays by HepG2, L6, 3T3-L1 and fat accumulation in 3T3-L1 adipocytes.
Diabetes Mellitus
In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations.
Diabetes Mellitus
In-Vitro Studies on Selected Jordanian Plants as Dipeptidyl Peptidase-IV Inhibitors for Management of Diabetes Mellitus.
Diabetes Mellitus
Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus.
Diabetes Mellitus
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Diabetes Mellitus
Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma.
Diabetes Mellitus
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus
Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis.
Diabetes Mellitus
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.
Diabetes Mellitus
Incretin drugs as modulators of atherosclerosis.
Diabetes Mellitus
Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus.
Diabetes Mellitus
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway.
Diabetes Mellitus
Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.
Diabetes Mellitus
Incretin-based therapies for type 2 diabetes mellitus.
Diabetes Mellitus
Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
Diabetes Mellitus
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Diabetes Mellitus
Incretin-mimetic therapies and pancreatic disease: a review of observational data.
Diabetes Mellitus
Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes.
Diabetes Mellitus
Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats.
Diabetes Mellitus
Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans.
Diabetes Mellitus
Influence of nutritional intervention on children with type 1 diabetes mellitus and DPP-4 in serum.
Diabetes Mellitus
Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus.
Diabetes Mellitus
Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
Diabetes Mellitus
Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Diabetes Mellitus
Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase-4 (DPP-4).
Diabetes Mellitus
Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Diabetes Mellitus
Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy.
Diabetes Mellitus
Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.
Diabetes Mellitus
Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment.
Diabetes Mellitus
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
Diabetes Mellitus
KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes.
Diabetes Mellitus
KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Diabetes Mellitus
Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes.
Diabetes Mellitus
Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.
Diabetes Mellitus
Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).
Diabetes Mellitus
Limited Extent of Pleiotropic Effects Mediated by Dipeptidyl Peptidase-4 Inhibitors in Patients With Diabetes Mellitus.
Diabetes Mellitus
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Diabetes Mellitus
Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Diabetes Mellitus
Linagliptin attenuates chronic post-ischemia pain: possible anti-inflammatory and anti-oxidant mechanisms.
Diabetes Mellitus
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Diabetes Mellitus
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Diabetes Mellitus
Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin.
Diabetes Mellitus
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled Phase III trial with a 34-week active-controlled extension.
Diabetes Mellitus
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Diabetes Mellitus
LINAGLIPTIN-INDUCED PANCREATITIS.
Diabetes Mellitus
Linagliptin-related pancreatitis in a diabetic patient with biliary calculus: A case report.
Diabetes Mellitus
Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Diabetes Mellitus
Linagliptin: A thorough Characterization beyond Its Clinical Efficacy.
Diabetes Mellitus
Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Diabetes Mellitus
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Diabetes Mellitus
Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.
Diabetes Mellitus
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Diabetes Mellitus
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Diabetes Mellitus
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Diabetes Mellitus
Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Diabetes Mellitus
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Diabetes Mellitus
Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
Diabetes Mellitus
Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.
Diabetes Mellitus
Macrocarpal C isolated from Eucalyptus globulus inhibits dipeptidyl peptidase 4 in an aggregated form.
Diabetes Mellitus
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.
Diabetes Mellitus
Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.
Diabetes Mellitus
Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
Diabetes Mellitus
MAXIMIZING PATIENT SAFETY WITH NEWLY APPROVED THERAPIES: FOCUS ON SGLT2 INHIBITORS.
Diabetes Mellitus
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Diabetes Mellitus
Meat Proteins as Dipeptidyl Peptidase IV Inhibitors and Glucose Uptake Stimulating Peptides for the Management of a Type 2 Diabetes Mellitus In Silico Study.
Diabetes Mellitus
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Diabetes Mellitus
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors.
Diabetes Mellitus
Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin.
Diabetes Mellitus
Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
Diabetes Mellitus
Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
Diabetes Mellitus
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Diabetes Mellitus
MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells.
Diabetes Mellitus
Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
Diabetes Mellitus
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients.
Diabetes Mellitus
Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Diabetes Mellitus
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Diabetes Mellitus
Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system.
Diabetes Mellitus
Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
Diabetes Mellitus
Navigating the chemical space of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes.
Diabetes Mellitus
Neurobehavioral effects of liraglutide and sitagliptin in experimental models.
Diabetes Mellitus
Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Diabetes Mellitus
Neuroprotective effect of vildagliptin against cerebral ischemia in rats.
Diabetes Mellitus
Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases.
Diabetes Mellitus
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Diabetes Mellitus
Nitrothiadiazolo[3,2-a]pyrimidines as promising antiglycating agents.
Diabetes Mellitus
Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
Diabetes Mellitus
Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Diabetes Mellitus
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.
Diabetes Mellitus
Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum.
Diabetes Mellitus
Odds of Acute Kidney Injury in Patients Receiving Dipeptidyl Peptidase 4 Inhibitors: A National Cohort Study Within the Department of Veterans Affairs.
Diabetes Mellitus
Oral therapy for type?1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic mice.
Diabetes Mellitus
Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
Diabetes Mellitus
Overcoming challenges in Type 2 diabetes management to improve patient outcomes.
Diabetes Mellitus
Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
Diabetes Mellitus
Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.
Diabetes Mellitus
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip.
Diabetes Mellitus
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Diabetes Mellitus
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Diabetes Mellitus
Pharmacokinetic and Pharmacodynamic Evaluation of Linagliptin in African American Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Pharmacokinetic and Pharmacodynamic Interaction Between Gemigliptin and Metformin in Healthy Subjects.
Diabetes Mellitus
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
Diabetes Mellitus
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Diabetes Mellitus
Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination?.
Diabetes Mellitus
Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study.
Diabetes Mellitus
Pharmacokinetic-Pharmacodynamic (Dipeptidyl Peptidase-4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those with Renal Impairment, for the Once-Weekly Administered Omarigliptin.
Diabetes Mellitus
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects.
Diabetes Mellitus
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
Diabetes Mellitus
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Pharmacokinetics and safety of evogliptin in hepatically impaired patients.
Diabetes Mellitus
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Diabetes Mellitus
Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
Diabetes Mellitus
Pharmacologic management of the older patient with type 2 diabetes mellitus.
Diabetes Mellitus
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus.
Diabetes Mellitus
Physiology and pathophysiology of incretins in the kidney.
Diabetes Mellitus
Phytochemicals in Garlic Extract Inhibit Therapeutic Enzyme DPP-4 and Induce Skeletal Muscle Cell Proliferation: A Possible Mechanism of Action to Benefit the Treatment of Diabetes Mellitus.
Diabetes Mellitus
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
Diabetes Mellitus
Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records.
Diabetes Mellitus
Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor.
Diabetes Mellitus
Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Possible ligand release pathway of dipeptidyl peptidase IV investigated by molecular dynamics simulations.
Diabetes Mellitus
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.
Diabetes Mellitus
Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus.
Diabetes Mellitus
Potential cardiovascular effects of incretin-based therapies.
Diabetes Mellitus
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Diabetes Mellitus
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Diabetes Mellitus
PPAR?/? Activation Induces Enteroendocrine L Cell GLP-1 Production.
Diabetes Mellitus
Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.
Diabetes Mellitus
Predicting DPP-IV inhibitors with machine learning approaches.
Diabetes Mellitus
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors.
Diabetes Mellitus
Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis.
Diabetes Mellitus
Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists.
Diabetes Mellitus
Prescription of DPP-4 Inhibitors to Patients With Adult Type 2 Diabetes Mellitus and Creatinine Clearance >50 mL/min: The UK Primary Care Experience.
Diabetes Mellitus
Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience.
Diabetes Mellitus
Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.
Diabetes Mellitus
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Diabetes Mellitus
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Diabetes Mellitus
Proteins and peptides from vegetable food sources as therapeutic adjuvants for the type 2 diabetes mellitus.
Diabetes Mellitus
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the "thorough QT/QTc" study (Q-SET study).
Diabetes Mellitus
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Quantitative Model of the Relationship Between Dipeptidyl Peptidase-4 (DPP-4) Inhibition and Response: Meta-Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results.
Diabetes Mellitus
Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
Diabetes Mellitus
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Diabetes Mellitus
Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
Diabetes Mellitus
Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors.
Diabetes Mellitus
Recent patents of dipeptidyl peptidase IV inhibitors.
Diabetes Mellitus
Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Diabetes Mellitus
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Diabetes Mellitus
Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Relapsing 6q24-related transient neonatal diabetes mellitus successfully treated with a dipeptidyl peptidase-4 inhibitor: a case report.
Diabetes Mellitus
Relationship Between Initial Renal Function and the Inhibitory Effect of Dipeptidyl Peptidase-4 Inhibitor Treatment on Renal Function Decline.
Diabetes Mellitus
Relative contribution of incretins to the glucose lowering effect of DP IV inhibitors in type 2 diabetes mellitus (T2DM).
Diabetes Mellitus
Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.
Diabetes Mellitus
Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Repurposing anti-diabetic drug "Sitagliptin" as a novel virulence attenuating agent in Serratia marcescens.
Diabetes Mellitus
Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study.
Diabetes Mellitus
Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).
Diabetes Mellitus
Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Diabetes Mellitus
Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting.
Diabetes Mellitus
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: comparison with sitagliptin.
Diabetes Mellitus
Review of linagliptin for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.
Diabetes Mellitus
Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Diabetes Mellitus
Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Diabetes Mellitus
Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Diabetes Mellitus
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.
Diabetes Mellitus
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus.
Diabetes Mellitus
Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
Diabetes Mellitus
Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan.
Diabetes Mellitus
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging.
Diabetes Mellitus
Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
Diabetes Mellitus
Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
Diabetes Mellitus
Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
Diabetes Mellitus
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Diabetes Mellitus
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged???65?years.
Diabetes Mellitus
Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
Diabetes Mellitus
Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects.
Diabetes Mellitus
Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.
Diabetes Mellitus
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.
Diabetes Mellitus
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
Diabetes Mellitus
Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus.
Diabetes Mellitus
Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Diabetes Mellitus
Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Diabetes Mellitus
Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Diabetes Mellitus
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus
Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus.
Diabetes Mellitus
Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus.
Diabetes Mellitus
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Diabetes Mellitus
SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
Diabetes Mellitus
SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials.
Diabetes Mellitus
SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus
Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
Diabetes Mellitus
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Diabetes Mellitus
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Diabetes Mellitus
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Diabetes Mellitus
Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial.
Diabetes Mellitus
Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.
Diabetes Mellitus
Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
Diabetes Mellitus
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
Diabetes Mellitus
Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study.
Diabetes Mellitus
Sitagliptin for Type 2 diabetes: a 2015 update.
Diabetes Mellitus
Sitagliptin Improves Plasma Apolipoprotein Profile in Type 2 Diabetes: A Randomized Clinical Trial of Sitagliptin Effect on Lipid and Glucose Metabolism (SLIM) Study.
Diabetes Mellitus
Sitagliptin in GAD antibody positive diabetes mellitus.
Diabetes Mellitus
Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
Diabetes Mellitus
Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties.
Diabetes Mellitus
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
Diabetes Mellitus
Sitagliptin protects against hypoxia/reoxygenation (H/R)-induced cardiac microvascular endothelial cell injury.
Diabetes Mellitus
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
Diabetes Mellitus
Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects.
Diabetes Mellitus
Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis.
Diabetes Mellitus
Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus
Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
Diabetes Mellitus
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Diabetes Mellitus
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Diabetes Mellitus
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Diabetes Mellitus
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Diabetes Mellitus
Solid-State Characterization of Different Crystalline Forms of Sitagliptin.
Diabetes Mellitus
Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release.
Diabetes Mellitus
Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Standardized Emblica officinalis fruit extract inhibited the activities of alpha-amylase, alpha-glucosidase, dipeptidyl peptidase-4 and displayed antioxidant potential.
Diabetes Mellitus
Structural Dynamics of DPP-4 and Its Influence on the Projection of Bioactive Ligands.
Diabetes Mellitus
Structural insights of dipeptidyl peptidase-IV inhibitors through molecular dynamics-guided receptor-dependent 4D-QSAR studies.
Diabetes Mellitus
Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial.
Diabetes Mellitus
Substance p increases sympathetic activity during combined Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
Diabetes Mellitus
Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes: a pilot study
Diabetes Mellitus
Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Diabetes Mellitus
Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Diabetes Mellitus
Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
Diabetes Mellitus
Systematic Review of Economic Evaluations of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.
Diabetes Mellitus
Targeting the intestinal L-cell for obesity and type 2 diabetes treatment.
Diabetes Mellitus
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
Diabetes Mellitus
Teneligliptin in management of type 2 diabetes mellitus.
Diabetes Mellitus
Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells.
Diabetes Mellitus
Teneligliptin: An Economic and Effective DPP-4 Inhibitor for the Management of Type-2 Diabetes Mellitus: A Comparative Study.
Diabetes Mellitus
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
Diabetes Mellitus
The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.
Diabetes Mellitus
The Alchemist's Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes?
Diabetes Mellitus
The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Diabetes Mellitus
The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
Diabetes Mellitus
The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
Diabetes Mellitus
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Diabetes Mellitus
The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes.
Diabetes Mellitus
The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats.
Diabetes Mellitus
The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus.
Diabetes Mellitus
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
Diabetes Mellitus
The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Diabetes Mellitus
The DPP-4 inhibitor Linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
Diabetes Mellitus
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Diabetes Mellitus
The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Diabetes Mellitus
The Effect of Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: a Systematic Review of Randomized Placebo-controlled Trials.
Diabetes Mellitus
The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.
Diabetes Mellitus
The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus.
Diabetes Mellitus
The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship.
Diabetes Mellitus
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.
Diabetes Mellitus
The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes Mellitus
The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Diabetes Mellitus
The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.
Diabetes Mellitus
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Diabetes Mellitus
The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells.
Diabetes Mellitus
The effects of incretin-based therapies on ?-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
Diabetes Mellitus
The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Diabetes Mellitus
The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Diabetes Mellitus
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
Diabetes Mellitus
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Diabetes Mellitus
The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus
The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Diabetes Mellitus
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial.
Diabetes Mellitus
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Diabetes Mellitus
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
Diabetes Mellitus
The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis.
Diabetes Mellitus
The management of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, ?-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2).
Diabetes Mellitus
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus. Possible role of stromal derived factor-1{alpha}
Diabetes Mellitus
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Diabetes Mellitus
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Diabetes Mellitus
The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Diabetes Mellitus
The relationship between carotid intima-media thickness and serum secreted frizzled-related protein-4 and dipeptidyl peptidase-4 in diabetic patients with cardiovascular diseases.
Diabetes Mellitus
The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients.
Diabetes Mellitus
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
Diabetes Mellitus
The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect.
Diabetes Mellitus
The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
Diabetes Mellitus
The role of incretin on diabetes mellitus.
Diabetes Mellitus
The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors.
Diabetes Mellitus
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Diabetes Mellitus
The role of vildagliptin in the management of type 2 diabetes mellitus.
Diabetes Mellitus
The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes Mellitus
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Diabetes Mellitus
The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration.
Diabetes Mellitus
Therapeutic Experience of Saxagliptin as First Add-on after Metformin in Indian Type 2 Diabetes Patients: A Non-interventional, Prospective, Observational Study (ONTARGET-INDIA).
Diabetes Mellitus
Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
Diabetes Mellitus
Therapeutic vaccine against DPP4 improves glucose metabolism in mice.
Diabetes Mellitus
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Diabetes Mellitus
Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Diabetes Mellitus
Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.
Diabetes Mellitus
Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?
Diabetes Mellitus
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Diabetes Mellitus
Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial.
Diabetes Mellitus
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Diabetes Mellitus
Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
Diabetes Mellitus
Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis.
Diabetes Mellitus
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension.
Diabetes Mellitus
Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.
Diabetes Mellitus
Update in cardiology: vascular risk and cardiac rehabilitation.
Diabetes Mellitus
Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
Diabetes Mellitus
Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Diabetes Mellitus
Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
Diabetes Mellitus
Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
Diabetes Mellitus
Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
Diabetes Mellitus
Vascular Protection with Dipeptidyl Peptidase-IV inhibitors in Diabetes: Experimental and Clinical Therapeutics.
Diabetes Mellitus
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.
Diabetes Mellitus
Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Diabetes Mellitus
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Diabetes Mellitus
Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.
Diabetes Mellitus
Vildagliptin in clinical practice: a review of literature.
Diabetes Mellitus
Vildagliptin induces ?-cell neogenesis and improves the lipid profile in a later phase of type 1 diabetes.
Diabetes Mellitus
Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.
Diabetes Mellitus
Vildagliptin Versus ?-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study.
Diabetes Mellitus
Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
Diabetes Mellitus
Vildagliptin-induced acute lung injury: a case report.
Diabetes Mellitus
Vildagliptin-induced acute pancreatitis without enzyme elevation.
Diabetes Mellitus
Vildagliptin.
Diabetes Mellitus
Vildagliptin: a review of its use in type 2 diabetes mellitus.
Diabetes Mellitus
Virtual Screening-Based Discovery of Potent Hypoglycemic Agents: In Silico, Chemical Synthesis and Biological Study.
Diabetes Mellitus
Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus.
Diabetes Mellitus
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Diabetes Mellitus
ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.
Diabetes Mellitus
[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
Diabetes Mellitus
[Acquired hemophilia A complicated by dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid].
Diabetes Mellitus
[Annual monitoring of side effects of administering sitagliptin in patients with type 2 diabetes mellitus].
Diabetes Mellitus
[Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Diabetes Mellitus
[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
Diabetes Mellitus
[Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].
Diabetes Mellitus
[Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers]
Diabetes Mellitus
[Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison]
Diabetes Mellitus
[Gliptins: a safe and effective treatment of diabetes mellitus].
Diabetes Mellitus
[Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV]
Diabetes Mellitus
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]
Diabetes Mellitus
[Recommendations of the main clinical practice guidelines].
Diabetes Mellitus
[Screening and identification of DPP-4 inhibitors from Xiaokean formula by a fluorescent probe].
Diabetes Mellitus
[The effect of antidiabetic treatment on the bone of patients with type 2 diabetes].
Diabetes Mellitus
[The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Diabetes Mellitus, Type 1
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Diabetes Mellitus, Type 1
Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect ?-cell function in LADA patients: A 1-year pilot study.
Diabetes Mellitus, Type 1
Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial.
Diabetes Mellitus, Type 1
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Diabetes Mellitus, Type 1
An effective treatment approach of DPP-IV inhibitor encapsulated polymeric nanoparticles conjugated with anti-CD-4 mAb for type 1 diabetes.
Diabetes Mellitus, Type 1
CD26/DPPIV inhibition alters the expression of immune response-related genes in the thymi of NOD mice.
Diabetes Mellitus, Type 1
Combination of monoclonal antibodies and DPP-IV inhibitors in the treatment of type 1 diabetes: a plausible treatment modality?
Diabetes Mellitus, Type 1
Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes.
Diabetes Mellitus, Type 1
Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces ?-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
Diabetes Mellitus, Type 1
Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
Diabetes Mellitus, Type 1
Development and analytical performance of a new ARCHITECT automated dipeptidyl peptidase-4 immunoassay.
Diabetes Mellitus, Type 1
Diabetic nephropathy: newer therapeutic perspectives.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase 4 inhibitor sitagliptin maintains ?-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase-4 activity might be a link between tumour necrosis factor alpha and insulin resistance in type 1 diabetes.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future.
Diabetes Mellitus, Type 1
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.
Diabetes Mellitus, Type 1
DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes.
Diabetes Mellitus, Type 1
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Diabetes Mellitus, Type 1
Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
Diabetes Mellitus, Type 1
Elevation of serum dipeptidyl peptidase-4 activity in type 1 diabetes: Potential explanations and implications.
Diabetes Mellitus, Type 1
Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus.
Diabetes Mellitus, Type 1
Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Diabetes Mellitus, Type 1
Higher Serum DPP-4 Enzyme Activity and Decreased Lymphocyte CD26 Expression in Type 1 Diabetes.
Diabetes Mellitus, Type 1
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.
Diabetes Mellitus, Type 1
Impact of type 1 diabetes mellitus and sitagliptin treatment on the neuropeptide Y system of rat retina.
Diabetes Mellitus, Type 1
Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
Diabetes Mellitus, Type 1
Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.
Diabetes Mellitus, Type 1
Influence of nutritional intervention on children with type 1 diabetes mellitus and DPP-4 in serum.
Diabetes Mellitus, Type 1
Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Diabetes Mellitus, Type 1
Investigating optimal ?-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial.
Diabetes Mellitus, Type 1
Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial.
Diabetes Mellitus, Type 1
Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1? and IL-12 in NOD mice.
Diabetes Mellitus, Type 1
Oral formulation of DPP-4 inhibitor plus Quercetin improves metabolic homeostasis in type 1 diabetic rats.
Diabetes Mellitus, Type 1
Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes.
Diabetes Mellitus, Type 1
Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people.
Diabetes Mellitus, Type 1
Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Diabetes Mellitus, Type 1
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Diabetes Mellitus, Type 1
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.
Diabetes Mellitus, Type 1
Saxagliptin co-therapy in C-peptide-negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia.
Diabetes Mellitus, Type 1
Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.
Diabetes Mellitus, Type 1
The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
Diabetes Mellitus, Type 1
The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves ?-cell mass in non-obese diabetic mice.
Diabetes Mellitus, Type 1
THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.
Diabetes Mellitus, Type 1
The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 1
The new insights of DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Diabetes Mellitus, Type 1
Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition.
Diabetes Mellitus, Type 1
Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Diabetes Mellitus, Type 1
Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8?T Effector Memory Subset.
Diabetes Mellitus, Type 1
Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease.
Diabetes Mellitus, Type 1
Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway.
Diabetes Mellitus, Type 1
Vildagliptin Ameliorates Oxidative Stress and Pancreatic Beta Cell Destruction in Type 1 Diabetic Rats.
Diabetes Mellitus, Type 1
Vildagliptin induces ?-cell neogenesis and improves the lipid profile in a later phase of type 1 diabetes.
Diabetes Mellitus, Type 1
Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes.
Diabetes Mellitus, Type 1
[Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison]
Diabetes Mellitus, Type 1
[Limited add-on value of oral glucose-lowering agents in type 1 diabetes].
Diabetes Mellitus, Type 2
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Diabetes Mellitus, Type 2
(3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
Diabetes Mellitus, Type 2
(R)-3-amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: design, synthesis, biological evaluation, and molecular modeling.
Diabetes Mellitus, Type 2
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Diabetes Mellitus, Type 2
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Diabetes Mellitus, Type 2
11 Years of cyanopyrrolidines as DPP-IV inhibitors.
Diabetes Mellitus, Type 2
16,17-Dihydro-17b-hydroxy isomitraphylline alkaloid as an inhibitor of DPP-IV, and its effect on incretin hormone and ?-cell proliferation in diabetic rat.
Diabetes Mellitus, Type 2
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
?-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.
Diabetes Mellitus, Type 2
A Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan.
Diabetes Mellitus, Type 2
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Diabetes Mellitus, Type 2
A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice.
Diabetes Mellitus, Type 2
A Comparative Study of the Effects of a Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability in Patients with Type 2 Diabetes with Inadequate Glycemic Control on Metformin.
Diabetes Mellitus, Type 2
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug.
Diabetes Mellitus, Type 2
A Decision-Focused Mixed Treatment Comparison (MTC) of Alternative Dpp-4 Inhibitors (Dpp-4i's) Used in Combination With Metformin or a Sulfonylurea for the Treatment of Type 2 Diabetes Mellitus (T2DM).
Diabetes Mellitus, Type 2
A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes.
Diabetes Mellitus, Type 2
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Diabetes Mellitus, Type 2
A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*
Diabetes Mellitus, Type 2
A DPP-4 Inhibitor Suppresses Fibrosis and Inflammation on Experimental Autoimmune Myocarditis in Mice.
Diabetes Mellitus, Type 2
A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.
Diabetes Mellitus, Type 2
A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma.
Diabetes Mellitus, Type 2
A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
A manganese-salen complex as dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans.
Diabetes Mellitus, Type 2
A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24?163 patients.
Diabetes Mellitus, Type 2
A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39 845 patients.
Diabetes Mellitus, Type 2
A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39,845 patients.
Diabetes Mellitus, Type 2
A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands.
Diabetes Mellitus, Type 2
A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes.
Diabetes Mellitus, Type 2
A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic ?-Cell Function and Reduces ?-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
Diabetes Mellitus, Type 2
A novel long acting DPP-IV inhibitor PKF-275-055 stimulates ?-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Diabetes Mellitus, Type 2
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Diabetes Mellitus, Type 2
A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2.
Diabetes Mellitus, Type 2
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Diabetes Mellitus, Type 2
A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.
Diabetes Mellitus, Type 2
A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation.
Diabetes Mellitus, Type 2
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Diabetes Mellitus, Type 2
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Diabetes Mellitus, Type 2
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Diabetes Mellitus, Type 2
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
Diabetes Mellitus, Type 2
A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Diabetes Mellitus, Type 2
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Diabetes Mellitus, Type 2
A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.
Diabetes Mellitus, Type 2
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
Diabetes Mellitus, Type 2
A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
Diabetes Mellitus, Type 2
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Diabetes Mellitus, Type 2
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Diabetes Mellitus, Type 2
A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Diabetes Mellitus, Type 2
A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Diabetes Mellitus, Type 2
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.
Diabetes Mellitus, Type 2
A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
Diabetes Mellitus, Type 2
A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Diabetes Mellitus, Type 2
A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment.
Diabetes Mellitus, Type 2
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
Diabetes Mellitus, Type 2
A review of gliptins for 2014.
Diabetes Mellitus, Type 2
A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
Diabetes Mellitus, Type 2
A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.
Diabetes Mellitus, Type 2
A siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice.
Diabetes Mellitus, Type 2
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Diabetes Mellitus, Type 2
A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
Diabetes Mellitus, Type 2
A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
Diabetes Mellitus, Type 2
Abelmoschus esculentus subfractions improved nephropathy with regulating dipeptidyl peptidase-4 and type 1 glucagon-like peptide receptor in type 2 diabetic rats.
Diabetes Mellitus, Type 2
Abscisic Acid Stimulates Glucagon-Like Peptide-1 Secretion from L-Cells and Its Oral Administration Increases Plasma Glucagon-Like Peptide-1 Levels in Rats.
Diabetes Mellitus, Type 2
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Diabetes Mellitus, Type 2
Absorption, metabolism and excretion of [(14)C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Diabetes Mellitus, Type 2
Absorption, metabolism and excretion of [(14)C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans.
Diabetes Mellitus, Type 2
Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Diabetes Mellitus, Type 2
Achieving glycemic control in patients with type 2 diabetes and renal impairment.
Diabetes Mellitus, Type 2
ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes.
Diabetes Mellitus, Type 2
ACP Journal Club. Review: in type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis.
Diabetes Mellitus, Type 2
ACP Journal Club: review: dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes.
Diabetes Mellitus, Type 2
Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan.
Diabetes Mellitus, Type 2
Activity and selectivity cliffs for DPP-IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening.
Diabetes Mellitus, Type 2
Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models.
Diabetes Mellitus, Type 2
Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Diabetes Mellitus, Type 2
Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Acute effects of sitagliptin on progenitor cells and soluble mediators in newly diagnosed type 2 diabetes.
Diabetes Mellitus, Type 2
Acute Kidney Injury Associated with Linagliptin.
Diabetes Mellitus, Type 2
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
Diabetes Mellitus, Type 2
Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis.
Diabetes Mellitus, Type 2
Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in ?-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study.
Diabetes Mellitus, Type 2
Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Diabetes Mellitus, Type 2
Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.
Diabetes Mellitus, Type 2
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks.
Diabetes Mellitus, Type 2
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Diabetes Mellitus, Type 2
Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Diabetes Mellitus, Type 2
Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan.
Diabetes Mellitus, Type 2
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.
Diabetes Mellitus, Type 2
Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model.
Diabetes Mellitus, Type 2
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Diabetes Mellitus, Type 2
All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.
Diabetes Mellitus, Type 2
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.
Diabetes Mellitus, Type 2
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.
Diabetes Mellitus, Type 2
Alogliptin benzoate for management of type 2 diabetes.
Diabetes Mellitus, Type 2
Alogliptin benzoate for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Alogliptin for the treatment of Type 2 diabetes.
Diabetes Mellitus, Type 2
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Diabetes Mellitus, Type 2
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Alogliptin inhibits IL-1?-induced inflammatory response in fibroblast-like synoviocytes.
Diabetes Mellitus, Type 2
Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies.
Diabetes Mellitus, Type 2
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Diabetes Mellitus, Type 2
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis.
Diabetes Mellitus, Type 2
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus.
Diabetes Mellitus, Type 2
Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Alogliptin: Safety, Efficacy, and Clinical Implications.
Diabetes Mellitus, Type 2
Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats.
Diabetes Mellitus, Type 2
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Diabetes Mellitus, Type 2
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
Diabetes Mellitus, Type 2
An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.
Diabetes Mellitus, Type 2
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Diabetes Mellitus, Type 2
An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivo.
Diabetes Mellitus, Type 2
An overview of recent dipeptidyl peptidase-IV inhibitors: linking their structure and physico-chemical properties with sar, pharmacokinetics and toxicity.
Diabetes Mellitus, Type 2
An update on DPP-4 inhibitors in the management of type 2 diabetes.
Diabetes Mellitus, Type 2
An update on the 'gliptins'.
Diabetes Mellitus, Type 2
An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
An updated review on cancer risk associated with incretin mimetics and enhancers.
Diabetes Mellitus, Type 2
An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.
Diabetes Mellitus, Type 2
Anagliptin, a Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
Diabetes Mellitus, Type 2
Analyzing a dipeptide library to identify human dipeptidyl peptidase IV inhibitor.
Diabetes Mellitus, Type 2
Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study).
Diabetes Mellitus, Type 2
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
Diabetes Mellitus, Type 2
Anti-Diabetic Agents and Heart Failure?- Response to the CARMELINA Study.
Diabetes Mellitus, Type 2
Anti-glycemic potential of benzophenone thio/semicarbazone derivatives: synthesis, enzyme inhibition and ligand docking studies.
Diabetes Mellitus, Type 2
Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke.
Diabetes Mellitus, Type 2
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
Diabetes Mellitus, Type 2
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
Diabetes Mellitus, Type 2
Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Antidiabetic Agent DPP-4i Facilitates Murine Breast Cancer Metastasis by Oncogenic ROS-NRF2-HO-1 Axis via a Positive NRF2-HO-1 Feedback Loop.
Diabetes Mellitus, Type 2
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
Diabetes Mellitus, Type 2
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Diabetes Mellitus, Type 2
Antihyperglycaemic activity of ethylacetate extract of Chlorophytum alismifolium in type 2 diabetes: The involvement of peroxisome proliferator-activated receptor-? and dipeptidyl peptidase-4.
Diabetes Mellitus, Type 2
Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Antihyperglycemic effect of a chicken feet hydrolysate via the incretin system: DPP-IV-inhibitory activity and GLP-1 release stimulation.
Diabetes Mellitus, Type 2
Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
Diabetes Mellitus, Type 2
Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?
Diabetes Mellitus, Type 2
ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Diabetes Mellitus, Type 2
Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
Diabetes Mellitus, Type 2
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Diabetes Mellitus, Type 2
Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes.
Diabetes Mellitus, Type 2
Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
Diabetes Mellitus, Type 2
Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Association between DPP4 gene polymorphism and serum lipid levels in Chinese type 2 diabetes individuals.
Diabetes Mellitus, Type 2
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
Diabetes Mellitus, Type 2
Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
Diabetes Mellitus, Type 2
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
Diabetes Mellitus, Type 2
Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan.
Diabetes Mellitus, Type 2
Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study.
Diabetes Mellitus, Type 2
Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study.
Diabetes Mellitus, Type 2
Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study.
Diabetes Mellitus, Type 2
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
Diabetes Mellitus, Type 2
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
Diabetes Mellitus, Type 2
Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.
Diabetes Mellitus, Type 2
Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects.
Diabetes Mellitus, Type 2
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Diabetes Mellitus, Type 2
Association of Plasma DPP4 Activity and Brain-Derived Neurotrophic Factor With Moderate to Severe Depressive Symptoms in Patients With Type 2 Diabetes: Results From a Cross-Sectional Study.
Diabetes Mellitus, Type 2
Association of Plasma DPP4 Activity to BDNF Ratio with Moderate to Severe Depressive Symptoms in Patients With Type 2 Diabetes: Results from a Cross-Sectional Study.
Diabetes Mellitus, Type 2
Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Diabetes Mellitus, Type 2
Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
Diabetes Mellitus, Type 2
Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Diabetes Mellitus, Type 2
Autophagy deficiency in ? cells blunts incretin-induced suppression of glucagon release from ? cells.
Diabetes Mellitus, Type 2
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Diabetes Mellitus, Type 2
Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study.
Diabetes Mellitus, Type 2
Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Diabetes Mellitus, Type 2
Beneficial Effects of Vildagliptin on Retinal Injury in Obese Type 2 Diabetic Rats.
Diabetes Mellitus, Type 2
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
Diabetes Mellitus, Type 2
Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management.
Diabetes Mellitus, Type 2
Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability.
Diabetes Mellitus, Type 2
Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Diabetes Mellitus, Type 2
Bifidobacteria possess inhibitory activity against dipeptidyl peptidase-IV.
Diabetes Mellitus, Type 2
Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats.
Diabetes Mellitus, Type 2
Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus, Type 2
Bioactive peptides in the management of lifestyle-related diseases: Current trends and future perspectives.
Diabetes Mellitus, Type 2
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Diabetes Mellitus, Type 2
Biologic actions and therapeutic potential of the proglucagon-derived peptides.
Diabetes Mellitus, Type 2
Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.
Diabetes Mellitus, Type 2
Biological function of dipeptidyl peptidase-4 on type 2 diabetes patients and diabetic mice.
Diabetes Mellitus, Type 2
Biology of incretins: GLP-1 and GIP.
Diabetes Mellitus, Type 2
Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Diabetes Mellitus, Type 2
Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.
Diabetes Mellitus, Type 2
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
Diabetes Mellitus, Type 2
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Bone: incretin hormones perceiver or receiver?
Diabetes Mellitus, Type 2
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
Diabetes Mellitus, Type 2
C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Canagliflozin (CANA) Added on to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) or Glucagon-like Peptide-1 (GLP-1) Agonists with or Without Other Antihyperglycemic Agents (AHAs) in Type 2 Diabetes Mellitus (T2DM).
Diabetes Mellitus, Type 2
Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Cardiometabolic Effects of a New Class of Antidiabetic Agents.
Diabetes Mellitus, Type 2
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus, Type 2
Cardiovascular actions of incretin-based therapies.
Diabetes Mellitus, Type 2
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Diabetes Mellitus, Type 2
Cardiovascular Biology of the Incretin System.
Diabetes Mellitus, Type 2
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
Diabetes Mellitus, Type 2
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Diabetes Mellitus, Type 2
Cardiovascular effects of gliptins.
Diabetes Mellitus, Type 2
Cardiovascular Effects of Incretin-Based Therapies.
Diabetes Mellitus, Type 2
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
Diabetes Mellitus, Type 2
Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.
Diabetes Mellitus, Type 2
Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
Diabetes Mellitus, Type 2
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial.
Diabetes Mellitus, Type 2
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Diabetes Mellitus, Type 2
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Diabetes Mellitus, Type 2
Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis.
Diabetes Mellitus, Type 2
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
Diabetes Mellitus, Type 2
Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Diabetes Mellitus, Type 2
Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
Diabetes Mellitus, Type 2
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Diabetes Mellitus, Type 2
Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
Diabetes Mellitus, Type 2
Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan.
Diabetes Mellitus, Type 2
Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study.
Diabetes Mellitus, Type 2
Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
Diabetes Mellitus, Type 2
Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons.
Diabetes Mellitus, Type 2
Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.
Diabetes Mellitus, Type 2
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Diabetes Mellitus, Type 2
Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.
Diabetes Mellitus, Type 2
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Cardiovascular safety of therapies for type 2 diabetes.
Diabetes Mellitus, Type 2
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.
Diabetes Mellitus, Type 2
CD26 in autoimmune diseases: The other side of "moonlight protein".
Diabetes Mellitus, Type 2
CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology.
Diabetes Mellitus, Type 2
Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis.
Diabetes Mellitus, Type 2
Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.
Diabetes Mellitus, Type 2
Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update.
Diabetes Mellitus, Type 2
Characterization of Novel Dipeptidyl Peptidase-IV Inhibitory Peptides from Soft-Shelled Turtle Yolk Hydrolysate Using Orthogonal Bioassay-Guided Fractionations Coupled with In Vitro and In Silico Study.
Diabetes Mellitus, Type 2
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
Diabetes Mellitus, Type 2
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Diabetes Mellitus, Type 2
Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure.
Diabetes Mellitus, Type 2
Chemometrics Optimized Extraction Procedures, Phytosynergistic Blending and in vitro Screening of Natural Enzyme Inhibitors Amongst Leaves of Tulsi, Banyan and Jamun.
Diabetes Mellitus, Type 2
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Diabetes Mellitus, Type 2
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Diabetes Mellitus, Type 2
Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Diabetes Mellitus, Type 2
Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Diabetes Mellitus, Type 2
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic {beta}-Cell Mass and Function in a Rodent Model of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models.
Diabetes Mellitus, Type 2
Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Diabetes Mellitus, Type 2
cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
Diabetes Mellitus, Type 2
Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
Diabetes Mellitus, Type 2
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.
Diabetes Mellitus, Type 2
CLINICAL CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS CONTINUED ON ORAL ANTIDIABETES MEDICATIONS IN THE HOSPITAL.
Diabetes Mellitus, Type 2
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
Clinical effectiveness of switching between DPP-4 inhibitors in patients with type 2 diabetes mellitus?.
Diabetes Mellitus, Type 2
Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Diabetes Mellitus, Type 2
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
Diabetes Mellitus, Type 2
Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Clinical overview of saxagliptin for Type 2 diabetes management.
Diabetes Mellitus, Type 2
Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Diabetes Mellitus, Type 2
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
Diabetes Mellitus, Type 2
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.
Diabetes Mellitus, Type 2
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Diabetes Mellitus, Type 2
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Diabetes Mellitus, Type 2
Clinical review of sitagliptin: a DPP-4 inhibitor.
Diabetes Mellitus, Type 2
Clinical Review: Safety and Efficacy comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin.
Diabetes Mellitus, Type 2
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.
Diabetes Mellitus, Type 2
Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Clinical Use of DPP-4 Inhibitors.
Diabetes Mellitus, Type 2
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.
Diabetes Mellitus, Type 2
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Diabetes Mellitus, Type 2
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Diabetes Mellitus, Type 2
Cognitive and Functional Influences of Vildagliptin, A DPP-4 Inhibitor, Added to ongoing Metformin Therapy in Elderly with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Diabetes Mellitus, Type 2
Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Diabetes Mellitus, Type 2
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes.
Diabetes Mellitus, Type 2
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Diabetes Mellitus, Type 2
Combination pharmacotherapy with incretins: what works best and when?
Diabetes Mellitus, Type 2
Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea.
Diabetes Mellitus, Type 2
Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Diabetes Mellitus, Type 2
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
Diabetes Mellitus, Type 2
Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Diabetes Mellitus, Type 2
Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Diabetes Mellitus, Type 2
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Diabetes Mellitus, Type 2
Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.
Diabetes Mellitus, Type 2
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
Diabetes Mellitus, Type 2
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice.
Diabetes Mellitus, Type 2
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Diabetes Mellitus, Type 2
Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Diabetes Mellitus, Type 2
CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements.
Diabetes Mellitus, Type 2
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Diabetes Mellitus, Type 2
Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.
Diabetes Mellitus, Type 2
Comparative Cardiovascular Safety of Glucagon-Like Peptide-1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study.
Diabetes Mellitus, Type 2
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
Diabetes Mellitus, Type 2
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.
Diabetes Mellitus, Type 2
Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Diabetes Mellitus, Type 2
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study.
Diabetes Mellitus, Type 2
Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
Diabetes Mellitus, Type 2
Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study.
Diabetes Mellitus, Type 2
Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Diabetes Mellitus, Type 2
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Diabetes Mellitus, Type 2
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Diabetes Mellitus, Type 2
Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
Diabetes Mellitus, Type 2
Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study.
Diabetes Mellitus, Type 2
Comparison between SGLT2 Inhibitors and DPP4 Inhibitors Added to Insulin Therapy in Type 2 Diabetes: A Systematic Review with Indirect Comparison Meta-analysis.
Diabetes Mellitus, Type 2
Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
Diabetes Mellitus, Type 2
Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).
Diabetes Mellitus, Type 2
Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis.
Diabetes Mellitus, Type 2
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Diabetes Mellitus, Type 2
Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Diabetes Mellitus, Type 2
Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
Diabetes Mellitus, Type 2
Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
Diabetes Mellitus, Type 2
Comparison of Efficacy between Dipeptidyl Peptidase-4 Inhibitor and Sodium-Glucose Cotransporter 2 Inhibitor on Metabolic Risk Factors in Japanese Patients with Type 2 Diabetes Mellitus: Results from the CANTABILE Study.
Diabetes Mellitus, Type 2
Comparison of Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter 2 Inhibitors Between Japanese and Non-Japanese Patients: A Meta-Analysis.
Diabetes Mellitus, Type 2
Comparison of Gemigliptin and Dapagliflozin Effects on Glycemic Variability in Type 2 Diabetes: A Randomized, Open-Label, Active-Controlled, 12-Week Study (STABLE II Study).
Diabetes Mellitus, Type 2
Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.
Diabetes Mellitus, Type 2
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Diabetes Mellitus, Type 2
Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Diabetes Mellitus, Type 2
Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Diabetes Mellitus, Type 2
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Diabetes Mellitus, Type 2
Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.
Diabetes Mellitus, Type 2
Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
Diabetes Mellitus, Type 2
Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.
Diabetes Mellitus, Type 2
Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Diabetes Mellitus, Type 2
Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
Diabetes Mellitus, Type 2
Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes.
Diabetes Mellitus, Type 2
Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides.
Diabetes Mellitus, Type 2
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
Diabetes Mellitus, Type 2
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Diabetes Mellitus, Type 2
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Diabetes Mellitus, Type 2
Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Diabetes Mellitus, Type 2
Comparisons of the efficacy of glucose control, lipid profile, and ?-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.
Diabetes Mellitus, Type 2
Comparng once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study.
Diabetes Mellitus, Type 2
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.
Diabetes Mellitus, Type 2
Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Diabetes Mellitus, Type 2
Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons.
Diabetes Mellitus, Type 2
Correction: Kim, Young-Gun; Jeon, Ja Young; Kim, Hae Jin; Kim, Dae Jung; Lee, Kwan-Woo; Moon, So Young; Han, Seung Jin. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors versus Sulfonylureas: A Real-World Population-Based Cohort Study. Journal of Clinical Medicine 2019, 8, 28.
Diabetes Mellitus, Type 2
Corrigendum to 'Demographic and Clinical Characteristics of Type 2 Diabetes Mellitus Patients Initiating Dipeptidyl Peptidase-4 Inhibitors - A Retrospective Study of UK General Practice' Clin Ther 2016;8:1825-1832.e15.
Diabetes Mellitus, Type 2
Corrigendum to 'Demographic and clinical characteristics of type 2 diabetes mellitus patients initiating dipeptidyl peptidase-4 inhibitors - a retrospective study of UK general practice'.
Diabetes Mellitus, Type 2
Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes.
Diabetes Mellitus, Type 2
Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Diabetes Mellitus, Type 2
Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Diabetes Mellitus, Type 2
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Diabetes Mellitus, Type 2
Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Diabetes Mellitus, Type 2
Cost-effectiveness of diabetes treatment sequences to inform step therapy policies.
Diabetes Mellitus, Type 2
Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand.
Diabetes Mellitus, Type 2
Cost-Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Monotherapy versus Sulfonylurea Monotherapy for People with Type 2 Diabetes and Chronic Kidney Disease in Thailand.
Diabetes Mellitus, Type 2
Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
Diabetes Mellitus, Type 2
Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.
Diabetes Mellitus, Type 2
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Diabetes Mellitus, Type 2
Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications.
Diabetes Mellitus, Type 2
Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden.
Diabetes Mellitus, Type 2
Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
Diabetes Mellitus, Type 2
Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
Diabetes Mellitus, Type 2
Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Diabetes Mellitus, Type 2
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Crystal structures of human dipeptidyl peptidase IV in its apo and diprotin B-complexed forms.
Diabetes Mellitus, Type 2
Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
Diabetes Mellitus, Type 2
Current management of diabetes mellitus and future directions in care.
Diabetes Mellitus, Type 2
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
Diabetes Mellitus, Type 2
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Diabetes Mellitus, Type 2
Dapagliflozin efficacy and safety: a perspective review.
Diabetes Mellitus, Type 2
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Diabetes Mellitus, Type 2
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Diabetes Mellitus, Type 2
Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
Diabetes Mellitus, Type 2
Dapagliflozin Versus a Dipeptidyl Peptidase 4 Inhibitor (DPP4) Both Added to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM): Impact on Health, Quality of Life and Costs in the Turkish Clinical Setting.
Diabetes Mellitus, Type 2
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture.
Diabetes Mellitus, Type 2
Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.
Diabetes Mellitus, Type 2
Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.
Diabetes Mellitus, Type 2
Decreased mortality after long term treatment with DPP-4 inhibitors: A retrospective study of US veterans with type 2 diabetes.
Diabetes Mellitus, Type 2
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12/CXCR4/mTOR/TGF? Signaling Pathway in Breast Cancer Cells.
Diabetes Mellitus, Type 2
Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Diabetes Mellitus, Type 2
Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
Diabetes Mellitus, Type 2
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Diabetes Mellitus, Type 2
Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Diabetes Mellitus, Type 2
Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Sitagliptin in the Real-world Setting.
Diabetes Mellitus, Type 2
Design and synthesis of aminocoumarin derivatives as DPP-IV inhibitors and anticancer agents.
Diabetes Mellitus, Type 2
Design and synthesis of sulfonamide derivatives of pyrrolidine and piperidine as anti-diabetic agents.
Diabetes Mellitus, Type 2
Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2-Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors.
Diabetes Mellitus, Type 2
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Design, Synthesis, and Pharmacological Evaluation of Fused ?-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors.
Diabetes Mellitus, Type 2
Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Design, synthesis, structure-activity relationships, and docking studies of 1-(?-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC-MS/MS and its application in a pharmacokinetics study.
Diabetes Mellitus, Type 2
Development and Validation of an HPLC Method for Determination of Antidiabetic Drug Alogliptin Benzoate in Bulk and Tablets.
Diabetes Mellitus, Type 2
Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma.
Diabetes Mellitus, Type 2
Development of a validated HPLC method for the quantitative determination of trelagliptin succinate and its related substances in pharmaceutical dosage forms.
Diabetes Mellitus, Type 2
Diabetes and cardiovascular disease: from new mechanisms to new therapies.
Diabetes Mellitus, Type 2
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.
Diabetes Mellitus, Type 2
Diabetes: advances in treatment.
Diabetes Mellitus, Type 2
Diabetic nephropathy: newer therapeutic perspectives.
Diabetes Mellitus, Type 2
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Diabetes Mellitus, Type 2
Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings?.
Diabetes Mellitus, Type 2
Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.
Diabetes Mellitus, Type 2
Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Diabetes Mellitus, Type 2
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Diabetes Mellitus, Type 2
Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.
Diabetes Mellitus, Type 2
Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and ?-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis.
Diabetes Mellitus, Type 2
Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 concentration influenced by serum insulin levels rather than arterial stiffness index in type 2 diabetics.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1?(1-67) in Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibitor sitagliptin maintains ?-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like Peptide 1-dependent mechanism.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase 4 Inhibitors and Venous Thromboembolism Risk in Patients with Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase 9 enzymatic activity influences the expression of neonatal metabolic genes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else ?
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in ?-cells.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D trial.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor treatment could decrease Klebsiella pneumoniae pneumonia in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor with ?-amino amide scaffold: Synthesis, SAR and biological evaluation.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link?
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study).
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 is increased in the abdominal aortic aneurysm vessel wall and is associated with aneurysm disease processes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in ?-lactoglobulin.
Diabetes Mellitus, Type 2
Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis.
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Diabetes Mellitus, Type 2
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Diabetes Mellitus, Type 2
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials.
Diabetes Mellitus, Type 2
Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials.
Diabetes Mellitus, Type 2
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.
Diabetes Mellitus, Type 2
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Diabetes Mellitus, Type 2
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Diabetes Mellitus, Type 2
Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool.
Diabetes Mellitus, Type 2
Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and de novo Evolution.
Diabetes Mellitus, Type 2
Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Discovery of potent dipeptidyl peptidase IV inhibitors derived from ?-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Diabetes Mellitus, Type 2
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1.
Diabetes Mellitus, Type 2
Divergent effects of various diabetes drugs on cardiovascular prognosis.
Diabetes Mellitus, Type 2
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials.
Diabetes Mellitus, Type 2
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
Diabetes Mellitus, Type 2
Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Diabetes Mellitus, Type 2
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Diabetes Mellitus, Type 2
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Diabetes Mellitus, Type 2
Dose-Ranging Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Diabetes Mellitus, Type 2
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Diabetes Mellitus, Type 2
DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Diabetes Mellitus, Type 2
DPP IV inhibitors: successes, failures and future prospects.
Diabetes Mellitus, Type 2
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
Diabetes Mellitus, Type 2
DPP-4 Inhibition and the Path to Clinical Proof.
Diabetes Mellitus, Type 2
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Diabetes Mellitus, Type 2
DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Diabetes Mellitus, Type 2
DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibition resembles exercise in preventing type 2 diabetes development by inhibiting hepatic protein kinase C? expression in a mouse model of hyperinsulinemia.
Diabetes Mellitus, Type 2
DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
Diabetes Mellitus, Type 2
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis.
Diabetes Mellitus, Type 2
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Diabetes Mellitus, Type 2
DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice ? cells.
Diabetes Mellitus, Type 2
DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism.
Diabetes Mellitus, Type 2
DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation.
Diabetes Mellitus, Type 2
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
Diabetes Mellitus, Type 2
DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis.
Diabetes Mellitus, Type 2
DPP-4 inhibitor treatment: ?-cell response but not HbA1c reduction is dependent on the duration of diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Diabetes Mellitus, Type 2
DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety.
Diabetes Mellitus, Type 2
DPP-4 Inhibitors and GLP-1 Receptor Agonists for Prevention or Delay of Type 2 Diabetes Mellitus and Associated Complications.
Diabetes Mellitus, Type 2
DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin.
Diabetes Mellitus, Type 2
DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews.
Diabetes Mellitus, Type 2
DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
DPP-4 inhibitors in clinical practice.
Diabetes Mellitus, Type 2
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Diabetes Mellitus, Type 2
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials.
Diabetes Mellitus, Type 2
DPP-4 inhibitors in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis.
Diabetes Mellitus, Type 2
DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.
Diabetes Mellitus, Type 2
DPP-4 inhibitors. A new class of drugs for type 2 diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibitors: a patent review (2012 - 2014).
Diabetes Mellitus, Type 2
DPP-4 inhibitors: Multi-target drugs, not only anti-diabetes.
Diabetes Mellitus, Type 2
DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.
Diabetes Mellitus, Type 2
DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes.
Diabetes Mellitus, Type 2
DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses.
Diabetes Mellitus, Type 2
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis.
Diabetes Mellitus, Type 2
DPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity.
Diabetes Mellitus, Type 2
DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
Diabetes Mellitus, Type 2
DPP4 inhibitor-induced polyarthritis: a report of three cases.
Diabetes Mellitus, Type 2
DPP4 inhibitors for diabetes--what next?
Diabetes Mellitus, Type 2
DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
Diabetes Mellitus, Type 2
DPPIV inhibition: promising therapy for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.
Diabetes Mellitus, Type 2
Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II.
Diabetes Mellitus, Type 2
Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease.
Diabetes Mellitus, Type 2
Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors.
Diabetes Mellitus, Type 2
Effect of a DPP-4 Inhibitor on Orthodontic Tooth Movement and Associated Root Resorption.
Diabetes Mellitus, Type 2
Effect of a Moderate Carbohydrate-Restricted Diet on DPP-4 Inhibitor Action among Individuals with Type 2 Diabetes Mellitus: A 6-Month Intervention Study.
Diabetes Mellitus, Type 2
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
Diabetes Mellitus, Type 2
Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.
Diabetes Mellitus, Type 2
Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Diabetes Mellitus, Type 2
Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study.
Diabetes Mellitus, Type 2
Effect of Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Events in Type-2 Diabetes Patients with Renal Impairment: A Systematic Review and Meta-analysis.
Diabetes Mellitus, Type 2
Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
Diabetes Mellitus, Type 2
Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-? concentrations: A systematic review and meta-analysis of controlled trials.
Diabetes Mellitus, Type 2
Effect of dipeptidyl peptidase-4 inhibitors on complement activation.
Diabetes Mellitus, Type 2
Effect of dipeptidyl peptidase-4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A meta-analysis of randomised controlled trials.
Diabetes Mellitus, Type 2
Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Effect of divalent cations on the porcine kidney cortex membrane-bound form of dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI.
Diabetes Mellitus, Type 2
Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis.
Diabetes Mellitus, Type 2
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?
Diabetes Mellitus, Type 2
Effect of exenatide on peripheral nerve excitability in type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
Diabetes Mellitus, Type 2
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Diabetes Mellitus, Type 2
Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
Diabetes Mellitus, Type 2
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of ?-cell function in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of linagliptin monotherapy on glycaemic control and markers of ?-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
Diabetes Mellitus, Type 2
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
Diabetes Mellitus, Type 2
Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.
Diabetes Mellitus, Type 2
Effect of linagliptin on pulse wave velocity in early type 2 diabetes (RELEASE): a randomized, double-blind, controlled 26-week trial.
Diabetes Mellitus, Type 2
Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice.
Diabetes Mellitus, Type 2
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Diabetes Mellitus, Type 2
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
Diabetes Mellitus, Type 2
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Diabetes Mellitus, Type 2
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Diabetes Mellitus, Type 2
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Diabetes Mellitus, Type 2
Effect of Renal Impairment on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin.
Diabetes Mellitus, Type 2
Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study.
Diabetes Mellitus, Type 2
Effect of Saxagliptin on the Pharmacokinetics of the Active Components of Ortho-Cyclen®, a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate, in Healthy Women.
Diabetes Mellitus, Type 2
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Diabetes Mellitus, Type 2
Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of single oral dose of proanthocyanidin on postprandial hyperglycemia in healthy rats: A comparative study with sitagliptin.
Diabetes Mellitus, Type 2
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of single-dose DPP-4 inhibitor sitagliptin on ?-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
Diabetes Mellitus, Type 2
Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
Diabetes Mellitus, Type 2
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
Diabetes Mellitus, Type 2
Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
Diabetes Mellitus, Type 2
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Diabetes Mellitus, Type 2
Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).
Diabetes Mellitus, Type 2
Effect of sitagliptin plus metformin on ?-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
Diabetes Mellitus, Type 2
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Diabetes Mellitus, Type 2
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease.
Diabetes Mellitus, Type 2
Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea.
Diabetes Mellitus, Type 2
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Diabetes Mellitus, Type 2
Effect of thymoquinone on high fat diet and STZ-induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies.
Diabetes Mellitus, Type 2
Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol.
Diabetes Mellitus, Type 2
Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial.
Diabetes Mellitus, Type 2
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Diabetes Mellitus, Type 2
Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.
Diabetes Mellitus, Type 2
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Diabetes Mellitus, Type 2
Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review.
Diabetes Mellitus, Type 2
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus, Type 2
Effectiveness of Liraglutide in Type 2 Diabetes Patients Switched from a DPP-4 Inhibitor: 1-Year Data from EVIDENCE®
Diabetes Mellitus, Type 2
Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Diabetes Mellitus, Type 2
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Diabetes Mellitus, Type 2
Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
Diabetes Mellitus, Type 2
Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effects of a D-xylose Preload With or Without Sitagliptin on Gastric Emptying, Glucagon-Like Peptide-1, and Postprandial Glycemia in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).
Diabetes Mellitus, Type 2
Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor.
Diabetes Mellitus, Type 2
Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
Diabetes Mellitus, Type 2
Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study.
Diabetes Mellitus, Type 2
Effects of alogliptin on the ratio of glycated albumin to HbA1c in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin.
Diabetes Mellitus, Type 2
Effects of anagliptin on the stress induced accelerated senescence of human umbilical vein endothelial cells.
Diabetes Mellitus, Type 2
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Diabetes Mellitus, Type 2
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Diabetes Mellitus, Type 2
Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A 18F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
Diabetes Mellitus, Type 2
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Diabetes Mellitus, Type 2
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.
Diabetes Mellitus, Type 2
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Diabetes Mellitus, Type 2
Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study.
Diabetes Mellitus, Type 2
Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Diabetes Mellitus, Type 2
Effects of exendin-4 on islets from type 2 diabetes patients.
Diabetes Mellitus, Type 2
Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption.
Diabetes Mellitus, Type 2
Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial.
Diabetes Mellitus, Type 2
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
Diabetes Mellitus, Type 2
Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Diabetes Mellitus, Type 2
Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Diabetes Mellitus, Type 2
Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of novel chalcone derivatives on ?-glucosidase, dipeptidyl peptidase-4, and adipocyte differentiation in vitro.
Diabetes Mellitus, Type 2
Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Diabetes Mellitus, Type 2
Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Diabetes Mellitus, Type 2
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic ?-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of saxagliptin on ?-cell stimulation and insulin secretion in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of selected antidiabetics on weight loss - A retrospective database analysis.
Diabetes Mellitus, Type 2
Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study.
Diabetes Mellitus, Type 2
Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Diabetes Mellitus, Type 2
Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?
Diabetes Mellitus, Type 2
Effects of sitagliptin on circulating zinc-?2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial.
Diabetes Mellitus, Type 2
Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.
Diabetes Mellitus, Type 2
Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study.
Diabetes Mellitus, Type 2
Effects of sitagliptin on counterregulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double blind placebo-controlled cross-over study.
Diabetes Mellitus, Type 2
Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study.
Diabetes Mellitus, Type 2
Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin.
Diabetes Mellitus, Type 2
Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
Diabetes Mellitus, Type 2
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Diabetes Mellitus, Type 2
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.
Diabetes Mellitus, Type 2
Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats.
Diabetes Mellitus, Type 2
Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying - preclinical evidence.
Diabetes Mellitus, Type 2
Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
Diabetes Mellitus, Type 2
Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan.
Diabetes Mellitus, Type 2
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Diabetes Mellitus, Type 2
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
Diabetes Mellitus, Type 2
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study.
Diabetes Mellitus, Type 2
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Diabetes Mellitus, Type 2
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Diabetes Mellitus, Type 2
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Diabetes Mellitus, Type 2
Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen.
Diabetes Mellitus, Type 2
Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.
Diabetes Mellitus, Type 2
Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Diabetes Mellitus, Type 2
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Diabetes Mellitus, Type 2
Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial.
Diabetes Mellitus, Type 2
Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor vs placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Diabetes Mellitus, Type 2
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.
Diabetes Mellitus, Type 2
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Diabetes Mellitus, Type 2
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Diabetes Mellitus, Type 2
Efficacy and safety of combination therapy with an ?-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
Diabetes Mellitus, Type 2
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Diabetes Mellitus, Type 2
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Diabetes Mellitus, Type 2
Efficacy and safety of DPP-IV inhibitors combined with basal insulin in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study.
Diabetes Mellitus, Type 2
Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.
Diabetes Mellitus, Type 2
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Diabetes Mellitus, Type 2
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
Diabetes Mellitus, Type 2
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.
Diabetes Mellitus, Type 2
Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials.
Diabetes Mellitus, Type 2
Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: an open-label, phase 3 exploratory study.
Diabetes Mellitus, Type 2
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Diabetes Mellitus, Type 2
Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Diabetes Mellitus, Type 2
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
Diabetes Mellitus, Type 2
Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Diabetes Mellitus, Type 2
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial.
Diabetes Mellitus, Type 2
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study.
Diabetes Mellitus, Type 2
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
Diabetes Mellitus, Type 2
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
Diabetes Mellitus, Type 2
Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Diabetes Mellitus, Type 2
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: A 24-week multicenter, randomized, double-blind, placebo-controlled phase III trial.
Diabetes Mellitus, Type 2
Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with ?-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
Diabetes Mellitus, Type 2
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, ?-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Diabetes Mellitus, Type 2
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Diabetes Mellitus, Type 2
Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.
Diabetes Mellitus, Type 2
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
Diabetes Mellitus, Type 2
Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Diabetes Mellitus, Type 2
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Diabetes Mellitus, Type 2
Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia.
Diabetes Mellitus, Type 2
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting.
Diabetes Mellitus, Type 2
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product - receptor for advanced glycation end product axis, and albuminuria in Japanese type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Diabetes Mellitus, Type 2
Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Diabetes Mellitus, Type 2
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.
Diabetes Mellitus, Type 2
Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on ?-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.
Diabetes Mellitus, Type 2
Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.
Diabetes Mellitus, Type 2
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
Diabetes Mellitus, Type 2
Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
Diabetes Mellitus, Type 2
Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
Diabetes Mellitus, Type 2
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
Diabetes Mellitus, Type 2
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Efficacy, safety and impact on ?-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.
Diabetes Mellitus, Type 2
Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Elevated amylase and lipase levels in patients using glucagonlike Peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
Diabetes Mellitus, Type 2
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Diabetes Mellitus, Type 2
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.
Diabetes Mellitus, Type 2
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Emerging Incretin Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors.
Diabetes Mellitus, Type 2
Emerging Role of Caveolin-1 in GLP-1 Action.
Diabetes Mellitus, Type 2
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Diabetes Mellitus, Type 2
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Diabetes Mellitus, Type 2
Emerging Roles of Dipeptidyl Peptidase 4 Inhibitors: Anti-Inflammatory and Immunomodulatory Effect and Its Application in Diabetes Mellitus.
Diabetes Mellitus, Type 2
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats.
Diabetes Mellitus, Type 2
Enhancing effects of anagliptin on myoblast differentiation and the expression of mitochondrial biogenetic factors in C2C12 mouse skeletal muscle cells.
Diabetes Mellitus, Type 2
Enhancing incretin action for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Diabetes Mellitus, Type 2
Enzymatic preparation of 5-hydroxy-L-proline, N-Cbz-5-hydroxy-L-proline, and N-Boc-5-hydroxy-L-proline from (?-N-protected)-L-ornithine using a transaminase or an amine oxidase.
Diabetes Mellitus, Type 2
Enzymatic release of dipeptidyl peptidase-4 inhibitors (gliptins) from pigeon pea (Cajanus cajan) nutrient reservoir proteins: In silico and in vitro assessments.
Diabetes Mellitus, Type 2
Ephedrine as a lead compound for the development of new DPP-IV inhibitors.
Diabetes Mellitus, Type 2
Epigenetic regulation of hepatic Dpp4 expression in response to dietary protein.
Diabetes Mellitus, Type 2
Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
Diabetes Mellitus, Type 2
Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139-148.
Diabetes Mellitus, Type 2
Erratum. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1?(1-67) in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.
Diabetes Mellitus, Type 2
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050.
Diabetes Mellitus, Type 2
Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study.
Diabetes Mellitus, Type 2
Ethnic difference in the pharmacodynamics-efficacy relationship of dipeptidyl peptidase-4 inhibitors between Japanese and non-Japanese patients: A Systematic Review.
Diabetes Mellitus, Type 2
Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Evaluating the effects of IADHFL on inhibiting DPP-IV activity and expression in Caco-2 cells and contributing to the amount of insulin released from INS-1 cells in vitro.
Diabetes Mellitus, Type 2
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
Diabetes Mellitus, Type 2
Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting.
Diabetes Mellitus, Type 2
Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs.
Diabetes Mellitus, Type 2
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Diabetes Mellitus, Type 2
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Diabetes Mellitus, Type 2
Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Diabetes Mellitus, Type 2
Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
Diabetes Mellitus, Type 2
Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial.
Diabetes Mellitus, Type 2
Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.
Diabetes Mellitus, Type 2
Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.
Diabetes Mellitus, Type 2
Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study.
Diabetes Mellitus, Type 2
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease.
Diabetes Mellitus, Type 2
Evogliptin attenuates bleomycin-induced lung fibrosis via inhibiting TGF-?/Smad signaling in fibroblast.
Diabetes Mellitus, Type 2
Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Diabetes Mellitus, Type 2
Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Evogliptin: First Global Approval.
Diabetes Mellitus, Type 2
Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease.
Diabetes Mellitus, Type 2
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
Diabetes Mellitus, Type 2
Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
Diabetes Mellitus, Type 2
Expanding treatment options for type 2 diabetes: the old and the new.
Diabetes Mellitus, Type 2
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan.
Diabetes Mellitus, Type 2
Exploration of DPP-IV inhibitors with a novel scaffold by multistep in silico screening.
Diabetes Mellitus, Type 2
Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
Diabetes Mellitus, Type 2
Expression of CD26 and its Association with Dipeptidyl Peptidase IV Activity in Lymphocytes of Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Fabrication of a water-soluble near-infrared fluorescent probe for selective detection and imaging of dipeptidyl peptidase IV in biological systems.
Diabetes Mellitus, Type 2
Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
Diabetes Mellitus, Type 2
Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States.
Diabetes Mellitus, Type 2
Factors associated with utilization of dipeptidyl-4 inhibitors in patients with type 2 diabetes mellitus: a cross-sectional retrospective study.
Diabetes Mellitus, Type 2
Factors Contributing to the Clinical Effectiveness of the DPP-4 Inhibitor Sitagliptin in Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
Diabetes Mellitus, Type 2
First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults.
Diabetes Mellitus, Type 2
Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
Diabetes Mellitus, Type 2
Fortification of Maize Tortilla with an Optimized Chickpea Hydrolysate and Its Effect on DPPIV Inhibition Capacity and Physicochemical Characteristics.
Diabetes Mellitus, Type 2
From sequence analysis of DPP-4 to molecular docking based searching of its inhibitors.
Diabetes Mellitus, Type 2
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Diabetes Mellitus, Type 2
Further possible mechanisms of dipeptidyl peptidase-4 inhibitors to decrease blood glucose in subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas.
Diabetes Mellitus, Type 2
Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Diabetes Mellitus, Type 2
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
Diabetes Mellitus, Type 2
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Generation and characterization of dipeptidyl peptidase-IV inhibitory peptides from trypsin-hydrolyzed ?-lactalbumin-rich whey proteins.
Diabetes Mellitus, Type 2
Generation of dipeptidyl peptidase-IV-inhibiting peptides from ?-lactoglobulin secreted by Lactococcus lactis.
Diabetes Mellitus, Type 2
Genetically Targeted Dipeptidyl Peptidase-4 Inhibitor Use in a Patient with a Novel Mutation of MODY type 4.
Diabetes Mellitus, Type 2
Geographical variation in anti-diabetic prescribing in Ireland in 2013 and 2014: a cross-sectional analysis.
Diabetes Mellitus, Type 2
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.
Diabetes Mellitus, Type 2
Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
Diabetes Mellitus, Type 2
Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
Diabetes Mellitus, Type 2
Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Diabetes Mellitus, Type 2
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Diabetes Mellitus, Type 2
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Diabetes Mellitus, Type 2
GLP-1 and type 2 diabetes: physiology and new clinical advances.
Diabetes Mellitus, Type 2
GLP-1 based therapy for type 2 diabetes.
Diabetes Mellitus, Type 2
GLP-1 for type 2 diabetes.
Diabetes Mellitus, Type 2
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
Diabetes Mellitus, Type 2
GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study.
Diabetes Mellitus, Type 2
GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Diabetes Mellitus, Type 2
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Diabetes Mellitus, Type 2
GLP-1R activation for the treatment of stroke: updating and future perspectives.
Diabetes Mellitus, Type 2
GLP1 and cancer: friend or foe?
Diabetes Mellitus, Type 2
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
Diabetes Mellitus, Type 2
Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science.
Diabetes Mellitus, Type 2
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Diabetes Mellitus, Type 2
Glucagon-like Peptide-1 and its cardiovascular effects.
Diabetes Mellitus, Type 2
Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes.
Diabetes Mellitus, Type 2
Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes.
Diabetes Mellitus, Type 2
Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential.
Diabetes Mellitus, Type 2
Glucose regulation of dipeptidyl peptidase IV gene expression is mediated by hepatocyte nuclear factor-1alpha in epithelial intestinal cells.
Diabetes Mellitus, Type 2
Glucose-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
Diabetes Mellitus, Type 2
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
Diabetes Mellitus, Type 2
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Diabetes Mellitus, Type 2
Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with ?-glucosidase inhibitors.
Diabetes Mellitus, Type 2
Glycemic Control in the Treatment of Psoriasis.
Diabetes Mellitus, Type 2
Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor?+?metformin in patients with Type 2 diabetes (GIFT study).
Diabetes Mellitus, Type 2
Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population.
Diabetes Mellitus, Type 2
Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Diabetes Mellitus, Type 2
GPR119 agonists for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Diabetes Mellitus, Type 2
Grape Seed-Derived Procyanidins Decrease Dipeptidyl-peptidase 4 Activity and Expression.
Diabetes Mellitus, Type 2
Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Diabetes Mellitus, Type 2
Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.
Diabetes Mellitus, Type 2
Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and ?-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Diabetes Mellitus, Type 2
Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
Diabetes Mellitus, Type 2
Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Diabetes Mellitus, Type 2
Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Diabetes Mellitus, Type 2
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.
Diabetes Mellitus, Type 2
Heterogeneous treatment effects on cardiovascular diseases with dipeptidyl peptidase-4 inhibitors versus sulfonylureas in type 2 diabetes patients.
Diabetes Mellitus, Type 2
High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study.
Diabetes Mellitus, Type 2
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD.
Diabetes Mellitus, Type 2
Highly efficient asymmetric synthesis of sitagliptin.
Diabetes Mellitus, Type 2
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
Diabetes Mellitus, Type 2
Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Diabetes Mellitus, Type 2
Hyper-Activation of Endogenous GLP-1 System to Gram-negative Sepsis Is Associated With Early Innate Immune Response and Modulated by Diabetes.
Diabetes Mellitus, Type 2
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.
Diabetes Mellitus, Type 2
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Diabetes Mellitus, Type 2
Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin.
Diabetes Mellitus, Type 2
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Diabetes Mellitus, Type 2
Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes.
Diabetes Mellitus, Type 2
Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Identification of a novel metabolite of vildagliptin in humans: Cysteine targets the nitrile moiety to form a thiazoline ring.
Diabetes Mellitus, Type 2
Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4.
Diabetes Mellitus, Type 2
Identification of angiotensin converting enzyme and dipeptidyl peptidase-IV inhibitory peptides derived from oilseed proteins using two integrated bioinformatic approaches.
Diabetes Mellitus, Type 2
Identification of dipeptidyl peptidase-IV inhibitory peptides from mare whey protein hydrolysates.
Diabetes Mellitus, Type 2
Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts.
Diabetes Mellitus, Type 2
Identification of Novel Metabolites of Vildagliptin in Rats: Thiazoline-Containing Thiol Adducts Formed via Cysteine or Glutathione Conjugation.
Diabetes Mellitus, Type 2
Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.
Diabetes Mellitus, Type 2
Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Diabetes Mellitus, Type 2
iDPPIV-SCM: A Sequence-Based Predictor for Identifying and Analyzing Dipeptidyl Peptidase IV (DPP-IV) Inhibitory Peptides Using a Scoring Card Method.
Diabetes Mellitus, Type 2
Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver.
Diabetes Mellitus, Type 2
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Diabetes Mellitus, Type 2
Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy.
Diabetes Mellitus, Type 2
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Diabetes Mellitus, Type 2
Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Diabetes Mellitus, Type 2
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Diabetes Mellitus, Type 2
Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
Diabetes Mellitus, Type 2
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.
Diabetes Mellitus, Type 2
Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.
Diabetes Mellitus, Type 2
Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
Diabetes Mellitus, Type 2
Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.
Diabetes Mellitus, Type 2
Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today.
Diabetes Mellitus, Type 2
Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide.
Diabetes Mellitus, Type 2
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.
Diabetes Mellitus, Type 2
Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Diabetes Mellitus, Type 2
Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
Diabetes Mellitus, Type 2
Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.
Diabetes Mellitus, Type 2
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
Diabetes Mellitus, Type 2
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
Diabetes Mellitus, Type 2
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus, Type 2
Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Diabetes Mellitus, Type 2
In silico identification of antidiabetic target for phytochemicals of A. marmelos and mechanistic insights by molecular dynamics simulations.
Diabetes Mellitus, Type 2
In silico studies on the interaction between bioactive ligands and DPP-IV: insights on potential candidates for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
In silico study to predict potential precursors of human dipeptidyl peptidase-IV inhibitors from hazelnut.
Diabetes Mellitus, Type 2
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
Diabetes Mellitus, Type 2
In vitro anti-diabetic effect of flavonoids and pheophytins from Allophylus cominia Sw. on the glucose uptake assays by HepG2, L6, 3T3-L1 and fat accumulation in 3T3-L1 adipocytes.
Diabetes Mellitus, Type 2
Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
Diabetes Mellitus, Type 2
Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study.
Diabetes Mellitus, Type 2
Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study.
Diabetes Mellitus, Type 2
Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma.
Diabetes Mellitus, Type 2
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus, Type 2
Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.
Diabetes Mellitus, Type 2
Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Diabetes Mellitus, Type 2
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.
Diabetes Mellitus, Type 2
Incretin drugs as modulators of atherosclerosis.
Diabetes Mellitus, Type 2
Incretin effect: GLP-1, GIP, DPP4.
Diabetes Mellitus, Type 2
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin therapy and its effect on body weight in patients with diabetes.
Diabetes Mellitus, Type 2
Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.
Diabetes Mellitus, Type 2
Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway.
Diabetes Mellitus, Type 2
Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists.
Diabetes Mellitus, Type 2
Incretin-based drugs and the risk of congestive heart failure.
Diabetes Mellitus, Type 2
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Diabetes Mellitus, Type 2
Incretin-based therapies and cardiovascular risk.
Diabetes Mellitus, Type 2
Incretin-based therapies for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
Diabetes Mellitus, Type 2
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Diabetes Mellitus, Type 2
Incretin-based therapies: review of current clinical trial data.
Diabetes Mellitus, Type 2
Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin-based therapies: where will we be 50 years from now?
Diabetes Mellitus, Type 2
Incretin-based therapy and type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Incretin-mimetic therapies and pancreatic disease: a review of observational data.
Diabetes Mellitus, Type 2
Incretins and microRNAs: Interactions and physiological relevance.
Diabetes Mellitus, Type 2
Incretins and other peptides in the treatment of diabetes.
Diabetes Mellitus, Type 2
Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes.
Diabetes Mellitus, Type 2
Incretins: What is known, new and controversial in 2013?
Diabetes Mellitus, Type 2
Indirect Comparison to Evaluate the Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors (DPP4I) and Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2I) Added to Insulin Therapy in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans.
Diabetes Mellitus, Type 2
Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Diabetes Mellitus, Type 2
Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Diabetes Mellitus, Type 2
Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
Diabetes Mellitus, Type 2
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Diabetes Mellitus, Type 2
Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease.
Diabetes Mellitus, Type 2
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as "Isoglycemic" Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Diabetes Mellitus, Type 2
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Diabetes Mellitus, Type 2
Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views.
Diabetes Mellitus, Type 2
Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Diabetes Mellitus, Type 2
Inhibitors of dipeptidyl peptidase-4 as therapeutic agents for individuals with type 2 diabetes: a 25-year journey.
Diabetes Mellitus, Type 2
Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Diabetes Mellitus, Type 2
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
Diabetes Mellitus, Type 2
Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Diabetes Mellitus, Type 2
Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.
Diabetes Mellitus, Type 2
Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.
Diabetes Mellitus, Type 2
Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Diabetes Mellitus, Type 2
Investigation into the bioavailability of milk protein-derived peptides with dipeptidyl-peptidase IV inhibitory activity using Caco-2 cell monolayers.
Diabetes Mellitus, Type 2
Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment.
Diabetes Mellitus, Type 2
Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.
Diabetes Mellitus, Type 2
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
Diabetes Mellitus, Type 2
Isolation and identification of casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats
Diabetes Mellitus, Type 2
Isolation of rugosin A, B and related compounds as dipeptidyl peptidase-IV inhibitors from rose bud extract powder.
Diabetes Mellitus, Type 2
Janumet: a combination product suitable for use in patients with Type 2 diabetes.
Diabetes Mellitus, Type 2
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Diabetes Mellitus, Type 2
KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes.
Diabetes Mellitus, Type 2
KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Diabetes Mellitus, Type 2
LAF-237 (Novartis).
Diabetes Mellitus, Type 2
LC-MS/MS determination of 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4-pyridinecarboxylic acid (ABT-279) in dog plasma with high-throughput protein precipitation sample preparation.
Diabetes Mellitus, Type 2
Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes.
Diabetes Mellitus, Type 2
Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.
Diabetes Mellitus, Type 2
Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin".
Diabetes Mellitus, Type 2
Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).
Diabetes Mellitus, Type 2
Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).
Diabetes Mellitus, Type 2
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Diabetes Mellitus, Type 2
Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
Diabetes Mellitus, Type 2
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.
Diabetes Mellitus, Type 2
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Diabetes Mellitus, Type 2
Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Diabetes Mellitus, Type 2
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Diabetes Mellitus, Type 2
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
Diabetes Mellitus, Type 2
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Diabetes Mellitus, Type 2
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Diabetes Mellitus, Type 2
Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin.
Diabetes Mellitus, Type 2
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled Phase III trial with a 34-week active-controlled extension.
Diabetes Mellitus, Type 2
Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis.
Diabetes Mellitus, Type 2
Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Diabetes Mellitus, Type 2
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Linagliptin-associated blistering and ulceration.
Diabetes Mellitus, Type 2
LINAGLIPTIN-INDUCED PANCREATITIS.
Diabetes Mellitus, Type 2
Linagliptin-related pancreatitis in a diabetic patient with biliary calculus: A case report.
Diabetes Mellitus, Type 2
Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Diabetes Mellitus, Type 2
Linagliptin: A thorough Characterization beyond Its Clinical Efficacy.
Diabetes Mellitus, Type 2
Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment.
Diabetes Mellitus, Type 2
Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats.
Diabetes Mellitus, Type 2
Liraglutide and DPP-4 inhibitors - side effects comparative clinical study.
Diabetes Mellitus, Type 2
Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Diabetes Mellitus, Type 2
Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells.
Diabetes Mellitus, Type 2
Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
Diabetes Mellitus, Type 2
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
Diabetes Mellitus, Type 2
Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Diabetes Mellitus, Type 2
Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis.
Diabetes Mellitus, Type 2
Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1? and IL-12 in NOD mice.
Diabetes Mellitus, Type 2
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Diabetes Mellitus, Type 2
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
Diabetes Mellitus, Type 2
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2?years exposure in 24-week phase III trials followed by a 78-week open-label extension.
Diabetes Mellitus, Type 2
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Diabetes Mellitus, Type 2
Long-term sustainability of glycaemic achievements with second-line anti-diabetic therapies in patients with type 2 diabetes: A real-world study.
Diabetes Mellitus, Type 2
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
Diabetes Mellitus, Type 2
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Diabetes Mellitus, Type 2
Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Diabetes Mellitus, Type 2
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
Diabetes Mellitus, Type 2
Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients.
Diabetes Mellitus, Type 2
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Diabetes Mellitus, Type 2
Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.
Diabetes Mellitus, Type 2
Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome.
Diabetes Mellitus, Type 2
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Diabetes Mellitus, Type 2
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Diabetes Mellitus, Type 2
Magnetic ligand fishing using immobilized DPP-IV for identification of antidiabetic ligands in lingonberry extract.
Diabetes Mellitus, Type 2
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.
Diabetes Mellitus, Type 2
Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
Diabetes Mellitus, Type 2
Managing the Course of Diabetic Kidney Disease: From the Old to the New.
Diabetes Mellitus, Type 2
MAXIMIZING PATIENT SAFETY WITH NEWLY APPROVED THERAPIES: FOCUS ON SGLT2 INHIBITORS.
Diabetes Mellitus, Type 2
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Meat Proteins as Dipeptidyl Peptidase IV Inhibitors and Glucose Uptake Stimulating Peptides for the Management of a Type 2 Diabetes Mellitus In Silico Study.
Diabetes Mellitus, Type 2
Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Diabetes Mellitus, Type 2
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Diabetes Mellitus, Type 2
Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?
Diabetes Mellitus, Type 2
Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
Diabetes Mellitus, Type 2
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Diabetes Mellitus, Type 2
Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
Diabetes Mellitus, Type 2
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.
Diabetes Mellitus, Type 2
Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system.
Diabetes Mellitus, Type 2
Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors.
Diabetes Mellitus, Type 2
Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell.
Diabetes Mellitus, Type 2
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
Diabetes Mellitus, Type 2
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors.
Diabetes Mellitus, Type 2
Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin.
Diabetes Mellitus, Type 2
Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
Diabetes Mellitus, Type 2
Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study.
Diabetes Mellitus, Type 2
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Metformin and the risk of anemia of advanced chronic kidney disease in patients with Type 2 Diabetes mellitus.
Diabetes Mellitus, Type 2
Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Diabetes Mellitus, Type 2
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Diabetes Mellitus, Type 2
Metformin in Combination With Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in The Treatment of Type 2 Diabetes: Clinical And Economic Impact.
Diabetes Mellitus, Type 2
Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors.
Diabetes Mellitus, Type 2
Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study.
Diabetes Mellitus, Type 2
MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells.
Diabetes Mellitus, Type 2
MK-431 (Merck).
Diabetes Mellitus, Type 2
Model Optimization and In Silico Analysis of Potential Dipeptidyl Peptidase IV Antagonists from GC-MS Identified Compounds in Nauclea latifolia Leaf Extracts.
Diabetes Mellitus, Type 2
Modulation of Sirt1/NF-?B interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation.
Diabetes Mellitus, Type 2
Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.
Diabetes Mellitus, Type 2
Molecular modeling and statistical analysis in the design of derivatives of human dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
Diabetes Mellitus, Type 2
Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Diabetes Mellitus, Type 2
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1.
Diabetes Mellitus, Type 2
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
Diabetes Mellitus, Type 2
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Diabetes Mellitus, Type 2
Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system.
Diabetes Mellitus, Type 2
Mutant HNF-1alpha and mutant HNF-1beta identified in MODY3 and MODY5 downregulate DPP-IV gene expression in Caco-2 cells.
Diabetes Mellitus, Type 2
Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Diabetes Mellitus, Type 2
N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
Diabetes Mellitus, Type 2
Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus, Type 2
Natural Products: Potential Source of DPP-IV Inhibitors.
Diabetes Mellitus, Type 2
Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.
Diabetes Mellitus, Type 2
Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.
Diabetes Mellitus, Type 2
Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
Diabetes Mellitus, Type 2
Neurobehavioral effects of liraglutide and sitagliptin in experimental models.
Diabetes Mellitus, Type 2
Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Diabetes Mellitus, Type 2
Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies.
Diabetes Mellitus, Type 2
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Diabetes Mellitus, Type 2
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus, Type 2
New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors.
Diabetes Mellitus, Type 2
New incretin hormonal therapies in humans relevant to diabetic cats.
Diabetes Mellitus, Type 2
New technologies and therapies in the management of diabetes.
Diabetes Mellitus, Type 2
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Diabetes Mellitus, Type 2
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Diabetes Mellitus, Type 2
Newly approved and promising antidiabetic agents.
Diabetes Mellitus, Type 2
Nitrothiadiazolo[3,2-a]pyrimidines as promising antiglycating agents.
Diabetes Mellitus, Type 2
Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
Diabetes Mellitus, Type 2
Novel 8-heterocyclyl xanthine derivatives in drug development - an update.
Diabetes Mellitus, Type 2
Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Diabetes Mellitus, Type 2
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Diabetes Mellitus, Type 2
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Diabetes Mellitus, Type 2
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23).
Diabetes Mellitus, Type 2
Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.
Diabetes Mellitus, Type 2
NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum.
Diabetes Mellitus, Type 2
Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor.
Diabetes Mellitus, Type 2
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Omarigliptin for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Omarigliptin: first global approval.
Diabetes Mellitus, Type 2
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Diabetes Mellitus, Type 2
Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.
Diabetes Mellitus, Type 2
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Diabetes Mellitus, Type 2
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Diabetes Mellitus, Type 2
Optimization and Validation of a Fluorogenic Dipeptidyl Peptidase 4 enzymatic assay in Human Plasma.
Diabetes Mellitus, Type 2
Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.
Diabetes Mellitus, Type 2
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.
Diabetes Mellitus, Type 2
Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close.
Diabetes Mellitus, Type 2
Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
Diabetes Mellitus, Type 2
Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies.
Diabetes Mellitus, Type 2
Overcoming challenges in Type 2 diabetes management to improve patient outcomes.
Diabetes Mellitus, Type 2
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Diabetes Mellitus, Type 2
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.
Diabetes Mellitus, Type 2
Pancreatic ? Cell-Derived Glucagon-Related Peptides Are Required for ? Cell Adaptation and Glucose Homeostasis.
Diabetes Mellitus, Type 2
Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes.
Diabetes Mellitus, Type 2
Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Diabetes Mellitus, Type 2
Pancreatic Safety of Sitagliptin in the TECOS Study.
Diabetes Mellitus, Type 2
Paracrine Crosstalk between Intestinal L- and D-cells Controls Secretion of Glucagon-Like Peptide-1 in mice.
Diabetes Mellitus, Type 2
Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
Diabetes Mellitus, Type 2
Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
Diabetes Mellitus, Type 2
Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.
Diabetes Mellitus, Type 2
Peptide array on cellulose support--a screening tool to identify peptides with dipeptidyl-peptidase IV inhibitory activity within the sequence of ?-lactalbumin.
Diabetes Mellitus, Type 2
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery?
Diabetes Mellitus, Type 2
Peptides Derived from Soy and Lupin Protein as Dipeptidyl-Peptidase IV Inhibitors: In Vitro Biochemical Screening and in Silico Molecular Modeling Study.
Diabetes Mellitus, Type 2
Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.
Diabetes Mellitus, Type 2
PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness.
Diabetes Mellitus, Type 2
Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes.
Diabetes Mellitus, Type 2
Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes.
Diabetes Mellitus, Type 2
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip.
Diabetes Mellitus, Type 2
Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.
Diabetes Mellitus, Type 2
Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes.
Diabetes Mellitus, Type 2
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Evaluation of Linagliptin in African American Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Interaction Between Gemigliptin and Metformin in Healthy Subjects.
Diabetes Mellitus, Type 2
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Diabetes Mellitus, Type 2
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
Diabetes Mellitus, Type 2
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Diabetes Mellitus, Type 2
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study.
Diabetes Mellitus, Type 2
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Pharmacokinetic-Pharmacodynamic (Dipeptidyl Peptidase-4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those with Renal Impairment, for the Once-Weekly Administered Omarigliptin.
Diabetes Mellitus, Type 2
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects.
Diabetes Mellitus, Type 2
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
Diabetes Mellitus, Type 2
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Diabetes Mellitus, Type 2
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Diabetes Mellitus, Type 2
Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.
Diabetes Mellitus, Type 2
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Pharmacokinetics and safety of evogliptin in hepatically impaired patients.
Diabetes Mellitus, Type 2
Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Diabetes Mellitus, Type 2
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Diabetes Mellitus, Type 2
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Diabetes Mellitus, Type 2
Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
Diabetes Mellitus, Type 2
Pharmacologic management of the older patient with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Pharmacological action and clinical results of Omarigliptin (MARIZEV(®) tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes.
Diabetes Mellitus, Type 2
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Diabetes Mellitus, Type 2
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Diabetes Mellitus, Type 2
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control.
Diabetes Mellitus, Type 2
Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans.
Diabetes Mellitus, Type 2
Physiology and pathophysiology of incretins in the kidney.
Diabetes Mellitus, Type 2
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
Diabetes Mellitus, Type 2
Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus.
Diabetes Mellitus, Type 2
Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.
Diabetes Mellitus, Type 2
Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people.
Diabetes Mellitus, Type 2
Plasma dipeptidyl peptidase IV activity and measures of body composition in apparently healthy people.
Diabetes Mellitus, Type 2
Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Diabetes Mellitus, Type 2
Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
Diabetes Mellitus, Type 2
Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records.
Diabetes Mellitus, Type 2
Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor.
Diabetes Mellitus, Type 2
Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
Diabetes Mellitus, Type 2
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.
Diabetes Mellitus, Type 2
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
Diabetes Mellitus, Type 2
Postprandial Plasma Glucagon Kinetics in Type 2 Diabetes Mellitus: Comparison of Immunoassay and Mass Spectrometry.
Diabetes Mellitus, Type 2
Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Potential cardiovascular effects of incretin-based therapies.
Diabetes Mellitus, Type 2
Potential for Combination of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter-2 Inhibitors for the Treatment of Type 2 Diabetes.
Diabetes Mellitus, Type 2
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Diabetes Mellitus, Type 2
Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Diabetes Mellitus, Type 2
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Diabetes Mellitus, Type 2
Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents.
Diabetes Mellitus, Type 2
PPAR?/? Activation Induces Enteroendocrine L Cell GLP-1 Production.
Diabetes Mellitus, Type 2
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.
Diabetes Mellitus, Type 2
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.
Diabetes Mellitus, Type 2
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists.
Diabetes Mellitus, Type 2
Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.
Diabetes Mellitus, Type 2
Predicting DPP-IV inhibitors with machine learning approaches.
Diabetes Mellitus, Type 2
Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels.
Diabetes Mellitus, Type 2
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
Diabetes Mellitus, Type 2
Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis.
Diabetes Mellitus, Type 2
Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides.
Diabetes Mellitus, Type 2
Prescription of DPP-4 Inhibitors to Patients With Adult Type 2 Diabetes Mellitus and Creatinine Clearance >50 mL/min: The UK Primary Care Experience.
Diabetes Mellitus, Type 2
Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience.
Diabetes Mellitus, Type 2
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Diabetes Mellitus, Type 2
Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.
Diabetes Mellitus, Type 2
Production of a novel wheat gluten hydrolysate containing dipeptidyl peptidase-IV inhibitory tripeptides using ginger protease.
Diabetes Mellitus, Type 2
Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran.
Diabetes Mellitus, Type 2
Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.
Diabetes Mellitus, Type 2
Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors.
Diabetes Mellitus, Type 2
Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.
Diabetes Mellitus, Type 2
Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.
Diabetes Mellitus, Type 2
Protective effect of vildagliptin on TNF-?-induced chondrocyte senescence.
Diabetes Mellitus, Type 2
PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES.
Diabetes Mellitus, Type 2
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Diabetes Mellitus, Type 2
Protective effects of gemigliptin against type II collagen degradation in human chondrocytes.
Diabetes Mellitus, Type 2
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Diabetes Mellitus, Type 2
Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
Diabetes Mellitus, Type 2
Protective role of sitagliptin against oxidative stress in a kainic acid-induced status epilepticus in rats models via Nrf2/HO-1 pathway.
Diabetes Mellitus, Type 2
Proteins and peptides from vegetable food sources as therapeutic adjuvants for the type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Pyrazole Incorporated New Thiosemicarbazones: Design, Synthesis and Investigation of DPP-4 Inhibitory Effects.
Diabetes Mellitus, Type 2
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.
Diabetes Mellitus, Type 2
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the "thorough QT/QTc" study (Q-SET study).
Diabetes Mellitus, Type 2
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
Diabetes Mellitus, Type 2
Quantitative Model of the Relationship Between Dipeptidyl Peptidase-4 (DPP-4) Inhibition and Response: Meta-Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results.
Diabetes Mellitus, Type 2
Random-effects meta-analysis of combined outcomes based on reconstructions of individual patient data.
Diabetes Mellitus, Type 2
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Diabetes Mellitus, Type 2
Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
Diabetes Mellitus, Type 2
Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Diabetes Mellitus, Type 2
Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
Diabetes Mellitus, Type 2
RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.
Diabetes Mellitus, Type 2
Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
Diabetes Mellitus, Type 2
Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Diabetes Mellitus, Type 2
Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors.
Diabetes Mellitus, Type 2
Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors.
Diabetes Mellitus, Type 2
Recent patents of dipeptidyl peptidase IV inhibitors.
Diabetes Mellitus, Type 2
Recent progress in natural products as DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Recombinant Lactococcus lactis expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro.
Diabetes Mellitus, Type 2
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Diabetes Mellitus, Type 2
Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition.
Diabetes Mellitus, Type 2
Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes.
Diabetes Mellitus, Type 2
Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis.
Diabetes Mellitus, Type 2
Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions.
Diabetes Mellitus, Type 2
Relationship Between Initial Renal Function and the Inhibitory Effect of Dipeptidyl Peptidase-4 Inhibitor Treatment on Renal Function Decline.
Diabetes Mellitus, Type 2
Relative contribution of incretins to the glucose lowering effect of DP IV inhibitors in type 2 diabetes mellitus (T2DM).
Diabetes Mellitus, Type 2
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Diabetes Mellitus, Type 2
Renal outcomes with dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.
Diabetes Mellitus, Type 2
Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.
Diabetes Mellitus, Type 2
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Repurposing Antidiabetic Drugs for Cardiovascular Disease.
Diabetes Mellitus, Type 2
Reshaping Diabetes Care: The Fundamental Role of DPP-4 Inhibitors and GLP-1 Receptor Agonists in Clinical Practice.
Diabetes Mellitus, Type 2
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Diabetes Mellitus, Type 2
Response to Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin".
Diabetes Mellitus, Type 2
Response to the dipeptidyl peptidase-4 inhibitors in Japanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotide polymorphisms on the interleukin-6 promoter region under a certain level of physical activity.
Diabetes Mellitus, Type 2
Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).
Diabetes Mellitus, Type 2
Response: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).
Diabetes Mellitus, Type 2
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting.
Diabetes Mellitus, Type 2
Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin.
Diabetes Mellitus, Type 2
Review Article: Preservation of Beta Cell Function in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: comparison with sitagliptin.
Diabetes Mellitus, Type 2
Review of linagliptin for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor.
Diabetes Mellitus, Type 2
Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia.
Diabetes Mellitus, Type 2
Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.
Diabetes Mellitus, Type 2
Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Diabetes Mellitus, Type 2
Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Diabetes Mellitus, Type 2
Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.
Diabetes Mellitus, Type 2
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Diabetes Mellitus, Type 2
Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Diabetes Mellitus, Type 2
Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Diabetes Mellitus, Type 2
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Diabetes Mellitus, Type 2
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.
Diabetes Mellitus, Type 2
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Diabetes Mellitus, Type 2
Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
Diabetes Mellitus, Type 2
Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
Diabetes Mellitus, Type 2
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging.
Diabetes Mellitus, Type 2
Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
Diabetes Mellitus, Type 2
Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Safety And Efficacy Of Dpp-4 Inhibitors For The Management Of Hospitalized General Medicine And Surgery Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Diabetes Mellitus, Type 2
Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
Diabetes Mellitus, Type 2
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged???65?years.
Diabetes Mellitus, Type 2
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial.
Diabetes Mellitus, Type 2
Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
Diabetes Mellitus, Type 2
Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects.
Diabetes Mellitus, Type 2
Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
Diabetes Mellitus, Type 2
Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.
Diabetes Mellitus, Type 2
Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.
Diabetes Mellitus, Type 2
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Diabetes Mellitus, Type 2
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
Diabetes Mellitus, Type 2
Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.
Diabetes Mellitus, Type 2
Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.
Diabetes Mellitus, Type 2
Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies.
Diabetes Mellitus, Type 2
Saxagliptin for type 2 diabetes.
Diabetes Mellitus, Type 2
Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase.
Diabetes Mellitus, Type 2
Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Diabetes Mellitus, Type 2
Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Diabetes Mellitus, Type 2
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Diabetes Mellitus, Type 2
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Saxagliptin: A Review in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Diabetes Mellitus, Type 2
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Seco-prolinenitrile inhibitors of dipeptidyl peptidase IV define minimal pharmacophore requirements at P1.
Diabetes Mellitus, Type 2
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Diabetes Mellitus, Type 2
Selectivity among dipeptidyl peptidases of the S9b family.
Diabetes Mellitus, Type 2
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Diabetes Mellitus, Type 2
Separation and identification of enzyme inhibition peptides from dark tea protein.
Diabetes Mellitus, Type 2
Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.
Diabetes Mellitus, Type 2
Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Diabetes Mellitus, Type 2
Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Diabetes Mellitus, Type 2
Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.
Diabetes Mellitus, Type 2
Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Diabetes Mellitus, Type 2
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
Diabetes Mellitus, Type 2
SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials.
Diabetes Mellitus, Type 2
SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
Diabetes Mellitus, Type 2
SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes.
Diabetes Mellitus, Type 2
Should Baseline Hemoglobin A1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review.
Diabetes Mellitus, Type 2
Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.
Diabetes Mellitus, Type 2
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Diabetes Mellitus, Type 2
Single-dose escalation study of yogliptin in healthy Chinese volunteers.
Diabetes Mellitus, Type 2
Sitagliptin (DPP-4 Inhibitor)-induced Rheumatoid Arthritis in Type 2 Diabetes Mellitus: A Case Report.
Diabetes Mellitus, Type 2
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Diabetes Mellitus, Type 2
Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.
Diabetes Mellitus, Type 2
Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial.
Diabetes Mellitus, Type 2
Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
Diabetes Mellitus, Type 2
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
SITAgliptin for Depressive Symptoms (SITADS) in type 2 diabetes: a feasibility randomized controlled trial.
Diabetes Mellitus, Type 2
Sitagliptin for Type 2 diabetes: a 2015 update.
Diabetes Mellitus, Type 2
Sitagliptin Improves Plasma Apolipoprotein Profile in Type 2 Diabetes: A Randomized Clinical Trial of Sitagliptin Effect on Lipid and Glucose Metabolism (SLIM) Study.
Diabetes Mellitus, Type 2
Sitagliptin in GAD antibody positive diabetes mellitus.
Diabetes Mellitus, Type 2
Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Diabetes Mellitus, Type 2
Sitagliptin Inhibits Extracellular Matrix Accumulation and Proliferation in Lung Fibroblasts.
Diabetes Mellitus, Type 2
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
Diabetes Mellitus, Type 2
Sitagliptin Mitigates Total Body Irradiation-Induced Hematopoietic Injury in Mice.
Diabetes Mellitus, Type 2
Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
Diabetes Mellitus, Type 2
Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties.
Diabetes Mellitus, Type 2
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
Diabetes Mellitus, Type 2
Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.
Diabetes Mellitus, Type 2
Sitagliptin protects against hypoxia/reoxygenation (H/R)-induced cardiac microvascular endothelial cell injury.
Diabetes Mellitus, Type 2
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
Diabetes Mellitus, Type 2
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.
Diabetes Mellitus, Type 2
Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation.
Diabetes Mellitus, Type 2
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects.
Diabetes Mellitus, Type 2
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34(+)CXCR4 (+) cells in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in Apc(Min/+) mice fed a high-fat diet.
Diabetes Mellitus, Type 2
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Diabetes Mellitus, Type 2
Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro.
Diabetes Mellitus, Type 2
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.
Diabetes Mellitus, Type 2
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy.
Diabetes Mellitus, Type 2
Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
Diabetes Mellitus, Type 2
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
Diabetes Mellitus, Type 2
Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.
Diabetes Mellitus, Type 2
Small intestinal glucose delivery affects the lowering of blood glucose by acute vildagliptin in type 2 diabetes.
Diabetes Mellitus, Type 2
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Diabetes Mellitus, Type 2
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Diabetes Mellitus, Type 2
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
Diabetes Mellitus, Type 2
Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence.
Diabetes Mellitus, Type 2
Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study.
Diabetes Mellitus, Type 2
Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study.
Diabetes Mellitus, Type 2
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
Diabetes Mellitus, Type 2
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
Diabetes Mellitus, Type 2
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Diabetes Mellitus, Type 2
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Diabetes Mellitus, Type 2
Solid-State Characterization of Different Crystalline Forms of Sitagliptin.
Diabetes Mellitus, Type 2
Soluble CD26?/?dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding.
Diabetes Mellitus, Type 2
Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release.
Diabetes Mellitus, Type 2
Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Standardized Emblica officinalis fruit extract inhibited the activities of alpha-amylase, alpha-glucosidase, dipeptidyl peptidase-4 and displayed antioxidant potential.
Diabetes Mellitus, Type 2
Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Diabetes Mellitus, Type 2
Structure based Lead optimization approach in discovery of selective DPP4 inhibitors.
Diabetes Mellitus, Type 2
Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.
Diabetes Mellitus, Type 2
Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial.
Diabetes Mellitus, Type 2
Substance p increases sympathetic activity during combined Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
Diabetes Mellitus, Type 2
Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: A case report and a review of the literature.
Diabetes Mellitus, Type 2
Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes: a pilot study
Diabetes Mellitus, Type 2
Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Diabetes Mellitus, Type 2
Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
Diabetes Mellitus, Type 2
Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4.
Diabetes Mellitus, Type 2
Synthesis and characterization of oxidovanadium complexes as enzyme inhibitors targeting dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin.
Diabetes Mellitus, Type 2
Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
Diabetes Mellitus, Type 2
Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
Diabetes Mellitus, Type 2
Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
Diabetes Mellitus, Type 2
Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors.
Diabetes Mellitus, Type 2
Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.
Diabetes Mellitus, Type 2
SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Diabetes Mellitus, Type 2
Systematic analysis of a dipeptide library for inhibitor development using human dipeptidyl peptidase IV produced by a Saccharomyces cerevisiae expression system.
Diabetes Mellitus, Type 2
Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
Diabetes Mellitus, Type 2
Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk.
Diabetes Mellitus, Type 2
Systematic Review of Economic Evaluations of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.
Diabetes Mellitus, Type 2
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.
Diabetes Mellitus, Type 2
Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations.
Diabetes Mellitus, Type 2
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Targeting the intestinal L-cell for obesity and type 2 diabetes treatment.
Diabetes Mellitus, Type 2
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Ten Years of Vildagliptin.
Diabetes Mellitus, Type 2
Teneligliptin for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
Diabetes Mellitus, Type 2
Teneligliptin in management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells.
Diabetes Mellitus, Type 2
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Diabetes Mellitus, Type 2
Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Teneligliptin: a review in type 2 diabetes.
Diabetes Mellitus, Type 2
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
Diabetes Mellitus, Type 2
The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The Alchemist's Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes?
Diabetes Mellitus, Type 2
The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
Diabetes Mellitus, Type 2
The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Diabetes Mellitus, Type 2
The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
The biology of incretin hormones.
Diabetes Mellitus, Type 2
The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
Diabetes Mellitus, Type 2
The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
Diabetes Mellitus, Type 2
The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway.
Diabetes Mellitus, Type 2
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Diabetes Mellitus, Type 2
The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin.
Diabetes Mellitus, Type 2
The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Diabetes Mellitus, Type 2
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of ?-cell function in type 2 diabetes.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin has the Capacity to Repair ?-Cell Dysfunction and Insulin Resistance.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase-4 inhibitory effect of flavonoids is hindered in protein rich environments.
Diabetes Mellitus, Type 2
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Diabetes Mellitus, Type 2
The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride.
Diabetes Mellitus, Type 2
The DPP-4 inhibitor Linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
Diabetes Mellitus, Type 2
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Diabetes Mellitus, Type 2
The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.
Diabetes Mellitus, Type 2
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Diabetes Mellitus, Type 2
The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.
Diabetes Mellitus, Type 2
The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy.
Diabetes Mellitus, Type 2
The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Diabetes Mellitus, Type 2
The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
Diabetes Mellitus, Type 2
The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
Diabetes Mellitus, Type 2
The Effect of Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: a Systematic Review of Randomized Placebo-controlled Trials.
Diabetes Mellitus, Type 2
The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.
Diabetes Mellitus, Type 2
The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1?/CXCR4 pathway.
Diabetes Mellitus, Type 2
The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship.
Diabetes Mellitus, Type 2
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
The effect of DPP-IV inhibition on bone in a mouse model of type 2 diabetes.
Diabetes Mellitus, Type 2
The effect of glucagon-like peptide 1 on cardiovascular risk.
Diabetes Mellitus, Type 2
The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Diabetes Mellitus, Type 2
The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells.
Diabetes Mellitus, Type 2
The effects of glucagon-like peptide-1 on the beta cell.
Diabetes Mellitus, Type 2
The effects of incretin-based therapies on ?-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
Diabetes Mellitus, Type 2
The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Diabetes Mellitus, Type 2
The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Diabetes Mellitus, Type 2
The effects of simvastatin on the pharmacokinectics of sitagliptin.
Diabetes Mellitus, Type 2
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Diabetes Mellitus, Type 2
THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE.
Diabetes Mellitus, Type 2
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Diabetes Mellitus, Type 2
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
Diabetes Mellitus, Type 2
The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy.
Diabetes Mellitus, Type 2
The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Diabetes Mellitus, Type 2
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial.
Diabetes Mellitus, Type 2
The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Diabetes Mellitus, Type 2
The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications.
Diabetes Mellitus, Type 2
The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects.
Diabetes Mellitus, Type 2
THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.
Diabetes Mellitus, Type 2
The future of incretin-based therapy: novel avenues-novel targets.
Diabetes Mellitus, Type 2
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Diabetes Mellitus, Type 2
The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Diabetes Mellitus, Type 2
THE IN VITRO CYTOTOXICITY, GENOTOXICITY AND OXIDATIVE DAMAGE POTENTIAL OF THE ORAL DIPEPTIDYL PEPTIDASE-4 INHIBITOR, LINAGLIPTIN, ON CULTURED HUMAN MONONUCLEAR BLOOD CELLS.
Diabetes Mellitus, Type 2
The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
Diabetes Mellitus, Type 2
The incretin hormones: from scientific discovery to practical therapeutics.
Diabetes Mellitus, Type 2
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Diabetes Mellitus, Type 2
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
Diabetes Mellitus, Type 2
The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis.
Diabetes Mellitus, Type 2
The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study.
Diabetes Mellitus, Type 2
The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.
Diabetes Mellitus, Type 2
The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
The natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Diabetes Mellitus, Type 2
The new insights of DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Diabetes Mellitus, Type 2
The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus. Possible role of stromal derived factor-1{alpha}
Diabetes Mellitus, Type 2
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Diabetes Mellitus, Type 2
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?
Diabetes Mellitus, Type 2
The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
The potential for renoprotection with incretin-based drugs.
Diabetes Mellitus, Type 2
The prolyl oligopeptidase family.
Diabetes Mellitus, Type 2
The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders.
Diabetes Mellitus, Type 2
The protective effects of saxagliptin against lipopolysaccharide (LPS)-induced inflammation and damage in human dental pulp cells.
Diabetes Mellitus, Type 2
The relationship between carotid intima-media thickness and serum secreted frizzled-related protein-4 and dipeptidyl peptidase-4 in diabetic patients with cardiovascular diseases.
Diabetes Mellitus, Type 2
The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients.
Diabetes Mellitus, Type 2
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
Diabetes Mellitus, Type 2
The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect.
Diabetes Mellitus, Type 2
The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
Diabetes Mellitus, Type 2
The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors.
Diabetes Mellitus, Type 2
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Diabetes Mellitus, Type 2
The role of vildagliptin in the management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
Diabetes Mellitus, Type 2
The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
The safety of gliptins : updated data in 2018.
Diabetes Mellitus, Type 2
The SNARE Protein Syntaxin-1a Plays an Essential Role in Biphasic Exocytosis of the Incretin Hormone Glucagon-Like Peptide 1.
Diabetes Mellitus, Type 2
The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
Diabetes Mellitus, Type 2
The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases.
Diabetes Mellitus, Type 2
The therapeutic role of incretin mimetics and DPP-4 inhibitors.
Diabetes Mellitus, Type 2
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.
Diabetes Mellitus, Type 2
The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents.
Diabetes Mellitus, Type 2
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Diabetes Mellitus, Type 2
The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease.
Diabetes Mellitus, Type 2
The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study.
Diabetes Mellitus, Type 2
The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration.
Diabetes Mellitus, Type 2
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Diabetes Mellitus, Type 2
Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.
Diabetes Mellitus, Type 2
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
Diabetes Mellitus, Type 2
Therapeutic Experience of Saxagliptin as First Add-on after Metformin in Indian Type 2 Diabetes Patients: A Non-interventional, Prospective, Observational Study (ONTARGET-INDIA).
Diabetes Mellitus, Type 2
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
Diabetes Mellitus, Type 2
Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia.
Diabetes Mellitus, Type 2
Therapeutic vaccine against DPP4 improves glucose metabolism in mice.
Diabetes Mellitus, Type 2
Therapy for obesity based on gastrointestinal hormones.
Diabetes Mellitus, Type 2
Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
Diabetes Mellitus, Type 2
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
Diabetes Mellitus, Type 2
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
Diabetes Mellitus, Type 2
Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
Diabetes Mellitus, Type 2
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.
Diabetes Mellitus, Type 2
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Diabetes Mellitus, Type 2
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.
Diabetes Mellitus, Type 2
Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Diabetes Mellitus, Type 2
Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
Diabetes Mellitus, Type 2
Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.
Diabetes Mellitus, Type 2
Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Diabetes Mellitus, Type 2
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Diabetes Mellitus, Type 2
Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?
Diabetes Mellitus, Type 2
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Diabetes Mellitus, Type 2
Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina.
Diabetes Mellitus, Type 2
Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
Diabetes Mellitus, Type 2
Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial.
Diabetes Mellitus, Type 2
Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin.
Diabetes Mellitus, Type 2
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands.
Diabetes Mellitus, Type 2
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Diabetes Mellitus, Type 2
Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Diabetes Mellitus, Type 2
Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Diabetes Mellitus, Type 2
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
Diabetes Mellitus, Type 2
Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis.
Diabetes Mellitus, Type 2
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Trp-Arg-Xaa tripeptides act as uncompetitive-type inhibitors of human dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension.
Diabetes Mellitus, Type 2
Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.
Diabetes Mellitus, Type 2
Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Diabetes Mellitus, Type 2
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
Diabetes Mellitus, Type 2
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.
Diabetes Mellitus, Type 2
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1RA and DPP4 Therapies in Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Unique binding mode of Evogliptin with human dipeptidyl peptidase IV.
Diabetes Mellitus, Type 2
Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm.
Diabetes Mellitus, Type 2
Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
Diabetes Mellitus, Type 2
Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea.
Diabetes Mellitus, Type 2
Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.
Diabetes Mellitus, Type 2
Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study.
Diabetes Mellitus, Type 2
Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.
Diabetes Mellitus, Type 2
Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Diabetes Mellitus, Type 2
Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
Diabetes Mellitus, Type 2
Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
Diabetes Mellitus, Type 2
Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
Diabetes Mellitus, Type 2
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.
Diabetes Mellitus, Type 2
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
Diabetes Mellitus, Type 2
Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.
Diabetes Mellitus, Type 2
Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
Diabetes Mellitus, Type 2
Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
Diabetes Mellitus, Type 2
Using computer-aided drug design and medicinal chemistry strategies in the fight against diabetes.
Diabetes Mellitus, Type 2
Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass.
Diabetes Mellitus, Type 2
Vascular Protection with Dipeptidyl Peptidase-IV inhibitors in Diabetes: Experimental and Clinical Therapeutics.
Diabetes Mellitus, Type 2
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.
Diabetes Mellitus, Type 2
Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Diabetes Mellitus, Type 2
Vildagliptin , a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Diabetes Mellitus, Type 2
Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.
Diabetes Mellitus, Type 2
Vildagliptin effects on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled, type 2 diabetes patients.
Diabetes Mellitus, Type 2
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.
Diabetes Mellitus, Type 2
Vildagliptin in clinical practice: a review of literature.
Diabetes Mellitus, Type 2
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Diabetes Mellitus, Type 2
Vildagliptin in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER Stress/NF-?B Pathway.
Diabetes Mellitus, Type 2
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Vildagliptin Versus ?-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study.
Diabetes Mellitus, Type 2
Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
Diabetes Mellitus, Type 2
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Diabetes Mellitus, Type 2
Vildagliptin-induced acute lung injury: a case report.
Diabetes Mellitus, Type 2
Vildagliptin.
Diabetes Mellitus, Type 2
Vildagliptin: A novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Vildagliptin: a review of its use in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Weekly Versus Daily Dipeptidyl Peptidase 4 Inhibitor Therapy for Type 2 Diabetes: Systematic Review and Meta-analysis.
Diabetes Mellitus, Type 2
What have we learnt from "real world" data, observational studies and meta-analyses.
Diabetes Mellitus, Type 2
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Diabetes Mellitus, Type 2
Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors.
Diabetes Mellitus, Type 2
Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications.
Diabetes Mellitus, Type 2
YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model.
Diabetes Mellitus, Type 2
YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Zinc oxide nanoparticles and a standard antidiabetic drug restore the function and structure of beta cells in Type-2 diabetes.
Diabetes Mellitus, Type 2
ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
Diabetes Mellitus, Type 2
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]
Diabetes Mellitus, Type 2
[About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
Diabetes Mellitus, Type 2
[Acquired hemophilia A complicated by dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid].
Diabetes Mellitus, Type 2
[Annual monitoring of side effects of administering sitagliptin in patients with type 2 diabetes mellitus].
Diabetes Mellitus, Type 2
[Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Diabetes Mellitus, Type 2
[Benefits and risks of current pharmacotherapy in the treatment of type 2 diabetes.]
Diabetes Mellitus, Type 2
[Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].
Diabetes Mellitus, Type 2
[Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
Diabetes Mellitus, Type 2
[Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors].
Diabetes Mellitus, Type 2
[DPP-4 inhibitor].
Diabetes Mellitus, Type 2
[Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus].
Diabetes Mellitus, Type 2
[Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
Diabetes Mellitus, Type 2
[Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison]
Diabetes Mellitus, Type 2
[Glucagon-like peptide-1(GLP-1)]
Diabetes Mellitus, Type 2
[How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
Diabetes Mellitus, Type 2
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Diabetes Mellitus, Type 2
[Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].
Diabetes Mellitus, Type 2
[Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism]
Diabetes Mellitus, Type 2
[Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins - new possibilities for pharmacotherapy of type 2 diabetes]
Diabetes Mellitus, Type 2
[Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV]
Diabetes Mellitus, Type 2
[Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin]
Diabetes Mellitus, Type 2
[Incretins in the treatment of diabetes]
Diabetes Mellitus, Type 2
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]
Diabetes Mellitus, Type 2
[New hypoglycemic agents in type 2 diabetes]
Diabetes Mellitus, Type 2
[New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)]
Diabetes Mellitus, Type 2
[Newer anti - diabetic therapies and chronic kidney disease].
Diabetes Mellitus, Type 2
[Recommendations of the main clinical practice guidelines].
Diabetes Mellitus, Type 2
[Screening and identification of DPP-4 inhibitors from Xiaokean formula by a fluorescent probe].
Diabetes Mellitus, Type 2
[Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].
Diabetes Mellitus, Type 2
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Diabetes Mellitus, Type 2
[Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
Diabetes Mellitus, Type 2
[Still a role for DPP-4 inhibitors in 2020?]
Diabetes Mellitus, Type 2
[The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].
Diabetes Mellitus, Type 2
[The effect of antidiabetic treatment on the bone of patients with type 2 diabetes].
Diabetes Mellitus, Type 2
[The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Diabetes Mellitus, Type 2
[The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus].
Diabetes Mellitus, Type 2
[The importance of integrated treatment of type 2 diabetes]
Diabetes Mellitus, Type 2
[Therapeutic options for a type 2 diabetic patient not well controlled with metformin plus basal insulin].
Diabetes Mellitus, Type 2
[Therapeutic potential of DPP-IV inhibitor for the treatment of Type 2 diabetes]
Diabetes Mellitus, Type 2
[Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
Diabetes Mellitus, Type 2
[Towards evidence-based medicine: large-scale intervention trials with dipeptidyl peptidase-4 inhibitors].
Diabetes Mellitus, Type 2
[Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: DPP-4 inhibitors. Contributions with respect to other families of oral antidiabetic agents].
Diabetes Mellitus, Type 2
[Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
Diabetes Mellitus, Type 2
[What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?]
Diabetes, Gestational
Association between maternal and umbilical cord serum dipeptidyl peptidase IV in pregnant women with and without gestational diabetes mellitus.
Diabetes, Gestational
Cord serum dipeptidyl-peptidase 4 activity in gestational diabetes.
Diabetes, Gestational
Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus.
Diabetes, Gestational
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Diabetes, Gestational
The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.
Diabetic Angiopathies
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications.
Diabetic Angiopathies
Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.
Diabetic Angiopathies
Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo.
Diabetic Angiopathies
Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents.
Diabetic Cardiomyopathies
Impact of vildagliptin on vascular and fibrotic remodeling of myocardium in experimental diabetic cardiomyopathy.
Diabetic Cardiomyopathies
Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.
Diabetic Cardiomyopathies
Medicinal chemistry of drugs used in diabetic cardiomyopathy.
Diabetic Cardiomyopathies
Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3? and p38?/MAPK in a rat model of diabetic cardiomyopathy.
Diabetic Cardiomyopathies
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy.
Diabetic Foot
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study.
Diabetic Foot
To the editor regarding article "Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study".
Diabetic Foot
Wound healing effects of dipeptidyl peptidase-4 inhibitors: An emerging concept in management of diabetic foot ulcer-A review.
Diabetic Foot
[Research progress of dipeptidyl peptidase 4 inhibitors on healing of chronic diabetic foot ulcers].
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Diabetic Ketoacidosis
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
Diabetic Ketoacidosis
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Diabetic Ketoacidosis
MAXIMIZING PATIENT SAFETY WITH NEWLY APPROVED THERAPIES: FOCUS ON SGLT2 INHIBITORS.
Diabetic Ketoacidosis
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Diabetic Ketoacidosis
SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
Diabetic Ketoacidosis
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Diabetic Ketoacidosis
THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.
Diabetic Nephropathies
Active subfractions of Abelmoschus esculentus substantially prevent free fatty acid-induced ? cell apoptosis via inhibiting dipeptidyl peptidase-4.
Diabetic Nephropathies
Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in ?-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study.
Diabetic Nephropathies
Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4.
Diabetic Nephropathies
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.
Diabetic Nephropathies
Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy.
Diabetic Nephropathies
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
Diabetic Nephropathies
Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Diabetic Nephropathies
Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study.
Diabetic Nephropathies
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
Diabetic Nephropathies
Cluster analysis and phylogenetic relationship in biomarker identification of type 2 diabetes and nephropathy.
Diabetic Nephropathies
Combined effect of sodium-glucose cotransporter-2 and dipeptidyl peptidase-4 inhibitors for diabetic kidney disease.
Diabetic Nephropathies
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Diabetic Nephropathies
Diabetic nephropathy: newer therapeutic perspectives.
Diabetic Nephropathies
Diagnostic significance of urinary enzymes for diabetes mellitus and hypertension.
Diabetic Nephropathies
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies.
Diabetic Nephropathies
Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.
Diabetic Nephropathies
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Diabetic Nephropathies
Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis.
Diabetic Nephropathies
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Diabetic Nephropathies
Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
Diabetic Nephropathies
Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection.
Diabetic Nephropathies
Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease.
Diabetic Nephropathies
Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Diabetic Nephropathies
DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy.
Diabetic Nephropathies
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1? in type 2 diabetic patients with incipient nephropathy.
Diabetic Nephropathies
DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Diabetic Nephropathies
Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus.
Diabetic Nephropathies
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Diabetic Nephropathies
Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin.
Diabetic Nephropathies
Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Diabetic Nephropathies
Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Diabetic Nephropathies
Efficacy of alogliptin combined with motor imagery under hyperbaric oxygen in diabetic nephropathy with silent cerebral infarction.
Diabetic Nephropathies
Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin.
Diabetic Nephropathies
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice.
Diabetic Nephropathies
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.
Diabetic Nephropathies
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.
Diabetic Nephropathies
Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
Diabetic Nephropathies
Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study.
Diabetic Nephropathies
Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
Diabetic Nephropathies
Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Diabetic Nephropathies
Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis.
Diabetic Nephropathies
Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
Diabetic Nephropathies
Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy.
Diabetic Nephropathies
More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.
Diabetic Nephropathies
National trends in the treatment of diabetic nephropathy in the United States.
Diabetic Nephropathies
Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor.
Diabetic Nephropathies
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Diabetic Nephropathies
Proteome analysis of acute kidney injury - Discovery of new predominantly renal candidates for biomarker of kidney disease.
Diabetic Nephropathies
Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Diabetic Nephropathies
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria.
Diabetic Nephropathies
Renal therapeutics: patent highlights January to June 2003.
Diabetic Nephropathies
Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy.
Diabetic Nephropathies
Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury.
Diabetic Nephropathies
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.
Diabetic Nephropathies
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Diabetic Nephropathies
Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy.
Diabetic Nephropathies
Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.
Diabetic Nephropathies
Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1?/CXCR4 pathway.
Diabetic Nephropathies
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Diabetic Nephropathies
The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-?/Smad signal pathway.
Diabetic Nephropathies
The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease.
Diabetic Nephropathies
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Diabetic Nephropathies
Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease.
Diabetic Nephropathies
[Sitagliptin inhibits cell apoptosis and inflammation of renal tissues in diabetic nephropathy model rats].
Diabetic Neuropathies
Biomarkers in diabetic neuropathy.
Diabetic Retinopathy
Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression.
Diabetic Retinopathy
Circulating dipeptidyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients.
Diabetic Retinopathy
Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study.
Diabetic Retinopathy
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
Diabetic Retinopathy
Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
Diabetic Retinopathy
Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Diabetic Retinopathy
Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy.
Diabetic Retinopathy
Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema.
Diabetic Retinopathy
Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640-8).
Diabetic Retinopathy
PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES.
Diabetic Retinopathy
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.
Diabetic Retinopathy
Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640-8).
Diabetic Retinopathy
[Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
Digestive System Diseases
[Diagnostic usefulness of glycylproline-dipeptidyl-aminopeptidase activities in sera of patients with various hepatobiliary diseases (author's transl)]
Digestive System Diseases
[Dipeptidylpeptidase IV activity in human lymphocytes in hepatobiliary diseases]
Digestive System Neoplasms
Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
dipeptidyl-peptidase iv deficiency
A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model.
dipeptidyl-peptidase iv deficiency
Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity.
dipeptidyl-peptidase iv deficiency
Colitis development and resolution in mice with target deletion of dipeptidyl peptidase IV/CD26.
dipeptidyl-peptidase iv deficiency
Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema.
dipeptidyl-peptidase iv deficiency
Dipeptidyl Peptidase-4 deficiency effectively protects the brain and neurological function in rodent after acute Hemorrhagic Stroke.
dipeptidyl-peptidase iv deficiency
Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis.
dipeptidyl-peptidase iv deficiency
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
dipeptidyl-peptidase iv deficiency
Effect of X-Prolyl Dipeptidyl Aminopeptidase Deficiency on Lactococcus lactis.
dipeptidyl-peptidase iv deficiency
Exendin-4 therapy still offered an additional benefit on reducing transverse aortic constriction-induced cardiac hypertrophy-caused myocardial damage in DPP-4 deficient rats.
dipeptidyl-peptidase iv deficiency
Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats.
dipeptidyl-peptidase iv deficiency
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
dipeptidyl-peptidase iv deficiency
Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice.
dipeptidyl-peptidase iv deficiency
Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy.
dipeptidyl-peptidase iv deficiency
The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease.
Dirofilariasis
Evaluation of urinary enzymes in dogs with early renal disorder.
Down Syndrome
CD26 surface antigen expression on peripheral blood T lymphocytes from children with Down's syndrome (trisomy 21).
Drug Eruptions
Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
Drug-Related Side Effects and Adverse Reactions
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors.
Drug-Related Side Effects and Adverse Reactions
Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database.
Drug-Related Side Effects and Adverse Reactions
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.
Drug-Related Side Effects and Adverse Reactions
Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Drug-Related Side Effects and Adverse Reactions
Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.
Dumping Syndrome
Effectiveness of sitagliptin in a patient with late dumping syndrome after total gastrectomy.
Dupuytren Contracture
Myofibroblast as a major cellular constituent of villous stroma in human placenta.
Dyslipidemias
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Dyslipidemias
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Dyslipidemias
Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals.
Dyslipidemias
Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Dyslipidemias
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.
Dyslipidemias
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).
Dyslipidemias
Gestational glucocorticoid exposure disrupts glucose homeostasis that is accompanied by increased endoglin and DPP-4 activity instead of GSK-3 in rats.
Dyslipidemias
High Fat and High Cholesterol Diet Induces DPP-IV Activity in Intestinal Lymph.
Dyslipidemias
Late gestational testosterone exposure causes glucose deregulation and elevated cardiac VCAM-1 and DPP-4 activity in rats.
Dyslipidemias
Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway.
Dyslipidemias
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Dyslipidemias
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.
Dyslipidemias
[Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
Encephalomyelitis
Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.
Encephalomyelitis
Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses.
Encephalomyelitis
PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice.
Encephalomyelitis
Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.
Encephalomyelitis
TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26.
Encephalomyelitis, Autoimmune, Experimental
Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.
Encephalomyelitis, Autoimmune, Experimental
Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses.
Encephalomyelitis, Autoimmune, Experimental
PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice.
Encephalomyelitis, Autoimmune, Experimental
Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.
Encephalomyelitis, Autoimmune, Experimental
TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26.
Endometrial Neoplasms
Dipeptidyl peptidase IV is required for endometrial carcinoma cell proliferation and tumorigenesis via the IL-6/STAT3 pathway.
Endometrial Neoplasms
DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis.
Endotoxemia
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Endotoxemia
Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin.
Endotoxemia
The paradox of dipeptidyl peptidase IV inhibition in enterocytic differentiation and epithelial-mesenchymal transition in rat cholestatic sepsis.
Enterocolitis, Necrotizing
Sex-Specific Survival, Growth, Immunity and Organ Development in Preterm Pigs as Models for Immature Newborns.
Epilepsy
Anticonvulsant agent DPP4 inhibitor sitagliptin downregulates CXCR3/RAGE pathway on seizure models.
Epilepsy
The effect of dipeptidyl peptidase IV on disease-associated microglia phenotypic transformation in epilepsy.
Erectile Dysfunction
DPP-4 inhibition improves a sexual condition?
Erythema
Efficacy of parenteral administration of bee venom in experimental arthritis in the rat: A comparison with methotrexate.
Esophageal Neoplasms
Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV.
Esophageal Neoplasms
Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase-IV.
Esophageal Neoplasms
Red Fluorescence Probe Targeted to Dipeptidylpeptidase-IV for Highly Sensitive Detection of Esophageal Cancer.
Esophageal Squamous Cell Carcinoma
Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV.
Essential Hypertension
Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension.
Eye Diseases
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Fabry Disease
A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV.
Fatigue Syndrome, Chronic
Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.
Fatty Liver
A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets.
Fatty Liver
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Fatty Liver
Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population.
Fatty Liver
Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Fatty Liver
Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.
Fatty Liver
Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes.
Fatty Liver
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Fatty Liver
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Fatty Liver
Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice.
Fatty Liver
Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
Fatty Liver
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
Fatty Liver
Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
Fatty Liver
Dipeptidyl peptidase-4: a key player in chronic liver disease.
Fatty Liver
DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
Fatty Liver
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Fatty Liver
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Fatty Liver
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Fatty Liver
Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study.
Fatty Liver
Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Fatty Liver
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
Fatty Liver
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
Fatty Liver
Epigenetic regulation of hepatic Dpp4 expression in response to dietary protein.
Fatty Liver
Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus.
Fatty Liver
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Fatty Liver
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Fatty Liver
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.
Fatty Liver
Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
Fatty Liver
Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor.
Fatty Liver
Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice.
Fatty Liver
Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
Fatty Liver
Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Fatty Liver
Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Fatty Liver
Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
Fatty Liver
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Fatty Liver
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
Fatty Liver
Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
Fetal Growth Retardation
Changes in placental dipeptidyl peptidase IV in preeclampsia with intrauterine growth restriction.
Fibroma
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Fibromatosis, Aggressive
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Fibromyalgia
Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia.
Fibromyalgia
Serum activities of adenosine deaminase, dipeptidyl peptidase IV and prolyl endopeptidase in patients with fibromyalgia: diagnostic implications.
Foot Ulcer
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes.
Foot Ulcer
Wound healing effects of dipeptidyl peptidase-4 inhibitors: An emerging concept in management of diabetic foot ulcer-A review.
Foot Ulcer
[Research progress of dipeptidyl peptidase 4 inhibitors on healing of chronic diabetic foot ulcers].
Gallbladder Diseases
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Gangliosidoses
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Gastrointestinal Diseases
Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Gastrointestinal Diseases
Immunoelectrophoretic studies on human small intestinal brush border proteins. A quantitative study of brush border enzymes from single small intestinal biopsies.
Gastrointestinal Diseases
Role of Incretin Axis in Inflammatory Bowel Disease.
Gaucher Disease
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Giant Cell Tumors
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Gingivitis
A simple, combined fluorogenic and chromogenic method for the assay of proteases in gingival crevicular fluid.
Glioblastoma
Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-? in transformed astrocytic cells.
Glioblastoma
Dipeptidyl peptidase IV in two human glioma cell lines.
Glioblastoma
Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas.
Glioma
Detection of dipeptidyl peptidase IV in glioma C6 and neuroblastoma SK-N-SH cell lines.
Glioma
Dipeptidyl peptidase IV in C6 rat glioma cell line differentiation.
Glioma
Dipeptidyl peptidase IV in two human glioma cell lines.
Glioma
Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity.
Glioma
Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade.
Glioma
Heterogeneity of dipeptidyl peptidase IV from C6 rat glioma cells.
Glioma
High DPP4 expression predicts poor prognosis in patients with low-grade glioma.
Glioma
Modulation of substance P signaling by dipeptidyl peptidase-IV enzymatic activity in human glioma cell lines.
Glomerulonephritis
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
Glomerulonephritis
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies.
Glomerulonephritis
Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells.
Glomerulonephritis
Involvement of dipeptidyl peptidase IV in immune complex-mediated glomerulonephritis.
Glomerulonephritis
Urinary excretion of dipeptidyl aminopeptidase i.v. in patients with renal diseases.
Glomerulonephritis
[Clinical investigation of urinary dipeptidyl aminopeptidase IV (DAP IV) activity in patients with primary glomerular diseases]
Glomerulonephritis, IGA
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies.
Glomerulonephritis, Membranous
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies.
Glomerulonephritis, Membranous
Identification of gp108, a pathogenic antigen of passive Heymann nephritis, as dipeptidyl peptidase IV.
Glomerulonephritis, Membranous
Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice.
Glomerulonephritis, Membranous
Role of dipeptidyl peptidase IV (gp 108) in passive Heymann nephritis. Use of dipeptidyl peptidase IV-deficient rats.
Glomerulosclerosis, Focal Segmental
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Glucose Intolerance
(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Glucose Intolerance
A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
Glucose Intolerance
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance.
Glucose Intolerance
Anti-?-glucosidase and Anti-dipeptidyl Peptidase-IV Activities of Extracts and Purified Compounds from Vitis thunbergii var. taiwaniana.
Glucose Intolerance
Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms.
Glucose Intolerance
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Glucose Intolerance
Bioprocessing of common pulses changed seed microstructures, and improved dipeptidyl peptidase-IV and ?-glucosidase inhibitory activities.
Glucose Intolerance
Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Glucose Intolerance
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.
Glucose Intolerance
Combination of Mangiferin and Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Impaired Glucose Tolerance in Streptozotocin-Diabetic Rats.
Glucose Intolerance
Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity.
Glucose Intolerance
Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
Glucose Intolerance
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
Glucose Intolerance
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Glucose Intolerance
DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
Glucose Intolerance
DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
Glucose Intolerance
Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.
Glucose Intolerance
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Glucose Intolerance
Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance.
Glucose Intolerance
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Glucose Intolerance
Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin.
Glucose Intolerance
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Glucose Intolerance
Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Glucose Intolerance
Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
Glucose Intolerance
Increased plasma dipeptidyl peptidase IV (DPP IV) activity and decreased DPP IV activity of visceral but not subcutaneous adipose tissue in impaired glucose tolerance rats induced by high-fat or high-sucrose diet.
Glucose Intolerance
Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
Glucose Intolerance
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Glucose Intolerance
Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Glucose Intolerance
Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
Glucose Intolerance
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Glucose Intolerance
The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Glucose Intolerance
The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE-A multicenter randomized controlled trial.
Goiter
Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.
Goiter
Staining for dipeptidyl aminopeptidase IV activity in nodular thyroid diseases.
Graft vs Host Disease
Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
Graft vs Host Disease
Redistribution of glomerular dipeptidyl peptidase type IV in experimental lupus nephritis. Demonstration of decreased enzyme activity at the ultrastructural level.
Granuloma
Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitor.
Graves Disease
Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control study.
Heart Diseases
Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
Heart Diseases
Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation.
Heart Diseases
Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Heart Diseases
Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure.
Heart Diseases
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research.
Heart Failure
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
Heart Failure
A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats.
Heart Failure
A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
Heart Failure
A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
Heart Failure
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
Heart Failure
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
Heart Failure
Analysis of the Correlation between the Myocardial Expression of DPP-4 and the Clinical Parameters of Patients with Heart Failure.
Heart Failure
Anti-Diabetic Agents and Heart Failure?- Response to the CARMELINA Study.
Heart Failure
Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?
Heart Failure
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Heart Failure
Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
Heart Failure
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
Heart Failure
Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Heart Failure
Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.
Heart Failure
Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.
Heart Failure
B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications.
Heart Failure
Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.
Heart Failure
Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats.
Heart Failure
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Heart Failure
Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
Heart Failure
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
Heart Failure
CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
Heart Failure
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes.
Heart Failure
Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
Heart Failure
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Heart Failure
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
Heart Failure
Cardiovascular Protection with Anti-hyperglycemic Agents.
Heart Failure
Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Heart Failure
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
Heart Failure
Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
Heart Failure
Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons.
Heart Failure
Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure.
Heart Failure
Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.
Heart Failure
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Heart Failure
Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example.
Heart Failure
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Heart Failure
Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Heart Failure
Contrasting effects on the risk of macrovascular and microvascular events associated with anti-hyperglycaemic drugs that enhance sodium excretion and lower blood pressure.
Heart Failure
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Heart Failure
Diabetic Cardiomyopathy: Clinical and Metabolic Approach.
Heart Failure
Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
Heart Failure
Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.
Heart Failure
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.
Heart Failure
Dipeptidyl peptidase IV and mortality after an acute heart failure episode.
Heart Failure
Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure.
Heart Failure
Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure.
Heart Failure
Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure.
Heart Failure
Dipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?
Heart Failure
Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
Heart Failure
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Heart Failure
Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
Heart Failure
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
Heart Failure
Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
Heart Failure
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Heart Failure
Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Heart Failure
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Heart Failure
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.
Heart Failure
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.
Heart Failure
Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
Heart Failure
Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions.
Heart Failure
Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction.
Heart Failure
Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside.
Heart Failure
Dipeptidyl-Peptidase IV Inhibition Improves Pathophysiology of Heart Failure and Increases Survival Rate in Pressure-Overloaded Mice.
Heart Failure
Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?
Heart Failure
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Heart Failure
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials.
Heart Failure
DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.
Heart Failure
DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
Heart Failure
DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.
Heart Failure
DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty.
Heart Failure
DPP-4 inhibitors and risk of heart failure EXAMINEd.
Heart Failure
DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.
Heart Failure
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Heart Failure
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
Heart Failure
Effect of Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Events in Type-2 Diabetes Patients with Renal Impairment: A Systematic Review and Meta-analysis.
Heart Failure
Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure?- Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
Heart Failure
Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials.
Heart Failure
Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Heart Failure
Effect of glucose-lowering therapies on heart failure.
Heart Failure
Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs.
Heart Failure
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease.
Heart Failure
Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study.
Heart Failure
Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
Heart Failure
Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Heart Failure
Effects of incretin-based therapy in patients with heart failure and myocardial infarction.
Heart Failure
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
Heart Failure
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Heart Failure
Glucagon and heart in type 2 diabetes: new perspectives.
Heart Failure
Glucagon-like Peptide-1 and its cardiovascular effects.
Heart Failure
Heart failure and dipeptidyl peptidase-4 inhibitors.
Heart Failure
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Heart Failure
Heart Failure as a Comorbidity of Diabetes: Role of Dipeptidyl Peptidase 4.
Heart Failure
Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.
Heart Failure
Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Heart Failure
Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments.
Heart Failure
Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
Heart Failure
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Heart Failure
Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
Heart Failure
Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.
Heart Failure
Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus.
Heart Failure
Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database.
Heart Failure
Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study.
Heart Failure
Incretin-based drugs and the risk of congestive heart failure.
Heart Failure
Incretin-related drug therapy in heart failure.
Heart Failure
Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice.
Heart Failure
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Heart Failure
Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Heart Failure
Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension.
Heart Failure
Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52).
Heart Failure
Long-Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats.
Heart Failure
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Heart Failure
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Heart Failure
Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Heart Failure
Meta-analyses of the effects of Dpp-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
Heart Failure
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Heart Failure
No increased heart failure risk is reported with DPP-4 inhibitors.
Heart Failure
No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Heart Failure
Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.
Heart Failure
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.
Heart Failure
Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions.
Heart Failure
Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes.
Heart Failure
Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
Heart Failure
Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure.
Heart Failure
Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
Heart Failure
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research.
Heart Failure
Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52).
Heart Failure
Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Heart Failure
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Heart Failure
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Heart Failure
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Heart Failure
Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Heart Failure
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Heart Failure
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Heart Failure
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus.
Heart Failure
Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes.
Heart Failure
Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Heart Failure
Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities.
Heart Failure
Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.
Heart Failure
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
Heart Failure
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Heart Failure
Soluble Glycoprotein 130 and Heat Shock Protein 27 as Novel Candidate Biomarkers of Chronic Heart Failure with Preserved Ejection Fraction.
Heart Failure
Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.
Heart Failure
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.
Heart Failure
The Alchemist's Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes?
Heart Failure
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Heart Failure
The contributions of dipeptidyl peptidase IV to inflammation in heart failure.
Heart Failure
The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.
Heart Failure
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure.
Heart Failure
The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
Heart Failure
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Heart Failure
The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure.
Heart Failure
Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Heart Failure
Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Heart Failure
Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies.
Heart Failure
Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Heart Failure
Update in cardiology: vascular risk and cardiac rehabilitation.
Heart Failure
Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
Heart Failure
Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Heart Failure
Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications.
Heart Failure
[Glucose-lowering therapy in patients with cardiac comorbidities].
Heart Failure
[The Diabetic Heart and Heart Failure - Update on Mechanisms and Therapy].
Heart Failure
[Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
Hematologic Neoplasms
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Hematologic Neoplasms
DPPIV - serum activity and expression on lymphocytes in different hematological malignancies.
Hematologic Neoplasms
Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint.
Hematologic Neoplasms
In Vivo DPP-4 Inhibition to Enhance Engraftment of Single-Unit Cord Blood Transplants in Adults with Hematological Malignancies.
Hemophilia A
Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan.
Hemophilia A
New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome.
Hemophilia A
[Acquired hemophilia A complicated by dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid].
Hemorrhagic Stroke
Dipeptidyl Peptidase-4 deficiency effectively protects the brain and neurological function in rodent after acute Hemorrhagic Stroke.
Hepatitis
Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka.
Hepatitis
Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
Hepatitis
[Dipeptidyl aminopeptidase IV in hospitalized patients and in galactosamine hepatitis of the rat: Activity and lectin affinity chromatography in serum and hepatic plasma membranes]
Hepatitis B
Efficacy and safety of repeated hepatocyte transplantation for significant liver repopulation in rodents.
Hepatitis C
Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
Hepatitis C
Dipeptidyl peptidase-4 inhibitor sitagliptin significantly reduced hepatitis C virus replication in a diabetic patient with chronic hepatitis C virus infection.
Hepatitis C
Dipeptidyl peptidase-4: a key player in chronic liver disease.
Hepatitis C
Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C.
Hepatitis C
Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections.
Hepatitis C
Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Hepatitis C
Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.
Hepatitis C, Chronic
Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Hepatitis C, Chronic
Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
Hepatitis C, Chronic
Dipeptidyl peptidase-4 inhibitor sitagliptin significantly reduced hepatitis C virus replication in a diabetic patient with chronic hepatitis C virus infection.
Hepatitis C, Chronic
Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis.
Hepatitis C, Chronic
Plasma concentrations of zinc, copper, interleukin-6 and interferon-?, and plasma dipeptidyl peptidase IV activity in chronic hepatitis C.
Hepatitis C, Chronic
Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C.
Hepatitis C, Chronic
Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections.
Hepatitis, Chronic
Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.
Herpes Simplex
Glycoprotein 110, the Epstein-Barr virus homolog of herpes simplex virus glycoprotein B, is essential for Epstein-Barr virus replication in vivo.
Herpes Simplex
The processing, transport and heterologous expression of Epstein-Barr virus gp110.
Herpes Zoster
Herpes zoster and diabetes.
Herpes Zoster
Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters.
Herpes Zoster
Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes.
HIV Infections
A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection.
HIV Infections
CD 26--to be or not to be a cofactor for CD 4 receptor of human immunodeficiency viruses.
HIV Infections
Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals.
HIV Infections
Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.
HIV Infections
The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding.
HIV Infections
The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
Hodgkin Disease
DPPIV - serum activity and expression on lymphocytes in different hematological malignancies.
Hodgkin Disease
Quantitative and qualitative enzyme studies of Hodgkin's disease-derived cell lines.
Hyperalgesia
Efficacy of parenteral administration of bee venom in experimental arthritis in the rat: A comparison with methotrexate.
Hyperalgesia
The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord.
Hypercholesterolemia
Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.
Hypercholesterolemia
Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A 18F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.
Hypercholesterolemia
Pharmacological properties of marine macroalgae-associated heterotrophic bacteria.
Hyperglycemia
(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Hyperglycemia
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Hyperglycemia
A linearization approach for the model-based analysis of combined aggregate and individual patient data.
Hyperglycemia
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Hyperglycemia
A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers.
Hyperglycemia
A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.
Hyperglycemia
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
Hyperglycemia
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Hyperglycemia
All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.
Hyperglycemia
Anagliptin prevented interleukin 1? (IL-1?)-induced cellular senescence in vascular smooth muscle cells through increasing the expression of sirtuin1 (SIRT1).
Hyperglycemia
Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking.
Hyperglycemia
Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?
Hyperglycemia
Challenges and Strategies for Inpatient Diabetes Management in Older Adults.
Hyperglycemia
Characterization of Novel Dipeptidyl Peptidase-IV Inhibitory Peptides from Soft-Shelled Turtle Yolk Hydrolysate Using Orthogonal Bioassay-Guided Fractionations Coupled with In Vitro and In Silico Study.
Hyperglycemia
Chitosan: A promising therapeutic agent and effective drug delivery system in managing diabetes mellitus.
Hyperglycemia
Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus.
Hyperglycemia
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Hyperglycemia
Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Hyperglycemia
Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.
Hyperglycemia
Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials.
Hyperglycemia
Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?
Hyperglycemia
Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells.
Hyperglycemia
Differentiating incretin-based therapies for population-based health care.
Hyperglycemia
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
Hyperglycemia
Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke.
Hyperglycemia
Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?
Hyperglycemia
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice.
Hyperglycemia
DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects.
Hyperglycemia
DPP-4 inhibitor treatment: ?-cell response but not HbA1c reduction is dependent on the duration of diabetes.
Hyperglycemia
DPP-IV Inhibitor Therapy in Patients after Pancreatic Transplant.
Hyperglycemia
DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses.
Hyperglycemia
Effect of single oral dose of proanthocyanidin on postprandial hyperglycemia in healthy rats: A comparative study with sitagliptin.
Hyperglycemia
Effect of thymoquinone on high fat diet and STZ-induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies.
Hyperglycemia
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).
Hyperglycemia
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.
Hyperglycemia
Effects of insulin and other antihyperglycemic agents on lipid profiles of patients with diabetes.
Hyperglycemia
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Hyperglycemia
Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats.
Hyperglycemia
Efficacy and safety of miglitol- or repaglinide-based combination therapy with alogliptin in drug-naïve patients with type 2 diabetes: An open-label, single-center, parallel, randomized control pilot study.
Hyperglycemia
Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.
Hyperglycemia
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.
Hyperglycemia
Further possible mechanisms of dipeptidyl peptidase-4 inhibitors to decrease blood glucose in subjects with type 2 diabetes.
Hyperglycemia
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Hyperglycemia
Glucagon like peptide-1 and atherosclerosis.
Hyperglycemia
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Hyperglycemia
Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.
Hyperglycemia
Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism.
Hyperglycemia
Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations.
Hyperglycemia
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Hyperglycemia
Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients.
Hyperglycemia
Incretin agents in type 2 diabetes.
Hyperglycemia
Incretin-based therapies.
Hyperglycemia
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Hyperglycemia
Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
Hyperglycemia
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Hyperglycemia
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
Hyperglycemia
MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice.
Hyperglycemia
Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: subgroup analysis of a randomized clinical trial.
Hyperglycemia
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.
Hyperglycemia
Pleiotropic Effects of the Dipeptidylpeptidase-4 Inhibitors on the Cardiovascular System.
Hyperglycemia
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists.
Hyperglycemia
Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
Hyperglycemia
Purification, identification, and molecular mechanism of DPP-IV inhibitory peptides from defatted Antarctic krill powder.
Hyperglycemia
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.
Hyperglycemia
Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
Hyperglycemia
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Hyperglycemia
Saxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adults.
Hyperglycemia
Serum Dipeptidyl peptidase-4 level is related to adiposity in type 1 diabetic adolescents.
Hyperglycemia
Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.
Hyperglycemia
Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study.
Hyperglycemia
Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.
Hyperglycemia
Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.
Hyperglycemia
Substance p increases sympathetic activity during combined Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
Hyperglycemia
Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents.
Hyperglycemia
Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Hyperglycemia
Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions.
Hyperglycemia
Teneligliptin for the treatment of type 2 diabetes.
Hyperglycemia
The Corn Protein, Zein Hydrolysate, Administered into the Ileum Attenuates Hyperglycemia via Its Dual Action on Glucagon-Like Peptide-1 Secretion and Dipeptidyl Peptidase-IV Activity in Rats.
Hyperglycemia
The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.
Hyperglycemia
The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
Hyperglycemia
The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.
Hyperglycemia
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
Hyperglycemia
The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1?/CXCR4 pathway.
Hyperglycemia
The impact of current and novel anti-diabetic therapies on cardiovascular risk.
Hyperglycemia
The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.
Hyperglycemia
The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes.
Hyperglycemia
Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
Hyperglycemia
Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice with Histone Acetylation in Dpp-4 Promoter.
Hyperglycemia
Treatment with DPP-4I Anagliptin or ?-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.
Hyperglycemia
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Hyperglycemia
Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes.
Hyperglycemia
When oral agents fail: optimizing insulin therapy in the older adult.
Hyperglycemia
[Analogues of amylin, alpha-glucosidase inhibitors and the digestive system in homeostasis regulation].
Hyperglycemia
[Efficacy of a DPP-4 inhibitor as assessed by continuous glucose monitoring (CGM)].
Hyperglycemia
[Efficacy of DPP-4 inhibitor evaluated by CGM (continuous glucose monitoring)].
Hyperglycemia
[Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison]
Hyperglycemia
[Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
Hyperglycemia
[Future targets in the treatment of type 2 diabetes]
Hyperglycemia
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Hyperglycemia
[The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].
Hyperinsulinism
DPP-4 inhibition resembles exercise in preventing type 2 diabetes development by inhibiting hepatic protein kinase C? expression in a mouse model of hyperinsulinemia.
Hyperinsulinism
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis.
Hyperinsulinism
Effect of thymoquinone on high fat diet and STZ-induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies.
Hyperinsulinism
GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering.
Hyperinsulinism
Inhibition of dipeptidyl peptidase-4 averts Free Fatty acids deposition in the hearts of oral estrogen-progestin contraceptive-induced hyperinsulinemic female rats.
Hyperinsulinism
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
Hyperinsulinism
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.
Hyperinsulinism
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
Hyperinsulinism
MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice.
Hyperlipidemias
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Hyperlipidemias
Effect of thymoquinone on high fat diet and STZ-induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies.
Hyperlipidemias
GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states.
Hyperlipidemias
Impact of primary care intensive management on medication adherence and adjustments.
Hyperlipidemias
Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.
Hyperlipoproteinemia Type II
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Hyperlipoproteinemia Type II
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Hypersensitivity
Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo.
Hypersensitivity
Periostin and Dipeptidyl Peptidase-4: Potential Biomarkers of Interleukin 13 Pathway Activation in Asthma and Allergy.
Hypersensitivity
Predicting DPP-IV inhibitors with machine learning approaches.
Hypersensitivity
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Hypersensitivity
Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) in breast-fed infants with symptoms of allergy.
Hypertension
A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis.
Hypertension
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Hypertension
Adaptive changes in the capillary network in the left ventricle of rat heart.
Hypertension
Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity.
Hypertension
Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.
Hypertension
Characterization of Antidiabetic and Antihypertensive Properties of Canary Seed ( Phalaris canariensis L.) Peptides.
Hypertension
Clinical features and therapeutic perspectives on hypertension in diabetics.
Hypertension
Comparison of Efficacy between Dipeptidyl Peptidase-4 Inhibitor and Sodium-Glucose Cotransporter 2 Inhibitor on Metabolic Risk Factors in Japanese Patients with Type 2 Diabetes Mellitus: Results from the CANTABILE Study.
Hypertension
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Hypertension
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Hypertension
Differentiating incretin-based therapies for population-based health care.
Hypertension
Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension.
Hypertension
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like Peptide 1-dependent mechanism.
Hypertension
Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema.
Hypertension
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
Hypertension
Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.
Hypertension
DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.
Hypertension
DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report.
Hypertension
DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice.
Hypertension
Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.
Hypertension
Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models.
Hypertension
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
Hypertension
Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial.
Hypertension
Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro.
Hypertension
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Hypertension
Glucagon-like Peptide-1 and its cardiovascular effects.
Hypertension
Histochemical evaluation of placental dipeptidyl peptidase IV (CD26) in pre-eclampsia: enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational hypertensive disorders.
Hypertension
Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin.
Hypertension
Identification of angiotensin converting enzyme and dipeptidyl peptidase-IV inhibitory peptides derived from oilseed proteins using two integrated bioinformatic approaches.
Hypertension
Identification of novel dipeptidyl peptidase-IV and angiotensin-I-converting enzyme inhibitory peptides from meat proteins using in silico analysis.
Hypertension
Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress.
Hypertension
Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension.
Hypertension
Long-Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats.
Hypertension
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients.
Hypertension
NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4.
Hypertension
Pharmacological properties of marine macroalgae-associated heterotrophic bacteria.
Hypertension
Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHR.
Hypertension
Predicted Release and Analysis of Novel ACE-I, Renin, and DPP-IV Inhibitory Peptides from Common Oat (Avena sativa) Protein Hydrolysates Using in Silico Analysis.
Hypertension
Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension.
Hypertension
Rapid redistribution and inhibition of renal sodium transporters during acute pressure natriuresis.
Hypertension
Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.
Hypertension
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Hypertension
The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha.
Hypertension
The pathophysiology of hypertension in patients with obesity.
Hypertension
The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors.
Hypertension
The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
Hypertension
Two Novel Bioactive Peptides from Antarctic Krill with Dual Angiotensin Converting Enzyme and Dipeptidyl Peptidase IV Inhibitory Activities.
Hypertension
Uncoupling Protein-2 Mediates DPP-4 Inhibitor-Induced Restoration of Endothelial Function in Hypertension Through Reducing Oxidative Stress.
Hypertension
Update in cardiology: vascular risk and cardiac rehabilitation.
Hypertension
Urinary excretion of dipeptidyl aminopeptidase i.v. in patients with renal diseases.
Hypertension
[Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers]
Hypertension
[Renal dipeptidylpeptidase IV excretion in drug-induced kidney changes]
Hypertension, Pregnancy-Induced
Histochemical evaluation of placental dipeptidyl peptidase IV (CD26) in pre-eclampsia: enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational hypertensive disorders.
Hypertension, Pulmonary
Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension.
Hypertension, Pulmonary
Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension.
Hyperthyroidism
Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
Hypertriglyceridemia
N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
Hypertrophy, Left Ventricular
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure.
Hypoalphalipoproteinemias
The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort.
Hypoglycemia
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Hypoglycemia
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.
Hypoglycemia
A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.
Hypoglycemia
A New Preventive Strategy for Hypoglycemia Incorporating Added Food Diet in Patients with Type 2 Diabetes Who Received Sitagliptin Therapy.
Hypoglycemia
A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes.
Hypoglycemia
A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
Hypoglycemia
A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease.
Hypoglycemia
A systematic review of the safety of incretin-based therapies in type 2 diabetes.
Hypoglycemia
Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.
Hypoglycemia
All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.
Hypoglycemia
Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus.
Hypoglycemia
Alogliptin benzoate for management of type 2 diabetes.
Hypoglycemia
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Hypoglycemia
An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective.
Hypoglycemia
An updated review on cancer risk associated with incretin mimetics and enhancers.
Hypoglycemia
An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.
Hypoglycemia
Approach Toward Diabetes Treatment in the Elderly.
Hypoglycemia
Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
Hypoglycemia
Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Hypoglycemia
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
Hypoglycemia
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Hypoglycemia
Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
Hypoglycemia
Characteristics and Early Hypoglycemic Medications of Patients at Risk of Progression to Type 2 Diabetes in Japan: A Retrospective Cohort Study of Health Checkup and Claims Data.
Hypoglycemia
Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians' Perspective in a Real-World Setting, Insight from a Web Survey.
Hypoglycemia
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.
Hypoglycemia
Clinical Effects of Exposure to DPP-4 Inhibitors as Reported to the National Poison Data System.
Hypoglycemia
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Hypoglycemia
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.
Hypoglycemia
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.
Hypoglycemia
Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes.
Hypoglycemia
Combination Therapy to Achieve Glycemic Goals: Advantages of Adding Incretin-based Therapies to Insulin in Patients With Type 2 Diabetes Mellitus.
Hypoglycemia
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Hypoglycemia
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Hypoglycemia
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
Hypoglycemia
Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Hypoglycemia
Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
Hypoglycemia
Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials.
Hypoglycemia
Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action.
Hypoglycemia
Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes.
Hypoglycemia
Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus.
Hypoglycemia
Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand.
Hypoglycemia
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes.
Hypoglycemia
Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Hypoglycemia
Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
Hypoglycemia
Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach.
Hypoglycemia
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Hypoglycemia
Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.
Hypoglycemia
Differentiating incretin-based therapies for population-based health care.
Hypoglycemia
Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes.
Hypoglycemia
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.
Hypoglycemia
Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond.
Hypoglycemia
Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
Hypoglycemia
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
Hypoglycemia
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences.
Hypoglycemia
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Hypoglycemia
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.
Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?
Hypoglycemia
Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Hypoglycemia
Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review.
Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience.
Hypoglycemia
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials.
Hypoglycemia
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Hypoglycemia
Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.
Hypoglycemia
Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Hypoglycemia
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Hypoglycemia
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials.
Hypoglycemia
DPP IV inhibitors: successes, failures and future prospects.
Hypoglycemia
DPP-4 inhibition and islet function.
Hypoglycemia
DPP-4 Inhibition and the Path to Clinical Proof.
Hypoglycemia
DPP-4 inhibition improves a sexual condition?
Hypoglycemia
DPP-4 inhibitors in clinical practice.
Hypoglycemia
DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Hypoglycemia
Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c???6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials.
Hypoglycemia
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Hypoglycemia
Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study.
Hypoglycemia
Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Hypoglycemia
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Hypoglycemia
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
Hypoglycemia
Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
Hypoglycemia
Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis.
Hypoglycemia
Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.
Hypoglycemia
Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System.
Hypoglycemia
Emergence of promising novel DPP-4 inhibitory heterocycles as anti-diabetic agents: A review.
Hypoglycemia
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Hypoglycemia
Emerging Incretin Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors.
Hypoglycemia
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Hypoglycemia
Encapsulation of 16-Hydroxycleroda-3,13-Dine-16,15-Olide in Mesoporous Silica Nanoparticles as a Natural Dipeptidyl Peptidase-4 Inhibitor Potentiated Hypoglycemia in Diabetic Mice.
Hypoglycemia
Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Hypoglycemia
Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes.
Hypoglycemia
Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.
Hypoglycemia
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan.
Hypoglycemia
Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients.
Hypoglycemia
GLP1 and cancer: friend or foe?
Hypoglycemia
Glucagon like peptide-1 and atherosclerosis.
Hypoglycemia
Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Hypoglycemia
Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population.
Hypoglycemia
Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
Hypoglycemia
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Hypoglycemia
Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin.
Hypoglycemia
Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats.
Hypoglycemia
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
Hypoglycemia
Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
Hypoglycemia
Incretin agents in type 2 diabetes.
Hypoglycemia
Incretin pharmacology: A review of the incretin effect and current incretin-based therapies.
Hypoglycemia
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Hypoglycemia
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Hypoglycemia
Incretin-based therapies.
Hypoglycemia
Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone.
Hypoglycemia
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.
Hypoglycemia
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Hypoglycemia
Insulin Therapy in Type 2 Diabetes.
Hypoglycemia
Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Hypoglycemia
Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling.
Hypoglycemia
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Hypoglycemia
Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
Hypoglycemia
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.
Hypoglycemia
Management of type 2 diabetes mellitus in self-motivated patients: optimized diet, exercise, and medication for weight loss and cardiometabolic fitness.
Hypoglycemia
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.
Hypoglycemia
Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
Hypoglycemia
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Hypoglycemia
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Hypoglycemia
Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin.
Hypoglycemia
Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Hypoglycemia
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus.
Hypoglycemia
Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.
Hypoglycemia
Natural compounds with DPP-4 inhibitory effects: Implications for the treatment of diabetes.
Hypoglycemia
Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV.
Hypoglycemia
Novel 4-heteroaryl-antipyrines as DPP-IV inhibitors.
Hypoglycemia
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Hypoglycemia
Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor.
Hypoglycemia
Oral antidiabetic agents in type 2 diabetes.
Hypoglycemia
Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
Hypoglycemia
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Hypoglycemia
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.
Hypoglycemia
PATHOPHYSIOLOGY AND MANAGEMENT OF HYPOGLYCEMIAIN END-STAGE RENAL DISEASE PATIENTS: A REVIEW.
Hypoglycemia
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.
Hypoglycemia
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Hypoglycemia
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Hypoglycemia
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Hypoglycemia
Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4.
Hypoglycemia
Potential for Combination of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter-2 Inhibitors for the Treatment of Type 2 Diabetes.
Hypoglycemia
Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.
Hypoglycemia
Predicting DPP-IV inhibitors with machine learning approaches.
Hypoglycemia
Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus.
Hypoglycemia
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Hypoglycemia
Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan.
Hypoglycemia
Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
Hypoglycemia
Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Hypoglycemia
Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors.
Hypoglycemia
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria.
Hypoglycemia
Restoration of the Hypothalamic-pituitary-adrenal Response to Hypoglycemia in Type 2 Diabetes by Avoiding Chronic Hypoglycemia.
Hypoglycemia
Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus.
Hypoglycemia
Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia.
Hypoglycemia
Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture.
Hypoglycemia
Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.
Hypoglycemia
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Hypoglycemia
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Hypoglycemia
Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013.
Hypoglycemia
Selecting among ADA/EASD tier 1 and tier 2 treatment options.
Hypoglycemia
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Hypoglycemia
Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Observational Studies.
Hypoglycemia
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
Hypoglycemia
Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
Hypoglycemia
Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Hypoglycemia
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus.
Hypoglycemia
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.
Hypoglycemia
The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
Hypoglycemia
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Hypoglycemia
The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Hypoglycemia
The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications.
Hypoglycemia
The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Hypoglycemia
Toxicology of Medications for Diabetes Mellitus.
Hypoglycemia
Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.
Hypoglycemia
Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
Hypoglycemia
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
Hypoglycemia
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.
Hypoglycemia
Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
Hypoglycemia
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Hypoglycemia
Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes.
Hypoglycemia
Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
Hypoglycemia
When oral agents fail: optimizing insulin therapy in the older adult.
Hypoglycemia
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]
Hypoglycemia
[Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
Hypoglycemia
[DPP-4 inhibitors in nephropatics].
Hypoglycemia
[Efficacy of DPP-4 inhibitor evaluated by CGM (continuous glucose monitoring)].
Hypoglycemia
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Hypoglycemia
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Hypoglycemia
[Incretin therapies and multifactorial clinical approach to cardiometabolic patients].
Hypoglycemia
[Incretin-based therapy in patients with type 1 diabetes mellitus].
Hypoglycemia
[New avenues for pharmacotherapy of type 2 diabetes mellitus]
Hypoglycemia
[Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].
Hypoglycemia
[The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus].
Hypoglycemia
[Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
Hypoglycemia
[Type 2 diabetes mellitus: New treatments.]
Hypotension
Marked improvement of elderly postprandial hypotension by dipeptidyl peptidase IV inhibitor.
Hypotension
Postprandial and Orthostatic Hypotension Treated by Sitagliptin in a Patient with Dementia with Lewy Bodies.
Hypotension, Orthostatic
Postprandial and Orthostatic Hypotension Treated by Sitagliptin in a Patient with Dementia with Lewy Bodies.
Hypothyroidism
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Ileus
Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study.
Ileus
Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients.
Immune System Diseases
Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability.
Immune System Diseases
CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
Immune System Diseases
DPP4 reduces proinflammatory cytokine production in human rheumatoid arthritis synovial fibroblasts.
Infections
A mouse model for MERS coronavirus-induced acute respiratory distress syndrome.
Infections
A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
Infections
A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines.
Infections
Adaptive Evolution of MERS-CoV to Species Variation in DPP4.
Infections
Antidiabetic oral treatment in older people: does frailty matter?
Infections
Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study.
Infections
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.
Infections
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
Infections
Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Infections
Conjugation of Human ?-Defensin 2 to Spike Protein Receptor-Binding Domain Induces Antigen-Specific Protective Immunity against Middle East Respiratory Syndrome Coronavirus Infection in Human Dipeptidyl Peptidase 4 Transgenic Mice.
Infections
Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus.
Infections
Development of a Mouse-Adapted MERS Coronavirus.
Infections
Diabetes and COVID-19.
Infections
Dipeptidyl amino peptidase IV cytochemistry in circulating lymphocytes from HIV-I-seropositive subjects.
Infections
Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.
Infections
Dipeptidyl-Peptidase 4 and Attractin Expression is Increased in Circulating Blood Monocytes of Obese Human Subjects.
Infections
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
Infections
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials.
Infections
DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Infections
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment.
Infections
Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.
Infections
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Infections
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Infections
Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease.
Infections
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Infections
Enolase and dipeptidyl peptidase IV protein sub-unit vaccines are not protective against a lethal Streptococcus suis serotype 2 challenge in a mouse model of infection.
Infections
Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4.
Infections
Fungal Mimicry of a Mammalian Aminopeptidase Disables Innate Immunity and Promotes Pathogenicity.
Infections
Fungalysin and dipeptidyl-peptidase gene transcription in Microsporum canis strains isolated from symptomatic and asymptomatic cats.
Infections
Generation of a transgenic mouse model of middle East respiratory syndrome coronavirus infection and disease.
Infections
Genetically Engineering a Susceptible Mouse Model for MERS-CoV-Induced Acute Respiratory Distress Syndrome.
Infections
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.
Infections
High Secretion of Interferons by Human Plasmacytoid Dendritic Cells upon Recognition of Middle East Respiratory Syndrome Coronavirus.
Infections
Human immunodeficiency virus type-1 susceptible whole cell and microcell hybrids.
Infections
Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).
Infections
Impairments in enzyme activity and biosynthesis of brush border-associated hydrolases in human intestinal Caco-2/TC7 cells infected by members of the Afa/Dr family of diffusely adhering Escherichia coli.
Infections
Inactivation of dipeptidyl peptidase IV attenuates the virulence of Streptococcus suis serotype 2 that causes streptococcal toxic shock syndrome.
Infections
Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+ T cells expressing relatively high levels of CD26.
Infections
Infectious complications of newer agents in the fight against diabetes.
Infections
Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors.
Infections
Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?
Infections
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Infections
Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1? and IL-12 in NOD mice.
Infections
Middle East respiratory syndrome-coronavirus infection into established hDDP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis.
Infections
Monitoring of the effects of transfection with baculovirus on Sf9 cell line and expression of human dipeptidyl peptidase IV.
Infections
Mouse dipeptidyl peptidase 4 is not a functional receptor for middle East respiratory syndrome coronavirus infection.
Infections
Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.
Infections
Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidyl peptidase IV.
Infections
New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome.
Infections
New-onset diabetes mellitus and the analysis of dipeptidyl-peptidase-4 after liver transplantation.
Infections
One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
Infections
Peptide Platform as a Powerful Tool in the Fight against COVID-19.
Infections
Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning.
Infections
Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4.
Infections
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
Infections
Rapid generation of a mouse model for Middle East respiratory syndrome.
Infections
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
Infections
Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance.
Infections
Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections.
Infections
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.
Infections
Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis.
Infections
Rotavirus impairs the biosynthesis of brush-border-associated dipeptidyl peptidase IV in human enterocyte-like Caco-2/TC7 cells.
Infections
Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.
Infections
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Infections
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Infections
Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C.
Infections
SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
Infections
Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes.
Infections
Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection.
Infections
Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation.
Infections
Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors.
Infections
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
Infections
The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Infections
The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.
Infections
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands.
Infections
Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.
Infections
Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
Infections
Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program.
Infections
Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2.
Infections
Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus.
Infections
[Histochemistry of selected peptidases in small intestine mucosa in piglets experimentally infected with Isospora suis]
Infertility
The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Inflammatory Bowel Diseases
Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting.
Inflammatory Bowel Diseases
Colitis development and resolution in mice with target deletion of dipeptidyl peptidase IV/CD26.
Inflammatory Bowel Diseases
Contribution of dipeptidyl peptidase IV to the severity of dextran sulfate sodium-induced colitis in the early phase.
Inflammatory Bowel Diseases
Corrigendum to: Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.
Inflammatory Bowel Diseases
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-World Evidence in U.S. Adults.
Inflammatory Bowel Diseases
Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
Inflammatory Bowel Diseases
Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
Inflammatory Bowel Diseases
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Inflammatory Bowel Diseases
DPP-4 as a Novel Biomarker for Inflammatory Bowel Disease: Is It Ready for Clinical Use?
Inflammatory Bowel Diseases
Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling.
Inflammatory Bowel Diseases
Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice.
Inflammatory Bowel Diseases
Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning.
Inflammatory Bowel Diseases
Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.
Inflammatory Bowel Diseases
Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)--a novel approach for the treatment of inflammatory bowel disease.
Inflammatory Bowel Diseases
[Dipeptidyl peptidase IV in inflammatory bowel diseases (DPP IV/CD26)].
Influenza, Human
Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Influenza, Human
Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives.
Insulin Resistance
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Insulin Resistance
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Insulin Resistance
Abelmoschus esculentus subfractions attenuate A? and tau by regulating DPP-4 and insulin resistance signals.
Insulin Resistance
Abelmoschus esculentus subfractions attenuate beta amyloid-induced neuron apoptosis by regulating DPP-4 with improving insulin resistance signals.
Insulin Resistance
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved ?-cell function and insulin sensitivity in metformin treated PCOS.
Insulin Resistance
Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects.
Insulin Resistance
Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.
Insulin Resistance
Alleviation of diabetes mellitus through the restoration of ?-cell function and lipid metabolism by Aloe vera (L.) Burm. f. extract in obesogenic WNIN/GR-Ob rats.
Insulin Resistance
Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance.
Insulin Resistance
Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.
Insulin Resistance
Atypical Mechanism of Glucose Modulation by Colesevelam in Patients with Type 2 Diabetes.
Insulin Resistance
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Insulin Resistance
Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: relationships to peptide YY, pancreatic peptide, and insulin sensitivity.
Insulin Resistance
Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Insulin Resistance
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic {beta}-Cell Mass and Function in a Rodent Model of Type 2 Diabetes.
Insulin Resistance
Circulating and adipose levels of adipokines associated with insulin sensitivity in non-obese subjects with type 2 diabetes.
Insulin Resistance
Circulating dipeptidyl peptidase-4 activity is associated with insulin resistance in type 1 diabetic patients.
Insulin Resistance
Clinical use of pasireotide for Cushing's disease in adults.
Insulin Resistance
Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Insulin Resistance
Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
Insulin Resistance
Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.
Insulin Resistance
Comparison of Two Commercial ELISAs against an In-House ELISA for Measuring Soluble CD26 in Human Serum.
Insulin Resistance
Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Insulin Resistance
Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease?
Insulin Resistance
Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers?
Insulin Resistance
Diabetes: the latest developments in inhibitors, insulin sensitisers, new drug targets and novel approaches. October 18-19, 2004, The Hatton, London, UK.
Insulin Resistance
Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and ?-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis.
Insulin Resistance
Dipeptidyl peptidase 4 (DPP4), adipose inflammation, and insulin resistance: is it time to look to the hepatocyte?
Insulin Resistance
Dipeptidyl Peptidase 4 Activity Is Related to Body Composition, Measures of Adiposity, and Insulin Resistance in Subjects with Excessive Adiposity and Different Degrees of Glucose Tolerance.
Insulin Resistance
Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats.
Insulin Resistance
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.
Insulin Resistance
Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.
Insulin Resistance
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Insulin Resistance
Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
Insulin Resistance
Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
Insulin Resistance
Dipeptidyl peptidase-4 activity might be a link between tumour necrosis factor alpha and insulin resistance in type 1 diabetes.
Insulin Resistance
Dipeptidyl peptidase-4 activity, lipopolysaccharide, C-reactive protein, glucose metabolism, and gut peptides 3 months after bariatric surgery.
Insulin Resistance
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
Insulin Resistance
Dipeptidyl peptidase-4 inhibition ameliorates western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function.
Insulin Resistance
Dipeptidyl peptidase-4 inhibition prevents cell death via extrinsic and intrinsic apoptotic pathways in rat pancreas with insulin resistance.
Insulin Resistance
Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid.
Insulin Resistance
Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
Insulin Resistance
Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance.
Insulin Resistance
Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice.
Insulin Resistance
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Insulin Resistance
Dose rectification of an imbalance between DPP4 and GLP-1 ameliorates chronic stress-related vascular aging and atherosclerosis?
Insulin Resistance
DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization.
Insulin Resistance
DPP-4 inhibition improves early mortality, ? cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid.
Insulin Resistance
DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
Insulin Resistance
DPP-4 inhibitor and PPAR? agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Insulin Resistance
DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates ?-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice.
Insulin Resistance
DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes.
Insulin Resistance
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.
Insulin Resistance
DPP4 activity is related to body weight and central fat in postmenopausal women.
Insulin Resistance
DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
Insulin Resistance
DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption.
Insulin Resistance
Effect of one-week administration of dipeptidyl peptidase-IV inhibitory peptides from chum salmon milt on postprandial blood glucose level: a randomised, placebo-controlled, double-blind, crossover, pilot clinical trial.
Insulin Resistance
Effect of stevia aqueous extract on the antidiabetic activity of saxagliptin in diabetic rats.
Insulin Resistance
Effect of thymoquinone on high fat diet and STZ-induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies.
Insulin Resistance
Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
Insulin Resistance
Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis.
Insulin Resistance
Effects of sitagliptin on circulating zinc-?2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial.
Insulin Resistance
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.
Insulin Resistance
Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats.
Insulin Resistance
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Insulin Resistance
Fasting serum dipeptidyl peptidase-4 activity is independently associated with alanine aminotransferase in type 1 diabetic patients.
Insulin Resistance
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats.
Insulin Resistance
Gestational glucocorticoid exposure disrupts glucose homeostasis that is accompanied by increased endoglin and DPP-4 activity instead of GSK-3 in rats.
Insulin Resistance
GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Insulin Resistance
Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
Insulin Resistance
Hibiscus sabdariffa polyphenols prevent palmitate-induced renal epithelial mesenchymal transition by alleviating dipeptidyl peptidase-4-mediated insulin resistance.
Insulin Resistance
Immune regulation of glucose and lipid metabolism.
Insulin Resistance
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Insulin Resistance
Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.
Insulin Resistance
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
Insulin Resistance
Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats.
Insulin Resistance
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.
Insulin Resistance
Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance.
Insulin Resistance
Inhibiting adipose tissue M1 cytokine expression decreases DPP4 activity and insulin resistance in a type 2 diabetes mellitus mouse model.
Insulin Resistance
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Insulin Resistance
Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
Insulin Resistance
Is DPP4 activity increased in PCOS?
Insulin Resistance
Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial.
Insulin Resistance
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity.
Insulin Resistance
Linagliptin, a DPP-4 inhibitor, ameliorates A? (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease.
Insulin Resistance
Liver disease and diabetes: Association, pathophysiology, and management.
Insulin Resistance
Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
Insulin Resistance
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
Insulin Resistance
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.
Insulin Resistance
Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome.
Insulin Resistance
Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA.
Insulin Resistance
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
Insulin Resistance
Natural Alkaloids and Diabetes Mellitus: A Review.
Insulin Resistance
Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats.
Insulin Resistance
Neuroprotective influence of sitagliptin against cisplatin-induced neurotoxicity, biochemical and behavioral alterations in Wistar rats.
Insulin Resistance
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Insulin Resistance
Omarigliptin protects against nonalcoholic fatty liver disease by ameliorating oxidative stress and inflammation.
Insulin Resistance
Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction.
Insulin Resistance
Pharmacotherapy in type 2 diabetes: a functional schema for drug classification.
Insulin Resistance
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.
Insulin Resistance
Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4.
Insulin Resistance
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.
Insulin Resistance
Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy.
Insulin Resistance
Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress.
Insulin Resistance
Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
Insulin Resistance
Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Insulin Resistance
Serum levels of pigment epithelium-derived factor (PEDF) are inversely associated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.
Insulin Resistance
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Insulin Resistance
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Insulin Resistance
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Insulin Resistance
Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.
Insulin Resistance
Targeting Soluble DPP-4 for Insulin Resistance: Origin Matters.
Insulin Resistance
Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells.
Insulin Resistance
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Insulin Resistance
The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome.
Insulin Resistance
The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin has the Capacity to Repair ?-Cell Dysfunction and Insulin Resistance.
Insulin Resistance
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Insulin Resistance
The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.
Insulin Resistance
The effects of incretin-based therapies on ?-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
Insulin Resistance
The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
Insulin Resistance
The new paradigm for androgenetic alopecia and plant-based folk remedies: 5?-reductase inhibition, reversal of secondary microinflammation and improving insulin resistance.
Insulin Resistance
The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.
Insulin Resistance
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Insulin Resistance
Therapeutic vaccine against DPP4 improves glucose metabolism in mice.
Insulin Resistance
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
Insulin Resistance
Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes.
Insulin Resistance
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.
Insulin Resistance
Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates ?-Cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Insulin Resistance
[New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)]
Insulin Resistance
[Type 2 diabetes and impaired glucose tolerance].
Insulinoma
Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.
Insulinoma
DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-?B activation.
Insulinoma
The expression of glucagon-like peptide-1 receptor and dipeptidyl peptidase-IV in neuroendocrine neoplasms of the pancreas and gastrointestinal tract.
Intestinal Neoplasms
DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells.
Intestinal Obstruction
Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Intracranial Aneurysm
Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
Iron Deficiencies
Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus.
Ischemic Attack, Transient
Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia.
Ischemic Attack, Transient
DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
Ischemic Stroke
Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity.
Ischemic Stroke
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Ischemic Stroke
Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.
Ischemic Stroke
Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
Ischemic Stroke
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Ischemic Stroke
Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
Ischemic Stroke
Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Ischemic Stroke
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ischemic Stroke
Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Ischemic Stroke
Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.
Ischemic Stroke
Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion/detorsion in rats: a possible role of HIF-1? and nitric oxide.
Ischemic Stroke
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Jaundice, Chronic Idiopathic
Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome.
Keloid
Dipeptidyl Peptidase-4 Inhibitor Reduces the Risk of Developing Hypertrophic Scars and Keloids following Median Sternotomy in Diabetic Patients: A Nationwide Retrospective Cohort Study Using the National Database of Health Insurance Claims of Japan.
Keloid
Dysregulation of DPP4-CXCL12 Balance by TGF-?1/SMAD Pathway Promotes CXCR4+ Inflammatory Cell Infiltration in Keloid Scars.
Keloid
Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.
Keloid
Reply: Dipeptidyl Peptidase-4 Inhibitor Reduces the Risk of Developing Hypertrophic Scars and Keloids following Median Sternotomy in Diabetic Patients: A Nationwide Retrospective Cohort Study Using the National Database of Health Insurance Claims of Japan.
Keloid
The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases.
Keratosis
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Keratosis, Seborrheic
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Ketosis
Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis.
Ketosis
Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Kidney Diseases
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
Kidney Diseases
Acute effects of acetaminophen on renal function and urinary excretion of some proteins and enzymes in patients with kidney disease.
Kidney Diseases
Adenosine deaminase binding protein, a new diagnostic marker for kidney disease.
Kidney Diseases
Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Kidney Diseases
Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Kidney Diseases
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
Kidney Diseases
Clinical assessment and treatment of diabetes in patients with chronic kidney disease.
Kidney Diseases
Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Kidney Diseases
Demonstration of glomerular DPP IV activity in kidney diseases.
Kidney Diseases
Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
Kidney Diseases
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Kidney Diseases
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Kidney Diseases
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Kidney Diseases
Linagliptin use in older individuals with type 2 diabetes.
Kidney Diseases
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Kidney Diseases
The MARLINA-T2D trial: putting the results into clinical perspective.
Kidney Diseases
The renoprotective effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on adenine-induced kidney disease in rats.
Kidney Diseases
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Kidney Diseases
Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.
Kidney Diseases
Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside.
Kidney Diseases
[DPP-4 inhibitors in nephropatics].
Kidney Failure, Chronic
A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease.
Kidney Failure, Chronic
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Kidney Failure, Chronic
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
Kidney Failure, Chronic
Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Kidney Failure, Chronic
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Kidney Failure, Chronic
DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Kidney Failure, Chronic
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Kidney Failure, Chronic
Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Kidney Failure, Chronic
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
Kidney Failure, Chronic
Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Kidney Failure, Chronic
Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
Kidney Failure, Chronic
Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Kidney Failure, Chronic
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Kidney Failure, Chronic
Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis.
Kidney Failure, Chronic
PATHOPHYSIOLOGY AND MANAGEMENT OF HYPOGLYCEMIAIN END-STAGE RENAL DISEASE PATIENTS: A REVIEW.
Kidney Failure, Chronic
Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016.
Kidney Failure, Chronic
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research.
Kidney Failure, Chronic
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Kidney Failure, Chronic
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Kidney Failure, Chronic
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Kidney Failure, Chronic
[Clinical investigation of urinary dipeptidyl aminopeptidase IV (DAP IV) activity in patients with primary glomerular diseases]
Kidney Failure, Chronic
[DPP-4 inhibitors in nephropatics].
Kidney Failure, Chronic
[Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
Kidney Neoplasms
Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.
Kidney Neoplasms
The antigen identified by a mouse monoclonal antibody raised against human renal cancer cells is the adenosine deaminase binding protein.
Latent Autoimmune Diabetes in Adults
Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect ?-cell function in LADA patients: A 1-year pilot study.
Latent Autoimmune Diabetes in Adults
Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial.
Latent Autoimmune Diabetes in Adults
Dipeptidyl peptidase 4 inhibitor sitagliptin maintains ?-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Latent Autoimmune Diabetes in Adults
Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future.
Latent Autoimmune Diabetes in Adults
Investigating optimal ?-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial.
Latent Autoimmune Diabetes in Adults
Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial.
Latent Autoimmune Diabetes in Adults
Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes.
Latent Autoimmune Diabetes in Adults
Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Leukemia
CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.
Leukemia
Cluster analysis and phylogenetic relationship in biomarker identification of type 2 diabetes and nephropathy.
Leukemia
Cytochemical distribution of dipeptidylaminopeptidase IV (DAP IV; EC-3.4.14.5) in T-lymphoblastic lymphoma/leukemia characterized with monoclonal antibodies.
Leukemia
Dipeptidylaminopeptidase IV activity in normal and leukemic T-cell subpopulations.
Leukemia
DPPIV - serum activity and expression on lymphocytes in different hematological malignancies.
Leukemia
[Selective staining of T-lymphoblastic leukemia cells by glycyl-prolyl-4-methoxy-beta-naphthylamiden-peptidase (DAP IV) (author's transl)]
Leukemia, Lymphocytic, Chronic, B-Cell
Characterization of dipeptidyl peptidase IV from lymphocytes of chronic lymphocytic leukemia of T-type.
Leukemia, Lymphocytic, Chronic, B-Cell
Dipeptidyl peptidase IV in human T-lymphocytes: cytochemical and histochemical investigations in patients with non-Hodgkin's lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Enzymecytochemical heterogeneity of human chronic T-lymphocytic leukemia as demonstrated by reactivity to dipeptidylaminopeptidase IV (DAP IV; EC 3.4.14.4).
Leukemia, Lymphocytic, Chronic, B-Cell
Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
Leukemia, Myeloid, Acute
Dipeptidyl Peptidase 9 Increases Chemoresistance and is an Indicator of Poor Prognosis in Colorectal Cancer.
Leukemia, T-Cell
Dipeptidylaminopeptidase IV activity in normal and leukemic T-cell subpopulations.
Leukemia-Lymphoma, Adult T-Cell
Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells.
Leukodystrophy, Metachromatic
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Lipodystrophy
Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2.
Lipodystrophy, Familial Partial
Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2.
Liver Cirrhosis
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.
Liver Cirrhosis
Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
Liver Cirrhosis
Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Liver Cirrhosis
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Liver Cirrhosis
Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis.
Liver Cirrhosis
Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Liver Cirrhosis
Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections.
Liver Cirrhosis
TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.
Liver Cirrhosis
Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38?, and NF-?B signaling.
Liver Cirrhosis
[Dipeptidyl aminopeptidase IV in hospitalized patients and in galactosamine hepatitis of the rat: Activity and lectin affinity chromatography in serum and hepatic plasma membranes]
Liver Cirrhosis, Biliary
Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis.
Liver Cirrhosis, Biliary
Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in patients with primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections.
Liver Cirrhosis, Biliary
[Dipeptidyl peptidase IV of peripheral blood lymphocytes in patients with primary biliary cirrhosis]
Liver Cirrhosis, Biliary
[Dipeptidyl-peptidase IV of human lymphocytes in patients with primary biliary cirrhosis and UDCA therapy]
Liver Cirrhosis, Experimental
Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis.
Liver Diseases
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Liver Diseases
A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets.
Liver Diseases
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Liver Diseases
Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population.
Liver Diseases
Changes of dipeptidylpeptidase IV as a membrane marker of lymphocytes in acute and chronic liver diseases--biochemical and cytochemical investigations.
Liver Diseases
Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Liver Diseases
Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.
Liver Diseases
Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Liver Diseases
Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.
Liver Diseases
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Liver Diseases
Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.
Liver Diseases
Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis.
Liver Diseases
Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
Liver Diseases
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism.
Liver Diseases
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
Liver Diseases
Dipeptidyl peptidase-4: a key player in chronic liver disease.
Liver Diseases
DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus.
Liver Diseases
DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility.
Liver Diseases
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Liver Diseases
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Liver Diseases
Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor.
Liver Diseases
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.
Liver Diseases
Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Liver Diseases
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
Liver Diseases
Epigenetic regulation of hepatic Dpp4 expression in response to dietary protein.
Liver Diseases
Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis.
Liver Diseases
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Liver Diseases
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Liver Diseases
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.
Liver Diseases
Liver disease and diabetes: Association, pathophysiology, and management.
Liver Diseases
Lower activity of serum peptidases in abstinent alcohol-dependent patients.
Liver Diseases
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Liver Diseases
Plasma concentrations of zinc, copper, interleukin-6 and interferon-?, and plasma dipeptidyl peptidase IV activity in chronic hepatitis C.
Liver Diseases
Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
Liver Diseases
Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Liver Diseases
Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.
Liver Diseases
Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections.
Liver Diseases
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Liver Diseases
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
Liver Diseases
Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study.
Liver Diseases
[Dipeptidylpeptidase IV activity in human lymphocytes in hepatobiliary diseases]
Liver Failure
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Liver Neoplasms
Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-?B activation and inflammatory cytokines.
Liver Neoplasms
Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2.
Liver Neoplasms
Inhibitory properties of camel whey protein hydrolysates toward liver cancer cells, dipeptidyl peptidase-IV, and inflammation.
Liver Neoplasms
Serum activities of dipeptidyl-aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patients.
Liver Neoplasms
Transcriptome analysis of PPAR? target genes reveals the involvement of lysyl oxidase in human placental cytotrophoblast invasion.
Liver Neoplasms, Experimental
Biochemical properties of dipeptidyl peptidase IV in liver and hepatoma plasma membranes.
Liver Neoplasms, Experimental
Biosynthesis and metabolism of dipeptidylpeptidase IV in primary cultured rat hepatocytes and Morris hepatoma 7777 cells.
Liver Neoplasms, Experimental
Development of monoclonal antibodies against different protein and carbohydrate epitopes of dipeptidyl peptidase IV from rat liver plasma membranes.
Lung Diseases
Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease.
Lung Diseases, Interstitial
Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
Lung Diseases, Interstitial
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Lung Diseases, Interstitial
Vildagliptin-induced acute lung injury: a case report.
Lung Diseases, Interstitial
Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation.
Lung Injury
Alleviation of remote lung injury following liver ischemia/reperfusion: Possible protective role of vildagliptin.
Lung Injury
Dipeptidyl peptidase-4 inhibition prevents lung injury in mice under chronic stress via the modulation of oxidative stress and inflammation.
Lung Injury
Ischemia/reperfusion injury: The role of CD26/dipeptidyl-peptidase-IV-inhibition in lung transplantation.
Lung Injury
Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.
Lung Injury
Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Lung Injury
Vildagliptin-induced acute lung injury: a case report.
Lung Neoplasms
Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).
Lung Neoplasms
Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.
Lung Neoplasms
Dipeptidyl peptidase IV in the human lung and spinocellular lung cancer.
Lung Neoplasms
Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Lung Neoplasms
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Lung Neoplasms
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Lung Neoplasms
Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.
Lupus Erythematosus, Systemic
Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis.
Lupus Erythematosus, Systemic
Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases.
Lupus Erythematosus, Systemic
Dipeptidyl peptidase IV in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Lupus Erythematosus, Systemic
Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.
Lupus Nephritis
Characterization and in vivo transfer of nephritogenic autoantibodies directed against dipeptidyl peptidase IV and laminin in experimental lupus nephritis.
Lupus Nephritis
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies.
Lupus Nephritis
Redistribution of glomerular dipeptidyl peptidase type IV in experimental lupus nephritis. Demonstration of decreased enzyme activity at the ultrastructural level.
Lymphatic Metastasis
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Lymphatic Metastasis
Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Lymphoma
CD26/dipeptidyl peptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas.
Lymphoma
Cytochemical reactivity of T mu lymphocytes in human lymphatic tissue for dipeptidylaminopeptidase IV.
Lymphoma
Dipeptidyl peptidases of human lymphocytes.
Lymphoma
Dipeptidylaminopeptidase IV activity in normal and leukemic T-cell subpopulations.
Lymphoma
Enzyme histochemistry of malignant T cell lymphoma due to chronic magnesium deficiency in rats.
Lymphoma
Histochemistry of dipeptidyl aminopeptidase (DAP) II and IV in reactive lymphoid tissues and malignant lymphoma.
Lymphoma
In situ identification and enumeration of helper T lymphocytes in cutaneous malignant lymphomas by dipeptidyl-peptidase IV (DPP IV).
Lymphoma, B-Cell
Cytochemical distribution of dipeptidylaminopeptidase IV (DAP IV; EC-3.4.14.5) in T-lymphoblastic lymphoma/leukemia characterized with monoclonal antibodies.
Lymphoma, B-Cell
Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
Lymphoma, Large B-Cell, Diffuse
Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.
Lymphoma, Non-Hodgkin
Comparative cytochemical study of dipeptidyl aminopeptidase (DAP) II and IV in normal and malignant haemic cells.
Lymphoma, Non-Hodgkin
Dipeptidyl peptidase IV in human T-lymphocytes: cytochemical and histochemical investigations in patients with non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
DPPIV - serum activity and expression on lymphocytes in different hematological malignancies.
Lymphoma, Non-Hodgkin
Histochemistry of dipeptidyl aminopeptidase (DAP) II and IV in reactive lymphoid tissues and malignant lymphoma.
Lymphoma, T-Cell
CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma.
Lymphoma, T-Cell
Histochemistry of dipeptidyl aminopeptidase (DAP) II and IV in reactive lymphoid tissues and malignant lymphoma.
Lymphoproliferative Disorders
[Protein kinase activity in lymphoid cells in various forms of lymphoproliferative disorders]
Lysosomal Storage Diseases
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Lysosomal Storage Diseases
Induction of dipeptidylpeptidase IV activity in human renal glomeruli--a histochemical study.
Macular Edema
Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema.
Mastocytosis, Systemic
Comparative cytochemical study of dipeptidyl aminopeptidase (DAP) II and IV in normal and malignant haemic cells.
Melanoma
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.
Melanoma
A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.
Melanoma
Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability.
Melanoma
Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation.
Melanoma
Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses.
Melanoma
Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.
Melanoma
Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation.
Melanoma
Expression of CD26/dipeptidyl-peptidase IV in benign and malignant pigment-cell lesions of the skin.
Melanoma
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Melanoma
Large-scale proteomic characterization of melanoma expressed proteins reveals nestin and vimentin as biomarkers that can potentially distinguish melanoma subtypes.
Melanoma
Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi.
Melanoma
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype.
Melanoma
Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.
Melanoma
Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
Melanoma
Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma.
Melanoma
The Long Noncoding RNA SPRIGHTLY Regulates Cell Proliferation in Primary Human Melanocytes.
Melanoma
[Renal dipeptidylpeptidase IV excretion in drug-induced kidney changes]
membrane alanyl aminopeptidase deficiency
Effect of X-Prolyl Dipeptidyl Aminopeptidase Deficiency on Lactococcus lactis.
Memory Disorders
Dipeptidyl peptidase 4 contributes to Alzheimer's disease-like defects in a mouse model and is increased in sporadic Alzheimer's disease brains.
Memory Disorders
DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.
Meningioma
Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
Mesothelioma
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
Mesothelioma, Malignant
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
Metabolic Diseases
Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII.
Metabolic Diseases
Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.
Metabolic Diseases
Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease?
Metabolic Diseases
Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms.
Metabolic Diseases
Hepatic DPP4 DNA Methylation Associates With Fatty Liver.
Metabolic Diseases
Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
Metabolic Diseases
Periostin and Dipeptidyl Peptidase-4: Potential Biomarkers of Interleukin 13 Pathway Activation in Asthma and Allergy.
Metabolic Diseases
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.
Metabolic Diseases
Pomegranate polyphenols and urolithin A inhibit ?-glucosidase, dipeptidyl peptidase-4, lipase, triglyceride accumulation and adipogenesis related genes in 3T3-L1 adipocyte-like cells.
Metabolic Diseases
Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum.
Metabolic Syndrome
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-?B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways.
Metabolic Syndrome
Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome.
Metabolic Syndrome
Diabetes: the latest developments in inhibitors, insulin sensitisers, new drug targets and novel approaches. October 18-19, 2004, The Hatton, London, UK.
Metabolic Syndrome
Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Metabolic Syndrome
Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.
Metabolic Syndrome
DPP4 Gene DNA Methylation in the Omentum is Associated With Its Gene Expression and Plasma Lipid Profile in Severe Obesity.
Metabolic Syndrome
Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study.
Metabolic Syndrome
Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.
Metabolic Syndrome
Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
Metabolic Syndrome
Evidence-based practice use of incretin-based therapy in the natural history of diabetes.
Metabolic Syndrome
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
Metabolic Syndrome
Identification of novel dipeptidyl peptidase-IV and angiotensin-I-converting enzyme inhibitory peptides from meat proteins using in silico analysis.
Metabolic Syndrome
Increased Plasma DPP4 Activity Is an Independent Predictor of the Onset of Metabolic Syndrome in Chinese over 4 Years: Result from the China National Diabetes and Metabolic Disorders Study.
Metabolic Syndrome
KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes.
Metabolic Syndrome
Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome.
Metabolic Syndrome
Pharmacological management of metabolic syndrome and its lipid complications.
Metabolic Syndrome
Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning.
Metabolic Syndrome
Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor.
Metabolic Syndrome
Sitagliptin Augments Angiotensin II-Induced Renal Vasoconstriction In Kidneys from Rats with the Metabolic Syndrome.
Metabolic Syndrome
The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome.
Metabolic Syndrome
The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors.
Metabolic Syndrome
Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus.
Metabolic Syndrome
Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: Role of AMPK/SIRT1 activation and DPP-4 inhibition.
Mouth Neoplasms
Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients.
Mouth Neoplasms
Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients.
Mouth Neoplasms
Sandwich enzyme-immunoassay for dipeptidyl aminopeptidase IV in the serum of people with oral cancer.
Mucolipidoses
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Mucopolysaccharidoses
Discovery of a new biomarker for the mucopolysaccharidoses (MPS), dipeptidyl peptidase IV (DPP-IV; CD26), by SELDI-TOF mass spectrometry.
Mucopolysaccharidoses
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Mucopolysaccharidoses
Monitoring of dipeptidyl peptidase-IV (DPP-IV) activity in patients with mucopolysaccharidoses types I and II on enzyme replacement therapy - Results of a pilot study.
Multiple Myeloma
Comparative cytochemical study of dipeptidyl aminopeptidase (DAP) II and IV in normal and malignant haemic cells.
Multiple Myeloma
DPPIV - serum activity and expression on lymphocytes in different hematological malignancies.
Multiple Myeloma
The importance of the number of transplanted cells with dipeptidyl peptidase-4 expression on the haematopoietic recovery and lymphocyte reconstitution in patients with multiple myeloma after autologous haematopoietic stem-cell transplantation.
Multiple Sclerosis
Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease.
Multiple Sclerosis
Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.
Multiple Sclerosis
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Multiple Sclerosis
Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Multiple Sclerosis
Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses.
Multiple Sclerosis
Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones.
Multiple Sclerosis
TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26.
Muscular Atrophy
Lysosomal and nonlysosomal hydrolases of skeletal muscle in neuromuscular diseases.
Muscular Atrophy
Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.
Muscular Diseases
A missed protective drug-drug interaction of DPP-4 inhibitors and statins on myopathy risk.
Muscular Diseases
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
Muscular Diseases
Risk of Myopathy Associated With DPP-4 Inhibitors in Combination With Statins: A Disproportionality Analysis Using Data From the WHO and French Spontaneous Reporting Databases.
Mutism
Anxiety Is Associated With DPPIV Alterations in Children With Selective Mutism and Social Anxiety Disorder: A Pilot Study.
Mycoses
Fungal Mimicry of a Mammalian Aminopeptidase Disables Innate Immunity and Promotes Pathogenicity.
Myocardial Infarction
A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
Myocardial Infarction
Acute myocardial infarction associated to DPP-4 inhibitors.
Myocardial Infarction
Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction.
Myocardial Infarction
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Myocardial Infarction
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Myocardial Infarction
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Myocardial Infarction
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Myocardial Infarction
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
Myocardial Infarction
Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
Myocardial Infarction
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
Myocardial Infarction
Cardiovascular Safety of the Dipetidyl Peptidase-4 inhibitor Alogliptin in Type 2 Diabetes Mellitus.
Myocardial Infarction
Cardiovascular safety outcomes of new antidiabetic therapies.
Myocardial Infarction
Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction - Long-term results of the SITAGRAMI trial.
Myocardial Infarction
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Myocardial Infarction
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.
Myocardial Infarction
Contrasting effects on the risk of macrovascular and microvascular events associated with anti-hyperglycaemic drugs that enhance sodium excretion and lower blood pressure.
Myocardial Infarction
Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
Myocardial Infarction
Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Myocardial Infarction
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Myocardial Infarction
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
Myocardial Infarction
Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
Myocardial Infarction
Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1?
Myocardial Infarction
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Myocardial Infarction
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Myocardial Infarction
Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients.
Myocardial Infarction
DPP-4 inhibition attenuates cardiac dysfunction and adverse remodelling following myocardial infarction in rats with experimental diabetes.
Myocardial Infarction
DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction.
Myocardial Infarction
DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.
Myocardial Infarction
Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.
Myocardial Infarction
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Myocardial Infarction
Effects of dipeptidyl peptidase-4 inhibitor in insulin resistant rats with myocardial infarction.
Myocardial Infarction
Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Myocardial Infarction
Effects of incretin-based therapy in patients with heart failure and myocardial infarction.
Myocardial Infarction
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Myocardial Infarction
FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following Sitagliptin + G-CSF therapy after acute myocardial infarction.
Myocardial Infarction
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Myocardial Infarction
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Myocardial Infarction
Glucagon-like Peptide-1 and its cardiovascular effects.
Myocardial Infarction
Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.
Myocardial Infarction
Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.
Myocardial Infarction
Meta-analyses of the effects of Dpp-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
Myocardial Infarction
Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
Myocardial Infarction
Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
Myocardial Infarction
Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Myocardial Infarction
Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.
Myocardial Infarction
Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis.
Myocardial Infarction
Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction.
Myocardial Infarction
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research.
Myocardial Infarction
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Myocardial Infarction
Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
Myocardial Infarction
Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial.
Myocardial Infarction
Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
Myocardial Infarction
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
Myocardial Infarction
Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.
Myocardial Infarction
Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.
Myocardial Infarction
The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Myocardial Infarction
The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications.
Myocardial Infarction
The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.
Myocardial Infarction
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Myocardial Infarction
The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.
Myocardial Infarction
Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
Myocardial Infarction
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
Myocardial Ischemia
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Myocardial Ischemia
Cardiovascular Biology of the Incretin System.
Myocardial Ischemia
Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions.
Myocardial Ischemia
Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease?- Recent Insights Focusing on Angiogenesis and Neovascularization.
Myocardial Ischemia
DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.
Myocardial Ischemia
Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
Myocardial Ischemia
Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes.
Myocardial Ischemia
Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro.
Myocardial Ischemia
Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.
Myocardial Ischemia
The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.
Myocarditis
A DPP-4 Inhibitor Suppresses Fibrosis and Inflammation on Experimental Autoimmune Myocarditis in Mice.
Myocarditis
Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis.
Nasopharyngitis
Antidiabetic oral treatment in older people: does frailty matter?
Nasopharyngitis
Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.
Nasopharyngitis
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Nasopharyngitis
Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4.
Nasopharyngitis
Predicting DPP-IV inhibitors with machine learning approaches.
Nasopharyngitis
Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.
Nasopharyngitis
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Nasopharyngitis
The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Neoplasm Metastasis
A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis.
Neoplasm Metastasis
Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.
Neoplasm Metastasis
Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway.
Neoplasm Metastasis
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
Neoplasm Metastasis
Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
Neoplasm Metastasis
Cancer Biology and Prevention in Diabetes.
Neoplasm Metastasis
CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12.
Neoplasm Metastasis
CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology.
Neoplasm Metastasis
CD26/DPPIV expression and 8-azaguanine response in T-acute lymphoblastic leukaemia cell lines in culture.
Neoplasm Metastasis
Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).
Neoplasm Metastasis
Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Neoplasm Metastasis
Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor.
Neoplasm Metastasis
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines.
Neoplasm Metastasis
Ectopeptidases in tumour biology: a review.
Neoplasm Metastasis
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue.
Neoplasm Metastasis
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Neoplasm Metastasis
Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy.
Neoplasm Metastasis
Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Neoplasm Metastasis
Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer?
Neoplasm Metastasis
Lu-ECAM-1 and DPP IV in lung metastasis.
Neoplasm Metastasis
Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin.
Neoplasm Metastasis
Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling.
Neoplasm Metastasis
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.
Neoplasm Metastasis
Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Neoplasm Metastasis
Protein Kinase C{epsilon} Mediates Polymeric Fibronectin Assembly on the Surface of Blood-borne Rat Breast Cancer Cells to Promote Pulmonary Metastasis.
Neoplasm Metastasis
Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+ cancer stem cells subsets.
Neoplasm Metastasis
The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.
Neoplasm Metastasis
[Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers]
Neoplasms
'Dipeptidyl peptidase-IV activity and/or structure homologs' (DASH) in growth-modulated glioma cell lines.
Neoplasms
30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study.
Neoplasms
A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis.
Neoplasms
A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling.
Neoplasms
A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Neoplasms
A sensitive and specific assay for dipeptidyl-aminopeptidase II in serum and tissues by liquid chromatography-fluorometry.
Neoplasms
A UNIVERSAL ASSAY FOR AMINOPEPTIDASE ACTIVITY AND ITS APPLICATION FOR DIPEPTIDYL PEPTIDASE-4 DRUG DISCOVERY.
Neoplasms
Activatable Near-Infrared Fluorescent Probe for Dipeptidyl Peptidase IV and Its Bioimaging Applications in Living Cells and Animals.
Neoplasms
Adenosine deaminase complexing protein (ADCP): a transformation sensitive protein with potentials of a cancer marker.
Neoplasms
Adenosine deaminase complexing protein in cancer studies.
Neoplasms
Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.
Neoplasms
Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway.
Neoplasms
Adenosine metabolism and cancer. Focus on "Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway".
Neoplasms
Aging promotes neoplastic disease through effects on the tissue microenvironment.
Neoplasms
Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.
Neoplasms
Alteration in dipeptidyl peptidase activities in cultured human carcinoma cells.
Neoplasms
Altered peptidase activities in thyroid neoplasia and hyperplasia.
Neoplasms
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Neoplasms
Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Neoplasms
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
Neoplasms
Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
Neoplasms
Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
Neoplasms
Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells.
Neoplasms
Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Neoplasms
Avian Reovirus P17 Suppresses Angiogenesis by Promoting DPP4 Secretion.
Neoplasms
Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability.
Neoplasms
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Neoplasms
Biochemical investigation of human exposure to aflatoxin M1 and its association with risk factors of diabetes mellitus.
Neoplasms
Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
Neoplasms
Cancer Biology and Prevention in Diabetes.
Neoplasms
Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein.
Neoplasms
CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma.
Neoplasms
CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion.
Neoplasms
CD26/dipeptidyl peptidase IV and its role in cancer.
Neoplasms
CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
Neoplasms
CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors.
Neoplasms
CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology.
Neoplasms
CD26/DPPIV expression and 8-azaguanine response in T-acute lymphoblastic leukaemia cell lines in culture.
Neoplasms
Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Neoplasms
Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier.
Neoplasms
Comparative tumor morphogenesis of two human colon adenocarcinoma cell clones xenografted in the immunosuppressed newborn rat.
Neoplasms
Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells.
Neoplasms
Compartment- and malignance-dependent up-regulation of ?-glutamyltranspeptidase and dipetidylpeptidase-IV activity in human brain gliomas.
Neoplasms
Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer.
Neoplasms
Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-? in transformed astrocytic cells.
Neoplasms
Critical role of Dipeptidyl Peptidase IV: A therapeutic target for cancer & diabetes.
Neoplasms
Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Neoplasms
Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines.
Neoplasms
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12/CXCR4/mTOR/TGF? Signaling Pathway in Breast Cancer Cells.
Neoplasms
Demonstration of proteases in basal cell carcinomas. A histochemical study using amino acid-4-methoxy-2-naphthylamides as chromogenic substrates.
Neoplasms
Design and synthesis of aminocoumarin derivatives as DPP-IV inhibitors and anticancer agents.
Neoplasms
Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV.
Neoplasms
Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
Neoplasms
Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma.
Neoplasms
Diagnostic role of markers dipeptidyl peptidase IV and thyroid peroxidase in thyroid tumors.
Neoplasms
Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours.
Neoplasms
Different expression of some molecular markers in sporadic cancer of the left and right colon.
Neoplasms
Differential chemokine receptor expression and usage by pre-cDC1 and pre-cDC2.
Neoplasms
Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
Neoplasms
Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.
Neoplasms
Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.
Neoplasms
Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.
Neoplasms
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Neoplasms
Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway.
Neoplasms
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Neoplasms
Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor.
Neoplasms
Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.
Neoplasms
Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation.
Neoplasms
Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?
Neoplasms
Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer.
Neoplasms
Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers.
Neoplasms
Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Neoplasms
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines.
Neoplasms
Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade.
Neoplasms
Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study.
Neoplasms
Dipeptidyl peptidase IV in the human lung and spinocellular lung cancer.
Neoplasms
Dipeptidyl peptidase IV in tumor progression.
Neoplasms
Dipeptidyl peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumors and lung parenchyma.
Neoplasms
Dipeptidyl peptidase-4 activity might be a link between tumour necrosis factor alpha and insulin resistance in type 1 diabetes.
Neoplasms
Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Neoplasms
Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
Neoplasms
Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration.
Neoplasms
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Neoplasms
Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer.
Neoplasms
Dipeptidyl peptidase-IV and related molecules: markers of malignancy?
Neoplasms
Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity.
Neoplasms
Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.
Neoplasms
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Neoplasms
Dipeptidylaminopeptidase IV (DAP IV) in B- and T-cell leukaemias.
Neoplasms
Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.
Neoplasms
Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?
Neoplasms
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV).
Neoplasms
DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness.
Neoplasms
DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
Neoplasms
DPPIV and seprase in cancer invasion and angiogenesis.
Neoplasms
DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells.
Neoplasms
DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis.
Neoplasms
Ectopeptidases in tumour biology: a review.
Neoplasms
Effect of a DPP-4 Inhibitor on Orthodontic Tooth Movement and Associated Root Resorption.
Neoplasms
Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors.
Neoplasms
Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-? concentrations: A systematic review and meta-analysis of controlled trials.
Neoplasms
Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study.
Neoplasms
Effects of oral squamous cell carcinoma-derived TGF-beta1 on CD26/DPPIV expression in T cells.
Neoplasms
Efficacy of parenteral administration of bee venom in experimental arthritis in the rat: A comparison with methotrexate.
Neoplasms
Enzymecytochemical heterogeneity of human chronic T-lymphocytic leukemia as demonstrated by reactivity to dipeptidylaminopeptidase IV (DAP IV; EC 3.4.14.4).
Neoplasms
Epitope analysis of the rat dipeptidyl peptidase IV monoclonal antibody 6A3 that blocks pericellular fibronectin-mediated cancer cell adhesion.
Neoplasms
Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
Neoplasms
Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study.
Neoplasms
Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease.
Neoplasms
Experimental photodynamic therapy with a copper metal vapor laser in colorectal cancer.
Neoplasms
Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.
Neoplasms
Expression and different polarity of aminopeptidase N in normal human colonic mucosa and colonic tumors.
Neoplasms
Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade.
Neoplasms
Expression and function of dipeptidyl peptidase IV and related enzymes in cancer.
Neoplasms
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue.
Neoplasms
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Neoplasms
Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint.
Neoplasms
Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade.
Neoplasms
Expression of dipeptidyl aminopeptidase IV activity in thyroid carcinoma.
Neoplasms
Expression of dipeptidyl aminopeptidase IV activity in thyroid tumours: a possible marker of thyroid malignancy.
Neoplasms
Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
Neoplasms
Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer.
Neoplasms
Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines.
Neoplasms
Fabrication of a water-soluble near-infrared fluorescent probe for selective detection and imaging of dipeptidyl peptidase IV in biological systems.
Neoplasms
Fibroblast activation protein-? promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions.
Neoplasms
Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy.
Neoplasms
Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma.
Neoplasms
GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.
Neoplasms
Glucagon-like peptide-1 (GLP-1) receptor agonists or DPP-4 inhibition do not accelerate neoplasia in carcinogen treated mice.
Neoplasms
Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression.
Neoplasms
GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Neoplasms
Heterogeneity of dipeptidyl peptidase IV from C6 rat glioma cells.
Neoplasms
Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas.
Neoplasms
High DPP4 expression predicts poor prognosis in patients with low-grade glioma.
Neoplasms
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Neoplasms
Human miscarriage is associated with increased number of CD26 decidual lymphocytes.
Neoplasms
Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells.
Neoplasms
Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects.
Neoplasms
Identification of the target of monoclonal antibody A6H as dipeptidyl peptidase IV/CD26 by LC MS\MS.
Neoplasms
Immunohistochemical detection of dipeptidyl peptidase IV (CD 26) in thyroid neoplasia using biotinylated tyramine amplification.
Neoplasms
Immunohistochemical localization of adenosine deaminase complexing protein in intestinal mucosa and in colorectal adenocarcinoma as a marker for tumour cell heterogeneity.
Neoplasms
Immunohistochemical localization of dipeptidyl aminopeptidase IV in thyroid papillary carcinoma.
Neoplasms
Immunohistological evidence, obtained with monoclonal antibodies, of small intestinal brush border hydrolases in human colon cancers and foetal colons.
Neoplasms
Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.
Neoplasms
Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.
Neoplasms
Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus.
Neoplasms
Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.
Neoplasms
Increased levels of urinary adenosine deaminase binding protein in children treated with cisplatin or methotrexate.
Neoplasms
Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma.
Neoplasms
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Neoplasms
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Neoplasms
Influence of age, sex and cancer on the activities of gamma-glutamyl transpeptidase and of dipeptidyl aminopeptidase IV in rat tissues.
Neoplasms
Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Neoplasms
Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?
Neoplasms
Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
Neoplasms
Intestinal brush-border-associated enzymes: co-ordinated expression in colorectal cancer.
Neoplasms
Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer.
Neoplasms
Involvement of DPPIV/CD26 in epithelial morphology and suppressed invasive ability in ovarian carcinoma cells.
Neoplasms
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Neoplasms
Landscape Profiling Analysis of DPP4 in Malignancies: Therapeutic Implication for Tumor Patients With Coronavirus Disease 2019.
Neoplasms
Lower activity of serum peptidases in abstinent alcohol-dependent patients.
Neoplasms
Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
Neoplasms
Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin.
Neoplasms
Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition.
Neoplasms
Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling.
Neoplasms
Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.
Neoplasms
Neoplasia and hyperplasia of large bowel: focal lesions in an abnormal epithelium.
Neoplasms
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.
Neoplasms
Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription.
Neoplasms
Omarigliptin Prevents TNF-?-Induced Cellular Senescence in Rat Aorta Vascular Smooth Muscle Cells.
Neoplasms
Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.
Neoplasms
Phenolic glycosides and other constituents from the bark of Magnolia officinalis.
Neoplasms
Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer.
Neoplasms
Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Neoplasms
Profiling of the tetraspanin web of human colon cancer cells.
Neoplasms
Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma.
Neoplasms
Protective effect of vildagliptin on TNF-?-induced chondrocyte senescence.
Neoplasms
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.
Neoplasms
Quantitative changes in adenosine deaminase isoenzymes in human colorectal adenocarcinomas.
Neoplasms
Red Fluorescence Probe Targeted to Dipeptidylpeptidase-IV for Highly Sensitive Detection of Esophageal Cancer.
Neoplasms
Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients.
Neoplasms
Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.
Neoplasms
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Neoplasms
Risk of dipeptidyl-peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis.
Neoplasms
Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.
Neoplasms
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Neoplasms
Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitor.
Neoplasms
Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.
Neoplasms
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Neoplasms
Serum activities of dipeptidyl-aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patients.
Neoplasms
Serum dipeptidyl peptidase activities as a possible marker of oral cancer.
Neoplasms
Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors.
Neoplasms
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in Apc(Min/+) mice fed a high-fat diet.
Neoplasms
Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus.
Neoplasms
Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro.
Neoplasms
Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.
Neoplasms
Structure?Activity Relationship and Molecular Docking of Natural Product Library Reveal Chrysin as a Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: An Integrated In Silico and In Vitro Study.
Neoplasms
Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.
Neoplasms
Studies on the alkaloids of the bark of Magnolia officinalis: isolation and on-line analysis by HPLC-ESI-MS(n).
Neoplasms
Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+ cancer stem cells subsets.
Neoplasms
Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.
Neoplasms
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.
Neoplasms
The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.
Neoplasms
The dipeptidyl peptidase IV family in cancer and cell biology.
Neoplasms
The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice.
Neoplasms
The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.
Neoplasms
The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease.
Neoplasms
The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.
Neoplasms
The expression of glucagon-like peptide-1 receptor and dipeptidyl peptidase-IV in neuroendocrine neoplasms of the pancreas and gastrointestinal tract.
Neoplasms
The role of CD26/dipeptidyl peptidase IV in cancer.
Neoplasms
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.
Neoplasms
Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation.
Neoplasms
Truncated dipeptidyl peptidase IV is a potent anti-adhesion and anti-metastasis peptide for rat breast cancer cells.
Neoplasms
Ultrasensitive Fluorescent Probes Reveal an Adverse Action of Dipeptide Peptidase IV and Fibroblast Activation Protein during Proliferation of Cancer Cells.
Neoplasms
Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.
Neoplasms
Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates ?-Cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Neoplasms
[Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers]
Neoplasms
[Dipeptidyl aminopeptidase-IV as a histochemical marker of differential diagnosis of large cell anaplastic CD30+-lymphoma and Hodgkin's disease]
Neoplasms
[Dipeptidyl peptidase IV (DPP IV, CD 26): a tumor marker in cytologic and histopathologic diagnosis of lesions of the thyroid gland]
Neoplasms
[Enzymes in tumors of the breast. Histochemical study of the stroma in breast carcinomas]
Neoplasms
[In situ - demonstration of helper-T-lymphocytes in cutaneous malignant lymphomas by diaminopeptidase IV (DAP IV)]
Neoplasms
[Sitagliptin inhibits cell apoptosis and inflammation of renal tissues in diabetic nephropathy model rats].
Neoplasms
[Tumor markers in the cytodiagnosis of thyroid nodules. Detection of dipeptidyl aminopeptidase IV (DAP IV) activity]
Nephritis
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
Nephritis
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Nephritis
The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis.
Nephritis, Interstitial
Urinary excretion of dipeptidyl aminopeptidase i.v. in patients with renal diseases.
Nephrotic Syndrome
[Clinical investigation of urinary dipeptidyl aminopeptidase IV (DAP IV) activity in patients with primary glomerular diseases]
Nervous System Diseases
GLP-1R activation for the treatment of stroke: updating and future perspectives.
Nervous System Diseases
Tackling dipeptidyl peptidase IV in neurological disorders.
Nervous System Malformations
Postprandial and Orthostatic Hypotension Treated by Sitagliptin in a Patient with Dementia with Lewy Bodies.
Neuroblastoma
Basic Gene Expression Characteristics of Glioma Stem Cells and Human Glioblastoma.
Neuroblastoma
Detection of dipeptidyl peptidase IV in glioma C6 and neuroblastoma SK-N-SH cell lines.
Neuroblastoma
Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation.
Neurodegenerative Diseases
DPP-4 inhibitor and PPAR? agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Neurodegenerative Diseases
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases.
Neurodegenerative Diseases
Neuroprotective effect of linagliptin against cuprizone-induced demyelination and behavioural dysfunction in mice: A pivotal role of AMPK/SIRT1 and JAK2/STAT3/NF-?B signalling pathway modulation.
Neurodegenerative Diseases
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.
Neurodegenerative Diseases
Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
Neurogenic Inflammation
Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa.
Neuroinflammatory Diseases
Activation of AMPK/mTOR-driven autophagy and inhibition of NLRP3 inflammasome by saxagliptin ameliorate ethanol-induced gastric mucosal damage.
Neuroinflammatory Diseases
Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-?B and miRNA-155/SOCS-1 Signaling Pathways.
Nevus
Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi.
Nevus
Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma.
Niemann-Pick Disease, Type C
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Niemann-Pick Diseases
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases.
Non-alcoholic Fatty Liver Disease
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Non-alcoholic Fatty Liver Disease
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population.
Non-alcoholic Fatty Liver Disease
Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Non-alcoholic Fatty Liver Disease
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Non-alcoholic Fatty Liver Disease
Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-?B signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.
Non-alcoholic Fatty Liver Disease
Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis.
Non-alcoholic Fatty Liver Disease
Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism.
Non-alcoholic Fatty Liver Disease
Dipeptidyl peptidase-4: a key player in chronic liver disease.
Non-alcoholic Fatty Liver Disease
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial.
Non-alcoholic Fatty Liver Disease
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Non-alcoholic Fatty Liver Disease
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Non-alcoholic Fatty Liver Disease
Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Non-alcoholic Fatty Liver Disease
Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Non-alcoholic Fatty Liver Disease
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.
Non-alcoholic Fatty Liver Disease
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Fatty liver disease in diabetes mellitus.
Non-alcoholic Fatty Liver Disease
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Non-alcoholic Fatty Liver Disease
Identification of Potential Plasma Biomarkers for Nonalcoholic Fatty Liver Disease by Integrating Transcriptomics and Proteomics in Laying Hens.
Non-alcoholic Fatty Liver Disease
Immune regulation of glucose and lipid metabolism.
Non-alcoholic Fatty Liver Disease
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.
Non-alcoholic Fatty Liver Disease
Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus.
Non-alcoholic Fatty Liver Disease
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Non-alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Adversely Affects the Glycemic Control Afforded by Sitagliptin.
Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review).
Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
Non-alcoholic Fatty Liver Disease
Novel glucose-lowering drugs for non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.
Non-alcoholic Fatty Liver Disease
PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Non-alcoholic Fatty Liver Disease
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Non-alcoholic Fatty Liver Disease
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
Obesity
(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Obesity
A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands.
Obesity
Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult.
Obesity
Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects.
Obesity
Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.
Obesity
Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats.
Obesity
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Obesity
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-?B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways.
Obesity
Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees.
Obesity
Bariatric surgery - time to replace with GLP-1?
Obesity
Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals.
Obesity
Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Obesity
Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.
Obesity
Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
Obesity
Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists.
Obesity
Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.
Obesity
Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Obesity
Dietary plant flavonoids in prevention of obesity and diabetes.
Obesity
Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting transforming growth factor-?l and Smad2/3 pathways in high-fat diet-induced obesity rat model.
Obesity
Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Obesity
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.
Obesity
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
Obesity
Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: Possible implications for the hypothalamic neuropeptidergic system.
Obesity
Dipeptidyl peptidase IV in the hypothalamus and hippocampus of monosodium glutamate obese and food-deprived rats.
Obesity
Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
Obesity
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
Obesity
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism.
Obesity
Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1.
Obesity
Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease?- Recent Insights Focusing on Angiogenesis and Neovascularization.
Obesity
Dipeptidyl-Peptidase 4 and Attractin Expression is Increased in Circulating Blood Monocytes of Obese Human Subjects.
Obesity
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
Obesity
Distinct effects of calorie restriction on adipose tissue cytokine and angiogenesis profiles in obese and lean mice.
Obesity
DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates ?-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice.
Obesity
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.
Obesity
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis.
Obesity
DPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity.
Obesity
DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice.
Obesity
Dual Glycation-Inflammation Modulation, DPP-IV and Pancraetic Lipase Inhibitory Potentials and Antiproliferative Activity of Novel Fluoroquinolones.
Obesity
Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose.
Obesity
Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice.
Obesity
Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
Obesity
Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
Obesity
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
Obesity
Epigenetic regulation of hepatic Dpp4 expression in response to dietary protein.
Obesity
Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care.
Obesity
GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study.
Obesity
GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials.
Obesity
Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Obesity
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Obesity
GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Obesity
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
Obesity
High DPP-4 Concentrations in Adolescents Are Associated With Low Intact GLP-1.
Obesity
Improvement of blood glucose levels and obesity in mice given aronia juice by inhibition of dipeptidyl peptidase IV and ?-glucosidase.
Obesity
Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients.
Obesity
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Obesity
Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2.
Obesity
Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway.
Obesity
Late gestational testosterone exposure causes glucose deregulation and elevated cardiac VCAM-1 and DPP-4 activity in rats.
Obesity
Long-term effect of dipeptidyl peptidase-4 inhibition on ?-cell mass in an advanced-aged diet-induced obesity mouse model.
Obesity
Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome.
Obesity
Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
Obesity
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
Obesity
Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study.
Obesity
New targets to treat obesity and the metabolic syndrome.
Obesity
Novel adipokines: their potential role in the pathogenesis of obesity and metabolic disorders.
Obesity
Obese patients have higher circulating protein levels of dipeptidyl peptidase IV.
Obesity
Obesity parameters, physical activity, and physical fitness are correlated with serum dipeptidyl peptidase IV activity in a healthy population.
Obesity
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.
Obesity
Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people.
Obesity
Plasma dipeptidyl peptidase IV activity and measures of body composition in apparently healthy people.
Obesity
Pomegranate polyphenols and urolithin A inhibit ?-glucosidase, dipeptidyl peptidase-4, lipase, triglyceride accumulation and adipogenesis related genes in 3T3-L1 adipocyte-like cells.
Obesity
Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol.
Obesity
Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor.
Obesity
Regulation of Dipeptidyl Peptidase-4, its Substrate Chemokines, and Their Receptors in Adipose Tissue of ob/ob Mice.
Obesity
Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.
Obesity
Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity.
Obesity
Structure?Activity Relationship and Molecular Docking of Natural Product Library Reveal Chrysin as a Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: An Integrated In Silico and In Vitro Study.
Obesity
The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice.
Obesity
The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity.
Obesity
The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice.
Obesity
The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
Obesity
The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
Obesity
The pathophysiology of hypertension in patients with obesity.
Obesity
Update in cardiology: vascular risk and cardiac rehabilitation.
Obesity
Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats.
Obesity
Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus.
Obesity
[Novel adipokines: their potential role in the pathogenesis of obesity and metabolic disorders].
Obesity, Abdominal
DPP4 activity is related to body weight and central fat in postmenopausal women.
Obesity, Morbid
Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Osteoarthritis
Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Dipeptidyl peptidase-IV in synovial fluid and in synovial fluid mononuclear cells of patients with rheumatoid arthritis.
Osteoporosis
Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients.
Osteoporosis
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Osteoporosis
Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
Osteoporosis
Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women.
Osteoporosis
Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of osteoporosis in postmenopausal women with normal glucose tolerance.
Osteoporosis
Letter to the Editor: Possible Decrease in GIP Levels May Explain Increased Plasma Dipeptidyl Peptidase-4 Activity-Associated Osteoporosis.
Osteoporosis
Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro.
Osteoporosis
[The effect of antidiabetic treatment on the bone of patients with type 2 diabetes].
Osteosarcoma
Enhancement of methotrexate nephrotoxicity after cisplatin therapy.
Osteosarcoma
GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Osteosarcoma
Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.
Otitis Media
Presence of dipeptidyl peptidase II, dipeptidyl peptidase IV, and prolyl endopeptidase in effusion from patients with serous otitis media.
Otitis Media with Effusion
Presence of dipeptidyl peptidase II, dipeptidyl peptidase IV, and prolyl endopeptidase in effusion from patients with serous otitis media.
Ovarian Neoplasms
Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer.
Ovarian Neoplasms
Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer.
Ovarian Neoplasms
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Ovarian Neoplasms
Possible involvement of SDF-1alpha/CXCR4-DPPIV axis in TGF-beta1-induced enhancement of migratory potential in human peritoneal mesothelial cells.
Ovarian Neoplasms
[Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma]
Overweight
Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult.
Overweight
Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis.
Overweight
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
Overweight
Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
Overweight
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Overweight
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050.
Overweight
Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care.
Overweight
Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Overweight
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.
Overweight
Liraglutide and DPP-4 inhibitors - side effects comparative clinical study.
Overweight
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Overweight
The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Overweight
Therapy for obesity based on gastrointestinal hormones.
Overweight
Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program.
Overweight
[COMMENTS ON FRENCH RECOMMENDATIONS ON GLYCEMIC CONTROL IN TYPE 2 DIABETES].
Pancreatic Neoplasms
An updated review on cancer risk associated with incretin mimetics and enhancers.
Pancreatic Neoplasms
Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study.
Pancreatic Neoplasms
Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.
Pancreatic Neoplasms
Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
Pancreatic Neoplasms
Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis.
Pancreatic Neoplasms
Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
Pancreatic Neoplasms
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Pancreatic Neoplasms
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Pancreatic Neoplasms
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Pancreatic Neoplasms
Incretin-mimetic therapies and pancreatic disease: a review of observational data.
Pancreatic Neoplasms
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Pancreatic Neoplasms
More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
Pancreatic Neoplasms
Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase-4 Inhibitors.
Pancreatic Neoplasms
Pancreatic Safety of Sitagliptin in the TECOS Study.
Pancreatic Neoplasms
Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Pancreatic Neoplasms
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
Pancreatic Neoplasms
The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients.
Pancreatic Neoplasms
Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation.
Pancreatitis
A plea to stop using the case-control design in retrospective database studies.
Pancreatitis
A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs.
Pancreatitis
ACP Journal Club. Review: in type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis.
Pancreatitis
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors.
Pancreatitis
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
Pancreatitis
Acute Pancreatitis Induced by Linagliptin: A Rare but Dangerous Side Effect.
Pancreatitis
Acute pancreatitis with dipeptidyl peptidase-4 (DPP4) inhibitor or fulminant type 1 diabetes?
Pancreatitis
Acute pancreatitis with gliptins: Is it a clinical reality?
Pancreatitis
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Pancreatitis
Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Pancreatitis
Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis: A meta-analysis.
Pancreatitis
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Pancreatitis
Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.
Pancreatitis
Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials.
Pancreatitis
Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier.
Pancreatitis
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
Pancreatitis
Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka.
Pancreatitis
Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Pancreatitis
Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
Pancreatitis
Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study.
Pancreatitis
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Pancreatitis
Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
Pancreatitis
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study.
Pancreatitis
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Pancreatitis
Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis.
Pancreatitis
Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.
Pancreatitis
Dipeptyl-peptidase 4 inhibitors: Pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Pancreatitis
DPP-4 Inhibitor-Related Pancreatitis: Rare but Real!
Pancreatitis
Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Pancreatitis
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.
Pancreatitis
Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study.
Pancreatitis
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Pancreatitis
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Pancreatitis
Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.
Pancreatitis
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Pancreatitis
Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study.
Pancreatitis
Incretin-mimetic therapies and pancreatic disease: a review of observational data.
Pancreatitis
Incretins: their physiology and application in the treatment of diabetes mellitus.
Pancreatitis
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Pancreatitis
LINAGLIPTIN-INDUCED PANCREATITIS.
Pancreatitis
Linagliptin-related pancreatitis in a diabetic patient with biliary calculus: A case report.
Pancreatitis
Mild acute pancreatitis with vildagliptin use.
Pancreatitis
Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase-4 Inhibitors.
Pancreatitis
PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.
Pancreatitis
Pancreatic Safety of Sitagliptin in the TECOS Study.
Pancreatitis
Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Pancreatitis
Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Pancreatitis
Polymorphism in DPPIV Gene in Acute Pancreatitis.
Pancreatitis
Predicting DPP-IV inhibitors with machine learning approaches.
Pancreatitis
Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
Pancreatitis
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Pancreatitis
Saxagliptin-induced recurrent acute pancreatitis.
Pancreatitis
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Pancreatitis
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
Pancreatitis
Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.
Pancreatitis
The effects of dipeptidyl-peptidase-IV inhibitor, vildagliptin, on the exocrine pancreas in spontaneously diabetic Goto-Kakizaki rats.
Pancreatitis
The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients.
Pancreatitis
The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
Pancreatitis
Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
Pancreatitis
Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.
Parkinson Disease
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Parkinson Disease
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
Parkinson Disease
Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Parkinson Disease
Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson's disease.
Parkinson Disease
GLP-1's role in neuroprotection: a systematic review.
Parkinson Disease
Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats.
Parkinson Disease
Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
Parkinson Disease
Repurposing GLP1 agonists for neurodegenerative diseases.
Parkinson Disease
Saxagliptin: a novel antiparkinsonian approach.
Parkinson Disease
The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.
Pemphigoid, Bullous
"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study".
Pemphigoid, Bullous
?ullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
Pemphigoid, Bullous
A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
Pemphigoid, Bullous
A case of dipeptidyl-peptidase 4 inhibitor-associated pemphigoid nodularis.
Pemphigoid, Bullous
A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.
Pemphigoid, Bullous
A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Pemphigoid, Bullous
Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
Pemphigoid, Bullous
Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
Pemphigoid, Bullous
Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
Pemphigoid, Bullous
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Pemphigoid, Bullous
Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
Pemphigoid, Bullous
Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
Pemphigoid, Bullous
Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database.
Pemphigoid, Bullous
Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors: A Case/Non-Case study in the French Pharmacovigilance Database.
Pemphigoid, Bullous
Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
Pemphigoid, Bullous
Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history.
Pemphigoid, Bullous
Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.
Pemphigoid, Bullous
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
Pemphigoid, Bullous
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication.
Pemphigoid, Bullous
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
Pemphigoid, Bullous
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
Pemphigoid, Bullous
Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
Pemphigoid, Bullous
Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: A Pharmacovigilance-Pharmacodynamic/Pharmacokinetic assessment through an analysis of the VigiBase®.
Pemphigoid, Bullous
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
Pemphigoid, Bullous
Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
Pemphigoid, Bullous
Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology.
Pemphigoid, Bullous
Case of dipeptidyl peptidase 4 inhibitor-associated bullous pemphigoid that developed after a scabies infestation.
Pemphigoid, Bullous
Changing prevalence of diabetes mellitus in bullous pemphigoid: It is the dipeptidyl peptidase-4 inhibitors.
Pemphigoid, Bullous
Clinical and immunological characterisation of 14 cases of dipeptidyl peptidase 4 inhibitor-associated bullous pemphigoid: a single centre study.
Pemphigoid, Bullous
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Pemphigoid, Bullous
Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients.
Pemphigoid, Bullous
Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.
Pemphigoid, Bullous
Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study".
Pemphigoid, Bullous
Commentary on "Changing prevalence of diabetes mellitus in bullous pemphigoid: It is the dipeptidyl peptidase-4 inhibitors".
Pemphigoid, Bullous
Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Pemphigoid, Bullous
Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
Pemphigoid, Bullous
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Pemphigoid, Bullous
Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
Pemphigoid, Bullous
Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid.
Pemphigoid, Bullous
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
Pemphigoid, Bullous
Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
Pemphigoid, Bullous
Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
Pemphigoid, Bullous
Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitor-associated anti-laminin-?1 (p200) pemphigoid in a patient with psoriasis vulgaris.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
Pemphigoid, Bullous
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Pemphigoid, Bullous
Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases.
Pemphigoid, Bullous
Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
Pemphigoid, Bullous
Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.
Pemphigoid, Bullous
Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab.
Pemphigoid, Bullous
Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis.
Pemphigoid, Bullous
Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
Pemphigoid, Bullous
DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient.
Pemphigoid, Bullous
DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Pemphigoid, Bullous
Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
Pemphigoid, Bullous
Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Pemphigoid, Bullous
Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Pemphigoid, Bullous
Exacerbation of well-controlled bullous pemphigoid by the administration of a dipeptidyl peptidase-4 inhibitor.
Pemphigoid, Bullous
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
Pemphigoid, Bullous
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.
Pemphigoid, Bullous
HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors.
Pemphigoid, Bullous
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Pemphigoid, Bullous
Linagliptin-Associated Alopecia and Bullous Pemphigoid.
Pemphigoid, Bullous
Linagliptin-associated bullous pemphigoid treated with rituximab.
Pemphigoid, Bullous
Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment.
Pemphigoid, Bullous
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.
Pemphigoid, Bullous
More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
Pemphigoid, Bullous
Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective longitudinal observational study.
Pemphigoid, Bullous
Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
Pemphigoid, Bullous
Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Pemphigoid, Bullous
Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Pemphigoid, Bullous
Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study'".
Pemphigoid, Bullous
Reply to: Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study" and a case report of glucagon-like peptide-1 receptor agonist induced bullous pemphigoid.
Pemphigoid, Bullous
Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
Pemphigoid, Bullous
The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
Pemphigoid, Bullous
The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
Pemphigoid, Bullous
The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Pemphigoid, Bullous
Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
Pemphigoid, Bullous
Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Pemphigoid, Bullous
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid.
Pemphigoid, Bullous
[Acquired hemophilia A complicated by dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid].
Pemphigoid, Bullous
[Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].
Pemphigus
Development of pemphigus vulgaris during treatment with dipeptidyl peptidase-4 inhibitors: a case report.
Pemphigus
Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor: A case report.
Periodontal Diseases
Alanine aminopeptidase and dipeptidylpeptidase IV in saliva: the possible role in periodontal disease.
Periodontal Diseases
[Collagenase, dipeptidylpeptidase IV, and cathepsin D activities in gingival fluid and whole saliva from patients with periodontal disease (author's transl)]
Periodontitis
A simple, combined fluorogenic and chromogenic method for the assay of proteases in gingival crevicular fluid.
Periodontitis
Activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in human gingiva with chronic marginal periodontitis.
Periodontitis
Alanine aminopeptidase and dipeptidyl peptidase IV in saliva of chronic periodontitis patients.
Periodontitis
Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.
Periodontitis
Importance of biofilm formation and dipeptidyl peptidase IV for the pathogenicity of clinical Porphyromonas gingivalis isolates.
Periodontitis
Molecular mechanism for connective tissue destruction by dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis.
Peripheral Arterial Disease
Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients.
Peripheral Arterial Disease
Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease?- Recent Insights Focusing on Angiogenesis and Neovascularization.
Peripheral Arterial Disease
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Peripheral Arterial Disease
Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
Peripheral Arterial Disease
Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease.
Peripheral Arterial Disease
[Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
Peripheral Nervous System Diseases
Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Peripheral Vascular Diseases
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Peritoneal Fibrosis
Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis.
Photosensitivity Disorders
Chemical modification of dipeptidyl peptidase iv: involvement of an essential tryptophan residue at the substrate binding site.
Plasmacytoma
DPPIV - serum activity and expression on lymphocytes in different hematological malignancies.
plasmin deficiency
Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity.
Pleural Diseases
Clinical significance of soluble CD26 in malignant pleural mesothelioma.
Pleural Effusion
Clinical diagnostic utility of adenosine deaminase, interferon-?, interferon-?-induced protein of 10 kDa, and dipeptidyl peptidase 4 levels in tuberculous pleural effusions.
Pleural Effusion
Concurrent measurement of adenosine deaminase and dipeptidyl peptidase IV activity in the diagnosis of tuberculous pleural effusion.
Pleural Effusion
Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease.
Pneumonia
Contribution of dipeptidyl peptidase 4 to non-typeable Haemophilus influenzae-induced lung inflammation in COPD.
Pneumonia
Dipeptidyl peptidase-4 inhibitor treatment could decrease Klebsiella pneumoniae pneumonia in patients with type 2 diabetes.
Pneumonia
Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.
Pneumonia
Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
Pneumonia
Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus.
Pneumonia
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Pneumonia
Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.
Pneumonia
SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
Pneumonia, Aspiration
Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
Polycystic Ovary Syndrome
Dipeptidyl peptidase 4 serum activity and concentration are increased in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
Polycystic Ovary Syndrome
DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
Polycystic Ovary Syndrome
Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor-?1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats.
Polycystic Ovary Syndrome
Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity.
Polycystic Ovary Syndrome
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
Polymyositis
Dipeptidyl peptidase IV (CD26) and Alzheimer amyloid protein precursor (APP) in polymyositis.
Pre-Eclampsia
Changes in placental dipeptidyl peptidase IV in preeclampsia with intrauterine growth restriction.
Pre-Eclampsia
Dipeptidyl peptidase IV reduces trophoblast invasion by inhibiting the activity of MMPs.
Pre-Eclampsia
Histochemical evaluation of placental dipeptidyl peptidase IV (CD26) in pre-eclampsia: enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational hypertensive disorders.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD26 and DPP IV expression in T acute lymphoblastic leukemia cells: immunocytochemistry and enzyme cytochemistry.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytochemical distribution of dipeptidylaminopeptidase IV (DAP IV; EC-3.4.14.5) in T-lymphoblastic lymphoma/leukemia characterized with monoclonal antibodies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dipeptidylaminopeptidase IV activity in normal and leukemic T-cell subpopulations.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of CD26 and DPP IV in T-acute lymphoblastic leukemia: comparison of immunocytochemistry with enzyme cytochemistry.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPP IV enzyme expression.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
CD26 and DPP IV expression in T acute lymphoblastic leukemia cells: immunocytochemistry and enzyme cytochemistry.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Cytochemistry of dipeptidylaminopeptidase IV and II in normal and neoplastic lymphoid cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Dipeptidyl peptidase IV activity in cells of T-lymphoid origin is decreased in cultures with 12-0-tetradecanoylphorbol-13-acetate (TPA).
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Expression of CD26 and DPP IV in T-acute lymphoblastic leukemia: comparison of immunocytochemistry with enzyme cytochemistry.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPP IV enzyme expression.
Prediabetic State
Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, Improves Trabecular Bone Mineral Density and Microstructure in Obese, Insulin-Resistant, Pre-diabetic Rats.
Prediabetic State
Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma.
Prediabetic State
Incretin-based therapies in prediabetes: Current evidence and future perspectives.
Prediabetic State
Management of a Prediabetes Case With the DPP-4 Inhibitor Sitagliptin.
Prediabetic State
Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients With Prediabetes or Diabetes After Cardiac Surgery.
Prediabetic State
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
Prediabetic State
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Prostatic Hyperplasia
Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study.
Prostatic Hyperplasia
Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.
Prostatic Neoplasms
A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer.
Prostatic Neoplasms
Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells.
Prostatic Neoplasms
CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12.
Prostatic Neoplasms
Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway.
Prostatic Neoplasms
Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor.
Prostatic Neoplasms
Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.
Prostatic Neoplasms
Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker.
Prostatic Neoplasms
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue.
Prostatic Neoplasms
Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters.
Prostatic Neoplasms
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Prostatic Neoplasms
Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.
Prostatic Neoplasms
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.
Prostatic Neoplasms
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Proteinuria
Angiotensin I converting enzyme activity in uranyl nitrate induced acute renal failure in rats.
Proteinuria
Angiotensin I converting enzyme in glycerol-induced acute renal failure in rats.
Proteinuria
Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Proteinuria
Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes.
Proteinuria
Involvement of dipeptidyl peptidase IV in immune complex-mediated glomerulonephritis.
Proteinuria
Proteinuria induced by anti-dipeptidyl peptidase IV (gp108); role of circulating and glomerular antigen.
Proteinuria
Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury.
Proteinuria
Role of dipeptidyl peptidase IV (gp 108) in passive Heymann nephritis. Use of dipeptidyl peptidase IV-deficient rats.
Proteinuria
Urinary angiotensin I-converting enzyme activity is increased in experimental acute renal failure.
Proteinuria
Urinary excretion of dipeptidyl aminopeptidase i.v. in patients with renal diseases.
Pruritus
A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus.
Pruritus
Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin.
Psoriasis
Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases.
Psoriasis
Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine.
Psoriasis
Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.
Psoriasis
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial.
Psoriasis
Dipeptidyl peptidase-4 inhibitor-associated anti-laminin-?1 (p200) pemphigoid in a patient with psoriasis vulgaris.
Psoriasis
Expression of dipeptidyl-peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis.
Psoriasis
Glycemic Control in the Treatment of Psoriasis.
Psoriasis
Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Psoriasis
Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial.
Psoriasis
Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis.
Psoriasis
The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases.
Psoriasis
[The behavior of dipeptidyl peptidase IV in PUVA therapy of patients with psoriasis]
Pulmonary Disease, Chronic Obstructive
Contribution of dipeptidyl peptidase 4 to non-typeable Haemophilus influenzae-induced lung inflammation in COPD.
Pulmonary Disease, Chronic Obstructive
Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD.
Pulmonary Disease, Chronic Obstructive
DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients.
Pulmonary Disease, Chronic Obstructive
Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable COPD.
Pulmonary Disease, Chronic Obstructive
Expression and Clinical Significance of Serum Dipeptidyl Peptidase IV Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Role of Proteases in Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
Pulmonary Edema
Noncardiac Pulmonary Edema induced by Sitagliptin Treatment.
Pulmonary Fibrosis
DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?
Pulmonary Fibrosis
Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Pyelonephritis
[Renal dipeptidylpeptidase IV excretion in drug-induced kidney changes]
receptor protein-tyrosine kinase deficiency
Evidence for an interaction between leptin, T cell costimulatory antigens CD28, CTLA-4 and CD26 (dipeptidyl peptidase IV) in BCG-induced immune responses of leptin- and leptin receptor-deficient mice.
Renal Insufficiency
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Renal Insufficiency
Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.
Renal Insufficiency
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Renal Insufficiency
Evaluation of urinary enzymes in dogs with early renal disorder.
Renal Insufficiency
Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
Renal Insufficiency
Renal therapeutics: patent highlights January to June 2003.
Renal Insufficiency
The Pharmacokinetics of PF-734200, a DPP-IV Inhibitor, in Subjects With Renal Insufficiency.
Renal Insufficiency
The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction.
Renal Insufficiency
Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
Renal Insufficiency
[Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
Renal Insufficiency, Chronic
A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.
Renal Insufficiency, Chronic
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
Renal Insufficiency, Chronic
A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease.
Renal Insufficiency, Chronic
Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Renal Insufficiency, Chronic
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Renal Insufficiency, Chronic
An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.
Renal Insufficiency, Chronic
Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Renal Insufficiency, Chronic
Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
Renal Insufficiency, Chronic
Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
Renal Insufficiency, Chronic
Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Renal Insufficiency, Chronic
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Renal Insufficiency, Chronic
Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
Cost-Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Monotherapy versus Sulfonylurea Monotherapy for People with Type 2 Diabetes and Chronic Kidney Disease in Thailand.
Renal Insufficiency, Chronic
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes.
Renal Insufficiency, Chronic
DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.
Renal Insufficiency, Chronic
Diabetic nephropathy: newer therapeutic perspectives.
Renal Insufficiency, Chronic
Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension.
Renal Insufficiency, Chronic
Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease.
Renal Insufficiency, Chronic
Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Renal Insufficiency, Chronic
Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.
Renal Insufficiency, Chronic
Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
Renal Insufficiency, Chronic
Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
Renal Insufficiency, Chronic
DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Renal Insufficiency, Chronic
Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease.
Renal Insufficiency, Chronic
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Renal Insufficiency, Chronic
Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
Renal Insufficiency, Chronic
Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
Renal Insufficiency, Chronic
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
Renal Insufficiency, Chronic
Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy.
Renal Insufficiency, Chronic
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Renal Insufficiency, Chronic
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Renal Insufficiency, Chronic
Metformin and the risk of anemia of advanced chronic kidney disease in patients with Type 2 Diabetes mellitus.
Renal Insufficiency, Chronic
Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
Renal Insufficiency, Chronic
PATHOPHYSIOLOGY AND MANAGEMENT OF HYPOGLYCEMIAIN END-STAGE RENAL DISEASE PATIENTS: A REVIEW.
Renal Insufficiency, Chronic
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Renal Insufficiency, Chronic
Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.
Renal Insufficiency, Chronic
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Renal Insufficiency, Chronic
Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.
Renal Insufficiency, Chronic
Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Renal Insufficiency, Chronic
Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.
Renal Insufficiency, Chronic
Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
Renal Insufficiency, Chronic
Sitagliptin and shock wave-supported peripheral blood derived endothelial progenitor cell therapy effectively preserves residual renal function in chronic kidney disease in rat-role of dipeptidyl peptidase 4 inhibition.
Renal Insufficiency, Chronic
The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes.
Renal Insufficiency, Chronic
The renoprotective effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on adenine-induced kidney disease in rats.
Renal Insufficiency, Chronic
The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease.
Renal Insufficiency, Chronic
Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment.
Renal Insufficiency, Chronic
Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
Renal Insufficiency, Chronic
[Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
Reperfusion Injury
A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
Reperfusion Injury
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Reperfusion Injury
Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury.
Reperfusion Injury
Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control.
Reperfusion Injury
DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning.
Reperfusion Injury
DPP-4 inhibitors: A promising feasible therapeutic approach for myocardial ischemia-reperfusion injury.
Reperfusion Injury
Estrogen and DPP-4 inhibitor share similar efficacy in reducing brain pathology caused by cardiac ischemia-reperfusion injury in both lean and obese estrogen-deprived rats.
Reperfusion Injury
Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Reperfusion Injury
Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats.
Reperfusion Injury
Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition.
Reperfusion Injury
Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats.
Reperfusion Injury
Protection of Glucagon-Like Peptide-1 in Cisplatin-Induced Renal Injury Elucidates Gut-Kidney Connection.
Reperfusion Injury
Sitagliptin ameliorates high glucose-induced cell proliferation and expression of the extracellular matrix in glomerular mesangial cells.
Reproductive Tract Infections
Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.
Respiratory Distress Syndrome
Dipeptidyl peptidase IV is a human and murine neutrophil chemorepellent.
Respiratory Tract Infections
Antidiabetic oral treatment in older people: does frailty matter?
Respiratory Tract Infections
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
Respiratory Tract Infections
Infectious complications of newer agents in the fight against diabetes.
Respiratory Tract Infections
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Respiratory Tract Infections
Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1? and IL-12 in NOD mice.
Respiratory Tract Infections
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Respiratory Tract Infections
The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Retinal Neovascularization
Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Retinal Neovascularization
Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy.
Rhinitis
Histochemical study of dipeptidylpeptidase IV in the nasal cavity organs of laboratory rodents and man.
Rhinitis, Allergic
Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes.
Root Resorption
Effect of a DPP-4 Inhibitor on Orthodontic Tooth Movement and Associated Root Resorption.
Sarcoma, Avian
Apical cell surface expression of rat dipeptidyl peptidase IV in transfected Madin-Darby canine kidney cells.
Sarcoma, Avian
Involvement of both vectorial and transcytotic pathways in the preferential apical cell surface localization of rat dipeptidyl peptidase IV in transfected LLC-PK1 cells.
Sarcoma, Ewing
Role of neuropeptide Y and dipeptidyl peptidase IV in regulation of Ewing's sarcoma growth.
Sarcopenia
Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors.
Scabies
Case of dipeptidyl peptidase 4 inhibitor-associated bullous pemphigoid that developed after a scabies infestation.
Scabies
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
Scleroderma, Systemic
Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
Scoliosis
Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts.
Seizures, Febrile
Decreased Methylation Level of H3K27me3 Increases Seizure Susceptibility.
Sepsis
Association between Use of Oral Anti-Diabetic Drugs and the Risk of Sepsis: A Nested Case-Control Study.
Sepsis
Decrease of serum dipeptidylpeptidase activity in severe sepsis patients: relationship to procalcitonin.
Sepsis
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Sepsis
Hyper-Activation of Endogenous GLP-1 System to Gram-negative Sepsis Is Associated With Early Innate Immune Response and Modulated by Diabetes.
Sepsis
The paradox of dipeptidyl peptidase IV inhibition in enterocytic differentiation and epithelial-mesenchymal transition in rat cholestatic sepsis.
Sepsis
Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Severe Acute Respiratory Syndrome
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.
Severe Acute Respiratory Syndrome
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
Severe Acute Respiratory Syndrome
Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study.
Severe Acute Respiratory Syndrome
Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus.
Severe Acute Respiratory Syndrome
SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications.
Sezary Syndrome
Dipeptidylaminopeptidase IV (DAP IV) in B- and T-cell leukaemias.
Shock, Septic
Inactivation of dipeptidyl peptidase IV attenuates the virulence of Streptococcus suis serotype 2 that causes streptococcal toxic shock syndrome.
Short Bowel Syndrome
Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome.
Short Bowel Syndrome
Dipeptidyl-peptidase IV in patients with short bowel syndrome.
Short Bowel Syndrome
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study.
Short Bowel Syndrome
Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model.
Short Bowel Syndrome
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
Skin Diseases
Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study.
Skin Diseases
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
Skin Diseases
Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases.
Skin Diseases
Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
Skin Diseases
The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea.
Sleep Apnea, Obstructive
Random-effects meta-analysis of combined outcomes based on reconstructions of individual patient data.
Sleep Apnea, Obstructive
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Small Cell Lung Carcinoma
Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Squamous Cell Carcinoma of Head and Neck
Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase-IV.
Squamous Cell Carcinoma of Head and Neck
[Changes in dipeptidyl peptidase IV activity in oral squamous cell carcinoma]
Stomach Neoplasms
[Dipeptidyl aminopeptidase IV activity in stomach cancer and high-risk groups]
Stomatitis
Dipeptidyl Peptidase-4 inhibitor (Vildagliptin) induced oral mucositis: A case report.
Streptococcal Infections
Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.
Stroke
Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity.
Stroke
Antidiabetic treatment, stroke severity and outcome.
Stroke
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
Stroke
Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
Stroke
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
Stroke
Cardiovascular Safety of the Dipetidyl Peptidase-4 inhibitor Alogliptin in Type 2 Diabetes Mellitus.
Stroke
Cardiovascular safety outcomes of new antidiabetic therapies.
Stroke
Contrasting effects on the risk of macrovascular and microvascular events associated with anti-hyperglycaemic drugs that enhance sodium excretion and lower blood pressure.
Stroke
Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
Stroke
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Stroke
Dipeptidyl Peptidase-4 deficiency effectively protects the brain and neurological function in rodent after acute Hemorrhagic Stroke.
Stroke
Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
Stroke
Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.
Stroke
Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke.
Stroke
DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects.
Stroke
DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway.
Stroke
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Stroke
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke.
Stroke
Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke.
Stroke
Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Stroke
Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.
Stroke
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
Stroke
Meta-analyses of the effects of Dpp-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
Stroke
No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Stroke
Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.
Stroke
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Stroke
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies.
Stroke
Stroke in the patient with diabetes (Part 2) - Prevention and the effects of glucose lowering therapies.
Stroke
The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Stroke
The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride.
Stroke
The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1?/CXCR4 pathway.
Stroke
The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors.
Stroke
Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database.
Stroke
Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
Stroke
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
Superinfection
Selection of viral variants during persistent infection of insectivorous bat cells with Middle East respiratory syndrome coronavirus.
Synovitis
Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edema syndrome.
Synovitis
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Associated with DPP-4 Inhibitor.
Synovitis
Remitting seronegative symmetrical synovitis with pitting edema syndrome in individuals with type 2 diabetes mellitus or impaired glucose tolerance.
Tachycardia
Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats.
Tauopathies
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
Tetanus
Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor.
Tetanus
Effects of nonapeptides derived from the N-terminal structure of human immunodeficiency virus-1 (HIV-1) Tat on suppression of CD26-dependent T cell growth.
Tetanus
Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells.
Tetanus
The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth.
Thrombosis
Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system.
Thrombosis
Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.
Thrombosis
Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.
Thrombosis
Increased dipeptidyl peptidase-4 accelerates chronic stress-related thrombosis in a mouse carotid artery model.
Thrombosis
Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis.
Thrombosis
Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
Thrombosis
Stress, NPY and vascular remodeling: Implications for stress-related diseases.
Thrombosis
The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury.
Thrombosis
Use of dipeptidyl peptidase-4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new-user active comparator cohort study.
Thymoma
Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV).
Thyroid Cancer, Papillary
Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Thyroid Cancer, Papillary
FosB recruits KAT5 to potentiate the growth and metastasis of papillary thyroid cancer in a DPP4-dependent manner.
Thyroid Cancer, Papillary
Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.
Thyroid Diseases
Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.
Thyroid Diseases
Staining for dipeptidyl aminopeptidase IV activity in nodular thyroid diseases.
Thyroid Diseases
[CD26/dipeptidyl peptidase IV and thyroid peroxidase as molecular markers for differentiated thyroid carcinoma]
Thyroid Neoplasms
An updated review on cancer risk associated with incretin mimetics and enhancers.
Thyroid Neoplasms
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
Thyroid Neoplasms
Biological significance of aminopeptidase N/CD13 in thyroid carcinomas.
Thyroid Neoplasms
Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines.
Thyroid Neoplasms
Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours.
Thyroid Neoplasms
Differential expression of dipeptidyl peptidase IV (CD26) and thyroid peroxidase in neoplastic thyroid tissues.
Thyroid Neoplasms
Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.
Thyroid Neoplasms
Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.
Thyroid Neoplasms
Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Thyroid Neoplasms
Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?
Thyroid Neoplasms
Expression of dipeptidyl aminopeptidase IV activity in thyroid carcinoma.
Thyroid Neoplasms
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
Thyroid Neoplasms
Immunohistochemical localization of dipeptidyl aminopeptidase IV in thyroid papillary carcinoma.
Thyroid Neoplasms
Serum level of dipeptidyl peptidase-4 as a potential biomarker for medullary thyroid cancer.
Thyroid Neoplasms
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
Thyroid Neoplasms
The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
Thyroid Neoplasms
The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.
Thyroid Neoplasms
[CD26/dipeptidyl peptidase IV and thyroid peroxidase as molecular markers for differentiated thyroid carcinoma]
Thyroid Nodule
Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Thyroid Nodule
Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.
Thyroid Nodule
[Tumor markers in the cytodiagnosis of thyroid nodules. Detection of dipeptidyl aminopeptidase IV (DAP IV) activity]
Thyroiditis
Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis.
Thyroiditis
Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.
Thyroiditis
Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.
Thyroiditis
In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Tonsillitis
Activity of soluble aminopeptidase A and dipeptidyl peptidase IV and membrane-bound aminopeptidase B and pyroglutamyl peptidase I in adenoid hyperplasia, tonsillar hyperplasia and chronic tonsillitis.
Tonsillitis
Altered dipeptidyl peptidase IV and prolyl endopeptidase activities in chronic tonsillitis, tonsillar hyperplasia and adenoid hyperplasia.
Tonsillitis
Distribution of dipeptidyl peptidase IV in patients with chronic tonsillitis.
Tonsillitis
Elevated serum dipeptidyl peptidase IV activity in patients with chronic tonsillitis.
Trypanosomiasis
The prolyl oligopeptidase family.
Tuberculosis
Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study.
Tuberculosis
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Tuberculosis, Pulmonary
Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease.
Tuberculosis, Pulmonary
Features purine metabolism in patients with pulmonary tuberculosis.
Uremia
Enzyme cytochemistry of rat organs after uremia with special reference to proteases.
Ureteral Obstruction
Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction.
Ureteral Obstruction
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice.
Ureteral Obstruction
Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.
Urinary Bladder Neoplasms
Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Urinary Tract Infections
Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study.
Urinary Tract Infections
Infectious complications of newer agents in the fight against diabetes.
Urinary Tract Infections
Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.
Urinary Tract Infections
Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.
Urinary Tract Infections
SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
Uterine Cervical Neoplasms
Targeting Dipeptidyl peptidase 8 genes inhibits proliferation, migration and invasion by inhibition of Cyclin D1 and MMP2MMP9 signal pathway in cervical cancer.
Vascular Calcification
Dipeptidyl Peptidase-4 Inhibition Prevents Vascular Calcification by Potentiating the Insulin-Like Growth Factor-1 Signaling Pathway.
Vascular Calcification
Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.
Vascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Vascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Vascular Diseases
Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease.
Vascular Diseases
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
Vascular System Injuries
Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
Vascular System Injuries
Dipeptidyl peptidase-4 inhibition prevents vascular dysfunction induced by ?-adrenergic hyperactivity.
Vascular System Injuries
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
Vascular System Injuries
Linagliptin protects rat carotid artery from balloon injury and activates the NRF2 antioxidant pathway.
Venous Thromboembolism
Dipeptidyl Peptidase 4 Inhibitors and Venous Thromboembolism Risk in Patients with Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
Venous Thromboembolism
Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system.
Venous Thromboembolism
DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database.
Venous Thromboembolism
Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study.
Ventricular Dysfunction
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Ventricular Dysfunction, Left
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Ventricular Dysfunction, Left
Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions.
Ventricular Dysfunction, Left
Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
Ventricular Dysfunction, Left
Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
Ventricular Dysfunction, Left
The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.
Ventricular Fibrillation
Aged male and female spontaneously hypertensive rats benefit from n-3 polyunsaturated fatty acids supplementation.
Ventricular Fibrillation
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Vesicular Stomatitis
A novel type of detergent-resistant membranes may contribute to an early protein sorting event in epithelial cells.
Virus Diseases
Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.
Virus Diseases
CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line.
Virus Diseases
Dipeptidyl peptidase-4 inhibitor sitagliptin significantly reduced hepatitis C virus replication in a diabetic patient with chronic hepatitis C virus infection.
Virus Diseases
Dipeptidyl peptidase-4: a key player in chronic liver disease.
Virus Diseases
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Virus Diseases
Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis.
Virus Diseases
Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections.
Vitamin D Deficiency
Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
Vitiligo
Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.
Werner Syndrome
Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome.
Whooping Cough
Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide.
Wolfram Syndrome
Different clinical entities of the same mutation: a case report of three sisters with Wolfram syndrome and efficacy of dipeptidyl peptidase-4 inhibitor therapy.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.